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During the past few years many tumour sequencing projects have been 
focused on the characterisation of genes harbouring somatic alterations with 
cancer promoting role, which have been named cancer driver genes. Since 
these genes have been shown to be subject to positive selection during cancer 
progression, it has been assumed that their mutation is observed more 
frequently than expected. However, the full characterisation of cancer drivers is 
particularly challenging in cancer types, such as oesophageal adenocarcinoma 
(OAC), in which the genomic landscape is highly variable and recurrent events 
are not frequent. 
To identify rare or even patient-specific cancer driver genes, a novel 
algorithm, sysSVM, was developed. SysSVM is based on support vector 
machines, a supervised machine-learning framework, and utilises systems-level 
properties of human genes and sequencing data from individual tumours to 
predict genes that promote cancer development. Unlike other state-of-the-art 
algorithms for driver gene prediction, sysSVM takes into account all types of 
damaging alterations simultaneously (mutations, copy number alterations and 
structural rearrangements). After the development phase, sysSVM was applied 
to 261 OACs from the Oesophageal Cancer Clinical and Molecular Stratification 
(OCCAMS) consortium. A large number of novel cancer driver genes that, 
together with well-known drivers, help promote OAC was discovered. Validation 
of sysSVM using 107 additional OACs confirmed the robustness of the 
approach. Moreover, the large majority of the newly discovered cancer genes 
was rare or patient-specific. Despite this, it was shown that they converged 
towards perturbing the same cancer-related processes, including intracellular 




than mutations in individual genes, divided OACs into six clusters that differ in 
their molecular and clinical features, suggesting patient stratifications for 
personalised treatments. Collaboration with bench researchers to 
experimentally mimic or reverting alterations of the predicted cancer driver 
genes, validated their contribution to cancer progression in OAC. 
The findings of this thesis accomplish three things. First, they describe the 
first attempt to develop an algorithm, which extends the discovery of somatically 
acquired perturbations contributing to cancer beyond those of recurrent driver 
genes. Second, they reveal a widespread somatic perturbation of biological 
processes in OAC, demonstrate OAC acquired dependencies and highlight 
potential therapeutic targets. Third, they provide insights into the potential use 
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Chapter 1. Introduction 
1.1 Cancer genome and cancer drivers 
Cancer is a disease of the genome and its pathogenesis lies in the 
accumulation of changes in the genome of somatic cells (Stratton, Campbell, 
and Futreal 2009). These changes lead to widespread deregulation of cell 
functions, which in turn provides tumours with sufficient diversity to adapt and 
proliferate in the ever-changing tumour microenvironment. Depending on the 
cancer type, cancer genomes can be genomically stable, with very few changes 
present, or highly unstable, exhibiting numerous genomic changes (Jefford and 
Irminger-Finger 2006; Lengauer, Kinzler, and Vogelstein 1998; Vogelstein et al. 
2013). These somatic alterations can affect the DNA sequence at various 
extents and thus, range from point mutations to large chromosomal 
abnormalities. Specifically, they are further divided in: (i) single nucleotide 
variants (SNVs), (ii) insertions/deletions of small or large DNA sequences 
(indels), (iii) DNA rearrangements, in which DNA segments are relocating from 
one genomic position to another via recombination or gene conversion, and (iv) 
copy number variations, which can be either increases, leading to gene 
amplification, or reductions, leading to removal of a DNA segment from the 
genome (Lawrence et al. 2013; Weir, Zhao, and Meyerson 2004; Stephens et 
al. 2009; Alexandrov et al. 2013). However, it should be noted that somatic 
changes that are critical for cancer initiation and progression are not merely 
genomic, rather they can be present in virtually every level of genome’s 
organisation (Network et al. 2013; Dulak et al. 2013; Jusakul et al. 2017; 
Sabarinathan et al. 2017). For example, epigenetic changes, such as DNA 




profoundly affect cancer onset and progression (Sharma, Kelly, and Jones 
2010).  
The compendium of alterations in cancer genomes is not fixed, but 
changes over time as tumours evolve and this evolutionary nature of neoplasms 
has been described since 1976 (Nowell 1976). Mutational patterns in cancer 
are shaped by external factors, such as exposure to cigarette carcinogens and 
UV light, or may be introduced by the cell’s own error-prone DNA repair 
mechanisms (Stratton 2011). Although randomly distributed mutations 
accumulate in normal cells even before cell transformation, they can be 
subsequently subject to positive selection. Therefore, at any point in time, the 
mutational landscape of cancer genome reflects the outcome of random events 
and selection of mutations that confer a fitness advantage to tumour cells 
(Martincorena et al. 2017, 2015; Tomasetti, Vogelstein, and Parmigiani 2012). 
Thus, cancer evolution has been characterised as a typical Darwinian system, 
in which selective pressures act on genetic alterations that trigger phenotypic 
changes (Greaves and Maley 2012; Cahill et al. 1999). The study of tumours 
from an evolutionary perspective is critical for the understanding of 
tumorigenesis and therapeutic resistance arising after treatment (Meads, 
Gatenby, and Dalton 2009; Moulder 2010). As tumour evolves, the set of 
somatic changes in cancer cells is continuously shaped by a combination of 
selective pressures and neutrality. Consequently, somatic alterations can be 
classified into: i) those that confer a selective advantage to the cell, called 
“driver” alterations, ii) those that are detrimental for cell’s fitness and thus, 
subject to negative selection, and iii) those that are selectively neutral with 




alterations (Pon and Marra 2015; Haber and Settleman 2007; Maley et al. 2004; 
Simpson 2009).  
More recently, it was suggested that in addition to these three types of 
alterations there is another intermediate form that lies between drivers and 
passengers. These alterations have been termed “mini drivers” and they 
exemplify an alleviated form of major drivers (Li and Thirumalai 2016; Castro-
Giner, Ratcliffe, and Tomlinson 2015). According to the mini driver hypothesis, 
in tumours lacking a major driver, oncogenic transformation may occur through 
a combined action of multiple mini-driver genes, each with a weak individual 
effect. Their potential role in tumorigenesis and disease progression will be 
discussed in more detail at the end of this chapter.  
Understanding the role that genetic modifications play in cancer and 
identifying driver mutations and the cancer genes that they alter have been the 
main focus of cancer research. The first findings came from observational 
studies in the beginning of the 20th century, which highlighted that abnormalities 
in the hereditary material of the cells was the cause for the cancerous cell 
phenotype (von Hansemann 1890; Boveri 1914). Shortly after the discovery of 
DNA, the development of cytogenetic methods led to association of a 
translocation between chromosomes 9 and 22, which is known as 
“Philadelphia” translocation, to chronic myeloid leukaemia (Rowley 1973). Apart 
from chromosomal changes, many viral agents were also linked to various 
cancer types. Prominent examples are Rous sarcoma virus (Rous 1910), 
Epstein-Barr virus, which has been linked to non-Hodgkin Lymphoma (Teras et 
al. 2015), and long-standing infections of hepatitis B or C viruses, which have 
been shown to lead to liver cancer (Koike et al. 2008). These discoveries 




understanding of the mode of action of cancer-causing agents and the 
molecular, tumour-promoting changes that they introduce at a subcellular level 
was lacking.  
Later on, several studies in the field of chemical carcinogenesis provided 
evidence that carcinogens deregulate cell proliferation by forming covalent 
bonds with cellular macromolecules, but their exact target was not identified 
(Miller and Miller 1947; Cook, Hewett, and Hieger 1933). The discovery of DNA 
as the genetic material and the description of its structure (Watson and Crick 
1953) made apparent that DNA is the macromolecule that is targeted by 
carcinogens. Therefore, understanding the effects of individual DNA mutations 
was the key in dissecting basic cancer mechanisms (Loeb and Harris 2008). 
Consequently, an increasing interest in characterising such mutations focused 
on the isolation of specific DNA segments responsible for tumorigenesis. These 
efforts eventually led to the seminal discovery of the first cancer-causing 
sequence change, the substitution of glycine to valine in codon 12 of the HRAS 
gene (Reddy et al. 1982; Stratton, Campbell, and Futreal 2009). 
Most driver alterations are associated with genes (also known as driver 
genes) that in normal cells are involved in pathways related to cellular 
proliferation, apoptosis and cell signalling. Based on their function, these genes 
can be broadly divided into two major classes – tumour suppressors and 
oncogenes (Futreal et al. 2004). Tumour suppressors act to repress the 
potential of uncontrolled proliferation of cells and their driver role in cancer is the 
result of inactivating mutations, whereas oncogenes result from the activating 
mutations of proto-oncogenes. The first tumour suppressor gene was 
discovered following the description of the “two-hit” hypothesis in 1971 by Alfred 




of retinoblastoma, a rare childhood eye tumour, requires two damaging 
mutations, and as further studies confirmed, both of these mutations must occur 
in the two functional copies of the retinoblastoma gene (Rb) (Sparkes et al. 
1980, 1983; Horowitz et al. 1990). 
Subsequent discoveries highlighted the role of another tumour suppressor 
gene, TP53, which was shown to be the key regulator of cell proliferation (Lane 
and Crawford 1979). TP53 is the most frequently mutated gene in human 
cancers and its role in the control of cell cycle (Levine 1997) renders it a primary 
target of inactivating, usually missense, mutations in cancer. Furthermore, 
inheritance of TP53 mutations predisposes to multiple cancers, such as breast 
carcinomas, sarcomas and brain tumours (Olivier, Hollstein, and Hainaut 2010). 
However, TP53 may also harbour gain-of-function mutations with oncogenic 
potential that make it a potential therapeutic target (Soussi and Wiman 2015). 
The discovery of the first tumour suppressor genes was followed by the 
identification of several oncogenes that were initially described in tumour-
inducing retroviruses (Vogt 2012). The src gene in Rous sarcoma virus was the 
first oncogene to be characterised, due to its ability to oncogenically transform 
normal cells by altering cell morphology, adhesion, motility, survival, and 
proliferation (Martin 1970; Hunter and Sefton 1980). Many human oncogenes, 
such as MYC and RAS, followed the discovery of src and they have been 
subsequently recognised as critical driving forces in many types of cancer 






1.2 Computational algorithms to identify cancer driver genes 
The discovery of driver genes was accelerated by the completion of the 
sequencing of the human genome (International Human Genome Sequencing 
Consortium 2004) and the subsequent advent of next generation sequencing 
technologies (Meyerson, Gabriel, and Getz 2010). With the base-level 
resolution of human genome available, many ambitious cancer sequencing 
projects were initiated, yielding sequencing data from thousands of cancer 
genomes (International Cancer Genome Consortium et al. 2010). Ultimately, 
owing to the advances in sequencing technologies and the generation of 
sequencing data, cancer genomics research inevitably became tightly 
connected to computer science and mathematics. The development of new 
algorithms aiming to interrogate sequencing data for somatic and germline 
alterations enabled a number of studies to unravel the complexity of cancer 
genomes in detail (Tian, Basu, and Capriotti 2015; Chin et al. 2011). 
Algorithms to identify driver genes amongst all mutated genes in a cohort 
of cancer samples can be conceptually divided into three groups: (i) those that 
predict the effect of the acquired mutations on the encoded protein, (ii) those 
that measure the background mutation rate of the cancer genome and identify 
genes deviating from it and (iii) those that utilize systems-biology data (mostly 
protein-protein interaction networks) to assess mutation significance (Ding et al. 
2014).  
The first group of methods relies on the hypothesis that drivers alter the 
function of the normal protein either by disrupting it (loss-of-function), or by 
enhancing it (gain-of-function). Such methods utilise genome annotation 
databases, for instance Ensembl or that of University of California Santa Cruz, 




 the functional impact on the encoded protein: SIFT (Kumar, Henikoff, and 
Ng 2009), PolyPhen-2 (Adzhubei et al. 2010), MutationTaster (Schwarz 
et al. 2010), MutationAssessor (Reva, Antipin, and Sander 2011),  
 sequence conservation across the tree of life: PhyloP (Pollard et al. 
2010), GERP++ RS (Davydov et al. 2010), SiPhy (Garber et al. 2009), or  
 mutation clustering: OncodriveClust (Tamborero, Gonzalez-Perez, and 
Lopez-Bigas 2013).  
To extend these methods, it has been hypothesised that genes exhibiting 
a bias towards accumulation of mutations with high functional impact (FM bias) 
may be subject to positive selection. Thus, an estimation of this bias can be 
used to detect candidate driver genes (Gonzalez-Perez and Lopez-Bigas 2012). 
Most importantly, the estimation of FM bias was one of the first efforts to 
overcome the limitations of recurrence-based methods (see below) and predict 
candidate driver genes in individual samples. This was feasible due to the  
premise that genes mutated in only a handful of samples may show high FM 
bias if the mutations they harbour are all highly deleterious. Bias estimation has 
not been assessed only by examining the functional impact of mutations, but 
also by estimating clustering of mutations around certain protein residues. The 
“20/20” rule first published by Vogelstein and colleagues (Vogelstein et al. 
2013), and later refined by the addition of a machine-learning-based algorithm 
(Tokheim et al. 2016), suggested that a gene should be classified as tumour 
suppressor if at least 20% of its mutations are inactivating. Conversely, genes 
with at least 20% missense mutations around a protein residue can be 
classified as oncogenes. In contrast to the evaluation of FM bias, the 20/20 rule 
cannot predict driver mutations in genes altered in very few samples, due to 




The second, and most widely used, group of methods employs an 
estimation of the expected number of mutations across different regions of the 
cancer genome, termed background mutations rate (BMR). To identify driver 
genes, these methods apply a statistical model to discover genes that carry 
more mutations that one would expect by chance, after correction for multiple 
testing (Getz et al. 2007; Sjoblom et al. 2006; Lawrence et al. 2013). These 
recurrence-based methods are based on the hypothesis that important 
mutations for the development of cancer recur across samples. Therefore, the 
prevalence of mutation of a gene is a sign of functional selection. Recurrence of 
mutations is, however, influenced by many factors, such as the gene length, 
BMR and gene replication time, with many recent approaches trying to account 
for these factors as well. For example, Mutational Significance in Cancer 
(MuSiC) implements a multidimensional statistical evaluation to identify 
significantly mutated genes across a given cohort of samples (Dees et al. 
2012). Moreover, recently developed methods started taking into account the 
non-uniform mutation rate across the genome. For instance, the latest version 
of Mutation Significance with Covariates (MutSigCV) calculates a gene-specific 
background mutation rate by incorporating expression levels and gene 
replication time (Lawrence et al., 2013). Despite their widespread usage, 
recurrence-based methods still have limitations; they fail to detect rare driver 
genes, such as those whose mutation rate is below the background mutation 
rate (Lawrence et al. 2014).  
Finally, the third group of methods builds on the idea that mutations target 
driver genes that are associated with a relatively small number of regulatory and 
signalling networks. These methods employ a rigorous statistical framework to 




interaction network (PIN) (Vandin, Upfal, and Raphael 2011). HotNet and its 
successor HotNet2 (Leiserson et al. 2015) are the most representative 
examples of such algorithms and both use a heat diffusion model to identify 
significantly mutated subnetworks. Specifically, mutated genes are assigned an 
initial heat value, based on their mutation frequency in the cohort of interest. 
This heat value successively fuses to their interactors through the edges of the 
network, thus yielding significantly “hot” subnetworks. Heat diffusion models can 
potentially identify genes mutated in low frequencies based on their proximity to 
recurrently mutated genes. However, they fail to coherently explore parts of the 
network containing only infrequent mutated genes as the initial heat in these 
regions will be low. Another network-based approach is the Mutual Exclusivity 
Modules (MEMo) (Ciriello et al. 2012), which is based on mutual exclusivity of 
mutations in given parts of the network. MEMo first identifies highly connected 
proteins and then tests whether sub-networks that include such proteins show 
mutually exclusive mutations.  
Apart from rigorous prediction algorithms, many studies during the last 
decade sought to investigate the drivers in several cancer types by simply 
ranking mutated genes in cancer samples by frequency of mutations, assuming 
that recurrence of mutations is indicative of significance. In fact, recurrence-
based driver discovery was the most commonly used method for driver 
identification, accounting for 44.7% of the total 188 mutational screenings that 
were reported as part of the Network of Cancer Genes database (An et al. 
2016) (Figure 1.1A). However, the number of recurrently mutated genes in 
cancer cohorts is far lower than the total number of mutated genes. As a result, 
the mutational landscape in cancer is comprised of a few mountains, i.e. genes 




i.e. genes mutated in low frequencies, as depicted in Figure 1.1B. Methods that 
rely on recurrence (or a refined version of it) of mutations are usually incapable 
of identifying hills in cancer cohorts. As a consequence, identification of cancer 
genes that are mutated at frequencies ≥ 20% is nearing saturation, while the 
discovery rate of genes that are mutated at lower frequencies is in steep 
increase (Lawrence et al. 2014) due to the development of novel methods 
(Figure 1.1C). To date, more than 3% of human genes have been associated 
with cancer with approximately 90% of them being somatically mutated and 
20% of them being altered in germline (Simon A. Forbes et al. 2017). In addition 
to those known driver genes, approximately another 1000 genes, usually 
referred to as candidate driver genes, have been implicated in multiple cancer 
types with their experimental validation pending further research (An et al. 
2016). 
The distribution of driver genes, both known and candidate, is not uniform, 
leaving certain cancer types with few drivers and others with hundreds. This 
impacts on the number of samples whose mutations can be associated with 
drivers. When cancer-type-specific cancer genes (collective term for known and 
candidate driver genes) are considered, approximately 30% of cancer samples 
across all cancer types remain without any driver genes altered (Figure 1.1D). 
To remedy this, careful curation of known and candidate driver coupled with 
transfer of knowledge of known cancer genes across cancer types has been 
very recently employed in an effort to refine drivers in a sample-specific manner 
(Sabarinathan et al. 2017). However, even with careful manual annotation of 
cancer genes in individual samples, the number of samples without driver 
genes can be as high as 50% in certain cancer types with the pan-cancer 







Figure 1.1. Recurrence-based driver gene identification. (a) Overview of the 
usage of methods to identify driver genes from the Network of Cancer Genes 
database (An et al. 2016). Pie chart was generated by the manual curation of 
188 mutational screening. Figure adapted from An et al. (An et al. 2016). (b) 




gene “mountains” present in a large proportion of tumours and numerous gene 
“hills” that are mutated infrequently. Figure taken from Wood et al. (Wood et al. 
2007). (c) Down-sampling analysis of significant genes as a function of cohort 
size using MutSig. Genes were stratified by their mutation frequency in 4,742 
cancer patients. Each point is a random subset of the 4,742 patients. Figure 
taken from Lawrence et al. (Lawrence et al. 2014). (d) Percentage of samples 
without known driver genes. Starting from 7,828 cancer samples from TCGA, all 
known and candidate driver genes with putative driver mutations (i.e. damaging, 
truncating and gain-of-function mutations, homozygous deletions, heterozygous 
deletions followed by damaging/truncating mutations in the second allele and 
amplifications) were extracted. Known and candidate driver genes were 
retrieved from the Network of Cancer Genes database (An et al. 2016) and 
associated with a specific cancer type. Full names of cancer types are reported 
in Table 1.1. (e) Stacked bar plot of tumours for 31 cancer types showing driver 
genes per sample. The heatmap represents the number of drivers. In contrast 
to figure 1d where cancer type-specific driver genes were used, in this analysis 
all known driver genes were considered for all samples regardless of which 
cancer type they had been discovered. Figure taken from Sabarinathan et al. 
(Sabarinathan et al. 2017). 
 
 
Table 1.1. Pan-cancer cohort of 7,828 samples from The Cancer Genome Atlas 
consortium. For each cancer type, the number of samples is shown. 
 
Cancer type Abbreviation 
Samples 
(n) 
Adrenocortical Carcinoma ACC 72 
Bladder Urothelial Carcinoma BLCA 232 
Breast Invasive Carcinoma BRCA 954 
Cervical squamous cell carcinoma and 
endocervical adenocarcinoma 
CESC 179 
Cholangiocarcinoma CHOL 35 
Colon adenocarcinoma COAD 255 
Esophageal carcinoma ESCA 179 
Glioblastoma multiforme GBM 143 
Head and Neck squamous cell carcinoma HNSC 491 
Kidney Chromophobe KICH 65 
Kidney renal clear cell carcinoma KIRC 423 
Kidney renal papillary cell carcinoma KIRP 164 
Acute Myeloid Leukemia LAML 169 
Brain Lower Grade Glioma LGG 506 
Liver hepatocellular carcinoma LIHC 187 
Lung adenocarcinoma LUAD 487 
Lung squamous cell carcinoma LUSC 174 
Ovarian serous cystadenocarcinoma OV 341 
Pancreatic adenocarcinoma PAAD 136 







Comparison and evaluation of the above-mentioned prediction algorithms 
and others, carried out by Tokheim and colleagues, highlighted that different 
approaches capture different aspects of the cancer mutational landscape and 
not always predict the same set of driver genes (Tokheim et al. 2016). Not 
surprisingly, the number of driver genes that were predicted by the various 
algorithms in this study ranged from approximately 200 to 2,500. Of note, 
methods directed towards the discovery of rare driver genes, such as 
OncodriveFM, identified a higher number of driver genes, as shown in figure 
1.2A. Moreover, using Cancer Gene Census as reference, known cancer driver 
genes were identified from the output of each algorithm and their frequency 
within the total of predicted genes was calculated (Figure 1.2B). Overall, there 
was a wide range of estimated fractions of known cancer genes across the 
different prediction tools; for certain methods 50% of their predictions were 
found to be known drivers, while for others this fraction was as low as 5%. 
Finally, in a similar analysis An et al. (An et al. 2016) showed high overlap of 
predicted driver genes with known drivers, but poor performance of the same 
methods towards candidate driver genes (Figure 1.2C), denoting an 
optimisation of most methods towards known drivers. Taken together these 
Prostate adenocarcinoma PRAD 409 
Rectum adenocarcinoma READ 110 
Sarcoma SARC 237 
Skin cutaneous melanoma SKCM 357 
Stomach adenocarcinoma STAD 335 
Testicular Germ Cell Tumors TGCT 143 
Thyroid carcinoma THCA 393 
Thymoma THYM 116 
Uterine Corpus Endometrial Carcinoma UCEC 229 
Uterine Carcinosarcoma UCS 53 
Uveal melanoma UVM 79 




observations suggest that current computational approaches aiming to identify 
driver genes reach a consensus gene set for highly recurrent drivers. However, 
they lack resolution for genes that are not frequently mutated in cancer cohorts, 
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Figure 1.2. Comparison of current methods for driver gene identification. (a) 
Outputs of the eight methods evaluated in Tokheim et al. (Tokheim et al. 2016). 
(b) Fraction of predicted driver genes (q ≤ 0.1) for the same methods evaluated 
in a. The Cancer Gene Census (CGC) was downloaded April 1, 2016 (Forbes et 
al. 2015). Raw count of predicted driver genes are indicated on top of each bar. 
(c) Heatmaps showing the overlap between methods identifying known and 
candidate driver genes in the Network of Cancer Genes database (An et al. 
2016). Each box represents the percentage of cancer genes identified with one 
method that are also supported by another. For each method, the total number 
of associated driver genes is reported in brackets. Figures a and b are taken 
from Tokheim et al. (Tokheim et al. 2016) and figure c is taken from An et al. 
(An et al. 2016). 
 
1.3 Mutational landscapes and cancer drivers across tumour types 
Unravelling the evolutionary history of tumours and, in particular, 
identifying the drivers, describing the order of their acquisition and 
understanding their functional relevance, have been the focus of a number of 
studies during the last decade (Garraway and Lander 2013; Kandoth et al. 
2013; Lawrence et al. 2013; Vogelstein et al. 2013; Hiley et al. 2014). 
Dissection of cancer drivers is clinically relevant, as prognosis in some cases is 
linked to the mutational landscape, with certain types of alterations exhibiting 
better or worse prognosis than others. For example, in breast and oesophageal 
cancers amplifications of the oncogene HER2 predicts for a good response to 
the anti-HER2 monoclonal antibody trastuzumab (Bang et al. 2010; Romond et 
al. 2005). In contrast, extensive chromosomal instability has been associated to 
poor prognosis in multiple solid tumours (Carter et al. 2006; Walther, Houlston, 
and Tomlinson 2008) and metastasis (Bakhoum et al. 2018). 
Despite the extraordinary efforts and the massive sequencing projects 
currently underway (International Cancer Genome Consortium et al. 2010), 
there is a number of fundamental questions that remain unanswered. One such 
question is the accurate estimation of the number of drivers required to convert 




1993; Vogelstein et al. 2013). Initial estimates based on age-incidence statistics 
predicted that most cancers carry more than one drivers (Armitage and Doll 
1954). In support of this, common adult epithelial cancers, such as colorectal 
and prostate, require five to seven rate-limiting events (i.e. drivers) to get 
established (Miller 1980; Stratton, Campbell, and Futreal 2009). The central 
premise of this approach is the assumption that all rate-limiting events are 
drivers, and consequently, all driver events are rate-limiting. Both assumptions 
were extensively challenged following evidence showing that selection is more 
important than increased mutation rate in terms of their ability to drive 
tumorigenesis (Tomlinson and Bodmer 1999; Tomlinson, Sasieni, and Bodmer 
2002; Tomlinson, Novelli, and Bodmer 1996; Martincorena et al. 2017). 
Moreover, it is still unclear whether there are any drivers exhibiting 
specificity for a particular cancer type. It has been demonstrated that the 
oncogenic fusion of BCR-ABL is strongly associated with the development of 
chronic myeloid leukaemia (Sawyers 1999). In contrast, lung adenocarcinoma 
shows a more diffused pattern of alterations in several signalling pathways, 
such as the receptor tyrosine kinase/RAS/RAF pathway, rather than recurrent 
alterations in specific genes (Cancer Genome Atlas Research Network 2014). 
Very recently Iranzo and colleagues (Iranzo, Martincorena, and Koonin 2017) 
examined the specificity of drivers using 7,665 samples, spanning 30 cancer 
types, and showed that drivers in several tumours, namely colorectal, 
pancreatic, endometrial, kidney (clear cell), breast, thyroid, and brain, were 
mostly tissue-specific. In contrast, other cancer types, including stomach, 
oesophagus and lung cancers, are characterised by a more diverse and less 




inter-patient heterogeneity at the gene level and proves that the pattern of driver 
accumulation can be vastly different when comparing different cancer types. 
Systematic analysis of pan-cancer cohorts revealed that different cancer 
types also exhibit different mutation frequencies (Kandoth et al. 2013; Lawrence 
et al. 2014; Vogelstein et al. 2013; Stratton, Campbell, and Futreal 2009). 
Mutagen-induced cancers, melanoma or lung cancer for example, tend to 
harbour many more mutations than genomically stable cancers, such as 
leukaemia, thyroid carcinoma, or paediatric tumours (Figure 1.3A). This 
heterogeneity is reflected at the functionally-relevant mutations as well, as 
damaging and truncating mutations are encountered in higher frequencies in 
mutagen-induced tumours (Figure 1.3B and C). In addition to the vast inter-
tumour differences across cancer types, cancer samples exhibit significant 
heterogeneity even within the same tumour type. For instance, lung cancers 
associated with cigarette smoking harbour 10-fold higher mutations when 
compared to lung cancers in non-smoker individuals (Govindan et al. 2012). 
The number of somatic mutations present in tumour samples is tightly linked to 
the number of drivers. Although it would be expected that a high number of 
mutations would generate numerous drivers, recent studies suggested that the 
number of driver point mutations is surprising stable and low across cancer 
types, ranging from one to 10 with a pan-cancer average of seven 
(Sabarinathan et al. 2017). Although, these results are striking, further 
investigation is warranted to determine whether this phenomenon is an intrinsic 
property of cancer genomes or merely an underestimation of drivers due to 






Figure 1.3. Distributions of (a) non-silent, (b) damaging, and (c) truncating 
mutations in 7,828 samples of 31 cancer types. In each plot, cancer types are 
sorted according to the median of the distribution (red diamond). Cancer type-
specific colours are kept the same across all four plots to facilitate comparisons. 




Pan-cancer analysis of driver genes revealed a wide range of cellular 
processes that are typically deregulated in cancer (Kandoth et al. 2013). These 
processes can be broadly classified in 20 categories, shown in Figure 1.4, each 
of which is perturbed at various frequencies in individual tumour types. The 
most frequently mutated gene across all cancer types is TP53, which is altered 
in 42% of samples, with most mutations found in ovarian cancer (95%), lung 
squamous cell carcinoma (80%), head and neck squamous cell carcinoma 
(70%) and colorectal cancer (60%). PIK3CA is the second most frequently 
mutated gene, whose alterations are occurring in >10% of samples, with 
particular enrichment in uterine corpus endometrial carcinoma (50%) and breast 
cancer (30%). Many cancer types carry mutations in genes which are rarely 
found mutated in other cancer types. For instance, FLT3 and NPM1 are 
predominantly altered in acute myeloid leukaemia, APC and KRAS are primarily 
mutated in colorectal cancer and VHL is typically mutated in kidney renal clear 
cell carcinoma (Figure 1.4). It is worth pointing out that a wide range of genes 
belonging to the same category of processes, such as histone modifiers, are 
mutated in low or intermediate frequencies within the same cancer type. This 
highlights that recurrence of gene mutations is not the single most important 
criterion for driver identification and that selection may act in the level of 
deregulated pathways whose perturbations can in turn be used to identify 







Figure 1.4. Pan-cancer identification of driver genes and their association with 
cellular processes. The 127 significantly mutated genes identified in 12 cancer 
types in Kandoth et al. (Kandoth et al. 2013) were broadly classified in 20 
processes. The number in each cell represents the percentages of samples 
mutated in individual cancer types and pan-cancer. The highest percentage in 
each cancer type is in bold. Figure taken from Kandoth et al. (Kandoth et al. 
2013). Full names of cancer types are reported in Table 1.1. 
 
 
1.4 Systems-biology approaches to identify cancer drivers: towards 
personalised medicine and patient-specific driver genes 
The functional heterogeneity of cancer drivers may initially suggest that 




However, this remarkable diversity of cancers does not necessarily imply 
absence of common properties or outcomes. It is well-documented that as 
normal cells progressively evolve to a neoplastic stage, they acquire alterations 
which affect “hallmark” capabilities. These hallmarks of cancer were described 
in 2000 by Hanahan and Weinberg and include sustaining of proliferative 
signalling, evasion of growth suppression, resistance to cell death, activation of 
invasion and metastasis, enabling of replicative immortality and induction of 
angiogenesis (Hanahan and Weinberg 2000). They were later updated to 
include emerging hallmarks, such as deregulation of cellular energetics and 
avoidance of immune destruction (Hanahan and Weinberg 2011). The 
description of these cancer hallmarks was ground-breaking as it was one of the 
first attempts to summarise the knowledge acquired from the inspection of the 
cancer genome and highlighted the fact that, irrespectively of individual 
mutations, there is a handful of key traits of cancer cells that encompass 
tumorigenesis.  
Examining the driver potential of a cancer cell at a process level allows for 
a massive reduction of heterogeneity in individual gene level; from 20,000 
human protein-coding genes to around two thousand pathways (Fabregat et al. 
2016). This reduction is not only one of convenience, but it is based on the 
hypothesis that multiple single mutations can have the same outcome by 
altering different parts of the same biological process. For example, several 
cancer genes directly control the transition from G0 or G1 cell cycle phases to S 
phase, denoting a conversion from a resting cell stage to a replication stage 
(Vogelstein and Kinzler 2004). Another example that pinpoints the reasons why 
focusing on pathways instead of individual genes might reduce the 




TP53. In many cancer types, it was shown that the most common way to disrupt 
TP53 is by point mutations (Olivier, Hollstein, and Hainaut 2010). However, 
cancer cells can also inactivate TP53 by amplification of MDM2 or after infection 
by DNA tumour viruses (Vogelstein and Kinzler 2004). These intriguing 
examples of indirect inactivation of TP53-related processes generated interest 
in the interplay of the multiple components of biological pathways and the 
dissection of their relative contribution in cancer cells.  
Apart from a simple description of pathways whose members are known 
driver genes, a systems-biology approach could assign a likely driver role to 
additional pathway components or even identify new pathways whose individual 
members are rarely mutated in cancer. Studies aiming to materialise on this 
hypothesis were assisted by the construction of comprehensive and accurate 
protein-protein interaction networks. Availability of high-throughput experimental 
data from complex organisms (Giot et al. 2003; Siming Li et al. 2004) enabled 
the first charting of interaction maps that consequently provided an insight into 
complex cellular functions and mechanisms (Jeong et al. 2001; Calvano et al. 
2005).  Furthermore, several computational methods were also developed with 
the objective to predict protein-protein interactions when experimental data 
were lacking or were insufficient to construct comprehensive interaction maps 
(Brown and Jurisica 2005; P. Jonsson et al. 2006). 
Studies examined the properties of known driver genes in the context of 
human protein-protein interaction networks and found that these proteins are 
highly connected and occupy central positions in the interactome (Jonsson and 
Bates 2006; Rambaldi et al. 2008). These findings were interpreted as 
indicative of “fragility” of driver genes and triggered a wider search to identify 




properties, are not strictly related to gene function in a cancer cell. They 
represent general attributes which render these genes different from the rest of 
human genes, and therefore, can be used to discriminate cancer drivers from 
passengers. 
In addition to highly connected and central proteins, cancer genes are 
longer and they encode proteins with a higher number of protein domains on 
average (An et al. 2016; D’Antonio and Ciccarelli 2013). They tend to maintain 
a single copy in the genome (D’Antonio and Ciccarelli 2011; Rambaldi et al. 
2008), and localise in heterochromatic regions of the genome. Moreover, 
evolutionary analysis showed that different types of cancer genes mostly 
appeared two times during evolution, with tumour suppressors originating in 
prokaryotes and oncogenes in metazoans (D’Antonio and Ciccarelli 2011; 
Rambaldi et al. 2008). This indicates that tumorigenesis arises from 
perturbation of either basic, as in the case of “old” tumour suppressor genes, or 
regulatory processes, as in the case of “young” oncogenes. Finally, cancer 
genes are regulated by a significantly higher number of miRNAs as compared 
to the rest of human genes (D’Antonio et al. 2012) and they tend to be 
ubiquitously expressed in normal human tissues (An et al. 2016; D’Antonio and 
Ciccarelli 2013). 
Taken together, the properties of cancer genes described above, highlight 
a form of complexity that has not been taken into consideration when predicting 
cancer driver genes. The decipherment of this complexity can facilitate the 
transition from a gene-centric view of cancer to an integrated system of genes, 
proteins and processes that eventually all contribute to cancer via interactions 




1.5 Redefining cancer drivers: from a few major drivers to numerous 
“mini”-drivers 
As cancer sequencing projects progressively incorporated higher number 
of samples, a striking feature of tumorigenesis became apparent: only a few 
new cancer driver genes have been found to be altered at high frequencies 
(Figure 1.1C). This observation highlighted the possibility that genes mutated in 
low number of samples, even in only one sample, may affect tumorigenesis 
and, in fact, they may act in addition to the few major drivers in cancer cells. 
This hypothesis was first described recently by Castro-Giner and colleagues 
(Castro-Giner, Ratcliffe, and Tomlinson 2015) and goes beyond the classical 
dichotomous description of genes mutated in cancer genomes as drivers and 
passengers. It provides an alternative perspective in which the driver potential 
of genes is continuous and includes a few major drivers and numerous genes 
that contribute in a modest way to tumour progression. These genes were 
designated “mini-drivers” as they represent an attenuated form of drivers and an 
amplified form of passengers.  
A piece of evidence towards supporting this hypothesis was the finding 
that mutations, which previously were thought to be passengers, can be 
deleterious. In particular, McFarland and colleagues showed, using simulations 
and mathematical modelling of missense mutations, that moderately deleterious 
passenger mutations can be detected, and they have a predicted, but 
nevertheless, major effect on cancer progression (McFarland et al. 2013). This 
observation, even though it might have been connected to the overall 
passenger load of the cancer genome, implied that a number of passengers 
can play cumulatively a driver-like role. Although the examples of genes 




of methods to identify them, there are examples of atypical mutations that are 
maintained in the cancer cell population and they seem to represent attenuated 
forms of known driver mutations. Examples of such mutations are changes in 
codons 146 and 117 of KRAS gene, which occur in a few cancer types (Smith 
et al. 2010). In contrast to typical driver mutations in KRAS, which occur in 
codons 12 and 13, these mutations are probably less effective in activating the 
RAS-RAF-MERK-ERK pathway (Smith et al. 2010; Castro-Giner, Ratcliffe, and 
Tomlinson 2015), and even when they co-occur, they are not driven out of 
cancer cell populations as a result of the presence of the main driver. 
The roles of mini-drivers are possibly very broad, ranging from enhancing 
several hallmarks of cancer (Hanahan and Weinberg 2000, 2011) to fine-tuning 
the interplay of multiple drivers present in the same cancer cells. It is not 
inconceivable that “mini-drivers” could act by optimising the effect of major 
drivers, removing their negative side-effects or arise as a result of pressures 
present in the tumour microenvironment. Anecdotic examples for such functions 
exist in colorectal cancer, where the optimal level of WNT pathway is initially 
controlled by mutations in APC and is subsequently optimised by additional 
alterations (e.g. copy number variations) of APC (Segditsas et al. 2009) or 
inactivation of regulators of the pathways, such as SOX9 (Castro-Giner, 
Ratcliffe, and Tomlinson 2015). Although the emergence of driver genes gives 
an overall selective advantage to the cancer cell, it also affects multiple 
pathways some of which may have contradicting functions. Mini-drivers may 
correct these contradicting functions and amplify tumorigenic signals. Finally, 
clonal expansions of tumour cells result in a highly heterogeneous population of 




there could be a co-operative relationship between cancer cells with only drivers 
and cancer cells with drivers and mini-drivers. 
There are several lines of evidence to support the mini-driver hypothesis 
(Bennett et al. 2018). However, examples are fairly limited to modifications of 
functions or specific mutations of known cancer genes. This can be explained 
by the fact that the ability to detect genes, which are mutated in such low 
frequencies, if not in single samples, is controlled by the sample size. It is, 
therefore, of interest to develop new methods to discover rare drivers or mini-
drivers, especially in cancer types in which known drivers are very few and 
present in a relatively small fraction of samples. Detection of mini-drivers will 
allow us to prove or disprove another hypothesis, under which multiple weak 
driver events can substitute a major driver. This is of particular importance to 
certain tumours for which no major driver effect is predicted using the currently 
existing methods (approximately 10% of all cancer samples).  
  
 
1.6 Aims of the thesis 
The main aim of this thesis was to develop a computational algorithm to 
detect cancer driver genes in individual samples. Computational methods 
developed to date are focused on the identification of genes that are subject to 
positive selection and are recurrently altered across cancer samples. In 
contrast, the algorithm presented in this thesis operates within each cancer 
sample and therefore, allows the discovery of patient-specific or rare cancer 
drivers.  
Extending the classical view of distinction between drivers and 




potential is, in fact, continuous with few major drivers and numerous genes 
contributing to different degrees to tumorigenesis. To identify novel and patient-
specific cancer drivers, I employed supervised machine learning and, in 
particular, support vector machines. The development phase of my algorithm is 
documented in the second chapter of this thesis, in which I describe in detail my 
efforts to characterise the distinctive features of known drivers that are 
subsequently used to train a one-class support vector classifier. In the third 
chapter, I describe the application of my algorithm to a cohort of 261 
oesophageal adenocarcinomas (OACs) from the International Cancer Genome 
Consortium (ICGC). This allowed the refinement of the algorithm and the 
identification of its limitations and future extensions. Finally, in the fourth chapter 
of this thesis, I describe the in-depth characterisation and experimental 
validation of the predicted drivers and their utility in patient stratification and 





Chapter 2. Development of one-class systems-level 
support vector machine to predict cancer drivers in 
individual patients 
2.1 Chapter overview 
In this chapter I describe the development of a novel algorithm that 
predicts patient-specific cancer driver genes. The algorithm, which was named 
sysSVM because it utilises systems-level properties of human genes and 
support vector machines, was developed using a pilot cohort of 18 OACs from 
ICGC. After introducing the mathematical framework and the features of support 
vector machines, I describe the algorithm itself, the preliminary predictions in 
the pilot cohort and their relevance for OAC, as well as its comparison with 




The increasing amount of data produced by high-throughput sequencing 
and imaging platforms require the development of new computational 
approaches for the exploration of the complex landscape of biological systems. 
Integrations of data across platforms can be facilitated by machine learning 
algorithms, which are capable of extracting high-dimensional patterns (Li, Wu, 
and Ngom 2016). These patterns are rules that describe the data in the form of 
mathematical functions. Machine learning systems can learn these patterns on 
their own by close examination of large datasets, where the patterns of interest 
are present. The process of learning begins with a set of observations, which 




then used to make decisions based on their similarity to unseen data. As a 
data-driven approach, machine learning is dependent on large and well-
structured trainings sets to be able to predict outcomes with confidence. 
Machine learning is a mathematical modelling process that uses equations 
(models) with carefully selected terms (parameters) to make predictions or 
calculate probabilities of possible outcomes, based on a n-dimensional vector of 
variables (features) that represent the training set. These parameters are 
selected via a trial-and-error process (optimisation), during which their values 
are selected based on the features of the training set. 
Different machine learning algorithms have been successfully used in 
biological research to discover biomarkers and subgroups of patients from gene 
expression data (Ramaswamy et al. 2001; Khan et al. 2001; Tibshirani et al. 
2002; Golub et al. 1999; Pal et al. 2007). Additionally, they have recently been 
applied in translational research to extract information from imaging 
technologies and improve diagnostic and prognostic accuracy (Gillies, Kinahan, 
and Hricak 2016). In general, machine learning algorithms can be used to 
estimate a continuous value, for example the probability of a patient to relapse, 
or for classification purposes, i.e. to assign observations to pre-defined 
categories. 
Machine learning algorithms can be broadly divided in unsupervised, 
semi-supervised and supervised. Unsupervised methods are used to detect 
patterns in the data when no ground truth or known observations related to 
these patterns are available (Hastie, Tibshirani, and Friedman 2009). 
Unsupervised tasks can be further categorised into two groups: i) clustering, in 
which the inherent grouping of the data is of interest, and ii) association 




popular clustering algorithms belong to unsupervised methods, with most 
prominent examples being hierarchical and k-means clustering (Rokach and 
Maimon 2005).  
Semi-supervised algorithms are applicable when data of known examples 
are limited and disproportionally less than the unknown observations. Many 
real-world applications of machine learning belong to this category, as it is 
usually time consuming and expensive to label data using expert knowledge 
(Chawla and Karakoulas 2005; Blum and Mitchell 1998).  
Finally, the majority of applications of machine learning use supervised 
learning, in which mathematical models are trained using labelled observations 
and they are subsequently used to categorise unlabelled data (Kotsiantis 2007). 
In many classification problems pre-defined rules do not exist and therefore, 
rules should be derived by a set of observations, which are considered to be 
representative of the objects that will be consequently classified. In the simplest 
scenario, there are two opposing classes of observations that are used during 
training, true positives and true negatives, but it is also possible to build 
supervised classifiers that derive rules from? additional classes of observations 
(Tsoumakas, Tsoumakas, and Katakis 2007). Often the type of function used to 
build a classifier is chosen beforehand and its parameters are optimised during 
training. Examples of these functions are linear/logistic regression (Freedman 
2009), neural networks (Hopfield 1982) and support vector machines (Cortes 
and Vapnik 1995). The optimisation phase is usually an iterative process, 
during which multiple subsets of the labelled data are used and the robustness 
of various parameters across different sets of training observations is assessed. 
The choice of the most suitable classification algorithm is not a trivial 




therefore, no single algorithm works best for all classification problems. The 
(usually limited) set of training observations might not resemble in full the true 
positive and negative observations in real life. In this case, the distributions of 
their features are not sufficiently separable in order to extract classification rules 
with high confidence. This issue is of particular importance for data derived from 
biological experiments, which are usually limited and noisy. Consequently, the 
optimal classifier has to be flexible enough to fit the data, but also robust 
enough to exclude random and uncharacteristic noise (Geman, Bienenstock, 
and Doursat 1992).  
A well-known issue in the selection of classification algorithms is the bias-
variance dilemma (Geman, Bienenstock, and Doursat 1992). This states that 
there is a trade-off between the bias and variance of a classification algorithm 
that needs to be considered and optimised during training. In a case where 
there are multiple training sets for a classification problem, which are equally 
good, variance refers to the amount by which the optimal function of the 
classifier will change when different training sets are used. Hence, variance 
reflects the adaptability of the algorithm to different training sets. On the other 
hand, bias refers to the error that is introduced by the algorithm during 
prediction and reflects its ability to model real life (Brighton and Gigerenzer 
2015). A flexible classification algorithm is highly adaptable and therefore, has 
low bias, but, if it is too flexible, it will model the training observations too 
closely. This problem is known as overfitting. Overfitted classification functions 
achieve high performance in very specific training sets, but their generalisation 
performance is very poor. The issue of overfitting is also affected by the number 
of features and the number of observations in the training set. Small training 




known as the curse of dimensionality (Cabestany et al. 2005). The most 
common solution to address the curse of dimensionality is feature selection, a 
process which retains only the most informative features for a given training set 
(Pudil, Novovieova, and Kittler 1994; Jain and Zongker 1997). 
Overall, although various classification algorithms and optimisation 
techniques are available, it is often difficult to derive classification rules that 
describe the training observations completely. Even the best classification 
algorithm for a given problem might leave regions of the feature space 
inadequately described. The inclusion of additional (and possibly suboptimal) 
classifiers can often help by capturing valuable information that is neglected by 
the single best classifier (Kuncheva 2004). In the rest of this chapter, after a 
short introduction of support vector machines and one-class classifiers, I 
describe the development of a meta-classifier, named sysSVM, which combines 
four classifiers using four different mathematical functions to predict cancer 
driver genes in individual patients. 
 
 
2.2.1 Support Vector Machines 
Support Vector Machines (SVMs) refer to a family of supervised machine 
learning algorithms that since their initial development in the 1990s (Cortes and 
Vapnik 1995) have been used for classification in a variety of tasks (Wang et al. 
2010; Chen et al. 2009; Li et al. 2003). SVMs try to address and generalise the 
problem of separating observations using a decision boundary in a high-
dimensional space (James 2013) (Figure 2.1A). The separation boundary can 
then be used to classify unknown observations (Figure 2.1B). In their simplest 




point (Figure 2.1C). In two dimensions it is a line and, in general, in a p-
dimensional space, the separation hyperplane is a subspace of p-1 dimensions 
(hyperplane; Figure 2.1D) and its mathematical definition follows the equation: 
 
𝛽0 + 𝛽1𝛸1 + 𝛽2𝛸2 = 0      (2.1) 
 
with parameters β0, β1 and β2. Equation 2.1 describes a line and it can be 
extended to p-dimensional problems by adding the relevant parameters as 
follows: 
 
𝛽0 + 𝛽1𝛸1 + 𝛽2𝛸2 + 𝛽3𝛸3 + ⋯ + 𝛽𝑝𝛸𝑝 = 0   (2.2) 
 
For a given point X = (X1, X2, X3, …, Xp)T, if X satisfies 2.2 then X lies on the 
separation hyperplane. It is therefore easily conceivable that observations that 
are located in either side of the hyperplane will satisfy one of the following two 
conditions: 
 
𝛽0 + 𝛽1𝛸1 + 𝛽2𝛸2 + 𝛽3𝛸3 + ⋯ + 𝛽𝑝𝛸𝑝 > 0     (2.3) 
 
𝛽0 + 𝛽1𝛸1 + 𝛽2𝛸2 + 𝛽3𝛸3 + ⋯ + 𝛽𝑝𝛸𝑝 < 0   (2.4) 
 
and therefore, the side in which each observation lies can be determined by 
calculating the sign of 2.2. 
If such a hyperplane exists, classification problems can be solved in a very 




equations 2.5 and 2.6 below), to observations with a positive or negative sign of 
equation 2.2, respectively (Schölkopf and Smola 2002). In fact, there will be an 
infinite number of hyperplanes that separate a given set of data (Figure 2.1E). 
This is because minor shifts of a hyperplane, where shifts can refer to rotations 
or small displacements, can lead to new hyperplanes. Therefore, selection 
criteria should be established in order to select the optimal hyperplane. A 
natural choice would be the hyperplane that is equally far from all classes of 
observations (i.e. positive and negative), and this is the maximal margin 
hyperplane (Figure 2.1F). Margin (M) refers to the minimum distance of the 
hyperplane from the training observations and one of the main objectives during 
training and parameter optimisation is to maximise M such that: 
 
𝛽0 + 𝛽1𝛸1 + 𝛽2𝛸2 + 𝛽3𝛸3 + ⋯ +  𝛽𝑝𝛸𝑝 > 0 if yi = +1               (2.5) 
   
𝛽0 +  𝛽1𝛸1 +  𝛽2𝛸2 + 𝛽3𝛸3 + ⋯ + 𝛽𝑝𝛸𝑝 < 0 if yi = -1                 (2.6) 
 
𝑦𝑖(𝛽0 + 𝛽1𝛸𝑖1 + 𝛽2𝛸𝑖2 + 𝛽3𝛸𝑖3 + ⋯ + 𝛽𝑝𝛸𝑖𝑝)   𝑀   𝑖 = 1, … , 𝑛   (2.7) 
 
This optimisation problem in equation 2.7 defines the constraint that guarantees 
that all observations reside in the correct side of the hyperplane with equal or 
greater distance than M.  
In many cases, it is desirable to deviate from such a strict definition of the 
constraint in equation 2.7 to avoid overfitting the hyperplane. An overfitted 
hyperplane describes too closely a given set of data and lacks the ability to be 
generalised and accurately predict future data (James 2013). A relaxed 




the wrong side of the hyperplane, accounting for natural variability in the data 
and providing robustness to individual observations (Figure 2.1G). This is the 
soft margin hyperplane (Figure 2.1H) and its optimisation is described by the 
following equations: 
 
𝑦𝑖(𝛽0 + 𝛽1𝛸1 + 𝛽2𝛸2 + ⋯ + 𝛽𝑝𝛸𝑝)   𝑀 (1 − 𝑒1)  𝑖 = 1, … , 𝑛      (2.7) 
 
𝑒1 0, ∑ 𝑒1
𝑛
𝑖=0  𝐶               (2.8) 
 
where e allows for training observations to be on the wrong side of the 
hyperplane and C is a non-negative tuning parameter (Chapelle and Bousquet 
2002). The role of parameter C is to control the overall severity of the constraint 
in equation 2.7, as it bounds the sum of e. It is optimised during cross-validation 
where the training set is split into training and test sets and multiple values of C 
are tested as upper bounds of 2.8. Small values of C (e.g. close to zero) define 
narrow margins that are rarely violated by training observations and, therefore, 
fit the given dataset closely. The higher the value of C, the softer the margin, 
thereby allowing for higher values of e (2.8) and more training observations to 
reside on the wrong side of the separation boundary. The constraint in equation 
2.7, owing to the presence of e, has the property of being sensitive only to the 
observations that are either located in the margin or those that violate the 
hyperplane. These observations are called support vectors. This is a unique 
feature of SVMs as observations that are on the correct side of the separation 





The boundaries described in the introduction of this chapter are all linear 
but, in many cases when biological data are concerned, a linear separation 
hyperplane does not exist (Figure 2.1I). These cases are often referred to as 
non-separable and a class of non-linear (or very soft linear) boundaries are 
employed instead (Suykens 2001). When the observations of interest are non-
separable, the constraint in equation 2.7 has no solution with M > 0. In these 
cases, SVMs employ helper functions (kernels) (Schölkopf and Smola 2002) in 
order to enlarge the feature space and solve 2.7 (Figure 2.1J-L). For instance, 
instead of trying to separate a given set of observations in a p-dimensional 
space, one could add quadratic versions of the features. This enlargement of 
the feature space might make positive and negative observations separable. 
There are multiple kernels of particular interest in this thesis that are widely 
used in literature. As explained in detail below, four kernels are used in 
sysSVM, namely linear, polynomial, radial and sigmoid. These four kernels are 
combined in a meta-classifier, in an effort to alleviate misclassifications by 
individual kernels and to prioritise genes that are predicted as positive by 
multiple kernels. 











Figure 2.1. An illustration of the main characteristics of support vector 
machines (SVM). Figure taken from (Noble 2006). (a) mRNA expression level of 
ZYX and MARCKSL1 in lymphoblastic leukaemia (ALL; red) and acute myeloid 
leukaemia (AML; green) patients. The main task of SVM is to assign a label 
(ALL or AML) to the unknown observation (blue). (b) A separating boundary 
(hyperplane) is drawn between ALL and AML. Based on this hyperplane the 
label of the unknown observation is “ALL”. (c) A hyperplane in one dimension. It 
is shown as a black point. (d) A hyperplane in three dimensions. (e) Many 
possible hyperplanes in two dimensions. (f) The maximum-margin hyperplane. 
The support vectors are circled. (g) Same data set as in a with one additional 
ALL patient. This patient is considered error or outlier because the expression 
profile resembles that of AML. (h) A soft margin separation hyperplane. (i) A 
non-separable one-dimension data set. (j) Separating data in i by applying a 
kernel that adds another variable, the square of expression (y axis) in the data 
set. (k) A non-linear separation hyperplane. (l) A non-linear separation 
hyperplane which potentially overfits the data. 
 
 
2.2.2 One-class classification 
Although in many cases classification problems can be described as 
binary (or multi-categorical) problems of positive and negative observations, 
there are cases for which only one class of observations is available. In such 
cases, the defined problem is the description of the target set of observations 
and the detection of all new observations that resemble the target set. 
Alternatively, the problem can also be defined as identifying all observations 
that are not similar with the target set. In a one-class classification framework 
both cases are identical. 
In literature, one-class classification has been described using numerous 
terms. The term “one-class classification” was first described in Moya et al. 
(Moya, Koch, and Hostetler 1993) but later, owing to the many applications of 
the method, it was also described as “outlier detection” (Ritter and Gallegos 
1997) and “novelty detection” (Bishop 1994). The first application of one-class 




generalisation of neural networks, with particular emphasis on minimising the 
size of the decision boundary in order to produce small classification mapping 
errors (Moya, Koch, and Hostetler 1993). As classifiers provide reliable 
estimates for unknown observations resembling the training set, extrapolations 
to sparse regions of the feature space are of low quality (Roberts, Penny, and 
Pillot 1996). In such cases, outlier detection and elimination should first be used 
before classification and prediction. 
Based on their statistical foundation, one-class algorithms can be broadly 
divided in i) proximity-based, ii) parametric methods, and iii) semi-parametric 
methods (Hodge and Austin 2004). Proximity-based techniques, such as k-
Nearest Neighbour (k-NN), are easier to implement, but their computational 
complexity increases proportionally to the dimensions of the data. Therefore, 
they need extensive optimisation. Parametric methods model the density of the 
data in the feature space and their complexity grows with the complexity of the 
model, rather than the size of the data. A well-known algorithm in this category 
is the Minimum Volume Ellipsoid estimation (MVE) (Rousseeuw 1985), which 
calculates the smallest ellipsoid volume around the majority of the data 
distribution model, representing the high-density areas of the feature space. 
Finally, semi-parametric methods apply local kernel models, instead of a single 
distribution model, to the whole data set and identify the outliers as 
observations located in regions of low density (Hodge and Austin 2004). One-
class support vector machines belong to this last category as they project the 





2.3 Algorithm development 
2.3.1 Selection of predictive features of known driver genes 
In chapter 1, I introduced numerous features of known driver genes that 
are collectively referred to as systems-level properties (D’Antonio and Ciccarelli 
2013; An et al. 2016; Rambaldi et al. 2008; D’Antonio and Ciccarelli 2011; 
Domazet-Lošo and Tautz 2010; Jonsson et al. 2006). The objective of this part 
of my thesis was to survey which of the systems-level properties can serve as 
predictors of novel driver genes and subsequently use them to develop a c-
lassifier. To this end, I hypothesised that the best features would be those that 
exhibit statistically significant difference between known driver genes and the 
rest of human genes.  
Starting from a total of 19,014 human protein-coding genes (see 
methods), I categorised 518 genes as known drivers according to the Cancer 
Gene Census (Forbes et al. 2017) and the remaining 18,496 comprised the rest 
of human genes. For each group, I annotated the corresponding system-level 
properties, as previously described (An et al. 2016), and broadly classified them 
in one of the following seven categories: 
i) Gene duplicability and evolutionary origin: number of copies that a 
gene maintained in the genome and the node of the tree of life that 
the oldest ortholog of a gene has been found in. Additionally, I 
collected data on whole genome duplication events from recent 
literature (Makino, McLysaght, and Kawata 2013) 
ii) Gene and protein expression: the number of human tissues that a 
gene was expressed in according to the Genotype-Tissue Expression 




iii) Protein-protein and miRNA-target interactions: properties that I 
derived from the human protein-protein interaction network, such as 
degree and betweenness, and the number of miRNAs interacting with 
a gene (Keshava Prasad et al. 2009; Ruepp et al. 2009; Milacic et al. 
2012). I also assessed the membership of each gene to protein 
complexes 
iv) Number of protein domains: protein domains in each gene as 
reported in the Conserved Domains Database (CDD) database 
(Marchler-Bauer et al. 2011) 
v) Chromatin accessibility: data for the chromatin compartment that 
each gene was located in from Mutation Significance database 
(MutSigDB; https://software.broadinstitute.org/gsea/msigdb/) 
vi) Replication timing: cell-cycle phase (e.g. early, intermediate or late) at 
which a gene was replicated 
vii) Gene length (D’Antonio and Ciccarelli 2013) 
Recent reports suggested that the chromatin compartment, in which a 
gene is located, and its replication timing during the cell cycle contribute to 
cancer mutational landscapes, due to restrictions to the accessibility of repairing 
enzymes and the depletion of the nucleotide pool of the cell, respectively 
(Lawrence et al. 2013). These properties have been previously implicated in 
algorithms for cancer driver discovery (Lawrence et al. 2013; Tokheim et al. 
2016).  
I next assessed the missing data for each property, and I excluded 
properties with no available data for a significant fraction of human genes from 
downstream analysis. I found that the systems-level property with the highest 




not available for 70% of human genes (Figure 2.2A). The majority of human 
genes had incomplete data in one or two systems-level properties (Figure 
2.2B), while only a very small proportion had missing data in more than two 
properties. To account for this, I performed median imputation for continuous 
properties and mode imputation for the categorical ones (Enders 2010). 
Specifically, for each property median or mode values were calculated for 
known drivers and the rest of human genes. All missing values were replaced 








Figure 2.2. Missing data in systems-level properties of human genes as 
percentage (a) and pattern of combinations of properties (b). 
 
 
I separately tested the distribution of each property in known drivers 
against the rest of human genes and I only considered properties with 
significant difference between the two groups for the development of the 
classifier. In accordance to previous studies (An et al. 2016), these properties 




exception being the replication time, which was excluded from downstream 
analysis (Figure 2.3). 
During the development of sysSVM, I decomposed systems-level 
properties to multiple features and included several of them in the final 
classifier, as both continuous and binary features. For example, I converted 
interactions to 4 features, namely degree, betweenness, hub and central 
protein. Hubs were genes whose proteins belonged to the top 25% of the most 
connected proteins in the human protein-protein interaction network as derived 
from the degree distribution. Similarly, I considered as central proteins those in 
the top 25th percentile of the betweenness distribution. Although, the continuous 
and the binary variants of the same feature carried the same type of information 
for the classifier, I reasoned that the binary features supplied a qualitative 
threshold of the distributions of the corresponding continuous variables, which 
could not be accurately captured when only continuous variables were used. 
Additionally, I converted single multi-level categorical properties to multiple 
binary ones. The final set of systems-level features was comprised of 24 
properties (Table 2.1). These were complemented by molecular features that I 
derived from sequencing data of individual cancer samples. In particular, these 
molecular features included somatic alterations with predicted damaging effect 
on the protein function, i.e. truncating and non-truncating damaging mutations, 
gain-of-function mutations, gene gains and losses (see Methods). In total, 7 
molecular features were additionally included in sysSVM (Table 2.1 and 







Figure 2.3. Systems-level properties. Distribution of degree and betweenness 
in the human protein-protein interaction network, the protein length, the number 
of protein domains, the percentage of genes maintaining a single or multiple 
copies in the genome, the chromatin compartment (measured from Hi-C 
experiment) and the number of mi-RNAs regulating the function of each gene 
were compared between known cancer drivers and the rest of human genes. 
For the comparison of gene copies, genes were also divided by mode of 
inheritance. Known cancer driver genes (n=505) were retrieved from the Cancer 
Gene Census (Tate et al. 2018) and their associated systems-level properties 
from the Network of Cancer Genes database (An et al. 2016). These properties 
were also annotated for the rest of human genes. P-values were estimated 
using a Wilcoxon Rank Sum test for all comparisons except for the duplication 







Table 2.1. Summary of features used during the development of sysSVM. For each feature, the type and description are reported. In 
total, 31 features were used in sysSVM to predict cancer genes in the pilot cohort. 
Features N Type Description 
Gene length 1. Systems-level (continuous) 
Length of the coding sequence (longest 
RefSeq) 
Gene duplicability 2. Systems-level (categorical) ≥1 gene duplicate ≥60% protein coverage  
Ohnolog 3. Systems-level (categorical) ≥1 duplicate from whole genome duplication  
Number of protein domains 4. Systems-level (continuous) 
Total number of CDD domains (longest 
RefSeq) 
Protein degree 5. Systems-level (continuous) Number of connections in the PIN 
Protein betweenness 6. Systems-level (continuous) Centrality in the PIN 
Hub 7. Systems-level (categorical) Top 25% most connected proteins (≥23) 
Central protein 8. Systems-level (categorical) Top 25% most central proteins (≥6105) 
Old gene 9. Systems-level (categorical) Origin before metazoans 
Origin in prokaryotes 10. Systems-level (categorical) Oldest ortholog found in prokaryotes 
Origin in single cell eukaryotes 11. Systems-level (categorical) Oldest ortholog found in eukaryotes 
Origin in opisthokonts 12. Systems-level (categorical) Oldest ortholog found in opisthokonts 
Origin in metazoans 13. Systems-level (categorical) Oldest ortholog found in metazoans 
Origin in vertebrates 14. Systems-level (categorical) Oldest ortholog found in vertebrates 
Origin in mammals 15. Systems-level (categorical) Oldest ortholog found in mammals 
Origin in primates 16. Systems-level (categorical) Oldest ortholog found in primates 
Ubiquitously expressed 17. Systems-level (categorical) Expressed in > 28/30 tissues (GTEx 4) 
Medium expressed 18. Systems-level (categorical) Expressed in 3-28 tissues (GTEx 4) 
Selectively expressed   19. Systems-level (categorical) Expressed in 2-3 tissues (GTEx 4) 
Specifically expressed 20. Systems-level (categorical) Expressed in 1/30 tissues (GTEx 4) 
Not expressed 21. Systems-level (categorical) Expressed in 0/30 tissues (GTEx 4) 
Number of tissues 22. Systems-level (continuous) 
Number of tissues where the gene is 
expressed (GTEx 4) 






Chromatin state 24. Systems-level (continuous) HiC statistic (Lieberman-Aiden Science 2009)   
Exonic SNVs and Indels 1. Molecular (continuous) Silent and non-silent mutations (ANNOVAR) 
Truncating mutations 2. Molecular (continuous) 




3. Molecular (continuous) 
Damaging non-frameshift, nonsynonymous, 
splicing alterations (dbNSFP) 
Gain of function mutations 4. Molecular (continuous) Gain of function (OncoDriveClust) 
Gene copy number 5. Molecular (continuous) Segment mean from ASCAT 
Gene loss 6. Molecular (categorical) Copy number 0 or 1 
Gene gain 7. Molecular (categorical) Copy number >=4 






2.3.2 Description of the pilot sample cohort 
As a pilot study to develop the classifier, I used a cohort of 18 OACs from 
ICGC (hereafter referred to as pilot cohort) for which somatic mutations and 
copy number variation data were available. The low number of known drivers in 
oesophageal adenocarcinoma in combination with the disappointing results in 
most recent clinical trials rendered this cancer type a particularly pertinent 
sample cohort for the development of the sysSVM method. However, the aim 
was to develop a method which was not cancer type-specific, but easily 
applicable to multiple cancer types. As it will become apparent in the following 
paragraphs, the only cancer type-specific part of my method was the 
construction of the training set, and by altering it, the method can be applied to 
any cancer type. 
The pilot cohort was comprised of 16 male and two female patients, 12 of 
which had no prior treatment, while six were of unknown treatment status. 
Fourteen of the specimens (77.8%) were of distal oesophagus (siewert type 1 & 
2) with the remaining four being either of subcardial stomach (siewert type 3) or 
of unknown origin. The average age at diagnosis was 69.7 years. One patient 
was diagnosed with distant metastasis and seven patients were diagnosed with 
metastasis to regional lymph nodes. A summary of all the clinical characteristics 






Table 2.2. Summary of the clinical characteristics of the pilot cohort (18 OAC 
samples). Percentages that do not sum up to 100% within each category 
denote missing data. Data were collected from the ICGC. Gastro-oesophageal 
junction (GOJ) types are reported according to Siewert classification. 
 
Mean age at diagnosis (stDev) 69.7 (10.25) 
Sex (% male) 88.8 
Treatment (%) 
 
No treatment 66.7 
Unknown 33.3 
Tumour location (%) 
 
GOJ Type 1 50 
GOJ Type 2 27.8 
GOJ Type 3 11.1 
Primary tumour (%) 
 
Stage I 27.8 
Stage II 11.1 
Stage III 38.9 
Stage IV 0.6 
Node positive (%) 44.4 
Metastasis (%) 0.6 
 
 
2.3.3 Systems-level one-class support vector machine (sysSVM) 
Classical approaches for the development of supervised classifiers have 
relied on the presence of both positive and negative observations during model 
training. In this case this was not feasible, as negative observations, i.e. a set of 
confirmed non-driver (passenger) genes, could not be defined. In fact, even if a 
set of negative observations existed (see below), it would not have been 




of the training set for model training. The discovery of genes exhibiting such 
patterns was one of the main aims of this thesis, as mentioned previously. Of 
note, a handful of possible non-driver genes have been described in recent 
literature, mainly showing that their function was irrelevant to tumorigenesis, 
such as in the case of olfactory receptors (Lawrence et al. 2013). The usage of 
these genes as negative observations would have led to an erroneous decision 
boundary, as their properties would not have been representative of those of all 
passenger genes. As a result, many genes whose properties would have not 
resemble those of the known cancer genes would have been predicted as 
cancer genes by the classifier, because the decision boundary was built to 
discriminate against the few genes in the non-representative negative set 
(Figure 2.4). This phenomenon was observed in the initial stages of my project, 









Figure 2.4. Schematic representation of two-class classification decision 
boundary formation in support vector machines. Non-representative set of true 
negatives can lead to erroneous decision boundary and inflation of false 
positives in the predictions. 
 
 
To address the discovery of cancer genes using only positive observations 
in the training set, I developed a supervised classifier using a previously 
developed novelty detection algorithm, which was based on one-class support 
vector machines (Schölkopf et al. 2001). Since the method was based primarily 
on systems-level properties, it was named systems-level support vector 
machine (sysSVM). SysSVM was developed in R using the e1071 R package. 
SysSVM initiated by constructing the training and prediction set for a given 
cohort. The training set, upon which the formation of the decision boundary was 
based, was comprised of all known cancer genes with damaging alterations in 




total 518 known cancer genes from the Cancer Gene Census (Forbes et al. 
2017). Of those, I annotated 491 (see Methods) with damaging alterations in 
one of the following 6 categories (see Methods): 
1. Truncating mutations (stopgain, stoploss and frameshift 
alterations) 
2. Non-truncating damaging mutations (damaging non-frameshift, 
nonsynonymous, splicing alterations) 
3. Gain-of-function mutations 
4. Homozygous deletions (Copy number = 0) 
5. Heterozygous deletions with truncating or non-truncating 
mutations in the second allele 
6. Copy number gains (Copy number  4) 
 
The final size of the training set was comprised of 3,330 positive 
observations (i.e. known cancer genes harbouring damaging alterations). 
Consistent with the excess of genomic amplifications in oesophageal 
adenocarcinoma (Secrier et al. 2016; Nones et al. 2014), the vast majority of 
the genes (98%) in the training set were amplified (Figure 2.5A). Of the 
remaining 2% of the genes, only 1.5% were mutated and 0.5% were 
homozygously deleted. As expected, most of the known drivers were found 
altered in a large number of OACs. On average, each known driver was altered 
in 40% of samples, with a median of 7.00 and a mean of 6.78 samples (Figure 
2.5B). Although the over-representation of one of the molecular features, in this 
case amplifications, makes the development and interpretation of the classifier 
challenging, the relative weight of each feature in the final model can be 




property can be dissected (see below). Nevertheless, the number of systems-
level properties is two times higher than that of molecular features, and their 
contribution is expected to be significant in the final classifier, regardless of the 
overrepresentation of amplifications. 
 
 
Figure 2.5. Genes in the training set of the pilot cohort. The total size of the 
training set was 3,330 genes (same gene in different samples counted multiple 
times), corresponding to 540 unique genes. (a) Distribution of alterations in the 
training set for redundant (left panel) and unique genes (right panel). (b) 
Distribution of the number of samples in which each gene was found altered. 
 
 
The prediction set was comprised of any gene with damaging alterations, 




unique genes, which corresponded to 121,649 redundant genes (i.e. altered 
genes in samples). Similar to the training set, I found that the predominant type 
of alteration was copy number gain and approximately 99% of genes in the 
prediction set belonged to this category. To account for the different numerical 
ranges, I scaled all continuous features (Table 2.1), in both training and 
prediction sets combined, to zero mean and unit variance using the following 
formula: 
 
𝑥𝑖 =  
𝑥𝑖−𝑚𝑒𝑎𝑛(𝑥)
𝜎(𝑥)
                                       (3.9) 
 
where x is the vector of values of feature i, which ranges from 1 to 12 for the 12 
continuous features.  
As already mentioned, sysSVM operates as a meta-classifier, 
incorporating the results of linear, radial, polynomial and sigmoid kernels. I 
optimised the parameters of each kernel using grid search. Depending on the 
kernel, I considered the following parameters: 
 
1) nu (all kernels), representing the upper bound on the fraction of 
outliers (i.e. training genes left outside the estimated region) and the 
lower bound on the fraction of support vectors. Values for nu range from 
0.05 to 0.9 with a step of 0.05 for a total of 18 values; 
2) gamma (radial, sigmoid, and polynomial kernels), accounting for the 
influence of individual training points in the final model and defined as: 
gamma = 2x, where x ∈ {-7, -6, …, 4}  




3) degree (polynomial kernel), representing the degree of the polynomial 
kernel function with three possible values (3, 4, 9);  
The grid search resulted in 18 possible combinations of parameters for the 
linear kernel, 216 combinations for the radial and sigmoid kernels and 648 
combinations for the polynomial kernel. For each combination of parameters, 
sysSVM performed a three-fold cross validation with 100 iterations. At each 
iteration, the genes of the training set were randomly split into three sub-sets, 
two of which (approximately 326 genes for the pilot cohort) were used for the 
training and the third (approximately 165 genes for the pilot cohort) as a test 
set. After the training was completed, the prediction was performed on the test 
set and the sensitivity of the model was computed for that iteration. At the end 
of the cross-validation, the distribution of sensitivity across all iterations was 
derived for each combination of parameters. The least variant (variance of 
sensitivity) model among the top five most sensitive models (considering the 
median sensitivity) in each kernel was chosen as the best model for that kernel. 
The resulting four best models were then trained on the whole training set and 
subsequently used to predict novel driver genes in the prediction set. A 
schematic workflow of the optimization of sysSVM, the selection of the best 







Figure 2.6. A schematic workflow of parameter optimisation using grid search in 
sysSVM. For a given model (M), kernel (k) and a set of parameters (p), sysSVM 
performs two steps. First, the genes in the training set are divided in two thirds 
which are used for training and one third which is used for prediction. Second, a 
confusion matrix is then calculated (an example is showed using 200 
observations) to derive sensitivity. It is noted that sysSVM uses one-class 
support vector machines in which the true negative observations are absent 
(“Actual NO” in the schematic). Steps 1 and 2 are repeated 100 times and the 







2.3.4 Best sysSVM models in the OAC pilot cohort 
In a two-class classification setting, in which true negative observations 
existed, the best models would have been selected using sensitivity, specificity 
and other true negative-based measures (Fawcett 2006). Since I developed 
SysSVM based on one-class classification, all of the above-mentioned metrics, 
except for sensitivity, could not be computed. Therefore, I implemented a 
stability measure (variance of sensitivity) as an additional metric of the 
performance of each model during cross-validation. Apart from the polynomial 
kernel, models of intermediate sensitivity (ranges from 0 to 1) exhibited overall 
higher variance and models with the highest or lowest sensitivity were relatively 
stable (Figure 2.7). The selected models achieved cross-validation sensitivity 
higher than 85%, meaning that when novel cancer driver genes were 
encountered by the models, they were classified as drivers in 85% of the cases. 
This reflected the fact that, in the absence of true negatives, sensitivity was 
measured as the ratio of the number of positive predictions by sysSVM over the 
total size of the test set. The parameters of the best models in the pilot cohort 







Figure 2.7. Mean sensitivity and variance for the four kernels in the pilot cohort. 
For each kernel, the mean sensitivity across all 100 iterations from the grid 
search is plotted as a function of variance. The best set of parameters was 




All four best models had a nu value of 0.05, which is the minimum of the 
tested nu range. Hence, at least 95% of the training set was considered during 
the training phase. Higher values of nu would have led to the exclusion of 
training observations and it would indicate higher dispersion of known cancer 




concentrated in a particular part of the tested range and the degree parameter 
was only applicable in the polynomial kernel. The number of support vectors 
(i.e. training observations used for the formation of the decision boundary) was 
comparable across the four kernels. The sigmoid kernel had the lowest number 
(167 genes), polynomial the highest (211 genes), and linear and radial had 181 
and 172 genes, respectively. A unique feature of SVMs is that the weights of 
the decision function are defined by only a small subset of the training 
observations, the support vectors. The magnitude of the decision value can 
approximate how confident the model is for the classification of a certain 
observation. Therefore, positive values belong to positive predictions and 
negative values to negative predictions. Decision values can be perceived as 
the distance from the decision boundary. In the pilot cohort, the radial kernel 
had the lowest average decision value of the training observations (4.981) and 
the polynomial kernel had the highest (578.98), with linear and sigmoid having 
54.78 and 100.35, respectively (Figure 2.8). As expected from the high 
sensitivity of the selected models, very few genes had negative decision values. 
SysSVM utilised the decision values of individual kernels to create a weighted 








Figure 2.8. Distribution of the decision values of the best models used for 
prediction in the pilot cohort. 
 
 
To examine which features carry the highest weight in each kernel, I 
employed recursive feature elimination (RFE) (Guyon et al. 2002). RFE is an 
iterative process in which the following three steps are repeated until all 
sysSVM features have been eliminated: 
1. Train the classifier 
2. Compute the ranking criterion 





For each kernel, I used the selected parameters from cross-validation to 
train the classifier and computed the weight vector (w) by multiplying the 
sysSVM coefficients with the support vectors. Then, I defined the ranking 
criterion as w2 and extracted the feature with the smallest w2 value. Since I 
developed sysSVM based on 31 features, RFE run 30 iterations per kernel to 
estimate the ranks of the features. Copy number gains was the feature with the 
highest weight (rank one in three out of four kernels) and the number of gain-of-
function mutations was the least important overall (Table 2.3 and Figure 2.9). 
This reflected the fact that I trained sysSVM using mostly amplified known 
cancer genes, due the high genomic instability of OAC and the number of gain-
of-function mutations that were identified in the pilot cohort was zero (Figure 
2.5). Overall, the molecular features were less important than the systems-level 
properties, except for the radial kernel in which 4 of the 7 molecular features 
were in the top 10 features of this classifier (Table 2.3). Besides copy number 
amplifications, other top-ranking features were universal expression of genes in 
all human tissues, whole-genome duplications, gene age and the number of 
connections in the protein-protein interaction network (Table 2.3). In the other 
end of the spectrum, the least important features were mainly molecular 
features, such as truncating mutations and the number of protein domains 






Table 2.3. Rank of features in individual kernels in sysSVM. Colour code represents molecular features (orange) and systems-level 
properties (blue).  
Rank Linear Polynomial Radial Sigmoid 
1 Gene gain  Gene gain  Protein degree  Gene gain  
2 Medium expressed Ubiquitously expressed miRNA interactions Ubiquitously expressed 
3 Ubiquitously expressed  Ohnolog Protein betweenness Old gene 
4 Ohnolog Medium expressed  Exonic SNVs Ohnolog 
5 Old gene Old gene Damaging mutations Central protein 
6 Origin in vertebrates Origin in vertebrates Ubiquitously expressed Hub 
7 Origin in mammals Origin in metazoans Gene gain Origin in eukaryotes 
8 Origin in metazoans Origin in mammals Hub Origin in prokaryotes 
9 Selectively expressed Selectively expressed Central protein Origin in metazoans 
10 Gene loss Hub Truncating mutations Medium expressed 
11 Specifically expressed Specifically expressed Ohnolog Gene duplication 
12 Origin in eukaryotes Origin in prokaryotes Old gene Origin in vertebrates 
13 Origin in prokaryotes Origin in eukaryotes Origin in metazoans miRNA interactions 
14 Hub Gene loss Gene duplication Origin in opisthokonts 
15 Gene duplication Gene duplication Origin in prokaryotes Origin in mammals 
16 Central protein Central protein Origin in eukaryotes Selectively expressed 
17 Not expressed Not expressed Medium expressed Not expressed 
18 Origin in primates Origin in primates Origin in vertebrates Specifically expressed 
19 Origin in opisthokonts Origin in opisthokonts Origin in opisthokonts Origin in primates 
20 Protein degree Chromatin state Gene loss Gene loss 
21 miRNA interactions Protein degree Copy number Protein degree 
22 Gene length miRNA interactions Origin in mammals Gene length 
23 Number of tissues Gene length Selectively expressed Number of tissues 
24 Damaging mutations Number of tissues Not expressed Protein betweenness 
25 Chromatin state Protein betweenness Specifically expressed Damaging mutations 
26 Exonic SNVs Exonic SNVs Origin in primates Exonic SNVs 
27 Copy number Damaging mutations Gene length Truncating mutations 
28 Protein betweenness Protein domains Protein domains Copy number 
29 Protein domains Copy number Number of tissues Chromatin state 
30 Gain-of-function mutations Truncating mutations Chromatin state Protein domains 










Figure 2.9. Summary of ranks retrieved by recursive feature elimination across all kernels implemented in sysSVM. Boxplots are sorted 





Table 2.4. Parameters and performance of the four best models used to predict 
cancer genes in the pilot cohort. After grid search with all possible combination 
of parameters (18 for the linear kernel, 216 for the radial and sigmoid kernels 
and 648 for the polynomial kernel), the best model in each of the four kernels 
were chosen based on the median and variance of the sensitivity distribution 
across 100 iterations of cross-validation. 
 
Kernel nu Gamma Degree 
Cross-validation sensitivity 
Minimum Median Maximum Variance 
Linear 0.05 NA NA 0.87 0.94 0.98 0.0005 
Polynomial 0.05 0.5 3 0.78 0.87 0.93 0.0008 
Radial 0.05 0.0078 NA 0.89 0.94 0.98 0.0004 






2.3.5 Formulation of sysSVM meta-score 
After I optimised the parameters, I trained the selected best model in each 
kernel on the whole training set. Subsequently, sysSVM constructed a meta-
classifier by combining the decision values of each kernel into a single score. I 
hypothesised, that although some kernels performed better than others (as 
measured by the sensitivity), it was not warranted that all regions of the features 
space were described equally well by the single best kernel. Therefore, a multi-
kernel approach could predict genes that would not have been visible using a 
single kernel, although each kernel should have contributed proportionally to its 
sensitivity to the final score. To this end, the formulation of the score equation 
was designed as a weighted average of individual kernels in which the 
sensitivity of each kernel was used as a weighting factor. Hence, sub-optimal 
kernels contributed to the final score of each gene but disproportionally to the 
more sensitive kernels. SysSVM computed a combined score (Sgs) for each 










    (2.10) 
 
where N is the number of altered genes in sample s; Rigs is the rank of gene g in 
sample s and kernel i; and BMSi   is the sensitivity of the best model in kernel i. 
Rigs is derived by sorting the decision values (indicative of the distance of the 
gene from the decision boundary) of kernel i within sample s so that high 
decision values correspond to top scoring genes.  
The combined score Sgs corrected for the total number of altered genes in 




normalisation factor (denominator of equation 2.10) to scale the resulting value 
between 0 and 1. Overall, genes that were predicted by higher number of 
kernels had higher scores (Figure 2.10). This suggested that the combined 
score sufficiently captured both the majority rule and the distance from the 




Figure 2.10. Distribution of sysSVM score for 121,649 genes in the prediction 
set of the pilot cohort as a function of kernels supported the positive prediction 






2.3.6 Relevance of sysSVM predictions to OAC pathogenesis 
In the initial stages of the development of sysSVM, it was essential to 
manually inspect genes and pathways in order to analyse the predictions of 
cancer genes in the pilot cohort and their relevance to OAC pathogenesis. 
Moreover, pathway information and limited experimental validation could 
feedback to the relevance of predictive features used in sysSVM and their 
potential to identify new driver genes in OAC. To this end, I selected the top 10 
scoring genes in each sample (88 genes) and performed pathway enrichment 
analysis using the Reactome database (Milacic et al. 2012). As expected, the 
majority of the predicted genes (70%) were altered in only one sample, whereas 
only 13% of them was recurrently altered in 5 samples or more (Table 2.5). 
From the 1,156 pathways that I tested (see Methods), 53 were found enriched 
(FDR<0.01; Figure 2.11). Given the limited number of samples in the pilot 
cohort, the primary focus of this analysis was the inspection and validation of 
some of the predictions, rather than the identification of novel pathways in OAC. 
For the latter, I applied sysSVM to a larger cohort of OACs (see chapter 3).  
I found that numerous genes that were predicted by sysSVM contributed 
to the enrichment of several pathways, whose implication to tumorigenesis and 
DNA damage response has been previously described. In particular, 
transcriptional regulation by TP53, Notch-related pathways, MAPK signalling, 
regulation of DNA replication and DNA damage checkpoints were all found 
enriched with several genes and samples involved in each one of them (Figure 
2.11). A particularly interesting test case was that of TP53-related pathways, 
since predicted genes in these pathways could have been potential true 
positives. In OAC, around 70% of patients have been reported to harbour 




(72%) samples had predicted damaging mutation in TP53. SysSVM scored high 
9 genes involved in TP53-related pathways in 14 samples. Of interest, sysSVM 
predicted interactors of TP53 in samples with wild-type TP53, suggesting that 
more samples had tumorigenic alterations in TP53-related pathways than those 
that were identified using only the TP53 status. In particular, four samples with 
wild-type TP53 had amongst their top 10 scoring genes AGO1 or AGO2, both of 
which are key components of the RNA-induced silencing complexes (RISCs) 
and have been previously linked to DNA damage response and miRNA-







Figure 2.11. Pathway enrichment analysis of 88 sysSVM top 10 scoring genes 
in the pilot cohort. For each one of the 53 pathways found enriched, the number 
of samples and genes contributed to the enrichment are reported. 
 
 
Another strong enrichment of sysSVM predictions was found in pathways 
related to Notch signalling. Given that Notch acts as an oncogene and its 
contribution to tumorigenesis of OAC has been previously reported (Wang et al. 
2014), I examined the genes involved in Notch-related pathways. Apart from 




according to REACTOME, KAT2B, a histone acetyl-transferase, and E2F1, a 
transcription factor, whose expression is increased in many cancer types, were 
also responsible for the enrichment.  
The human KAT2B, and its 70% identical paralogue KAT2A, catalyse 
lysine acetylation, which is the process of transferring the acetyl group of acetyl-
CoA to the epsilon amino group of lysing residues (Yang and Seto 2008). As 
histone acetyl-transferases (HATs), KAT2A and KAT2B are members of a 
family of ~20 enzymes (Sadoul et al. 2011), which are involved in lysine 
acetylation and post-transcriptional modification of more than 6,000 proteins 
(Hornbeck et al. 2012). Through the acetylation of histones and other proteins, 
KATs play an essential role in the modulation of transcription activation and 
DNA replication and repair (Espinosa et al. 2010; Kelly et al. 2009; Pai et al. 
2014; Orpinell et al. 2010). This makes them particularly interesting targets for 
further experimental validation of their driver role in OAC. Apart from histones, 
KAT2A and KAT2B can also acetylate non-histone targets, such as CDC6 and 
cyclin A, both of which regulate G1/S cell cycle transition and mitosis (Paolinelli 
et al. 2009), a process that is dysregulated via multiple sysSVM predictions in a 
significant fraction of OACs (see chapter 4). Using expression data from the 
Xena browser (https://xenabrowser.net/) for a cohort of more than 11,000 
cancer samples from TCGA, both KAT2B and KAT2A expression were found 
associated with E2F1 expression. However, KAT2B showed a negative 
association (Figure 2.12A), while KAT2A expression was positively associated 
with E2F1 expression levels (Figure 2.12B), suggesting a differential functional 
dependency of the two genes to E2F1. Unlike KAT2B, the functional link of 
E2F1 and KAT2A has been reported before (Chen et al. 2013). It is intriguing 




of an antiapoptotic gene, such as KAT2A. The seemingly opposite functions of 
KAT2A and E2F1 highlight a negative functional feedback in which E2F1-
induced cell death is antagonised by overexpression of KAT2A to promote 
cancer progression (Farria, Li, and Dent 2015). Apart from colon and lung 
cancer, where this dependency has been demonstrated before, our data 
suggest that E2F1 and KATs might be functionally connected also in OAC. 
To examine the prevalence of KAT2A and KAT2B somatic alterations in 
multiple cancer types, I performed a pan-cancer analysis of 7,828 cancer 
samples from 31 cancer types (Table 1.1), which revealed 1,196 samples 
(15.3% of the total) with non-silent mutations and deletions. Overall, 25 cancer 
types had damaging modifications in >5% of the samples (Figure 2.12C). In 
particular, I found that more than 35% of sequenced samples in kidney 
chromophobe, ovarian serous cystadenocarcinoma, uveal melanoma, 
cholangiocarcinoma and kidney renal clear cell carcinoma harboured 
modifications in these genes. The most frequent type of alteration was gene 
loss (91%), followed by nonsynonymous SNVs (6.5%) (Figure 2.12D). In the 
OAC pilot cohort, KAT2B harboured predicted damaging alterations in six 
OACs, while in one sample was ranked in the top 10 scoring genes. In the 
remaining five OACs, KAT2B was ranked as the 11th, 12th, 15th, 21st and 33rd, 
very close to the top 10 in at least three of the five. Additionally, E2F1 was 
predicted by sysSVM in three OACs (Table 2.5).  
To test whether alterations of KATs, and in particular of KAT2A and 
KAT2B, leads to a cancer-related phenotype, we1 knocked-out both genes in 
OE19 oesophageal cancer cell line using a vector-free CRISPR system that 
was previously developed in our lab (Benedetti et al. 2017). Briefly, three 
                                                 




pooled crRNAs were co-transfected with Cas9 and tracrRNA in OE19 cells 
(Table 2.6). We then verified that edited OE19 cells exhibited increased 
proliferation (Figure 2.12E) and decreased apoptosis as compared to wild-type 
cells (Figure 2.12F). These data suggest that KAT2A and KAT2B upon loss of 
function modification contribute to tumorigenesis in OAC and, therefore, were 


















Figure 2.12. Pan-cancer analysis and experimental validation of KAT2A and 
KAT2B acetyl-transferases. Correlation of expression levels of (a) KAT2A and 
(b) KAT2B with E2F1 expression in colon adenocarcinoma (COAD), lung 
adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), oesophageal 
adenocarcinoma (OAC) and pan-cancer cohorts from TCGA. (c) Percentage of 
patients with non-silent mutations or gene deletions (i.e. heterozygous or 
homozygous copy number aberrations) in 7,828 samples from TCGA. 
Abbreviations and number of samples per cancer type are reported in table 1.1. 
(d) Most prevalent types of alterations of KAT2A and KAT2B in the pan-cancer 
cohort. Gene knock-out of KAT2A and KAT2B was performed on OE19 
oesophageal cancer cell line, using a vector-free CRISPR-mediated editing 
approach as previously described (Benedetti et al. 2017) (see Methods). (e) For 
proliferation, four replicates per condition were measured every three hours up 
to 75 hours in Incucyte Live Cell analysis system. Growth rate was calculated 
for each condition by fitting initially a sigmoid model in the data and 
subsequently a linear model in exponential phase of each experiment. An 
average growth rate was calculated across the four replicates. Conditions were 
compared using the two-tailed Student’s t-test. (f) For the same conditions as in 
e, apoptosis was estimated by measuring the caspase activity in Incucyte Live 
Cell analysis system. The normalised apoptosis score was derived as the ratio 
of the caspase activity measurement in each experiment over its confluence, to 
account for slight deviations of the proliferation rate across experiments. Three 




Table 2.5. SysSVM top 10 scoring predictions in each OAC in the pilot cohort. 
For each gene the number of OACs in which it was predicted as driver, the 
average sysSVM score and the kernels predicted its driver role are reported.  
Gene 
symbol OACs (#) 
Average 
sysSVM score Kernels with positive prediction 
NCOA3 11 0.471348555 linear, radial, polynomial, sigmoid 
TRIM28 11 0.476008422 linear, radial, polynomial, sigmoid 
BAG6 10 0.446418377 linear, radial, polynomial, sigmoid 
HNRNPUL1 8 0.444488626 linear, radial, polynomial, sigmoid 
AGO2 6 0.434619329 linear, radial, polynomial, sigmoid 
DNMT1 5 0.441461596 linear, radial, polynomial, sigmoid 
GANAB 5 0.42215355 linear, radial, polynomial, sigmoid 
KPNB1 5 0.436417317 linear, radial, polynomial, sigmoid 
LARP1 5 0.437587079 linear, radial, polynomial, sigmoid 
POGZ 5 0.432702271 linear, radial, polynomial, sigmoid 
SPTBN1 5 0.425580056 linear, radial, polynomial, sigmoid 
AGO1 4 0.428647663 linear, polynomial 
ATN1 4 0.433762497 linear, radial, polynomial, sigmoid 
ASAP1 3 0.458644783 linear, radial, polynomial, sigmoid 




E2F1 3 0.461876384 linear, radial, polynomial, sigmoid 
HIPK2 3 0.436336561 linear, radial, polynomial, sigmoid 
NOP2 3 0.432275619 linear, radial, polynomial, sigmoid 
TXLNA 3 0.460353624 linear, radial, polynomial, sigmoid 
CHD4 2 0.454131694 linear, radial, polynomial, sigmoid 
ERBB2IP 2 0.426749082 linear, radial, polynomial, sigmoid 
FLT1 2 0.491169343 linear, radial, polynomial, sigmoid 
GATAD2B 2 0.441963149 linear, radial, polynomial, sigmoid 
GLI1 2 0.439110303 linear, radial, polynomial, sigmoid 
HIF1A 2 0.438197968 linear, radial, polynomial, sigmoid 
MCM7 2 0.466751676 linear, radial, polynomial, sigmoid 
PRRC2A 2 0.432629967 linear, radial, polynomial, sigmoid 
SIN3B 2 0.441902237 linear, radial, polynomial, sigmoid 
ACACA 1 0.508598838 linear, radial, polynomial, sigmoid 
ACTN4 1 0.505733986 linear, radial, polynomial 
AKAP11 1 0.489678272 linear, radial, polynomial, sigmoid 
APPL1 1 0.503229099 linear, radial, polynomial, sigmoid 
ATP7B 1 0.546960402 linear, radial, polynomial, sigmoid 
ATP8B2 1 0.451790665 linear, radial, polynomial, sigmoid 
CALU 1 0.413428841 linear, radial, polynomial, sigmoid 
CANX 1 0.410961215 linear, radial, polynomial, sigmoid 
CCNA1 1 0.457717273 linear, radial, polynomial, sigmoid 
CDC20 1 0.428716654 linear, radial, polynomial, sigmoid 
CDC25A 1 0.498309324 linear, radial, polynomial, sigmoid 
CDK19 1 0.486220951 linear, radial, polynomial, sigmoid 
CTBP2 1 0.424220966 linear, radial, polynomial, sigmoid 
CUX1 1 0.423540355 linear, radial, polynomial, sigmoid 
DDX17 1 0.44619495 linear, radial, polynomial, sigmoid 
DHX30 1 0.441318096 linear, radial, polynomial, sigmoid 
DNMT3B 1 0.421640013 linear, radial, polynomial, sigmoid 
EEF2 1 0.424448845 linear, radial, polynomial 
EIF4G1 1 0.423686843 linear, radial, polynomial, sigmoid 
FYCO1 1 0.461600916 linear, radial, polynomial, sigmoid 
HMGB1 1 0.51535323 linear, radial, polynomial, sigmoid 
HNRNPL 1 0.514180501 linear, radial, polynomial, sigmoid 
HSPH1 1 0.557846097 linear, radial, polynomial, sigmoid 
KAT2B 1 0.42817236 linear, radial, polynomial, sigmoid 
KATNAL1 1 0.502438335 linear, radial, polynomial, sigmoid 
KDM5B 1 0.40509567 linear, radial, polynomial, sigmoid 
KIF2C 1 0.426583094 linear, radial, polynomial, sigmoid 
LATS2 1 0.484914521 linear, radial, polynomial, sigmoid 
MAP4 1 0.455923164 linear, radial, polynomial, sigmoid 
MMP9 1 0.44220687 linear, radial, polynomial, sigmoid 




MYO1C 1 0.479637608 linear, radial, polynomial, sigmoid 
OXSR1 1 0.442391667 linear, radial, polynomial, sigmoid 
PABPC1 1 0.412361002 linear, radial, polynomial, sigmoid 
PEX5 1 0.432331984 linear, radial, polynomial, sigmoid 
PITPNA 1 0.425100624 linear, radial, polynomial, sigmoid 
PRPF8 1 0.511162116 linear, radial, polynomial, sigmoid 
PSMD11 1 0.421977785 linear, radial, polynomial, sigmoid 
PUM1 1 0.478116616 linear, radial, polynomial, sigmoid 
RASA1 1 0.461295249 linear, polynomial 
RBL1 1 0.420673799 linear, radial, polynomial, sigmoid 
RBM10 1 0.440777578 linear, radial, polynomial, sigmoid 
RIMS2 1 0.450053941 linear, polynomial 
RPS2 1 0.478204533 linear, radial, polynomial 
RTN4 1 0.40329935 linear, radial, polynomial, sigmoid 
SF3B3 1 0.427319113 linear, radial, polynomial, sigmoid 
SKI 1 0.410332875 linear, radial, polynomial, sigmoid 
SLC7A1 1 0.478120625 linear, radial, polynomial, sigmoid 
SMARCC1 1 0.461495874 linear, radial, polynomial, sigmoid 
STX12 1 0.447389895 linear, radial, polynomial, sigmoid 
TGFBR2 1 0.473708203 linear, radial, polynomial, sigmoid 
TRAPPC3 1 0.439131231 linear, radial, polynomial, sigmoid 
UBA1 1 0.444941414 linear, radial, polynomial, sigmoid 
USP19 1 0.455257781 linear, radial, polynomial, sigmoid 
VAPB 1 0.437985891 linear, radial, polynomial, sigmoid 
VEGFA 1 0.433731516 linear, polynomial 
WASF1 1 0.453245359 linear, radial, polynomial, sigmoid 
WNK1 1 0.437629951 linear, radial, polynomial, sigmoid 
XPO7 1 0.413108333 linear, radial, polynomial, sigmoid 
YBX1 1 0.449267139 linear, radial, polynomial 
 
 
Table 2.6. Oligos used to knock-out KAT2A and KAT2B via CRISPR 













2.3.7 Comparison of sysSVM predictions to those of other methods 
To further evaluate the predictions of sysSVM, I compared the top 10 
scoring genes in the pilot cohort to the cancer genes predicted by other 
methods, such as IntOGen (Gonzalez-Perez et al. 2013) and Hotnet2 
(Leiserson et al. 2015). These are the only methods that were designed to 
predict rare cancer drivers and, therefore, they were selected as the most 
appropriate ones to be compared with sysSVM. IntOGen was run via its web 
interface (https://www.intogen.org/analysis/home), and Hotnet2 as described in 
the corresponding manual (https://github.com/raphael-group/hotnet2). The 
default parameters were used for both tools. The input used for both methods 
was that of sysSVM, i.e. genes with predicted damaging alterations, as 
described above. IntOGen predicted 19 significant genes (Table 2.7), six of 
which were known cancer genes and two had been previously reported to play 
a role in tumorigenesis (An et al. 2016). Hotnet2 predicted 82 genes (Table 
2.8), seven of which were known cancer genes and 24 had been previously 
linked to tumorigenesis (An et al. 2016). As sysSVM used known cancer genes 
for training, and therefore, no prediction was performed, those were excluded 
from the comparison. No overlap was observed with the 13 IntOGen genes and 
only 2 genes (ERBB2IP and RIMS2) were also predicted by HotNet2, while the 
overlap between IntOGen and HotNet2 was 3 genes (ERBB4, CACNA1A and 
PTPN13). The low overlap between the predictions of all three tools suggests 
different and possibly complementary principles for the discovery of cancer 
genes. It also highlights the difficulties in identifying rare cancer genes when 






Table 2.7. IntOGen predictions (n=19) in the pilot cohort. For each gene that was predicted as cancer gene by IntOGen in the pilot 
cohort, the ensembl gene id, the gene symbol, the cancer involvement (Yes = Known cancer gene; No = Not involved in tumorigenesis; 
Maybe = limited evidence), the functional bias p value before and after correction, the sample frequency and the total number of 
samples used for the analysis are reported. 
Gene Symbol 
Cancer 





ENSG00000072121 ZFYVE26 No 0.01178255 0.190663083 3 0.166666667 
ENSG00000168036 CTNNB1 Yes 0.01942333 0.230490187 10 0.555555556 
ENSG00000163629 PTPN13 No 0.049575556 0.460289999 14 0.777777778 
ENSG00000172296 SPTLC3 No 0.016026343 0.218932085 9 0.5 
ENSG00000141646 SMAD4 Yes 5.47076E-05 0.003245987 4 0.222222222 
ENSG00000178568 ERBB4 Maybe 0.017219378 0.218932085 18 1 
ENSG00000115414 FN1 No 0.007474242 0.179945302 12 0.666666667 
ENSG00000141837 CACNA1A No 0.009072385 0.179945302 17 0.944444444 
ENSG00000134982 APC Yes 0.000894472 0.039803989 9 0.5 
ENSG00000137124 ALDH1B1 No 0.022633011 0.251792243 2 0.111111111 
ENSG00000047410 TPR Yes 0.014909216 0.218932085 5 0.277777778 
ENSG00000160145 KALRN Maybe 0.034316715 0.359316187 16 0.888888889 
ENSG00000020633 RUNX3 No 0.009599619 0.179945302 5 0.277777778 
ENSG00000062370 ZFP112 No 0.008659662 0.179945302 6 0.333333333 
ENSG00000159307 SCUBE1 No 0.010109287 0.179945302 7 0.388888889 
ENSG00000073331 ALPK1 No 0.008687294 0.179945302 6 0.333333333 
ENSG00000176102 CSTF3 No 0.04259737 0.421240658 9 0.5 
ENSG00000141510 TP53 Yes 0 0 15 0.833333333 






Table 2.8. HotNet2 predictions (n=82) in the pilot cohort. For each gene that was predicted as cancer gene by HotNet2 in the pilot 
cohort, the gene symbol and the cancer involvement (Yes = Known cancer gene; No = Not involved in tumorigenesis; Maybe = limited 







































































































































































SysSVM builds on previous efforts of our lab to identify novel cancer genes in 
individual tumours independently as opposed to focusing on recurrently altered 
genes across patient cohorts (D’Antonio and Ciccarelli 2013). This is useful in the 
context of precision medicine, as future therapeutics will be tailored to the 
mutational landscape of individual patients. In this chapter, I showed that systems-
level properties can indeed distinguish known cancer genes from the rest of human 
genes. If used in a machine-learning framework, these properties can be utilised to 
identify novel driver genes. Such an approach requires no calculation of 
background mutational rate and, thus, it can reveal rare and patient-specific driver 
genes. 
The main obstacle I faced while developing sysSVM was the definition of a 
negative set of observations, as currently there are no properties to define genes 
with no involvement in cancer. Soon it became apparent that a definition of an 
absolute set of non-cancer genes was challenging, but also irrelevant from a 
biological perspective, as several passenger genes in a certain cancer type might 
be drivers in others. In fact, the discovery of such genes is of great interest as 
context-specific driver potential of genes could highlight different underlying 
tumorigenic processes across cancer types. 
Therefore, sysSVM models only the density of known driver genes (positive 
observations) in the input feature space and utilises one-class SVM for novelty 
detection (Schölkopf et al. 2001). SysSVM learns the decision boundary from the 
systems-level and molecular properties of known and cancer type-specific driver 




cohort according to their similarity to known drivers. The best models that were 
selected during the development phase of sysSVM showed high sensitivity (Table 
2.4) and the construction of decision boundary utilised the majority of training 
observations. Overall, sysSVM operates as a meta-classifier and incorporates 
information from 4 different kernels (linear, radial, polynomial and sigmoid). This 
incorporation step was added because the high complexity of the input space and 
the multiple areas in which known cancer genes reside might not be sufficiently 
described by only one kernel. I showed that the sysSVM meta-score closely 
represented the raw predictions of individual kernels, as genes predicted by higher 
number of kernels had higher meta-score (Figure 2.10).  
Assessment and ranking of each sysSVM feature revealed that on average 
molecular properties (sequencing data) were of lower importance for the classifiers 
than systems-level properties (Table 2.3 and Figure 2.9). However, the contribution 
of molecular properties towards predictions was not negligible, as their inclusion 
provided sysSVM with information on cancer type-specific alterations. For instance, 
the extensive genomic instability in OAC was captured by the high ranking of gene 
amplification in three out of four kernels used (Table 2.3).  
As expected, predicted driver genes were mostly private to individual OACs 
(Table 2.5) and subject to genomic amplifications. Gene set enrichment analysis 
highlighted a number of enriched pathways with proven contribution to 
tumorigenesis, such as transcriptional regulation of TP53 and DNA replication 
(Figure 2.11). The fact that sysSVM predictions, albeit not known driver genes, 
belong to well-known tumorigenic pathways is encouraging and denotes that high-
scoring predictions might be true positives. Although experimental validation is 




support for the tumorigenic role of multiple predicted drivers in the pilot cohort. For 
example, AGO2, a member of the RNA-induced silencing complex (RISC), was 
predicted in seven OACs (39%). AGO2 has been reported to be involved in 
tumorigenesis through multiple miRNA-dependent pathways and has been found 
overexpressed in multiple carcinomas (Ye, Jin, and Qian 2015). Additionally, 
sysSVM predicted KAT2B, a histone acetyl-transferase, as a private top scoring 
prediction (Table 2.5). Closer examination of this gene revealed its involvement in 
the Notch signalling pathway, which has been previously reported to contribute to 
tumorigenesis in OAC (Wang et al. 2014), and its direct link with another top-
scoring prediction, E2F1, which was predicted as a driver by sysSVM in three 
OACs (17%; Table 2.5). Pan-cancer expression analysis highlighted possible 
functional dependencies between E2F1 and KAT2B, as well as its paralogue 
KAT2A (Figure 2.12). Finally, our first trial to experimentally validate KAT2B in the 
oesophageal cancer cell line OE19 confirmed its tumorigenic role in OAC (Figure 
2.12). 
In summary, sysSVM predictions in a pilot cohort of 18 OACs were 
particularly encouraging for further implementation of the method to larger cohorts, 
as they were in accordance with our initial hypothesis that rare or patient-specific 
cancer drivers can be predicted by systems-level and molecular properties. 
Although very limited, our initial experimental results and literature search 
supported the driver role of several predicted drivers. However, to fully explore the 
perturbed processes in OAC and identify novel genes and pathways involved in its 
tumorigenesis, a higher number of samples is needed. To this end, the third 
chapter of this thesis describes my first attempt to apply sysSVM to a cohort of 261 




Chapter 3. Application of sysSVM to 261 Oesophageal 
adenocarcinomas 
3.1 Chapter overview 
In this chapter, I describe the application of sysSVM to a cohort of 261 OACs 
from ICGC to predict novel driver genes. The application of my method to a large 
cohort of samples allowed the optimisation of the algorithm and its refinement. Of 
particular interest was the fact that some of the OACs in this cohort had been 
published before (Secrier et al. 2016) and only a handful of drivers had been 
previously identified, suggesting that our understanding of the molecular landscape 
of this disease lags behind other cancer types. In the following paragraphs, I 
describe the landscape of rare and patient-specific sysSVM predictions, the 
perturbation of pathways to which these genes contribute to and their relevance to 
OAC. Interestingly, sysSVM predictions often converge towards the perturbation of 




Oesophageal cancer is the sixth leading cause of cancer-related mortality 
and the ninth most common cancer, affecting more than 550,000 people worldwide 
(Ferlay et al. 2015). The five-year survival rate ranges from 15% to 25% 
(Pennathur et al. 2013) and diagnosis at advanced stages is associated with 
poorer outcomes (Ek et al. 2013). The incidence of oesophageal cancer is rapidly 




highest rates are observed along two geographic areas or “cancer belts”, one 
extending from China to Iran through central Asian countries and a second one 









Histologically, oesophageal cancer is classified as oesophageal squamous 
cell carcinoma (OSCC) or oesophageal adenocarcinoma (OAC), but both types 
exhibit very distinct geographical distributions and unique clinical characteristics. 
OSCC is the most prevalent subtype, accounting for more than 80% of all cases of 
oesophageal cancer worldwide and shows a higher incidence rate in African 
American and Asian populations (Cook 2011; Dawsey et al. 1994). There are 




tobacco use, alcohol consumption, low socioeconomic status, poor oral hygiene, 
and nutritional deficiencies  (Pennathur et al. 2013). 
During the last decades, however, the epidemiology of oesophageal cancer 
has changed in Western populations. There has been a rapid increase in the 
incidence of OAC, which has become the most predominant subtype in many 
developed countries (Coleman, Xie, and Lagergren 2018; Thrift and Whiteman 
2012). OAC has surpassed OSCC in a number of industrialised countries and 
almost 50% of OAC cases worldwide are reported in Europe and North America. In 
particular, OAC incidence is high in United Kingdom, Ireland, France, Sweden and 
the Netherlands, indicating a bias towards Northern European populations 
(Rubenstein and Shaheen 2015). It is also worth noting that OAC exhibits a striking 
male predominance, as the incidence rates in all populations are significantly 
higher in men than women (Nordenstedt and El-Serag 2011; Cook, Chow, and 
Devesa 2009). The observed steep increase in OAC incidence cannot be 
explained by changes in the population’s genetic make-up over a short timeframe 
of a few decades. Therefore, numerous epidemiological studies sought to 
investigate the contribution of non-genetic factors to OAC development. Based on 
the reported data, gastroesophageal reflux disease (GERD) (Lagergren et al. 
1999), obesity (Thrift et al. 2014), and tobacco smoking (Cook et al. 2012, 2010) 
were identified as the major factors associated with increased risks of developing 
OAC. Taken together, these three factors account for nearly 80% of all cases of 
OAC in Western populations (Olsen et al. 2011). 
GERD was identified as risk factor for OAC in the 1990s, when studies 
provided epidemiological evidence that GERD may predispose to oesophageal 




based study conducted in Sweden reported that individuals with frequent (at least 
once weekly) symptoms of GERD (heartburn, regurgitation or both) had 8-fold 
higher probability of developing OAC, when compared to individuals without or with 
less frequent symptoms (Lagergren et al. 1999).  Additionally, this risk was found 
further increased when the symptoms were persistent for over 20 years. These 
observations were further confirmed in subsequent independent studies (Pandeya, 
Olsen, and Whiteman 2013; Cook et al. 2014).  
Although the molecular mechanism by which severe GERD may lead to OAC 
development is not yet fully elucidated, the prevailing hypothesis is that gastric acid 
induces chronic damage to the oesophageal lining. This may consequently lead to 
metaplastic changes, whereby the normal oesophageal squamous mucosa is 
replaced by a specialized columnar epithelium. This condition is called Barret’s 
oesophagus (BE) and is considered a precursor of OAC (Reid et al. 2010). BE can 
indeed progress to low- and high-grade dysplasia, adenocarcinoma in situ and 
ultimately invasive adenocarcinoma (Anaparthy and Sharma 2014). The reported 
prevalence of BE is 1-2% in the general population and 10-15% in individuals with 
chronic reflux symptoms (Ronkainen et al. 2005; Voutilainen et al. 2000). As 
compared to the general population, patients with BE exhibit approximately a 10-
fold higher risk of developing OAC (Hvid-Jensen et al. 2011) and are therefore 
periodically screened for dysplastic BE or early stage OAC. 
Obesity has also been implicated in the development of OAC and it has been 
proposed that the increase in the incidence of OAC reflects the increasing obesity 
in Western populations (Kroep et al. 2014). However, the extent to which the 
increase in obesity can account for the rise in OAC has been debated (Kong et al. 




adipose tissue in the abdominal area leads to increased intra-gastric pressure and 
diminished lower oesophageal sphincter pressure, and subsequently promotes 
GERD (Friedenberg et al. 2008; Lagergren 2011). In addition, visceral adipose 
tissue can be metabolically active and release proinflammatory adipocytokines that 
can contribute to metaplastic and neoplastic changes (Nam et al. 2010). In support 
of this, increased serum levels of leptin and insulin are associated with increased 
risk of BE (Chandar et al. 2015). Moreover, the distribution of adipose tissue in the 
body may be more important than the overall adiposity when determining the risk 
of BE and OAC (Trevellin et al. 2015). This could partially explain the sex disparity 
observed in oesophageal adenocarcinoma (Singh et al. 2013; Steffen et al. 2015). 
Excess abdominal body fat, typically observed in males, is associated with 
increased risk for OAC (Steffen et al. 2015). On the contrary, gluteo-femoral 
adiposity, predominantly observed in women, is inversely correlated (Kendall et al. 
2016). 
Tobacco smoking has also been associated with increased risk for 
developing OAC. A pooled analysis of 12 studies conducted on OAC patients and 
control cohorts demonstrated that the risk of OAC is increased by two-fold among 
individuals that had a history of tobacco smoking (Cook et al. 2010). Furthermore, 
the same analysis reported a strong dose-response association between pack-
years of smoking and OAC risk. Tobacco is a known carcinogen that has been 
linked to higher DNA damage in Barrett's mucosa (Olliver et al. 2005). Another 
potential mechanism through which cigarette smoking might promote OAC is its 
ability to relax the lower oesophageal sphincter, therefore predisposing to GERD 




Curative treatment in OAC is currently based on esophagectomy, with 
additional peri-operative chemotherapy or chemoradiotherapy (Allum et al. 2009; 
Cunningham et al. 2006; van Hagen et al. 2012). In contrast to other cancer types, 
the use of targeted agents has been lagging behind and many recent phase III 
trials reported disappointing or inconclusive results (Woo, Cohen, and Grim 2015; 
Young and Chau 2016; Kopp and Hofheinz 2016). To date, only trastuzumab, a 
monoclonal antibody targeting HER2, has led to an improvement in patient 
outcome (Bang et al. 2010). Advances in this area have been hindered by the fact 
that OAC is characterised by extensive genomic instability, manifested in both 
somatic mutational burden and copy number variations (The Cancer Genome Atlas 
Research Network 2017). As a result, the number of potential tumorigenic 
alterations that may confer selective advantage to cancer cells, and, thus drive 
their growth is high. Therefore, the identification of genes that play an integral part 
in this process, i.e. driver genes, is critical to fully understand the molecular 
determinants of OAC and to inform the development of targeted therapeutic 
approaches.  
OAC, as a genomically unstable cancer type, is characterized by widespread 
inter-patient heterogeneity, with very few alterations exceeding 10% of recurrence 
across patients (Secrier et al. 2016). This makes the full characterisation of driver 
events particularly challenging, as the genomic landscape of OAC is highly variable 
and recurrent events are rare. Therefore, current methods, which are based on the 
recurrence of gene alterations to identify drivers are insufficient. OAC genomes are 
characterised by complex patterns of rearrangements and genomic catastrophes 
(Nones et al. 2014). Chromosomal shattering (chromothripsis) and mis-segregation 




nucleotide variants, and have been shown to drive cancer development (Zhang, 
Leibowitz, and Pellman 2013). For example, chromothripsis might contribute to the 
generation of double-minute chromosomes, which are extrachromosomal elements 
containing multiple copies of genes, whose amplification can lead to an oncogenic 
phenotype (Sanborn et al. 2013). Well-known drivers in OAC are genes involved in 
tumorigenesis of multiple other cancer types, such as TP53, CDKN2A, SMARCA4, 
ARID1A, SMAD4, ERBB2 and amplifications of VEGFA, ERBB2, EGFR, GATA4/6, 
CCNE1 (Agrawal et al. 2012; Dulak et al. 2013; Weaver et al. 2014; Ross-Innes et 
al. 2015; Secrier et al. 2016; The Cancer Genome Atlas Research Network 2017). 
The low number of driver genes leaves approximately 10-20% of patients without 
known genetic determinants and often the number of identified drivers per sample 
is too low to fully explain the disease.  
OAC provides a good example of a cancer type where genes altered in low 
frequencies could play a patient-specific tumorigenic role, and as such, it is ideal 
for the development of new methods aiming to identify rare cancer drivers. I 
hypothesised that alongside the critical role of recurrent and well-known cancer 
drivers, complementary somatic alterations of several other genes help cancer 
progression in individual patients. These “cancer helper” genes have potentially a 
very broad spectrum of functions, ranging from optimisation of the function of major 
drivers to the promotion of competition between or even cooperation of cancer 
cells (explained in chapter 1). 
To comprehensively characterise the molecular mechanisms relevant to 
OAC, I applied sysSVM to 261 OACs from the UK OCCAMS Consortium. I first 




which were described in chapter 2) and then prioritized 952 genes that, together 
with the known drivers, promote cancer development. By applying sysSVM to a 
much larger cohort than the one used in the pilot phase of this thesis (chapter 2), 
apart from the characterisation of ‘helper’ genes relevant to OAC, I had the 
opportunity to further optimise several parts of my method. These are described in 
the following paragraphs and include: i) the assessment of convergence of the best 
parameters during cross validation, ii) the usage of additional features, such as 





3.3.1 OAC mutational landscape 
WGS data from a diverse collection of OACs, including Siewert types 1, 2 and 
3 (Table 3.1), allowed me to examine the types of alterations that dominate the 
mutational landscape of this disease. Confirming previous studies (Dulak et al. 
2013), OACs in our cohort had a high burden of point mutations with an average of 
166 protein-coding SNVs per sample (ranging from 1 to 860) (Figure 3.2A). 
However, OAC mutation landscape was dominated by large-scale alterations, such 
as genomic amplifications and structural variations. On average, copy number and 
structural somatic aberrations affected twice as much protein-coding genes as 
compared to point mutations (384 genes per sample ranging from 17 to 1,840) 
(Figure 3.2A). Most OACs in our cohort exhibited a highly fragmented genomic 




or loss (Figure 3.2B). Overall, the number of OAC genomes undergoing 
catastrophic chromosomal events is higher than those in other cancer types 
(Stephens et al. 2011; Molenaar et al. 2012). Unlike melanoma or pancreatic 
adenocarcinoma, which are driven by oncogenic point mutations in KRAS and 
BRAF, OAC is driven by oncogenic amplifications (Nones et al. 2014).  
In terms of point mutations, known driver genes in OAC were highly 
heterogeneous amongst the cases included in our cohort. With the exception of 
TP53, which was found mutated in more than 70% of OACs, all other known 
drivers were mutated in less than 15% of OACs (Figure 3.3). Taken together, these 
observations confirmed that the mutational landscape of OAC is highly 
heterogeneous and is dominated by large-scale genomic catastrophes. As 
mentioned in the introduction of this chapter, therapeutic approaches using 
targeted therapies in OAC lag behind those of other cancer types and this is due to 
the limited understanding of cancer drivers in this cancer type. Given that one of 
the main attributes of sysSVM is its ability to integrate both point mutations and 
structural variations to identify cancer drivers, I considered OAC and its 






Table 3.1. Summary of clinical characteristics of the 261 OAC samples. 
Percentages that do not sum up to 100% within each category denote missing 
data. Data were collected from the ICGC. Gastro-oesophageal junction (GOJ) 
types are reported according to Siewert classification. 
 
Mean age at diagnosis (stDev) 65.5 (9.97) 




No treatment 47.1 
Radiation therapy 0.3 
Surgery 0.6 
Other therapy 0.3 
Tumour location (%) 
 
GOJ Type 1 34.9 
GOJ Type 2 25.3 
GOJ Type 3 6.1 
Primary tumour (%) 
 
Stage I 18.8 
Stage II 14.2 
Stage III 43.7 
Stage Iv 2.3 
Node positive (%) 50.9 






Figure 3.2. Overview of genomic alterations in the OAC cohort (n=261). (a) The 
total number of protein-coding genes affected by copy number alterations or 
structural variants (above x axis) and point mutations or indels (below x axis). (b) A 
representative copy number profile of an OAC tumour (LP6008031-DNA_A01) 
affected by large-scale amplifications and deletions. The two colours (green and 
black) represent the copy number of major and minor alleles (y axis) across 










Figure 3.3. Frequency of frameshift, nonsynonymous, stop gain or loss and splicing alterations for 7 seven driver genes that 





3.3.2 SysSVM workflow  
SysSVM applies supervised machine learning to predict altered genes 
contributing to cancer based on the similarity of their systems-level and 
molecular properties to those of known cancer genes (as mentioned in chapter 
2). Systems-level properties are genomic, epigenomic, evolutionary and gene 
expression features that distinguish cancer genes from the rest of human genes 
and were described in detail in the previous chapter. Briefly, they include gene 
length and protein domain organisation (D’Antonio and Ciccarelli 2013; An et al. 
2016), gene duplicability (Rambaldi et al. 2008; D’Antonio and Ciccarelli 2011), 
chromatin state (Lieberman-Aiden et al. 2009), connections and position of the 
encoded proteins in the protein-protein interaction network (Rambaldi et al. 
2008), number of associated regulatory miRNAs (D’Antonio and Ciccarelli 
2011), gene evolutionary origin (D’Antonio and Ciccarelli 2011) and breadth of 
gene expression in human tissues (D’Antonio and Ciccarelli 2013; An et al. 
2016). Moreover, as more sequencing data became available from ICGC, I 
extended the catalogue of the molecular properties from seven to 10, including 
data on structural variation (Table 3.2). In particular, I added translocations, 
inversions, and insertions to the molecular features of sysSVM. Also, to control 
for the high number of amplifications in OAC, I corrected gene copy number, 
using the estimated ploidy of each sample (see Methods). In addition to what 
was described in chapter 2, I added an extra step to the sysSVM algorithm in 
order to check for the convergence of cross-validation (see step 3 below).  
In its optimised version, sysSVM workflow is composed of three main 
conceptual steps (Figure 3.4A): 
 Step 1: Feature mapping. sysSVM maps 34 features of all altered 




derived from molecular properties and 24 features are derived from 
systems-level properties of known cancer genes, as summarized in 
Table 3.2. These 34 features are used to define the regions of the 
feature space where the known cancer genes reside. Twenty-two of 
them are categorical and 12 are continuous or discrete variables.  
 
 Step 2: Model selection. sysSVM applies a grid search to optimise 
the parameters used in each kernel. The parameter space in which 
sysSVM searches was described in detail in chapter 2. Briefly, 18 
combinations of parameters are examined for the linear kernel, 216 
combinations for the radial and sigmoid kernels and 648 
combinations for the polynomial kernel, for a total of 1,098 
parameter combinations. To identify the best combination of 
parameters for each kernel, a user-defined number of iterations of 
three-fold cross-validation is performed (default = 10,000). At each 
iteration, the genes of the training set are randomly split into two 
subsets, one used for training (2/3 of the genes) and one as a test 
set (1/3 of the genes). Predictions are performed on the test set and 
the sensitivity of each set of parameters is computed, as described 
in chapter 2. To ensure robustness of cross-validation and to avoid 
artificial inflation of sensitivity, because the same gene can be 
altered in multiple samples, the split of training and test set is 
performed on the unique set of genes. This results in slight 
variations of the size of training/test sets during the cross-validation. 
Subsequently, the distribution of sensitivity every n iterations 




five most sensitive models in each kernel (considering the mean 
sensitivity) is chosen as the best model for that kernel, as described 
in chapter 2. To account for the effect of increasing number of cross 
validation iterations, at each increment of n cross validations 
(default = 100), the selection of best models takes into account all 
previous cross-validation iterations. To account for the effect of the 
order of iterations, this cumulative assessment is repeated a 
number of times (default = 5) where the iterations of cross 
validation are randomly reordered. This produces m sets of best 
models (from a default of 5 re-orderings of 100 increments, m = 
500).  
 
 Step 3: Training and prediction. All m sets of best models 
identified in step 2 are used for training using the whole training set. 
This is a modification of sysSVM compared to what was described 
in chapter 2, as we2 sought to investigate how the number of cross-
validation iterations affected the selection of the best models.  For 
each set of best models, cancer genes are predicted in individual 
samples and combined using the formula 2.10. This results in m 
lists of top k genes (default k = 10) in each sample. The most 
frequent list of top k genes overall is selected as the final list of 
predicted cancer genes. 
 
 
                                                 




I applied sysSVM to 261 OACs from OCCAMS and the ICGC, which are 
summarised in Table 3.3. In the first step, I extracted 17,078 genes with (i) 
truncating, (ii) non-truncating damaging or (iii) gain-of-function mutations, (iv) 
homozygous deletions, (v) amplifications, (vi) insertions, (vii) inversions and (vii) 
translocations in the whole cohort (median of 382 damaged genes per patient, 
Figure 3.4B, Table 3.3) and mapped their 34 molecular and systems-level 
features. As expected, most of the altered genes were amplified (average of 
307.9 amplified genes per sample; Table 3.3), owing to the high genomic 
instability in OAC. In the second step, 476 of the extracted genes, harbouring 
4,091 damaging alterations in total, were annotated as known cancer genes 
based on data provided from Cancer Gene Census (Forbes et al. 2017) and are 
listed in appendix table 7.1. These known cancer genes comprised the training 
set of sysSVM. To optimise the parameters of each kernel, three-fold cross-
validation was ran with 10,000 iterations and the results were combined every 
100 iterations to obtain 500 sets of best parameters for the four kernels (Table 
3.4), as described in step 3 above. In the third step, the best models from step 
two (one per kernel each 100 iterations) were used for training and prediction. 
All genes except those used for training (n=16,602) were first scored in each 
patient individually by combining the decision values of the four kernels (using 
the formula 2.10) and then ranked according to the resulting score. Overall, the 
best parameters in each kernel converged on a limited number of values during 
cross-validation (Table 3.4). Multiple sets of parameters could result in the 
same set of genes and a single set of parameters could result in slightly 
different sets of genes (usually differing by one or two genes) depending on the 
cross-validation sensitivity. In order to address the fact that in some cases 




the list of top 10 scoring genes that were most frequently predicted in each 
sample, I selected 952 genes (referred to as 952A in Table 3.4) for downstream 
analysis. Overall, these genes along with the almost identical gene lists 952B, 
952C, 951A, 951B, 950 accounted for 434 out of the 500 gene lists (86.8%; 
Table 3.4). 
Taken together, these results highlight a set of 952 genes that were 
predicted by sysSVM as drivers of tumorigenesis in OAC. Moreover, the 
application of sysSVM to a larger cohort than the one used for its development 
(18 OACs described in chapter 2) allowed me to refine the algorithm, assess 
the robustness of selection of the best parameters and thereby ensure 











Figure 3.4. Overview of sysSVM. (a) Step-by-step description of sysSVM, which was used to identify cancer genes on 261 OACs. (b) 
Genes extracted for each sysSVM step. Genes with somatic damaging alterations (n=116,989) were extracted from 261 OACs and 
divided into training (known cancer genes, blue) and prediction (rest of altered genes, green) sets. All altered genes (n=112,898) were 
scored in each patient individually after the selection of the best set of parameters per kernel during cross-validation. The final list of top-








Table 3.2. Description of sysSVM features. Listed are 10 molecular and 24 systems-level features used in sysSVM. For each of them, 
described are: the original gene property, whether it is categorical or continuous, its operational definition (see Methods) and the number 
of unique and redundant (in brackets) genes in 261 OACs. The description of systems-level properties of cancer genes is also given. For 
all systems-level properties, except gene length, duplication status and ohnologs, the number of unique genes before imputation is given 
(see Methods). CG = cancer gene; TSG = tumour suppressor gene; OG = oncogene; WGD = whole genome duplication; n = number; l = 
length. 
Gene property Feature for classification Type Cancer gene feature Operational definition Genes in 261 OACs 
Copy number 
variation 
Gene gain Molecular (categorical) Not applicable CN >= 2*sample ploidy 13,622 (79,216) 
Gene loss Molecular (categorical) Not applicable  CN = 0 1,117 (3,089) 
Gene copy number (n) Molecular (continuous) Not applicable  Somatic copy number (ASCAT) 17,078 (116,989) 
Structural variation 
Gene translocation Molecular (categorical) Not applicable  Somatic translocation event (Manta) 5,577 (11,137) 
Gene inversion Molecular (categorical) Not applicable  Somatic inversion event (Manta) 5,546 (10,320) 
Gene insertion Molecular (categorical) Not applicable  Somatic insertion event (Manta) 519 (646) 
SNVs and indels 
Truncating alterations (n) Molecular (continuous) Not applicable  





Molecular (continuous) Not applicable  
Damaging nonframeshit, nonsynonymous, 
splicing alterations (dbNSFP) 
7,287 (15,508) 
Gain of function alterations (n) Molecular (continuous) Not applicable  Gain of function (OncodriveClust) 170 (614) 
All exonic SNVs and indels (n) Molecular (continuous) Not applicable 
Silent and non-silent alterations 
(ANNOVAR) 
8,359 (18,941) 
Gene length Gene length (l) Systems-level (continuous) CGs tend to be long (1) Length of the longest isoform (RefSeq) 17,078 
Gene duplication 
status 
Gene duplication status Systems-level (categorical) 
TSGs are enriched in single-
copy genes (2) 





Ohnolog Systems-level (categorical) 
OGs are enriched in ohnologs 
(3) 
Gene duplicate retained after whole 
genome duplications 
17,078 
Protein domains Protein domains (n) Systems-level (continuous) 
CGs are enriched in multi-
domain proteins (4) 
Number of protein domains (CDD)  17,039 
Chromatin state Chromatin state Systems-level (continuous) 
CGs localise preferentially in 
open chromatin (5)  
Chromatin state from Hi-C experiment in 




Protein degree (n) Systems-level (continuous) CGs encode preferentially 
protein hubs (2) 
Number of connections in the protein-
protein interaction network 
13,268 
 
Hub  Systems-level (categorical) Top 25% most connected proteins  
Protein betweenness (n) Systems-level (continuous) 
CGs encode preferentially 
central proteins (2) 








Central protein Systems-level (categorical) Top 25% most central proteins  
miRNA interaction 
network 
miRNA interactions (n) Systems-level (continuous) 
CGs tend to be regulated by a 
larger number of miRNAs (3) 




Old gene Systems-level (categorical) 
TSGs are enriched in old genes 
and OGs are enriched in genes 
originated in Metazoans (3) 
The gene originated before metazoans 
16,354 
 
Origin in prokaryotes Systems-level (categorical) Oldest ortholog found in prokaryotes 
Origin in single cell eukaryotes Systems-level (categorical) Oldest ortholog found in eukaryotes 
Origin in opisthokonts Systems-level (categorical) Oldest ortholog found in opisthokonts 
Origin in metazoans Systems-level (categorical) Oldest ortholog found in metazoans 
Origin in vertebrates Systems-level (categorical) Oldest ortholog found in vertebrates 
Origin in mammals Systems-level (categorical) Oldest ortholog found in mammals 
Origin in primates Systems-level (categorical) Oldest ortholog found in primates 
Expression 
Ubiquitously expressed Systems-level (categorical) 
CGs are enriched in genes 
ubiquitously expressed (1,4) 
Gene is expressed in > 28/30 tissues 
16,728 
 
Medium expressed Systems-level (categorical) Gene is expressed in 3-28 tissues 
Selectively expressed   Systems-level (categorical) Gene is expressed in 2-3 tissues 
Specifically expressed Systems-level (categorical) Gene is expressed in 1 tissue 
Not expressed Systems-level (categorical) Gene is expressed in 0 tissues 
Tissues where the gene is 
expressed (n) 






Table 3.3. Description of somatically altered genes in the 261 OACs. For each 
sample, the number of genes with predicted damaging alterations is provided. 
The total number of altered genes is 116,989 (17,087 unique hits). 
 
Sample 











LP6005334-DNA_A02 330 23 26 29 2 8 49 0 442 
LP6005334-DNA_A03 506 0 9 16 0 17 57 1 589 
LP6005334-DNA_B01 285 1 29 32 0 5 36 3 373 
LP6005334-DNA_C01 241 17 44 47 0 10 49 1 393 
LP6005334-DNA_C03 35 2 12 39 0 5 57 1 148 
LP6005334-DNA_D01 86 0 16 16 0 1 2 1 99 
LP6005334-DNA_D03 199 32 15 13 0 1 34 0 279 
LP6005334-DNA_H02 494 0 45 32 0 9 79 4 638 
LP6005409-DNA_A02 857 23 43 33 0 4 26 1 965 
LP6005409-DNA_E02 74 41 13 12 0 6 38 0 180 
LP6005409-DNA_F01 109 9 45 74 1 2 43 1 262 
LP6005500-DNA_A02 476 0 12 36 0 12 72 4 590 
LP6005500-DNA_B02 405 16 37 53 2 10 70 1 580 
LP6005500-DNA_C01 159 21 4 11 0 4 33 1 229 
LP6005500-DNA_D01 190 1 23 18 0 2 41 1 269 
LP6005500-DNA_H03 53 0 19 18 2 10 48 6 149 
LP6005690-DNA_A02 473 21 33 30 2 5 47 0 598 
LP6005690-DNA_B03 420 1 21 29 0 10 43 0 512 
LP6005690-DNA_C01 899 22 103 22 3 2 37 1 1063 
LP6005690-DNA_D03 250 3 27 16 1 8 51 3 350 
LP6005690-DNA_F01 131 6 21 26 3 10 73 7 258 
LP6005690-DNA_G01 91 38 30 45 1 9 71 2 265 
LP6005690-DNA_H01 27 1 28 19 2 11 64 2 142 
LP6005935-DNA_B01 516 9 35 85 0 6 33 2 636 
LP6005935-DNA_C03 171 0 6 10 0 6 21 1 211 
LP6005935-DNA_H02 400 3 43 52 1 12 59 2 530 
LP6007401-DNA_A01 64 0 28 25 0 5 75 5 178 
LP6007409-DNA_A01 418 3 61 27 1 8 59 1 566 
LP6007436-DNA_A01 134 5 14 16 0 7 64 5 230 
LP6007512-DNA_A01 952 6 19 36 2 12 65 5 1062 
LP6007538-DNA_A01 248 3 11 5 1 10 57 5 331 
LP6008031-DNA_B01 422 0 30 52 0 5 31 1 518 
LP6008031-DNA_B03 52 20 9 7 0 7 42 2 130 
LP6008031-DNA_C01 371 17 23 33 3 13 86 2 524 
LP6008031-DNA_D02 573 0 32 32 3 7 56 2 676 
LP6008031-DNA_E01 38 0 14 0 4 60 281 6 393 
LP6008031-DNA_H02 10 4 18 10 0 36 192 2 261 
LP6008051-DNA_A02 169 23 24 42 2 8 40 0 287 
LP6008051-DNA_B01 74 1 37 33 2 3 54 3 191 
LP6008051-DNA_C02 45 45 49 40 13 8 44 1 234 
LP6008141-DNA_B01 241 51 41 19 0 7 47 1 393 
LP6008141-DNA_B02 295 3 102 68 11 6 41 3 500 
LP6008141-DNA_D01 649 17 157 129 10 25 98 0 995 
LP6008202-DNA_A01 512 36 106 67 10 10 139 11 829 
LP6008202-DNA_B01 187 1 51 28 7 11 83 3 350 
LP6008202-DNA_B02 49 11 26 34 0 6 65 2 176 
LP6008202-DNA_C02 277 0 25 31 0 7 30 4 347 
LP6008202-DNA_D01 490 7 10 37 1 5 40 7 584 
LP6008202-DNA_E01 441 0 53 50 3 12 121 7 644 
LP6008202-DNA_E02 82 2 41 12 3 7 32 0 170 
LP6008221-DNA_A02 86 10 53 42 3 6 60 0 236 
LP6008221-DNA_C02 465 20 16 22 0 6 23 1 545 
LP6008221-DNA_F02 359 0 44 70 4 115 226 1 780 
LP6008280-DNA_C01 630 28 38 61 1 16 95 2 822 
LP6008280-DNA_E02 398 16 56 43 8 8 89 3 579 
SS6003109 36 1 26 25 1 9 67 1 160 
SS6003115 154 5 21 14 0 8 80 1 270 
SS6003308 326 1 29 249 10 6 29 3 621 
LP2000104-DNA_A01 963 3 16 26 0 13 74 4 1076 
LP6005334-DNA_E01 1002 3 133 97 1 8 62 3 1235 
LP6005334-DNA_F01 316 2 44 27 2 18 72 2 466 
LP6005334-DNA_H01 775 9 32 76 2 16 71 1 940 
LP6005500-DNA_A01 305 1 61 40 1 7 34 2 433 
LP6005500-DNA_F02 817 3 43 16 0 10 98 2 967 
LP6005500-DNA_G03 1108 3 32 46 2 8 39 0 1208 
LP6005690-DNA_C03 1323 4 17 32 4 9 90 6 1465 
LP6005935-DNA_B02 459 2 24 35 0 8 76 1 582 
LP6005935-DNA_C04 111 4 235 29 1 11 97 6 471 




LP6005935-DNA_E03 362 86 61 43 1 6 54 1 585 
LP6005935-DNA_G01 960 0 37 68 2 6 74 2 1096 
LP6005935-DNA_G02 294 43 40 63 0 9 65 1 475 
LP6007430-DNA_A01 708 0 25 49 0 9 76 2 847 
LP6007523-DNA_A01 453 1 13 19 2 4 45 3 525 
LP6007531-DNA_A01 785 19 42 51 0 7 62 8 937 
LP6007544-DNA_A01 351 18 8 15 0 9 50 0 447 
LP6007550-DNA_A01 701 1 10 15 0 9 74 4 797 
LP6008031-DNA_G01 354 20 52 12 4 10 42 1 486 
LP6008141-DNA_E01 174 16 22 48 2 15 61 1 321 
LP6008221-DNA_B02 368 1 45 46 1 5 42 4 487 
SS6003111 703 0 25 19 0 14 64 3 802 
SS6003121 715 1 53 40 0 11 101 4 900 
LP6005334-DNA_G02 275 0 44 33 1 8 69 6 414 
LP6005409-DNA_G03 452 1 20 18 0 8 55 1 542 
LP6005409-DNA_H01 167 1 17 46 0 11 45 0 267 
LP6005500-DNA_E01 0 25 61 13 5 14 56 0 164 
LP6005935-DNA_E01 97 12 26 39 2 13 89 3 255 
LP6007404-DNA_A01 35 0 8 30 0 9 42 1 118 
LP6007440-DNA_A01 287 4 28 21 0 10 80 6 410 
LP6007520-DNA_A01 480 0 49 67 0 14 30 0 601 
LP6008031-DNA_D01 192 43 39 41 1 5 35 1 330 
LP6008031-DNA_E02 386 5 25 57 8 12 54 3 503 
LP6008051-DNA_E02 243 24 43 28 9 11 65 4 408 
LP6008141-DNA_C01 913 1 51 58 3 9 44 2 1043 
LP6008221-DNA_D01 443 39 101 62 3 15 102 3 695 
LP6008280-DNA_B01 19 2 5 8 0 48 290 9 374 
LP6008280-DNA_F01 505 18 25 47 0 10 77 1 653 
LP6008280-DNA_H01 119 17 21 31 1 12 42 0 222 
SS6003149 114 6 62 30 0 13 91 5 301 
SS6003314 131 0 6 27 0 3 38 3 196 
LP2000106-DNA_A01 577 50 63 57 1 5 40 15 730 
LP2000108-DNA_A01 354 52 34 65 0 2 38 2 530 
LP2000328-DNA_A01 306 45 55 62 3 13 46 2 509 
LP2000332-DNA_A01 654 7 68 24 4 14 76 3 827 
LP6005334-DNA_A04 2 17 39 36 0 8 24 1 112 
LP6005334-DNA_E03 26 1 8 4 0 9 53 1 100 
LP6005409-DNA_D02 344 2 13 33 0 11 97 3 483 
LP6005409-DNA_E01 17 28 16 20 0 6 36 2 118 
LP6005409-DNA_F03 317 5 51 34 0 5 27 0 406 
LP6005500-DNA_E03 487 14 175 99 3 19 188 9 923 
LP6005690-DNA_C02 2 11 43 14 3 9 61 1 131 
LP6005690-DNA_E01 270 24 92 36 2 19 86 3 507 
LP6005690-DNA_H02 188 22 19 13 2 18 77 6 336 
LP6005935-DNA_G03 222 0 33 35 0 5 22 0 283 
LP6007420-DNA_A01 127 7 78 36 0 7 61 2 301 
LP6007434-DNA_A01 65 16 21 14 1 9 53 3 173 
LP6007542-DNA_A01 104 20 30 26 0 10 93 3 278 
LP6007552-DNA_A01 266 13 34 41 0 10 53 1 396 
LP6007602 131 4 17 11 3 9 98 4 263 
LP6008031-DNA_A01 752 181 31 55 3 7 74 2 1073 
LP6008031-DNA_A02 30 1 496 125 123 14 106 2 786 
LP6008031-DNA_D03 260 1 62 32 0 10 45 1 375 
LP6008031-DNA_F01 355 1 34 48 1 3 45 1 464 
LP6008031-DNA_F02 281 16 22 23 0 2 17 0 350 
LP6008031-DNA_G02 216 1 24 30 4 13 37 0 314 
LP6008051-DNA_A01 456 2 53 56 1 4 30 0 536 
LP6008051-DNA_D01 454 3 31 60 0 12 69 1 600 
LP6008141-DNA_A01 74 16 35 32 5 14 78 2 231 
LP6008141-DNA_F02 261 3 45 35 2 13 93 4 431 
LP6008221-DNA_B01 638 0 15 12 1 0 8 1 666 
LP6008221-DNA_D02 393 1 28 17 2 6 40 1 478 
LP6008221-DNA_E01 82 6 112 49 8 7 46 3 281 
LP6008221-DNA_G01 665 24 47 59 0 7 22 0 777 
LP6008280-DNA_B03 177 2 9 19 6 14 34 1 258 
LP6008280-DNA_D02 8 1 132 60 19 4 52 2 247 
LP6008280-DNA_G02 637 49 20 33 1 5 22 0 746 
SS6003317 575 40 43 31 1 8 61 1 732 
LP6005334-DNA_D02 21 15 60 28 0 8 81 1 207 
LP6005409-DNA_F02 167 17 16 23 0 9 46 1 268 
LP6005409-DNA_H03 79 0 22 31 0 2 15 2 141 
LP6005500-DNA_C03 321 28 9 11 0 10 56 1 428 
LP6005690-DNA_D01 156 20 32 30 0 14 43 1 288 
LP6005690-DNA_D02 56 0 91 30 1 7 49 4 225 
LP6005690-DNA_F02 40 0 43 48 0 6 60 4 186 
LP6005935-DNA_A03 202 3 44 48 5 15 36 0 298 
LP6005935-DNA_C02 0 6 10 8 0 13 88 4 125 
LP6007398-DNA_A01 169 24 88 28 1 11 52 1 355 
LP6007416-DNA_A01 150 0 73 75 1 9 66 1 338 




LP6007516-DNA_A01 734 30 36 40 0 3 48 1 873 
LP6007567-DNA_A01 171 6 91 50 1 7 49 3 338 
LP6007597 64 0 30 26 0 11 110 2 235 
LP6008031-DNA_A04 13 1 57 16 0 5 50 3 139 
LP6008031-DNA_B02 180 11 44 43 1 11 42 1 316 
LP6008051-DNA_G01 220 0 72 70 0 8 41 1 391 
LP6008141-DNA_F01 785 0 70 101 3 10 37 1 945 
LP6008141-DNA_G01 163 85 24 52 0 3 50 4 355 
LP6008141-DNA_G02 95 67 49 36 7 8 66 2 313 
LP6008202-DNA_G01 40 5 15 25 0 4 27 1 110 
LP6008221-DNA_A01 138 15 51 55 2 6 54 3 279 
LP6008280-DNA_A01 119 5 30 12 1 6 39 1 208 
SM-4AX85 156 20 27 19 0 5 50 2 265 
SM-4AX86 0 0 17 11 0 6 62 3 96 
SM-4AX87 0 0 10 15 0 1 20 0 43 
SM-4B295 478 4 27 18 0 7 54 3 582 
SS6003302 227 5 39 832 10 6 34 1 1092 
LP2000105-DNA_A01 584 23 105 64 9 11 61 16 801 
LP2000325-DNA_A01 347 14 119 51 3 9 55 6 564 
LP2000327-DNA_A01 137 17 6 30 0 5 37 3 215 
LP2000329-DNA_A01 255 0 39 41 0 8 60 4 384 
LP2000330-DNA_A01 1766 7 58 32 2 6 39 3 1874 
LP2000331-DNA_A01 44 44 53 29 1 9 32 0 199 
LP2000333-DNA_A01 347 20 42 22 1 6 33 5 448 
LP6005334-DNA_B02 263 65 16 30 0 12 68 1 445 
LP6005334-DNA_C02 302 1 28 25 0 7 32 2 381 
LP6005334-DNA_E02 50 3 7 13 0 1 11 1 78 
LP6005334-DNA_F02 466 0 149 51 0 11 65 0 700 
LP6005334-DNA_F03 54 1 42 21 0 0 9 0 124 
LP6005334-DNA_G01 470 56 25 29 1 13 89 1 663 
LP6005334-DNA_H03 522 1 29 76 2 6 77 8 646 
LP6005496-DNA_B01 67 16 14 10 0 8 51 6 162 
LP6005500-DNA_A03 763 4 61 35 2 7 37 0 879 
LP6005500-DNA_B01 37 1 25 31 1 3 39 1 136 
LP6005500-DNA_B03 1243 88 19 15 0 8 51 3 1411 
LP6005500-DNA_D02 528 2 70 47 1 14 69 5 709 
LP6005500-DNA_D03 490 4 14 19 0 3 48 4 570 
LP6005500-DNA_E02 54 0 17 33 0 7 69 4 171 
LP6005500-DNA_F01 1353 22 44 17 1 4 40 3 1461 
LP6005500-DNA_G01 425 2 30 43 1 8 55 4 534 
LP6005500-DNA_G02 130 5 14 22 0 2 16 0 178 
LP6005500-DNA_H01 119 5 50 30 0 15 56 3 260 
LP6005500-DNA_H02 224 8 23 12 0 11 44 2 318 
LP6005690-DNA_B01 691 11 17 4 0 3 40 1 756 
LP6005690-DNA_B02 329 1 42 63 2 18 114 6 536 
LP6005690-DNA_F03 395 4 98 11 15 10 42 2 565 
LP6005690-DNA_G02 820 16 23 31 1 7 58 1 940 
LP6005935-DNA_A01 287 0 37 33 0 12 96 4 444 
LP6005935-DNA_A02 259 3 19 57 0 9 69 3 394 
LP6005935-DNA_B03 152 39 34 28 7 10 88 7 351 
LP6005935-DNA_B04 631 3 25 80 0 11 65 3 746 
LP6005935-DNA_D01 13 15 54 55 1 11 70 0 206 
LP6005935-DNA_D02 476 23 73 78 0 8 41 3 653 
LP6005935-DNA_F01 373 28 43 52 1 3 30 1 501 
LP6005935-DNA_F02 185 0 249 31 0 14 140 4 586 
LP6005935-DNA_H01 117 4 31 38 0 12 76 1 253 
LP6007358-DNA_A01 246 2 5 12 0 8 47 3 307 
LP6007396-DNA_A01 144 2 102 43 2 11 50 2 324 
LP6007407-DNA_A01 109 10 24 40 1 14 71 2 258 
LP6007414-DNA_A02 29 53 17 11 0 8 28 0 144 
LP6007422-DNA_A01 311 25 25 30 0 11 30 0 425 
LP6007424-DNA_A01 412 1 106 97 4 13 82 2 666 
LP6007427-DNA_A01 120 3 25 44 1 16 117 2 313 
LP6007432-DNA_A01 309 8 23 16 3 11 64 3 428 
LP6007438-DNA_A01 591 0 104 93 0 4 29 1 768 
LP6007504-DNA_A01 125 0 34 34 0 3 25 1 209 
LP6007518-DNA_A01 355 6 21 22 0 7 90 3 489 
LP6007529-DNA_A01 80 0 18 13 1 9 59 1 171 
LP6007533-DNA_A01 141 3 18 31 0 7 23 1 214 
LP6007535-DNA_A01 562 2 40 42 3 4 18 1 648 
LP6007540-DNA_A01 63 0 7 16 0 9 43 4 139 
LP6007546-DNA_A01 35 0 9 11 0 8 32 2 89 
LP6007591 73 0 33 29 1 17 81 4 224 
LP6007594 587 0 52 27 1 6 67 2 717 
LP6008031-DNA_C02 243 2 32 52 0 7 45 1 349 
LP6008031-DNA_C03 38 0 2 0 0 0 0 0 40 
LP6008031-DNA_F03 83 1 31 32 1 12 71 4 215 
LP6008031-DNA_G03 144 6 68 43 4 13 104 0 363 
LP6008031-DNA_H01 203 1 38 29 2 8 57 1 317 




LP6008051-DNA_C01 143 4 61 82 2 11 46 1 331 
LP6008051-DNA_E01 68 11 15 32 0 14 55 2 185 
LP6008051-DNA_F01 140 1 50 46 3 5 38 1 263 
LP6008051-DNA_F02 278 18 43 20 7 20 106 3 482 
LP6008141-DNA_E02 152 1 10 8 2 9 57 2 234 
LP6008141-DNA_H02 169 15 60 53 8 7 63 1 328 
LP6008202-DNA_A02 549 20 88 57 9 9 76 3 744 
LP6008202-DNA_C01 177 6 46 75 1 12 72 11 369 
LP6008202-DNA_D02 508 4 33 30 1 6 51 2 607 
LP6008202-DNA_F02 0 0 13 4 1 7 41 2 64 
LP6008202-DNA_H01 105 0 39 34 2 6 54 3 230 
LP6008221-DNA_C01 415 0 44 40 5 6 73 2 551 
LP6008221-DNA_E02 94 4 152 24 37 7 66 1 367 
LP6008221-DNA_F01 256 42 23 39 3 7 42 2 399 
LP6008221-DNA_G02 188 4 71 46 30 14 64 1 382 
LP6008221-DNA_H01 104 35 19 22 4 10 62 5 249 
LP6008280-DNA_A02 226 48 59 50 2 4 27 1 382 
LP6008280-DNA_B02 158 7 16 28 1 7 25 2 231 
LP6008280-DNA_C02 23 1 13 5 0 6 53 3 102 
LP6008280-DNA_C03 226 3 21 51 3 9 127 2 417 
LP6008280-DNA_E01 246 0 30 16 4 7 54 2 349 
LP6008280-DNA_G01 47 0 4 8 0 0 4 0 60 
SM-4AX84 19 0 2 5 0 9 57 2 90 
SM-4B296 468 3 85 76 1 22 151 2 750 
SS6003113 1 0 16 11 0 10 27 2 63 
SS6003117 7 0 7 4 0 8 39 2 65 
SS6003119 489 25 10 19 0 7 14 0 546 
SS6003129 5 28 25 12 3 6 83 7 155 
SS6003305 299 5 40 37 2 12 57 0 412 
SS6003311 189 2 30 37 2 14 69 0 308 
SS6003320 32 0 31 31 4 14 52 0 155 







Table 3.4. Selection of best models and final list of helper genes. Shown are the parameters of the 38 unique best models in the four 
kernels and 24 associated unique lists of top 10 genes. These lists are named using the number of genes that compose them, followed 
by a letter where the same number (but not the same genes) was found multiple times. The number of times and corresponding 






Radial kernel Sigmoid kernel Polynomial kernel 
List of top 10 
genes 
Occurrence over 500 
nu nu gamma nu gamma nu gamma degree n ID times (n) % 
1 0.05 0.05 0.03125 0.05 4 0.05 0.03125 3 1 952A 207 41.4 
2 0.05 0.05 0.03125 0.05 4 0.05 0.0625 3 2 952B 161 32.2 
2 0.05 0.05 0.03125 0.05 4 0.05 0.0625 3 23 952C 1 0.2 
3 0.05 0.05 0.03125 0.05 4 0.05 0.125 3 2 952B 161 32.2 
3 0.05 0.05 0.03125 0.05 4 0.05 0.125 3 5 951B 19 3.8 
4 0.05 0.05 0.03125 0.05 4 0.05 0.25 3 2 952B 161 32.2 
4 0.05 0.05 0.03125 0.05 4 0.05 0.25 3 5 951B 19 3.8 
5 0.05 0.05 0.03125 0.05 4 0.05 1 3 2 952B 161 32.2 
6 0.05 0.05 0.03125 0.05 4 0.05 4 3 2 952B 161 32.2 
7 0.05 0.05 0.03125 0.05 4 0.05 8 3 2 952B 161 32.2 
8 0.05 0.05 0.03125 0.05 4 0.05 16 3 2 952B 161 32.2 
9 0.05 0.05 0.03125 0.05 4 0.05 0.015625 3 3 951A 43 8.6 
9 0.05 0.05 0.03125 0.05 4 0.05 0.015625 3 10 950 3 0.6 
10 0.05 0.05 0.03125 0.05 8 0.05 0.015625 3 4 934A 28 5.6 
10 0.05 0.05 0.03125 0.05 8 0.05 0.015625 3 24 934B 1 0.2 
11 0.05 0.05 0.03125 0.05 8 0.05 0.03125 3 4 934A 28 5.6 
12 0.05 0.05 0.03125 0.05 8 0.05 0.0625 3 4 934A 28 5.6 







14 0.05 0.05 0.03125 0.05 8 0.05 0.5 3 4 934A 28 5.6 
15 0.05 0.05 0.03125 0.05 8 0.05 1 3 4 934A 28 5.6 
16 0.05 0.05 0.03125 0.05 8 0.05 16 3 4 934A 28 5.6 
17 0.05 0.05 0.03125 0.05 4 0.05 0.5 3 5 951B 19 3.8 
18 0.05 0.05 0.03125 0.05 4 0.05 2 3 5 951B 19 3.8 
19 0.05 0.05 0.03125 0.05 16 0.05 0.0625 3 6 929A 8 1.6 
20 0.05 0.05 0.03125 0.05 16 0.05 0.25 3 6 929A 8 1.6 
20 0.05 0.05 0.03125 0.05 16 0.05 0.25 3 25 931A 1 0.2 
21 0.05 0.05 0.03125 0.05 16 0.05 2 3 6 929A 8 1.6 
22 0.05 0.05 0.03125 0.05 16 0.05 4 3 6 929A 8 1.6 
23 0.05 0.05 0.03125 0.05 16 0.05 16 3 6 929A 8 1.6 
24 0.05 0.05 0.03125 0.05 2 0.05 0.015625 3 7 915 5 1 
24 0.05 0.05 0.03125 0.05 2 0.05 0.015625 3 22 916 1 0.2 
25 0.05 0.05 0.03125 0.05 2 0.05 0.25 3 7 915 5 1 
26 0.05 0.05 0.015625 0.05 4 0.05 0.015625 3 8 928 4 0.8 
26 0.05 0.05 0.015625 0.05 4 0.05 0.015625 3 9 929B 3 0.6 
26 0.05 0.05 0.015625 0.05 4 0.05 0.015625 3 18 931B 1 0.2 
27 0.05 0.05 0.015625 0.05 4 0.05 8 3 8 928 4 0.8 
28 0.05 0.1 0.015625 0.05 16 0.05 0.25 3 11 920 3 0.6 
29 0.05 0.05 0.015625 0.05 16 0.05 0.015625 3 12 926A 2 0.4 
30 0.05 0.05 0.0078125 0.05 2 0.05 0.25 3 13 898 1 0.2 
31 0.05 0.05 0.0078125 0.05 16 0.05 0.25 3 14 911 1 0.2 
32 0.05 0.05 0.015625 0.05 0.5 0.05 0.0625 3 15 907 1 0.2 
33 0.05 0.05 0.015625 0.05 1 0.05 0.0625 3 16 909 1 0.2 







35 0.05 0.05 0.015625 0.05 8 0.05 0.015625 3 19 926B 1 0.2 
36 0.05 0.05 0.03125 0.05 0.5 0.05 0.015625 3 20 906B 1 0.2 
37 0.05 0.05 0.03125 0.05 1 0.05 0.25 3 21 919 1 0.2 





3.3.3 Feature correlation 
All sysSVM features exhibit statistically significant difference between 
known cancer genes (as those are defined in the Cancer Gene Census) and 
the rest of human genes (see chapter 2). However, the correlation of these 
features was not thoroughly explored during the pilot phase of my thesis. To 
this end, I performed a pairwise correlation analysis of the sysSVM features 
(Figure 3.5A).  
Overall, I observed positive correlations between i) the number of exonic 
mutations (mutational burden) and the number of damaging mutations, ii) the 
protein degree and betweenness, and iii) the gene length and the number of 
protein domains. Moreover, several sysSVM features were mutually exclusive, 
and therefore exhibited high negative correlation (Figure 3.5A). These features 
included various expression measurements derived from GTEx 
(https://www.gtexportal.org/home/) across human tissues, and features related 
to the evolutionary origin of human genes. As it is easily conceivable, a gene 
cannot be ubiquitously expressed and not expressed at the same time. Cancer 
genes have been found to be expressed in a significantly higher number of 
normal tissues than the rest of human genes, thus, features representing low or 
no expression in normal tissues were mostly constant in the OAC training set. 
The high positive correlation of the damaging mutations with the mutation 
burden (SNVs and indels) suggested that these features carry some degree of 
redundancy. However, I argued that although highly correlated, the two features 
would be relevant to sysSVM, if their ratio exhibited significant difference 
between known cancer genes and the rest of human genes. To avoid biased 
results on the OAC training set, this analysis was performed pan-cancer. To this 




Genome Atlas (TCGA; data downloaded on 01/03/2015) for 7,828 tumour 
samples covering 31 cancer types (Table 3.5). TCGA somatic mutations were 
re-annotated using an in-house mutation annotation pipeline in order for variant 
calls across different cancer types to be comparable (see Methods). The total 
number of mutations analysed was 579,699 and 1,237,039 for silent and non-
silent mutations, respectively (Table 3.5). I found that known cancer genes had 
significantly higher ratio of damaging mutations to all mutations in the pan-
cancer analysis (Figure 3.5B), and therefore I decided to retain the number of 
all exonic mutations in the feature list of sysSVM. Although such “ratiometric” 
gene features have been used before to identify driver genes (Tokheim et al. 
2016), I acknowledged that their contribution to sysSVM was expected to be 
minimal. This is because, in sysSVM, each gene in each patient is considered 
separately and therefore the number of mutations for both exonic and damaging 
mutations per gene will be low (mostly 1). 
Protein degree and betweenness were also very strongly correlated. It has 
been previously shown that network centrality measurements, such that of 
degree and betweenness, are correlated in several complex networks (Lee 
2006). However, they capture different characteristics of the network. Degree 
describes the number of primary neighbours of a vertex, while betweenness is a 
measure of the influence of a vertex over the flow of information between every 
pair of vertices, under the assumption that information primarily flows over the 
shortest path between them. Therefore, both were retained in the feature list of 
sysSVM for this part of my thesis. Finally, as gene length and the number of 
protein domains exhibited significant difference between known cancer genes 
and the rest of human genes, both features were maintained in the feature list 









Figure 3.5. Correlation of sysSVM features. (a) Pairwise correlation matrix of 
sysSVM features. Blue denotes positive pearson correlation coefficient while 
red denotes negative correlation coefficient. Only coefficients higher than 0.5 or 
lower than -0.5 are shown. White colour denotes coefficients between -0.5 and 
0.5. (b) Distribution of the ratio of predicted damaging mutations over all exonic 
mutations for known cancer genes, candidate cancer genes and the rest of 
human genes. Known cancer genes were derived from the Cancer Gene 
Census (Tate et al. 2018). Candidate cancer genes were derived from the 
Network of Cancer Genes database (An, Dall’Olio, et al. 2016) and they 
represent genes that have been predicted as drivers by various methods, but 
their driver role is pending further validation. Finally, the rest of human gene set 
is comprised of all human genes that were neither in the known cancer genes 








Table 3.5. Pan-cancer cohorts from The Cancer Genome Atlas. Shown are the number of patients, and the number of silent and non-
silent mutations for 31 cancer types. 
 
Cancer type Abbreviation Patients Silent mutations 
Non-silent 
mutations 
Adrenocortical Carcinoma ACC 72 2,538 3,905 
Bladder Urothelial Carcinoma BLCA 232 19,322 46,723 
Breast Invasive Carcinoma BRCA 954 20,108 42,780 
Cervical squamous cell carcinoma and 
endocervical adenocarcinoma CESC 179 26,648 41,343 
Cholangiocarcinoma CHOL 35 1,968 3,227 
Colon adenocarcinoma COAD 255 20,956 52,773 
Oesophageal carcinoma ESCA 179 27,687 45,685 
Glioblastoma multiforme GBM 143 2,898 7,576 
Head and Neck squamous cell carcinoma HNSC 491 37,931 86,993 
Kidney Chromophobe KICH 65 2,401 5,097 
Kidney renal clear cell carcinoma KIRC 423 8,575 21,241 
Kidney renal papillary cell carcinoma KIRP 164 7,356 18,099 
Acute Myeloid Leukaemia LAML 169 616 1,534 
Brain Lower Grade Glioma LGG 506 7,936 17,547 
Liver hepatocellular carcinoma LIHC 187 35,222 55,802 
Lung adenocarcinoma LUAD 487 77,086 211,964 
Lung squamous cell carcinoma LUSC 174 14,596 42,471 
Ovarian serous cystadenocarcinoma OV 341 5,283 13,952 
Pancreatic adenocarcinoma PAAD 136 8,758 11,941 







Prostate adenocarcinoma PRAD 409 4,267 8,634 
Rectum adenocarcinoma READ 110 3,010 7,575 
Sarcoma SARC 237 16,650 25,032 
Skin cutaneous melanoma SKCM 357 142,039 249,273 
Stomach adenocarcinoma STAD 335 47,526 128,524 
Testicular Germ Cell Tumours TGCT 143 2,977 4,537 
Thyroid carcinoma THCA 393 1,154 3,116 
Thymoma THYM 116 5,863 10,623 
Uterine Corpus Endometrial Carcinoma UCEC 229 22,832 59,180 
Uterine Carcinosarcoma UCS 53 1,631 2,587 
Uveal melanoma UVM 79 1,506 2,481 






3.3.4 Distribution of known cancer genes in the feature space 
After I established that sysSVM features were descriptive of known cancer 
genes (as they exhibited statistically significant difference between known cancer 
genes and the rest of human genes), I sought to investigate whether specific 
combinations of these features can define classes of training observations in the 
feature space of sysSVM. To this end, I performed a dimensionality reduction 
analysis using t-distributed stochastic neighbour embedding (t-SNE) and measured 
the average distance of known cancer genes from their closest high-density peak 
in the t-SNE map. I found that there were multiple clusters of known cancer genes, 
each defining a certain region of the feature space (Figure 3.6A). Moreover, 
permutation analysis showed that these clusters were not random (Figure 3.6B). 
When specific features were mapped onto the 2-dimensional space, it 
became evident that each high-density region (as those defined by the training 
observations in Figure 3.6A) represented genes harbouring a particular sysSVM 
feature (Figure 3.7). For instance, genes with high degree in the protein-protein 
interaction network, translocations, inversions, and truncating mutations were 
clustered together; in contrast several other features, such as amplifications, the 
breadth of expression, and the chromatin compartment were uniformly distributed 
across the whole feature space (Figure 3.7). Of note, such features with uniform 
distribution would be non-informative for a two-class classifier. This is because in a 
two-class setting only the features that maximise the differences between the two 
classes are of interest. Conversely, uniformly distributed features are informative in 
one-class classification algorithms, such as sysSVM, owing to the presence of only 









Figure 3.6. Clustering of the training observations in the feature space of sysSVM. (a) Dimensionality reduction of the training 
set of sysSVM using t-distributed stochastic neighbour embedding (tSNE). (b) Permutation analysis of the clustering of the 
training observations in a. To assess whether the training observations were clustered more than expected in the high-density 
regions of the 2-D feature space, I randomly sampled 4,091 genes (equal size as the training set) 1,000 times. After defining the 
peaks of their distribution in the 2-D feature space, I measured the distance of each gene from the closest density peak and 
averaged the distance of all genes within each iteration. The mean of gene distance for the random samples was significantly 












Figure 3.7. For each property, a 2-D map of the high-dimensional data was rebuilt 
for the 476 known cancer genes altered 4,091 times in the cohort of 261 OACs. 
Black curves represent the density of known cancer genes. For continuous or 
multi-value variables, a colour code is reported. For categorical variables genes 
are labelled according to whether they have (red) or not (grey) that property. All 
properties are summarised in Table 3.2. 
 
 
3.3.5 Description of the best models 
Confirming the observations in the pilot cohort (Table 2.4), the best value of 
the parameter nu for all kernels in the extended OAC cohort was 0.05, suggesting 
that at least 95% of the training set was considered for the construction of the 
decision boundary during the training phase. Gamma, although it fluctuated 
between three possible values (Table 3.4), converged to the value of 0.03125, with 
the exception of the sigmoid kernel in which the best value was 4. Finally, the best 
parameter for degree in the polynomial kernel was 3. 
Next, I examined the distribution of the decision values in the best models. As 
noted in chapter 2, decision values correspond to the distance from the decision 
boundary and in sysSVM they are used to calculate the meta-score used to rank 
the genes (equation 2.10). Overall, very few genes in the training set had negative 
decision values (Figure 3.8), confirming the high sensitivity that was estimated 
during the cross-validation. Specifically, linear and sigmoid kernels had the highest 
average decision values (75.35 and 121.85, respectively; Figure 3.8) and the 
lowest number of support vectors (214 and 205, respectively). 
To examine the weights of individual features in the final models, I performed 
a recursive feature elimination analysis (Guyon et al. 2002). Briefly, the weight 




coefficients with the support vectors and all features were ranked according to the 
second power of w (for details see chapter 2). Recursive feature elimination was 
run 33 times per kernel to estimate the ranks of all 34 features. In contrast to the 
pilot cohort, copy number gains was not the feature with the highest weight in any 
of the kernels (Table 3.6). Instead, it was ranked fifth and sixth in linear and 
polynomial kernels, respectively. Other top-ranking features were the expression of 
genes in human tissues, and the number of connections in the protein-protein 
interaction network (Table 3.6). Interestingly, high-ranking features were different 
across different kernels, in contrast to the more homogeneous ranking in the pilot 
cohort. This suggested that the low number of training observations in the pilot 
phase affected the ranking of the features in the best models. Interestingly, radial 
and sigmoid kernels assigned higher weights to degree, betweenness and gain-of-
function mutations, while linear and polynomial kernels weighted more expression, 
origin and the age of the genes (Table 3.6). Taken together, these results highlight 
that molecular features were ranked on average higher in the best model of the 
extended cohort than in the pilot cohort, despite the fact that the weight of copy 















Table 3.6. Ranks of systems-level (blue) and molecular (orange) features in sysSVM as derived from recursive feature 
elimination for each kernel. 
Rank Linear Polynomial Radial Sigmoid 
1 Medium expressed  Ubiquitously expressed Protein degree Protein betweenness 
2 Ubiquitously expressed Medium expressed  Protein betweenness Protein degree 
3 Origin in vertebrates Origin in vertebrates Gain-of-function mutations miRNA interactions 
4 Origin in metazoans Origin in metazoans miRNA interactions Gain-of-function mutations 
5 Gene gain  Old gene Copy number Ubiquitously expressed 
6 Old gene Gene gain  Hub Ohnolog 
7 Selectively expressed Selectively expressed Central protein Central protein 
8 Ohnolog Ohnolog Ubiquitously expressed Hub 
9 Central protein Central protein Ohnolog Origin in opisthokonts 
10 Origin in prokaryotes Origin in eukaryotes Old gene Old gene 
11 Origin in eukaryotes Origin in prokaryotes Truncating mutations Damaging mutations 
12 Origin in mammals Origin in mammals Gene gain  Exonic SNVs 
13 Gene loss Gene loss Origin in metazoans Origin in eukaryotes 
14 Origin in opisthokonts Origin in opisthokonts Exonic SNVs Origin in metazoans 
15 Specifically expressed Specifically expressed Origin in eukaryotes Origin in prokaryotes 
16 Hub Hub Gene loss Truncating mutations 
17 Not expressed Not expressed Origin in opisthokonts Medium expressed  
18 Origin in primates Origin in primates Gene duplication Gene loss 
19 Gene duplication Gene duplication Origin in prokaryotes Gene duplication 
20 Exonic SNVs Copy number Medium expressed  Origin in vertebrates 
21 Gene translocation Protein degree Origin in vertebrates Gene gain  
22 Gene inversion Damaging mutations Selectively expressed Specifically expressed 
23 Protein degree Chromatin state Specifically expressed Selectively expressed 
24 Damaging mutations Gene length Origin in mammals Not expressed 
25 Truncating mutations Gene translocation Not expressed Origin in primates 
26 Chromatin state Gene inversion Origin in primates Origin in mammals 
27 miRNA interactions Protein betweenness Damaging mutations Gene length 
28 Protein domains Protein domains Gene insertion Gene translocation 
29 Gain-of-function mutations Gene insertion Gene inversion Gene inversion 
30 Gene length Gain-of-function mutations Number of tissues Chromatin state 
31 Gene insertion miRNA interactions Gene length Copy number 
32 Protein betweenness Truncating mutations Gene translocation Number of tissues 
33 Copy number Exonic SNVs Chromatin state Gene insertion 




3.3.6 The landscape of patient-specific cancer genes in OAC 
My working hypothesis was that the driver potential of genes with predicted 
damaging alterations could be predicted by the similarity of their properties to those 
of known cancer genes and their relative contribution to tumorigenesis declined 
with decreasing sysSVM score. Therefore, I considered the top scoring genes in 
each patient as the most likely contributors to cancer progression. Overall, these 
genes localised closely to the high-density regions of known cancer genes (Figure 
3.9A). Furthermore, using the mean distance from the centre of each high-density 
area in the tSNE map, I verified that the top scoring genes occupied positions 
proximal to those of known cancer genes, (Figure 3.9B). This indicated that the 
properties of top scoring genes indeed resembled those of known cancer genes, 
and that the scoring function accurately recapitulated the distance from the 





Figure 3.9. Overview of altered genes in the 261 OACs in the feature space. (a) t-
distributed Stochastic Neighbour Embedding (t-SNE) plot of 116,989 altered genes 
in 261 OACs. Starting from the 34 properties used in sysSVM, a 2-D map of the 
high-dimensional data was built using Rtsne package in R. Curves are coloured 
according to the density of 4,091 known cancer genes (blue dots) used as a 
training set and the rest of altered genes are coloured according to their sysSVM 
score. (b) Average distance from the center of the highest-density regions of 




gene set, the distance of each helper gene from the center was calculated and the 
mean of the distribution across the set was derived. 
 
 
To evaluate how the sysSVM classifier, trained on the ICGC cohort, 
performed on independent cohorts, I used 86 OACs from The Cancer Genome 
Atlas (TCGA) and 21 OACs from a previous study (Nones et al. 2014) (Table 3.7). I 
scored all altered genes, including known cancer genes, in each of the 107 OACs 
independently, using the four classifiers trained on the ICGC cohort. In both 
datasets, known cancer genes (e.g. TP53, ERBB2, EGFR, SMAD4) had 
significantly higher scores than the rest of the altered genes (Figure 3.10), 
indicating that sysSVM was able to recognise them as major cancer contributors in 
previously unseen cancer samples. 
To further investigate the top sysSVM predictions in the 261 OACs, I 
analysed the 952 helper genes (top 10 scoring genes in each patient; Appendix 
Table 7.2). As sysSVM uses no pre-defined cut-off to distinguish driver from 
passenger genes, I also checked whether the main findings hold true when a 
higher or lower number of top scoring genes were considered (see chapter 5 for 
the analysis of the alternative cut-offs). The vast majority (nearly 80%) of newly 
predicted helpers underwent copy number gain (Figure 3.11A), consistently with 
the prevalence of gene amplification in OAC (Table 3.2). To examine the 
consequence of helper amplification, I analysed the expression of amplified helpers 
in 92 OACs for which expression data were available. Amplified helpers were 
found over-expressed in OACs in which they were amplified, as compared to 




amplification of these helpers may have functional implications in OAC. Moreover, 
approximately 60% of helper genes were rare or patient-specific (Figure 3.11C). A 
few helper genes, however, were altered in more than 5% of OACs (Table 3.8) and 
their relatively higher frequency of alteration could not be explained by large-scale 
amplification events containing neighbouring known drivers (i.e. concomitant 
amplification of the closest driver gene; Figure 3.11D) (Secrier et al. 2016). Overall, 
171 helpers (18%) had been predicted as candidate cancer genes in previous 
studies (Repana et al. 2018), and 41 helpers (4%) were recently added to Tiers 1 
and 2 of the Cancer Gene Census (Tate et al. 2018), indicating that their 
tumorigenic potential has been validated3.  
The most recurrently altered helper was TOMM34, a translocase of the outer 
membrane of mitochondria, which was found amplified in 33 OACs (12.6%; Table 
3.8). TOMM34 is an essential factor for protein import in mitochondria, and it has 
been shown to interact with the mature portion of several preproteins during their 
translocation through the mitochondrial membrane (Nuttall et al. 1997). 
Overexpression of TOMM34 has been reported in colon (Shimokawa et al. 2006) 
and early invasive breast cancer (Aleskandarany et al. 2012), suggesting that 
mitochondrial dysfunction plays a role in tumorigenesis. In particular, protein 
expression of TOMM34 has been associated with higher tumour grade, advanced 
nodal stage and larger tumour size in breast cancer, demonstrating the utility of 
this gene as a potential biomarker. Although, no difference in tumour grade or 
nodal status was observed in OAC, TOMM34 was predicted as helper in almost all 
the samples in which it was amplified (33/35). Other recurrent helpers (NCOA3, 
                                                 
3 Intersection of helpers with genes from previous studies was performed by Damjan 




E2F1, MCM7, VAPB, DNMT3B) have been reported to play a role in tumour 
progression in multiple tissues (Wagner et al. 2013; Liang et al. 2016; Qu et al. 
2017; Rao et al. 2012; Peralta-Arrieta et al. 2017). A more comprehensive view of 
all predicted helpers, along with data on their experimental validation is presented 
in chapter 4. 
To analyse the impact of false positive predictions in sysSVM, I collected two 
lists of previously described false positive drivers from the literature. The first list 
was composed of 49 genes that had been previously considered as false positive 
cancer driver genes (Lawrence et al. 2013; An et al. 2016). Overall, only three of 
these genes (PCLO, CNTNAP2 and NRXN3) were predicted by sysSVM to be 
cancer helpers. PCLO has been considered as a false positive, because of its long 
coding sequence and biased base composition (Lawrence et al. 2013). However, 
PCLO has been shown to exert an oncogenic role in oesophageal cancer by 
interfering with the EGFR signalling pathway (Zhang et al. 2017). The second list 
was a manually curated set of 488 genes (Bailey et al. 2018). I found 44 helpers in 
this list (4.6% of the total). This fraction was smaller than the fraction of known 
cancer genes (Futreal et al. 2004) that were present in the same list of false 
positives (46/719, 6.4%). Altogether, these analyses indicate that sysSVM robustly 
predicts cancer genes in multiple patient cohorts, with minimal false positive rate. 
Patient-specific analysis of helpers was also conducted to investigate whether 
the 2-dimensional feature space (Figure 3.6A) could be utilised to infer patient sub-
groups, based on which high-density area the corresponding helpers were 
localised in. As the location of helpers in the 2-D feature space reflects their 
similarity to known cancer genes, this analysis could highlight groups of patients 




were identified. Those that had all their helpers clustered in one region (Figure 
3.12A), those with the majority of the helpers positioned in multiple high-density 
regions (Figure 3.12B) and, finally, those with helpers located in sparse areas of 
the feature space (Figure 3.12C). I reasoned that an overall high similarity of 
helpers to the major drivers (Figure 3.12A and 3.12B) could serve as a biomarker 
for tumour aggressiveness. Conversely, a dispersed pattern of helpers, away from 
the high-density areas (Figure 3.12C), would indicate helpers with lower driver 
potential and, therefore, possibly a less aggressive tumour. However, I found no 
evidence of association of sysSVM score with survival when examined OACs with 
high-scored helpers versus OACs with low-scored helpers (Figure 3.12D) or when I 








Figure 3.10. Comparison of sysSVM scores between known drivers and the rest of 
altered genes for 86 OACs from TCGA (a) and 21 OACs from Nones et al. (Nones 
et al. 2014) (b). Starting from all altered genes, known drivers were identified as 
described in the Methods. All genes that are not expressed in healthy esophagus 
were removed from both gene sets. Distributions were compared using two tailed 







Figure 3.11. Characteristics of cancer helpers. (a) Distribution of damaging 
alterations in 952 cancer helpers. Overall, these genes acquire 2,608 damaging 
alterations. (b) Comparison of the expression of cancer helpers in OACs in which 
they have been found amplified with OACs in which they were not predicted as 
helpers and they were copy number neutral. (c) Recurrence of cancer helpers 
across 261 OACs. Only samples acquiring alterations with a damaging effect are 
considered (see main text). (d) Scatterplot of co-amplified driver and helper genes 
in 261 OACs as a function of the total number of samples where they are altered. 
For each pair of drivers or helpers in the same chromosome, ASCAT breakpoints 














Figure 3.12. Similarity of cancer helpers with known driver genes within OACs. Representative examples of OACs: (a) all helpers 
concentrated in one region of the 2-D feature space; (b) all helpers concentrated in multiple high-density regions; (c) a more dispersed 
distribution of helpers. (d) Survival analysis of OACs with helpers located very close to known drivers versus OACs with helpers located 
further away from known drivers in the 2-D feature space. For each helper in each OAC, the distance of the closest known driver was 
calculated, and an average distance of all helpers was computed per OAC. OACs in the upper and bottom quartiles of the average 
distance were compared. (e) Same as d but for all scored genes within each OAC. 
 
 
Table 3.7. Summary of somatically altered genes in the two validation cohorts (86 OACs from The Cancer Genome Atlas and 21 OACs 
from previous literature). For each of the 86 TCGA and 21 OACs, the number of genes with predicted damaging alterations is provided. 















03aa1df3-5156-4bfd-a36d-4daff2b6d06c Nones et al 2014 227 23 0 0 0 19 50 0 319 
09681159-48b2-4607-b455-4284c49b49a5 Nones et al 2014 593 10 0 0 0 16 62 0 678 
2206848d-3794-4061-a379-3eb1582e4ea5 Nones et al 2014 815 9 0 0 0 6 26 0 853 
430b3d28-2f55-4cd8-91ec-3b94cadb34b8 Nones et al 2014 531 0 0 0 0 8 72 0 609 
50553323-38f6-4042-a9f6-f953e7fe9072 Nones et al 2014 331 1 0 0 0 10 78 0 417 
52b05e15-0412-4679-92f2-0b97cc69d4f4 Nones et al 2014 359 2 0 0 0 12 47 0 417 
5871129b-4b66-4261-b326-353c41aa4cce Nones et al 2014 112 5 0 0 0 3 21 0 140 
5fd4044e-2b5b-4747-9ec3-5022830abd63 Nones et al 2014 117 0 0 0 0 13 72 0 202 
6804574e-a38a-48f8-ab1a-bbfd12c524a9 Nones et al 2014 490 2 0 0 0 20 92 0 602 
6e394b7c-8555-4a64-b342-e1d952991f29 Nones et al 2014 169 59 0 0 0 8 75 0 310 
6ed62b87-fd7d-4c51-8a7b-2cae3fea56de Nones et al 2014 575 37 0 0 0 21 100 0 723 
76d63ac1-5985-47b8-9236-0f821572bfaf Nones et al 2014 473 18 0 0 0 12 79 0 574 
7deb8b86-e212-41ca-9d14-de0007b7ac90 Nones et al 2014 437 1 0 0 0 15 50 0 499 
8ba60960-727c-4f82-b545-10087b99eb7c Nones et al 2014 105 36 0 0 0 8 33 0 182 
9bb9ff43-7a94-4823-8d4d-97e1d383fe3b Nones et al 2014 575 2 0 0 0 9 65 0 645 
aade4a47-aaeb-40ce-ab3b-cba53c34cc41 Nones et al 2014 425 47 0 0 0 5 39 0 516 







dbda7a52-9043-4510-9145-b2c998dd3d91 Nones et al 2014 203 1 0 0 0 2 20 0 226 
e03d78a2-3481-4c89-868b-b8c2f9148445 Nones et al 2014 243 0 0 0 0 9 77 0 326 
e5789831-aee2-43f2-910c-605b04705c16 Nones et al 2014 40 22 0 0 0 7 38 0 107 
fe1ac755-51c4-4735-b94a-f4a5d1279986 Nones et al 2014 259 2 0 0 0 10 39 0 310 
TCGA-2H-A9GF-01 TCGA 3504 41 0 0 0 18 156 0 3681 
TCGA-2H-A9GH-01 TCGA 2145 0 0 0 0 9 74 0 2215 
TCGA-2H-A9GI-01 TCGA 1737 0 0 0 0 23 120 1 1856 
TCGA-2H-A9GJ-01 TCGA 3332 0 0 0 0 8 82 0 3404 
TCGA-2H-A9GK-01 TCGA 986 0 0 0 0 12 119 0 1112 
TCGA-2H-A9GL-01 TCGA 1153 0 0 0 0 16 109 0 1265 
TCGA-2H-A9GM-01 TCGA 1748 16 0 0 0 9 79 0 1842 
TCGA-2H-A9GN-01 TCGA 3958 3 0 0 0 8 69 0 4016 
TCGA-2H-A9GO-01 TCGA 1450 0 0 0 0 8 81 0 1535 
TCGA-2H-A9GQ-01 TCGA 2596 15 0 0 0 13 86 0 2695 
TCGA-2H-A9GR-01 TCGA 696 0 0 0 0 17 170 0 876 
TCGA-IC-A6RE-01 TCGA 1163 0 0 0 0 24 259 1 1433 
TCGA-IG-A4QS-01 TCGA 3005 0 0 0 0 20 111 0 3111 
TCGA-IG-A7DP-01 TCGA 0 0 0 0 0 1 16 0 17 
TCGA-JY-A6F8-01 TCGA 1712 1 0 0 0 15 99 0 1816 
TCGA-JY-A6FB-01 TCGA 1284 0 0 0 0 14 75 0 1361 
TCGA-JY-A6FH-01 TCGA 1661 1 0 0 0 7 87 0 1744 
TCGA-JY-A938-01 TCGA 1290 0 0 0 0 10 73 0 1365 
TCGA-JY-A939-01 TCGA 170 0 0 0 0 2 68 0 240 
TCGA-JY-A93C-01 TCGA 1417 0 0 0 0 14 53 0 1478 
TCGA-JY-A93D-01 TCGA 503 0 0 0 0 9 90 0 600 
TCGA-JY-A93E-01 TCGA 1086 0 0 0 0 13 120 0 1208 
TCGA-L5-A43C-01 TCGA 333 0 0 0 0 9 66 0 407 
TCGA-L5-A43E-01 TCGA 1371 1 0 0 0 9 83 0 1451 
TCGA-L5-A43I-01 TCGA 2665 0 0 0 0 15 89 0 2758 
TCGA-L5-A43M-01 TCGA 805 0 0 0 0 2 28 0 833 
TCGA-L5-A4OE-01 TCGA 2230 0 0 0 0 33 149 0 2392 
TCGA-L5-A4OF-01 TCGA 2153 0 0 0 0 8 43 0 2197 
TCGA-L5-A4OG-01 TCGA 1167 0 0 0 0 15 72 0 1240 
TCGA-L5-A4OH-01 TCGA 4110 0 0 0 0 10 155 0 4222 
TCGA-L5-A4OJ-01 TCGA 593 1 0 0 0 25 159 0 766 
TCGA-L5-A4ON-01 TCGA 3130 0 0 0 0 8 76 0 3195 
TCGA-L5-A4OO-01 TCGA 460 0 0 0 0 10 48 0 517 
TCGA-L5-A4OP-01 TCGA 1476 0 0 0 0 5 56 0 1531 







TCGA-L5-A4OR-01 TCGA 2225 1 0 0 0 16 85 1 2309 
TCGA-L5-A4OS-01 TCGA 875 0 0 0 0 5 41 0 917 
TCGA-L5-A4OT-01 TCGA 1521 0 0 0 0 12 78 0 1600 
TCGA-L5-A4OU-01 TCGA 1115 0 0 0 0 11 75 0 1199 
TCGA-L5-A4OW-01 TCGA 1882 0 0 0 0 10 104 0 1984 
TCGA-L5-A4OX-01 TCGA 1364 1 0 0 0 12 57 0 1429 
TCGA-L5-A88T-01 TCGA 25 0 0 0 0 4 40 0 68 
TCGA-L5-A88V-01 TCGA 2453 1 0 0 0 17 84 0 2536 
TCGA-L5-A88Y-01 TCGA 1812 0 0 0 0 14 90 0 1903 
TCGA-L5-A891-01 TCGA 3916 0 0 0 0 17 110 0 4010 
TCGA-L5-A893-01 TCGA 1220 0 0 0 0 10 94 0 1316 
TCGA-L5-A8NE-01 TCGA 2795 1 0 0 0 17 116 0 2913 
TCGA-L5-A8NF-01 TCGA 2945 2 0 0 0 18 77 0 3020 
TCGA-L5-A8NG-01 TCGA 831 0 0 0 0 8 98 0 934 
TCGA-L5-A8NH-01 TCGA 2406 0 0 0 0 9 98 0 2499 
TCGA-L5-A8NI-01 TCGA 1918 0 0 0 0 11 115 0 2020 
TCGA-L5-A8NJ-01 TCGA 3462 4 0 0 0 12 125 0 3573 
TCGA-L5-A8NL-01 TCGA 593 0 0 0 0 9 96 0 694 
TCGA-L5-A8NN-01 TCGA 2930 0 0 0 0 11 76 0 3007 
TCGA-L5-A8NR-01 TCGA 2122 0 0 0 0 22 98 0 2222 
TCGA-L5-A8NS-01 TCGA 1032 0 0 0 0 28 191 0 1235 
TCGA-L5-A8NT-01 TCGA 1251 0 0 0 0 10 87 0 1339 
TCGA-L5-A8NU-01 TCGA 42 0 0 0 0 5 30 0 77 
TCGA-L5-A8NV-01 TCGA 782 0 0 0 0 8 89 0 876 
TCGA-L5-A8NW-01 TCGA 3588 0 0 0 0 21 89 0 3678 
TCGA-L7-A6VZ-01 TCGA 2353 1 0 0 0 9 129 0 2477 
TCGA-M9-A5M8-01 TCGA 679 0 0 0 0 9 34 0 720 
TCGA-Q9-A6FW-01 TCGA 789 0 0 0 0 10 97 0 892 
TCGA-R6-A6DN-01 TCGA 3318 2 0 0 0 9 50 0 3365 
TCGA-R6-A6DQ-01 TCGA 2112 0 0 0 0 6 49 1 2164 
TCGA-R6-A6KZ-01 TCGA 1884 0 0 0 0 6 79 0 1963 
TCGA-R6-A6L4-01 TCGA 4398 0 0 0 0 7 59 0 4447 
TCGA-R6-A6L6-01 TCGA 772 0 0 0 0 13 75 0 854 
TCGA-R6-A6XG-01 TCGA 2030 49 0 0 0 12 132 0 2211 
TCGA-R6-A6XQ-01 TCGA 1873 11 0 0 0 11 77 0 1963 
TCGA-R6-A6Y0-01 TCGA 1216 0 0 0 0 16 113 0 1338 
TCGA-R6-A6Y2-01 TCGA 773 0 0 0 0 14 90 0 873 
TCGA-R6-A8W5-01 TCGA 1037 3 0 0 0 10 56 0 1105 







TCGA-R6-A8WC-01 TCGA 848 2 0 0 0 16 90 0 951 
TCGA-R6-A8WG-01 TCGA 1805 1 0 0 0 8 85 0 1892 
TCGA-RE-A7BO-01 TCGA 2225 0 0 0 0 11 137 0 2348 
TCGA-S8-A6BV-01 TCGA 1146 0 0 0 0 9 76 0 1223 
TCGA-V5-A7RB-01 TCGA 1677 0 0 0 0 12 105 0 1783 
TCGA-V5-A7RE-01 TCGA 1734 0 0 0 0 11 77 0 1805 
TCGA-V5-AASW-01 TCGA 3598 4 0 0 0 7 68 1 3664 
TCGA-V5-AASX-01 TCGA 771 0 0 0 0 16 155 0 933 
TCGA-VR-A8EQ-01 TCGA 1193 0 0 0 0 21 106 0 1308 
TCGA-VR-AA4D-01 TCGA 1319 0 0 0 0 9 61 0 1385 
TCGA-X8-AAAR-01 TCGA 439 0 0 0 0 6 71 0 514 










Table 3.8. Most recurrently altered cancer helpers in the 261 OACs. For each gene reported are the gene description, the number and 
percentage of samples where it is altered and the type of alteration. 
    



























translocase of outer 
mitochondrial 
membrane 34 33 12.6 33 0 0 0 0 0 0 0 
NCOA3 
nuclear receptor 
coactivator 3 32 12.3 30 0 0 1 0 0 1 0 
E2F1 
E2F transcription 













beta 25 9.6 24 0 0 0 0 1 0 0 
BAG6 
BCL2-associated 
athanogene 6 24 9.2 23 0 0 0 0 0 1 0 
DLC1 
DLC1 Rho GTPase 
activating protein 24 9.2 19 0 5 8 0 0 6 0 
VEGFA 
vascular endothelial 
growth factor A 23 8.8 23 0 0 0 0 0 0 0 
ASAP1 
ArfGAP with SH3 
domain, ankyrin 
repeat and PH domain 









receptor, alpha 20 7.7 20 0 1 2 0 0 0 0 
PRRC2A 
proline-rich coiled-coil 
2A 19 7.3 18 0 0 2 0 0 2 0 
SCRIB 
scribbled planar cell 
polarity protein 19 7.3 19 0 0 0 0 0 0 0 
LONRF1 
LON peptidase N-
terminal domain and 








receptor type 1 18 6.9 18 0 0 0 0 0 0 0 
NBEA neurobeachin 17 6.5 9 0 1 0 0 0 10 0 
AGO2 
argonaute RISC 








protein kinase 1 15 5.7 13 0 0 6 0 0 0 0 




protein 1 14 5.4 14 0 0 0 0 0 0 0 
JUP junction plakoglobin 14 5.4 12 0 3 6 0 0 0 0 
PTK2 
protein tyrosine kinase 
2 14 5.4 13 0 0 0 0 0 2 0 
SOX5 
SRY (sex determining 
region Y)-box 5 14 5.4 10 0 1 4 0 0 5 0 
STK3 
serine/threonine 




3.3.7 Patient-specific helpers perturb related biological processes 
The observation that OAC helpers are mostly rare or patient-specific 
(Figure 3.11C) poses the question of whether these genes act on similar or 
different biological processes. Therefore, I sought to investigate the pathways in 
which helpers are enriched in to gain insight into their cancer promoting 
functions. To this end, I analysed the biological processes perturbed by helpers 
and compared them to those of drivers, as a means to quantify both the novel 
and known biological processes that helpers contribute to. 
I manually reviewed all 476 known cancer genes (Forbes et al. 2017) with 
damaging alterations in the OCCAMS cohort and retained 202 of them based 
on the concordance between the type of acquired modification and the literature 
evidence of their cancer role (Methods, summarized in Appendix Table 7.1). 
Analysis of these 202 genes showed that the median number of drivers per 
OAC was seven (Figure 3.13A) and their recurrence profile was skewed 
towards high values, with more than 25% of genes altered in 10 samples or 
more (Figure 3.13B). Both of these characteristics were in accordance with 
recent estimates (Martincorena et al. 2017; Sabarinathan et al. 2017). Finally, 
as expected from the high number of genomic regions in OAC undergoing 
amplifications, the majority (nearly 50%) of these drivers were subject to 
somatic copy number amplifications (Figure 3.13C).  
I then performed two independent gene set enrichment analyses4, one 
with the 202 known drivers and one with the 952 helpers, to dissect their 
relative functional contribution to OAC. This led to 212 and 189 enriched 
pathways out of the 1,877 tested in drivers and helpers, respectively (Appendix 
Tables 7.3 and 7.4). Interestingly, the analysis of known drivers resulted in a 
                                                 




higher number of enriched pathways than helpers, despite their lower number. 
This reflected the higher number of pathways that drivers mapped to (median of 
four pathways for known drivers and two pathways for helpers). As expected, 
owing to the high alteration recurrence of known drivers, OACs had on average 
more enriched pathways due to the contribution of known drivers rather than 




Figure 3.13. Characteristics of cancer drivers. (a) Distribution of known drivers 
across 261 OACs. (b) Recurrence of cancer drivers across 261 OACs. Only 
samples acquiring alterations with a damaging effect are considered. (c) 
Distribution of damaging alterations in 202 cancer drivers. Overall, these genes 
acquire 1,967 damaging alterations. Distribution of altered pathways per 
samples (d) and altered samples per pathway (e) for known drivers and newly 
predicted helpers. 
 
Seventy-three pathways (34%) enriched in known drivers were perturbed 




cancer pathways’ are involved in well-known cancer-related processes5, such 
as intracellular signalling, cell cycle control, apoptosis and DNA repair, and are 
associated with the most recurrently altered known drivers (TP53, CDKN2A, 
MYC, ERBB2, SMAD4, CDK6, KRAS). Interestingly, 51 of the 73 (70%) were 
also enriched in helpers and 86 patients with altered helpers in a universal 
cancer pathway had no known drivers in that pathway (Figure 3.15). This 
indicates that helpers often contribute to the perturbation of key cancer 
pathways and that their alteration may be sufficient for cancer development in 
the absence of known drivers.  
Taken together, these results demonstrated that helpers contribute 
towards the perturbation of well-known cancer-related pathways. The 
implication of helpers in these pathways denotes that these genes are true 
positive predictions, as they are direct interactors of known drivers. However, 
further experimental validation is needed in order to dissect their role in 
tumorigenesis (see chapter 4). Finally, the high number of OACs (n=86) with 
helpers, but no known driver in those pathways, suggests that helpers 
contribute towards the refinement of the tumorigenic molecular landscape of 
these samples. Therefore, both helpers and known drivers should be 
considered when tumorigenic alterations are taken into account.  
                                                 











Figure 3.14. Hierarchical clustering on the presence/absence matrix of samples 
and perturbed pathways was performed as described in Methods. Each row 
represents a sample and each column an enriched pathway. Samples were 
assigned to a given pathway if they had at least one altered known driver mapping 
to that pathway. Seventy-three universal pathways perturbed in at least 50% of 
samples are coloured in light blue. 
 
 
Figure 3.15. Scatterplot of 51 ‘universal’ pathways enriched in known drivers and 
helpers. For each pathway, the number of OACs with altered drivers and the 
number of OACs with altered drivers and helpers is shown. The size of dots is 
proportional to the additional OACs with perturbations in these pathways because 





3.3.8 Mutational signatures in OAC helpers 
Different mutational processes generate specific patterns of point 
mutations in OAC genomes. Some of these processes have been previously 
described (Nik-Zainal et al. 2012; Alexandrov et al. 2013), but several 
signatures still remain of unknown origin. In OAC, five main signatures have 
been reported previously (Secrier et al. 2016) and can be found summarised in 
COSMIC (https://cancer.sanger.ac.uk/cosmic/signatures):  
 S1 (endogenous mutational process initiated by spontaneous 
deamination of 5-methylcytosine),  
 S2 (attributed to activity of the AID/APOBEC family of cytidine 
deaminases),  
 S3 (associated with BRCA1 and BRCA2 mutations),  
 S17 (of unknown aetiology, but associated with “mutator” phenotype in 
OAC),  
 S18 (of unknown aetiology with strong preference for C>A mutations in a 
GCA and TCT trinucleotide context) and their prevalence within OAC 
genomes facilitated patient stratification with potential therapeutic 
implications.  
To investigate the mutational processes operating on cancer helpers, I 
analysed all point mutations that were associated with them. To this end, I 
compiled a list of 5,898 somatic substitutions corresponding to an average of 
23.4 mutations per OAC (ranging from 1 to 270). In total, 251 OACs were 
included in this analysis as 10 OACs had only amplified helpers. Overall, three 
out of five previously described signatures were identified in helpers (Figure 
3.16A) and those were: signature 1 (cosine similarity of 0.79 with signature 1 




COSMIC) and signature 17 (cosine similarity of 0.98 with signature 17 from 
COSMIC). No new signatures were identified in this analysis. Confirming 
previous results, there was an association between the number of mutations in 
helpers of each OAC and the exposure to signature 17 (characteristic of the 
mutagenic group in Secrier et al.) (Figure 3.16B). Finally, this analysis further 
confirmed that mutations in helpers are not sequencing artefacts, as no atypical 











Figure 3.16. Mutational signature analysis of point mutations in helpers. (a) Three 
mutational signatures discovered in 251 cohort with point mutations in helpers. 
Analysis was performed using BayesNMF (Tan and Fevotte 2013). (b) Exposure of 
each OAC to the mutational signature discovered in a. Exposure is plotted as 




In this chapter, I described the application of sysSVM to identify rare and 
patient-specific driver genes in OAC, a genomically unstable cancer type. High 
genomic instability leads to inter-patient heterogeneity and a high number of genes 
being somatically altered in low number of OACs. The working hypothesis of this 
study was that, in the absence of recurrently mutated genes, major driver genes 
are complemented by multiple privately (or rarely) altered genes that contribute to 
tumorigenesis (named cancer helpers). Although sysSVM was not developed to 
identify exclusively cancer helpers, but cancer drivers in general, its ability to score 
genes based on their driver potential in individual samples renders OAC a very 
good case study for the application of sysSVM. Of note, sysSVM could 
successfully identify known drivers, when applied to previously unseen OAC 
cohorts (Figure 3.10). 
Cancer helpers are expected to be subject to weak selection. In support of 
this hypothesis, the overall selection acting on oesophageal cancer genomes is 
among the lowest across cancer types (Martincorena et al. 2017), despite a 
median of 382 damaged genes per OAC. This indicates that the exclusive focus on 
genes under strong selection is likely to return only a partial representation of the 




An advantage of not measuring selection directly is that sysSVM considers all 
types of alterations (SNVs, indels, CNVs, and structural variations) simultaneously. 
These alterations combined with the systems-level properties, which have been 
shown to be discriminant of known cancer genes from the rest of human genes, 
can be used to derive a global similarity metric of any altered gene to known 
cancer drivers. Therefore, a comprehensive overview of the genetic modifications 
that play a cancer promoting role in each patient can be constructed regardless of 
how frequent each alteration is.  
I applied sysSVM to 261 OACs from ICGC and prioritized 952 genes that, 
together with known drivers, help cancer progression. The large number of these 
cancer helpers is in agreement with the recent observation of a positive correlation 
between mutational burden and number of driver genes, which is only partially 
explained by a sample size effect (Bailey et al. 2018). As speculated in the 
introduction of this chapter, it is possible that this positive correlation may indicate 
that the number of functionally relevant genes increases with the number of altered 
genes. However, this might not be true for all cancer types and further research is 
warranted towards deciphering the relationship between the number of alterations 
and the number of drivers and helpers in a pan-cancer setting. 
As a further proof towards the existence of cancer helpers, I showed in this 
chapter that helpers, indeed, converge towards the perturbation of the same 
pathways. In other words, although helpers are possibly subject to weak selection, 
the perturbation of the pathways that they are involved in are important for 
tumorigenesis in OAC. Several of the processes that were discovered to be 
enriched here, due to helpers, are well-known contributors to cancer development, 




while the known drivers tend to encode upstream players in these processes, 
helpers are often downstream effectors, suggesting a more local role of helpers at 
a single patient level. 
The interplay of cancer helpers and major drivers is not fully understood. 
Recent mathematical modelling of the complex relationship between major drivers 
and beneficial passengers (or cancer helpers as those defined in this thesis) 
showed that tumour cell population grows continuously with varying growth rates 
(Li and Thirumalai 2016). When deleterious passengers were also considered in 
the models, population homeostasis was observed, which can be supported by the 
observations that tumour growth is often interrupted by periods of dormancy 
(Ghajar et al. 2013). I anticipate that the function of cancer helpers is context-
dependant and their tumorigenic potential will be dependent on not only the 
combination of major drivers, but also the existence of other cancer helpers. This 
makes our ability to experimentally validate these genes quite challenging, as the 
readouts of the experimental assays also need to be context-dependant.  
In summary, I described one of the first attempts to extend the discovery of 
acquired perturbations contributing to cancer, beyond those of recurrent drivers. An 
obvious criticism to this work is that it depends on the current knowledge of known 
cancer genes, as it needs a well-defined training set. However, I argue that the 
discovery rate of known (and recurrent) cancer genes has already reached a 
plateau, therefore our capacity to identify new recurrently mutated genes is limited. 
Moreover, a machine learning framework, such as that of sysSVM, can provide a 
useful tool, whose models will become increasingly better as new cancer genes 




process, during which newly-identified and validated drivers and helpers will 
transition from prediction to training set, allowing the discovery of more novel driver 
genes. Additional efforts are warranted to fully exploit the potential of these 
approaches with the aim to offer a more comprehensive view of the molecular 









Chapter 4. Oesophageal cancer patient stratification using 
sysSVM predictions 
4.1 Chapter overview 
In this chapter, I describe the utility of sysSVM predictions to stratify patients 
into subgroups in an effort to understand the biology of OAC and suggest putative 
therapeutic interventions. After showing that cancer helpers converge towards 
perturbations of similar pathways (chapter 3), I now use the perturbed biological 
processes instead of individual helper genes to define patient groups. Previous 
approaches for patient stratification using molecular data proved informative for 
clinical practice in multiple cancer types, including OAC, in which a proportion of 
patients (~20%) responded positively to trastuzumab, a monoclonal antibody 
targeting HER2 receptor tyrosine kinase (Bang et al. 2010). Most recent studies 
focused on mutational signatures and defined three distinct molecular subtypes in 
OAC with potential therapeutic relevance (Secrier et al. 2016). Therefore, 
additional studies are needed to dissect the full potential of molecular subtyping of 
OAC patients and inform precision medicine. This part of my thesis builds on the 
potential of a well-described compendium of cancer drivers and its utility to stratify 
patients in OAC. 
  
4.2 Introduction 
Despite the advances in drug development, not all patients respond 
favourably to treatment. Many available therapies, such as chemotherapy and 




(Crawford 2013; Emens et al. 2017). However, the fraction of patients that does not 
respond to cancer therapy varies significantly across different cancer types, with 
certain types being more amenable to treatment. For instance, current treatment 
protocols for most childhood hematologic malignancies exhibit high success rates 
(Suttorp et al. 2018); five-year survival rates of patients with acute lymphoblastic 
leukaemia (ALL), the commonest childhood cancer, are as high as 90% (Saletta, 
Seng, and Lau 2014). In contrast, in adult advanced melanoma only 20% of 
patients respond to immunotherapy treatments, such as ipilimumab (monoclonal 
antibody targeting CTLA-4 on the surface of T-cells) monotherapy (Schadendorf et 
al. 2015). 
A possible explanation to these differences across cancer types might be the 
fact that, often, treatment strategies are chosen according to clinical and 
pathological criteria, ignoring molecular alterations and subgroups of patients. 
Historically, clinical management of cancer has been guided by the organ system 
classification, primarily relying on histological and immunohistochemical analysis of 
tumour tissues (Song, Merajver, and Li 2015). In the past decade, this approach 
has begun to change, and new tumour stratification systems based on specific 
molecular alterations have started to emerge (Torkamani, Verkhivker, and Schork 
2009). Many cancer genome sequencing initiatives, such as TCGA and ICGC, 
contributed to this change, by unravelling the somatic alterations in cancer 
genomes (Lander and Weinberg 2000; Kaiser 2008; Collins and Barker 2007). 
Analysis of several cancer types revealed that tumours from the same anatomical 
site can exhibit different mutation profiles, while cancers from different tissues can 
share driver genes and mutational profiles (Hoadley et al. 2014). Therefore, 




driver and passenger genes, genomic characterisation of cancer has facilitated its 
molecular classification.  
Advances in the molecular profiling of tumour tissues have helped in 
developing a personalised medicine approach, whereby cancer treatment is 
adjusted according to the molecular aberrations of individual tumours. 
Personalised treatment allows the selection of the most potent and effective 
therapy, while simultaneously sparing the patient from ineffective and costly 
treatments. In this context, numerous genetic changes led to the development of 
therapeutic agents over the past two decades. Targeting the BCR-ABL 
translocation with small-molecule inhibitors, such as imatinib, in chronic myeloid 
leukemia (CML) has been particularly successful (Deininger and Druker 2003; 
Druker 2003; Druker et al. 2001; Druker, Talpaz, et al. 2001). Imatinib (Glivec), the 
FDA approved tyrosine kinase inhibitor with activity against BCR-ABL protein, 
improved CML patient survival and is considered a paradigm of targeted therapies 
(Hochhaus et al. 2009; Druker 2004; Lydon and Druker 2004). Moreover, due to its 
ability to additionally inhibit the KIT protein and platelet-derived growth factor 
receptor, imatinib has also been used to treat gastro-intestinal tumours (Blanke et 
al. 2008; Verweij et al. 2004). HER-2 overexpression is also used to inform patient 
stratification in breast cancer and anti-HER2-specific treatment has been shown to 
improve survival in these patients (Piccart-Gebhart et al. 2005; Vogel et al. 2002). 
Similarly, KRAS mutations are used to guide therapy for colorectal carcinoma 
patients (Van Cutsem et al. 2011, 2009). KRAS, in contrast to other genes that are 
direct targets of therapies, is a molecular biomarker for anti-EGFR therapy. 
Patients carrying KRAS mutations showed no response to cetuximab, an EGFR 




tumour-specific therapeutic approaches and improved patient outcomes (Douillard 
et al. 2010; Mok et al. 2009). 
Until recently oesophageal cancer was treated as one disease and no sub-
classification of patients was implemented to guide its clinical management. In fact, 
many clinical trials even treated oesophageal and gastric cancer as one disease, 
enrolling patients with both diseases (Kopp and Hofheinz 2016; Woo, Cohen, and 
Grim 2015; Young and Chau 2016). However, genomic characterisation revealed 
that oesophageal squamous cell carcinoma resembled squamous cell carcinomas 
of other tissues more than OAC, whereas OAC strongly resembled chromosomally 
unstable gastric cancer (The Cancer Genome Atlas Research Network 2017). 
These data further proved that clinical management of OAC is not optimal and 
provided a possible explanation for the disappointing and inconclusive results of 
most clinical trials (Woo, Cohen, and Grim 2015; Young and Chau 2016; Kopp and 
Hofheinz 2016). 
Efforts to characterise molecular subgroups in OAC (and gastric cancer) that 
would respond favourably to specific treatment led to the identification of HER2 
amplification in approximately 20% of tumours. Trastuzumab, a monoclonal 
antibody targeting HER2, was approved for clinical use based on results of the 
phase III clinical trial ToGA (Bang et al. 2010), which enrolled 594 previously 
untreated HER2-positive patients with oesophagogastric cancer. Overall, 
trastuzumab not only significantly improved the response rate from 35 to 47% of 
cases, but also prolonged the median survival of these patients from 11.1 to 13.8 
months (Kopp and Hofheinz 2016), emphasising the importance of patient 




However, there are no effective therapeutic interventions for patients without 
HER2 amplification, and patients might acquire resistance to trastuzumab or other 
inhibitors of receptor tyrosine kinases. Therefore, a recent study (Secrier et al. 
2016) sought to investigate the use of mutational signatures (Alexandrov et al. 
2013) for stratification of OACs. Based on this, Secrier et al. defined three groups 
of OACs – namely DDR impaired, C>A/T dominant and mutagenic - with distinct 
mutational patterns and aetiologies. In the DDR-impaired group (~18% of OACs) 
defects in homologous recombination and chromosome segregation pathways 
were discovered, suggesting a possible benefit from synthetic lethality-based 
therapeutic approaches using PARP inhibitors. Moreover, patients in the 
mutagenic group would probably benefit from immunotherapy-based interventions 
as they exhibited higher nonsynonymous mutation and neoantigen burden than the 
rest of OACs (Secrier et al. 2016). Patients in the C>A/T dominant group would 
continue to be treated with conventional chemotherapy until more progress is 
made on this group of patients. Further studies will be needed for pre-clinical 
validation of these patient subgroups before their implementation in the clinical 
management of OAC. 
Since OAC helper genes predicted with sysSVM perturb similar pathways 
(chapter 3), I sought to use these pathways to define OAC subgroups and test 
whether these subgroups are related to clinical features. Finally, I collaborated with 
two wet-lab scientists6 to experimentally validated several helpers in each OAC 
subgroup to investigate the tumorigenic potential of these perturbations. 
  
                                                 





4.3.1 Cancer helpers reveal six molecular subgroups of OAC patients 
The discovery of cancer helpers and the fact that they converged towards 
perturbations of the same biological processes (chapter 3) allowed patient 
stratification using perturbed processes instead of individual genes. As cancer 
helpers are mainly rare or patient-specific, I clustered OACs according to the 
proportion of perturbed pathways they had in common, calculating the Jaccard 
index between each pair of samples. I then used hierarchical clustering to group 
pairs of samples with similar values of Jaccard indices (see Methods). To dissect 
and compare the contribution of helpers and known drivers separately, I performed 
two gene set enrichment analyses considering both gene sets. As described in 
chapter 3, in this cohort of 261 OACs, I manually annotated 202 known driver 
genes from the Cancer Gene Census and predicted 952 cancer helper genes 
using sysSVM. Overall, 212 and 189 pathways out of the 1,877 tested were found 
enriched for known drivers and helpers, respectively. Then, I calculated the 
similarity of perturbed pathways for each pair of OACs (i and j) using the Jaccard 
index for both known drivers (Jaccard Dij) and helpers (Jaccard Hij) (Figure 4.1). 
Finally, I used hierarchical clustering to group samples based on the values of 
Jaccard D and Jaccard H and find subgroups of OACs with the same number (and 
identity) of perturbed pathways. The results of the hierarchical clustering are 








Figure 4.1. Patient stratification using shared perturbed processes in OACs. 
Schematic of the procedure to cluster OACs according to pathways enriched in 
known drivers or helpers. Enriched pathways are mapped to individual OACs and 
the Jaccard index is calculated as the proportion of shared pathways over the total 
pathways in each pair of samples (i, j). Hierarchical clustering was then performed.  
 
 
When I used pathways enriched in known drivers, OACs were clustered 
based on the most recurrently altered genes and they were broadly divided in two 
major groups depending on TP53 mutation status (Figure 4.2A left panel and 
4.2B). Overall, I identified five statistically supported clusters of patients with 
median silhouette score of 0.5 (Figure 4.3A). These clusters were driven by the 
mutational status of recurrent known drivers, such as EGFR, ERBB2 and MYC in 
cluster 1D, and MYC and KRAS in cluster 2D (Figure 4.2B). OACs with no 




burden (p = 0.03, Wilcoxon rank sum test), fewer known drivers and consequently 
a lower number of enriched pathways (p = 7x10-6, Wilcoxon rank sum test). 
Therefore, patient stratification using known drivers was confounded by the 
mutation status of TP53. 
When I grouped OACs according to the pathways enriched in helpers, I 
identified six well-supported clusters (clusters 1H-6H, Figure 4.2A right panel) with 
a median silhouette score of 0.3 (Figure 4.3B). In contrast to the patient groups 
that were derived using known drivers, OACs were brought together not by the 
mutational status of TP53 (or other recurrent known drivers), but by several helpers 
mapping to the same or related pathways (Table 4.1). For example, both clusters 
1H and 3H showed perturbations in intracellular signalling (Figure 4.2A, Table 4.1), 
often involving “universal” cancer pathways (perturbed in more than 50% of OACs, 
see chapter 3; Figure 4.4). In a large fraction of OACs (~45%) comprising clusters 
1H and 3H, the perturbations in universal cancer pathways occurred in samples 
with no known drivers. This suggested that more patients can be associated with 
perturbations in well-known cancer-related pathways if helpers were considered. 
Other pathways perturbed in cluster 1H, but not in 3H, involved cell cycle 
regulation, Toll-like receptor (TLR) signalling and proteasome activity (Figure 4.4). 
Finally, OACs in cluster 3H were enriched in tobacco smokers (Figure 4.5A), but 
no smoking mutational signature could be recovered when their mutations were 
analysed. 
Similar to what I observed in clusters 1H and 3H, the biological pathways 
perturbed in clusters 2H and 4H were also functionally related. In this case, both 
exhibited alterations in cell cycle regulation (Figure 4.2A, Table 4.1, Figure 4.4). All 




as members of the E2F family of transcription factors and their associated co-
activators, competitors and downstream targets (Table 4.1). Cluster 4H instead 
harboured perturbations in DNA replication, with alterations in the MCM complex 
(Table 4.1), which is a downstream target of E2F (Ohtani et al. 1999; Yoshida and 
Inoue 2004). Dysregulation of E2F transcription factors or the MCM complex can 
increase genomic instability through either aberrant cell-cycle control or replicative 
stress (Hills and Diffley 2014; Nath et al. 2015). Consistently with this, OACs in 
clusters 2H and 4H exhibited high genomic instability. In particular, samples in 2H 
had a significantly higher number of genes with damaging somatic point mutations, 
indels and amplifications when compared to the rest of OACs (Figure 4.5A). 
Samples in 4H harboured a significantly higher number of somatically deleted 
genes (Figure 4.5A). The mutational profiles of OACs in cluster 2H showed 
significant enrichment in mutational signature 2 (attributed to the activity of 
AID/APOBEC family of cytidine deaminases), while OACs in cluster 4H showed 
enrichment in mutational signature 3 (associated with germline and somatic 
BRCA1 and BRCA2 mutations) (Figure 4.5A). Finally, OACs in cluster 4H had 
significantly lower survival time compared to the rest of the cohort (Figure 4.5B). 
Interestingly, elevated expression of the MCM complex has been previously 
associated with poor patient survival in multiple tumour types, including 
oesophageal squamous cell carcinoma, but not adenocarcinoma (Giaginis et al. 
2010). The perturbation of MCM proteins and their related pathways might 
therefore contribute to tumour aggressiveness and poor outcome in patients of this 
cluster. Taken together, the results of this thesis associate MCM proteins (mainly 




Cluster 5H showed perturbations in the Toll-like receptor signalling cascade 
(Table 4.1, Figure 4.4) that has recently been reported to be dysregulated in OAC 
(Fels Elliott et al. 2017). In our cohort of 261 OACs, cluster 5H accounted for 
11.1% (n=29) of OACs. TLR cascades are critical for host-microbe interactions and 
genes in this pathway have been found mutated in other solid tumours exposed to 
microbial communities, such as uterine endometrial carcinoma (Husseinzadeh and 
Davenport 2014) and stomach adenocarcinoma (Schmaußer et al. 2005). 
Therefore, a better understanding of the contribution of TLR signalling cascades to 
tumorigenesis and the inflammation of tumour microenvironment in OAC could 
inform potential therapeutic interventions. 
Overall, clusters 1H to 5H accounted for 166 OACs (64% of the total cohort) 
(Table 4.1). The remaining 95 OACs in cluster 6H shared fewer perturbed 
pathways than OACs in the other five groups, but, nevertheless, they exhibited 
shared perturbations in pathways related to Rho GTPase activity. Specifically, 55 
of them (58%) had alterations in pathways related to Rho GTPase activity (Table 
4.1, Figure 4.4) with modifications of Rho GTPase effectors, such as ROCK1, 
PTK2, PAK1, LIMK1 and NDE1.  
The purpose of hierarchical clustering using the Jaccard index for both known 
drivers and helpers (Figure 4.2A) was to examine whether helpers could lead to 
patient subgroups that were not identifiable using known drivers. Results showed 
that helper-derived OAC groups were indeed dispersed in the clustering analysis 
using known drivers (Figure 4.2A). This indicated that helpers brought together 
OACs with similar perturbed processes, a finding that could not have been 
appreciated if the analysis was merely focused on recurrent drivers. Thus, 








Figure 4.2. Perturbed processes in 261 OACs. (a) Clustering of 261 OACs 
according to pathways enriched in known drivers and helpers. Five clusters were 
identified using known drivers (1D-5D) and six using helpers (1H-6H). Cluster-
matching coloured lines show where OACs clustered by pathways enriched in 
helpers map in the driver clusters. (b) Mutational status of selected known drivers 
across 261 OACs. Drivers enriched in clusters of helpers are highlighted and their 
associated significance is reported on the right-hand side of the plot. Significance 
was assessed using Fisher’s exact test, after corrected for False Discovery Rate 










Figure 4.3. Identification of the optimal number of clusters. Silhouette analysis to 
measure clustering robustness of (a) known drivers and (b) helper genes. For each 
number of clusters between 3 and 10, clusters were derived from the dendrogram 
(Figure 4.2A) and the silhouette value  (Rousseeuw 1987) was then calculated for 
each sample using the Euclidean distance between rows of the Jaccard matrix A ij. 
The number of clusters with the highest median silhouette value over all samples 












Figure 4.4. OAC clustering using pathways enriched in helpers. Hierarchical 
clustering was performed using a presence/absence matrix of perturbed 
pathways and OACs as described in Methods. The order of OACs along the y 
axis corresponds to that shown in figure 4.2A for helpers, including the six 
clusters (1H-6H). Samples were assigned to a given pathway if they had at 
least one altered helper mapping to that pathway. Fifty-one of the 73 universal 
pathways perturbed in at least 50% of OACs are coloured in light blue. All other 




Figure 4.5. Features of OAC clusters driven by pathways enriched in helpers. 
For each helper cluster (1H-6H) indicated are the molecular features 
(mutational signatures, number of genes with damaging mutations, undergoing 




smoking habits of the patients that show significant associations with one of the 
six clusters of helpers. Enrichment in number of altered genes, tumour staging 
and smoking habits was assessed using Fisher’s exact test. Distributions of 
mutational signatures were compared using Wilcoxon rank-sum test. FDR = 
false discovery rate after correction for multiple testing. b. Kaplan-Meier survival 
curves of OACs in cluster 4H (n = 37) and the rest of OACs (n = 224). Analysis 
was performed using survival and survminer R packages with default 








Table 4.1. Summary of patient clusters derived using cancer helpers. For each cluster the number of samples, a set of representative 
genes and pathways are reported. For genes and pathways, the number in parenthesis denotes the corresponding number of OACs 










ARMS-mediated activation(58),DAP12 interactions(58),DAP12 signalling(58), 
Downstream signal transduction(58),Fc epsilon receptor (FCERI) signalling(58),Frs2-
mediated activation(58),GRB2 events in EGFR signalling(58),IGF1R signalling 





Assembly of the pre-replicative complex(24),CDC6 association with the ORC:origin 
complex(24),Cyclin D associated events in G1(24),DNA Replication(24),DNA Replication 
Pre-Initiation(24),G1 Phase(24),M/G1 Transition(24),Mitotic G1-G1/S phases(24),Oncogene 





DAP12 interactions(18),DAP12 signalling(18),Downstream signal transduction(18),Fc 
epsilon receptor (FCERI) signalling(18),NGF signalling via TRKA from the plasma 
membrane(18),Signalling by the B Cell Receptor (BCR)(18),Downstream signalling events of 







Mitotic G1-G1/S phases(37),G1/S Transition(29),DNA Replication(26),Regulation of DNA 
replication(26),S Phase(26),Assembly of the pre-replicative complex(24),DNA Replication 






Activated TLR4 signalling(29),MyD88:Mal cascade initiated on plasma membrane(29),Toll 
Like Receptor 2 (TLR2) Cascade(29),Toll Like Receptor 4 (TLR4) Cascade(29),Toll Like 
Receptor TLR1:TLR2 Cascade(29),Toll Like Receptor TLR6:TLR2 Cascade(29),Toll-Like 
Receptors Cascades(29),MyD88-independent TLR3/TLR4 cascade(28),Toll Like Receptor 






Neutrophil degranulation(46),RHO GTPase Effectors(38),VEGFA-VEGFR2 
Pathway(36),Transcriptional Regulation by TP53(35),EPH-Ephrin signalling(33),Rho 
GTPase cycle(31),Deubiquitination(29),Fatty acid, triacylglycerol, and ketone body 




4.3.2 Helper-defined OAC subgroups are associated with specific 
perturbations of known drivers 
The initial hypothesis of this work was that sysSVM predictions could have a 
helper role in OAC. Consequently, I hypothesised that helpers might occur 
concomitantly with specific known drivers. To understand the dynamics of helpers 
and known drivers, I searched for over-represented altered known drivers in each 
one of the OAC subgroups described above.  
OACs in cluster 1H were significantly associated with five known drivers 
(RECQL4, RARA, MYC, SMARCE1 and ERBB2; Figure 4.2B), which were often, 
but not always, co-amplified. Interestingly, SCRIB, a recurrent helper in cluster 1H 
(Table 4.1) was recently found to inhibit liver cancer cell proliferation by 
suppressing the expression of MYC (Kapil et al. 2017), suggesting a functional 
association between a predicted helper and a known driver. However, although this 
finding suggested a tumour-suppressing role, in OAC, SCRIB was predicted as an 
amplified helper (Appendix Table 7.2), an indication of a tumour-promoting role. 
Cluster 2H was characterised by significant alterations of the known drivers GNAS, 
SS18L1, and FHIT (Figure 4.2B). FHIT is linked to increased genomic instability 
(Saldivar et al. 2012) and regulates the expression of cell cycle-related genes 
(Weiske, Albring, and Huber 2007), therefore potentially affecting the G1/S 
transition pathways of this cluster (Table 4.1). Finally, cluster 4H showed frequent 
alterations in the known drivers TRAPP and CDK6 (Figure 4.2B). The latter 
functions in various cell cycle-related pathways, including the mitotic G1/S phase 




Taken together, these results showed that pathways perturbed by helpers 
were associated with alterations of specific known drivers in at least three of the six 
OAC clusters that were identified. This dynamic relationship of known drivers and 
helpers, although hypothesised in the initial stages of this thesis, is well supported 
by my data. Further investigation is warranted to dissect the exact interaction of 
helpers and these known drivers across different OAC subgroups. 
Finally, to test whether patient stratification was affected by considering only 
the top 10 helper genes in each OAC, I performed the same analysis considering 
as helpers the top five or top 15 scoring genes (528 and 1,297 unique genes, 
respectively). By altering the arbitrary cut-off of top 10 scoring genes, I confirmed 
that both pathway enrichment analysis and the corresponding OAC subgroups 
were reproducible across multiple sets of high-scoring genes from sysSVM. In 
particular, the vast majority of pathways enriched in top five and top 15 (99% and 
77%) were also enriched in the top 10 scoring genes (Figure 4.6A, B). This 
indicated that the recurrently perturbed processes were highly overlapping among 
different sets of top scoring genes. I then clustered OACs according to the 
proportion of shared perturbed pathways, as described before in Figure 4.1. 
Thereby, I verified that the six clusters obtained using pathways enriched in top 10 
genes recapitulated well the clusters obtained using pathways enriched in top five 
or top 15 genes (Figure 4.6C, D). Therefore, the clustering was robust regardless 









Figure 4.6. Comparison of helpers using different ranking cut offs. Comparison of 
enriched pathways between top ten and (a) top five or (b) top 15 scoring genes in 
each sample. Gene set enrichment analysis using top five and top 15 scoring 
genes led to 71 and 223 enriched pathways, respectively (FDR <0.01). 
Comparison of sample positions in the clustering dendrograms of top 10 and (c) 
top five or (d) top 15 scoring genes in each sample. Complete linkage hierarchical 
clustering with Euclidean distance was used to group 261 OACs according to 
pathways enriched in the different datasets of helpers. The dendrogram of top 10 






4.3.3 Pan-cancer prevalence of alterations in cell-cycle-related helpers 
The dysregulation of cell-cycle is a hallmark of cancer cells. In this cohort of 
261 OACs, sysSVM predicted several helpers that were part of cell cycle regulation 
pathways. In particular, transcription factors of the E2F gene family and members 
of MCM complex were found recurrently altered in OAC clusters 2H and 4H (Table 
4.1). Therefore, they were selected for experimental validation (see below) and 
pan-cancer analysis in order to dissect the prevalence and mode of their alteration 
in multiple cancer types. 
E2F family of transcription factors consists of eight proteins (E2F1-8), which 
can be further sub-classified in activators (E2F1-3) and repressors (E2F4-8) based 
on their downstream effect on gene transcription (Ogawa et al. 2002). Activator 
E2Fs promote cell proliferation, while repressors control cell cycle exit and 
differentiation (Ishida et al. 2001). Amplification and overexpression of E2Fs 
(mainly E2F1) has been detected in multiple cancer types, such as ductal breast 
cancer and non-small cell lung cancer (Montenegro et al. 2014; Lu et al. 2012; 
Hung et al. 2012). Although often discovered overexpressed, E2F1 is thought to 
play a dual role in cancer cells. There is accumulating evidence that apart from its 
oncogenic role via overexpression, it also acts as a tumour suppressor by inducing 
apoptotic cell death upon perturbation of normal cell cycle control (Johnson 2000). 
In OAC, sysSVM predicted E2F1 as an amplified helper in 23 out of 24 
samples of cluster 2H (9% of the total cohort; Table 4.1). Pan-cancer analysis of 
7,828 TCGA patients revealed that E2Fs were amplified in various frequencies 
across different cancer types. Overall, more than 50% of the samples had at least 




Although this frequency might be slightly overestimated, as the copy number of 
genes was not corrected with the ploidy of each sample (see Methods), it clearly 
demonstrated that E2Fs were frequently amplified in multiple cancer types. The 
highest frequency was observed in uveal melanoma, rectum adenocarcinoma, 
uterine carcinosarcoma, ovarian serous cystadenocarcinoma and adrenocortical 
carcinoma, while acute myeloid leukaemia, kidney renal clear cell carcinoma, 
thymoma and thyroid carcinoma had a low fraction of samples with E2F 
amplifications (Figure 4.7A). When the prevalence of amplification of each E2F 
was examined separately, E2F5 was the most frequently amplified gene (53% of 
patients), while E2F2 was the least amplified gene (5% of patients) (Figure 4.7B). 
Overall, from a total of 3,284 patients with at least one E2F amplified, 1,961 (60%) 
patients harboured amplification in only one E2F gene, suggesting a possible 
mutual exclusivity of amplification events in multiple members of the E2F gene 
family.  
From the inspection of altered E2Fs across different cancer types, interesting 
patterns of E2F amplifications were revealed (Figure 4.7C). Both E2F1 and E2F5 
were found frequently amplified in colon and rectum cancers, kidney chromophobe, 
ovarian serous carcinoma, uterine carcinosarcoma, uveal melanoma and 
adrenocortical carcinoma. Frequent amplifications of E2F5, but not E2F1 were 
observed in head and neck squamous cell carcinoma, breast invasive carcinoma 
and testicular germ cell tumours. E2F4, although rarely amplified in the pan-cancer 
cohort (8%; Figure 4.7B), was frequently amplified in adrenocortical carcinoma, 
kidney chromophobe and kidney renal papillary cell carcinoma. On the other hand, 
very low number of samples were found with E2F amplifications in brain tumours 




and pancreatic adenocarcinomas. Consistent with my results in the OAC cohort, 
oesophageal carcinoma, showed high number of patients with E2F1 amplifications 
(Figure 4.7C). Taken together, these observations suggest that there are four 
groups of cancer types with respect to amplifications of E2Fs: i) those with 
amplifications of both E2F1 and E2F3, ii) those with only E2F5 amplifications, ii) 
those with only E2F1 amplifications and iv) those with very low frequency of 
amplifications of E2Fs.  
Another cycle-related amplified helper that was predicted by sysSVM in 18 
out of the 37 OACs (7% of the total cohort; Table 4.1) in cluster 4H was MCM7. 
MCM proteins (MCM2-7) are part of the minichromosome maintenance complex, 
which serves as the eukaryotic replicative helicase that unwinds double-stranded 
DNA and promotes the formation of DNA replication forks (Bochman and 
Schwacha 2009). MCM genes have been found in both eukaryotes and archaea 
and they share significant sequence similarity mainly around the 250-amino-acid 
region that encodes the ATPase active site (Koonin 1993). The MCM complex is 
loaded to the origins of DNA replication during the G1 phase of the cell cycle and it 
is subsequently activated by cyclin-dependent kinases (CDKs) and Dbf4-
dependant kinase (DDK) to promote the assembly of the replication forks 
(Nougarède et al. 2000). Inactivation of any of the MCMs blocks DNA elongation 
and leads to the loss of integrity of the replication fork. There is substantial 
evidence that fine-tuning of phosphorylation and dephosphorylation of MCMs 
regulate cell cycle and protects genome integrity, while aberrant phosphorylation 
associates with uncontrolled proliferation and the development of multiple cancers 
(Fei and Xu 2018). Recent studies that evaluated the expression of MCMs across 




(Liu et al. 2017) and breast cancer (Kwok et al. 2015) and their association with 
shorter overall survival time. 
MCMs were found frequently amplified in many cancer types in the pan-
cancer cohort (Figure 4.8A). Some of the cancer types with high frequency of MCM 
amplifications, such as uterine carcinosarcoma, ovarian serous carcinoma and 
adrenocortical carcinoma, also harboured frequent E2F amplifications (Figure 
4.7A). Interestingly, other cancer types, such as glioblastoma and lung squamous 
cell carcinoma, that harboured no E2F amplifications, showed quite frequent 
amplifications of MCMs (Figure 4.8A). This suggested that aberrations in these two 
regulators of the cell cycle (i.e. E2Fs and MCMs) were not always mutually 
exclusive, as observed in OAC and glioblastoma, but they could also co-occur. 
Amplification of MCMs was associated with overexpression in the pan-cancer 
cohort and the level of expression of different members of the MCM complex was 
co-regulated, as patients with at least one component amplified tended to have all 
components overexpressed (Figure 4.8B). This suggested that MCM amplification 
had a functional effect in cancer cells, which led to the elevated expression of the 
MCM complex as a whole and eventually increased proliferation rate (see next 
paragraph). 
Taken together, these results showed that amplification of the components of 
cell cycle is a frequent event across multiple cancer types. This, in combination 
with results from recent literature, further supports the fact that these predictions of 
sysSVM are involved in tumorigenesis. In OAC, amplifications of E2Fs and MCMs 
were predicted as helpers in more than 15% of the total cohort and these 
amplifications were linked to overexpression (see next paragraph). In the 




genes, and others, in an effort to investigate the magnitude of their tumorigenic 
















Figure 4.7. Pan-cancer analysis of amplification events associated with E2F transcription factors. (a) Percentage of patients 
with amplified E2Fs (E2F1-8) across 31 cancer types from TCGA. The cohort was comprised of 7,828 patients and 
amplifications were defined as described in Methods. (b) Pan-cancer prevalence of E2F amplifications for all 8 genes of the 
E2F family of transcription factors. (c) Pan-cancer prevalence of E2F amplifications across different cancer types from TCGA. 















Figure 4.8. Pan-cancer analysis of amplification events associated with members of the MCM complex. (a) Percentage of 
patients with amplified MCMs (MCM2-7) across 31 cancer types from TCGA. The cohort was comprised of 7,828 patients and 
amplifications were defined as described in Methods. (b) Pan-cancer analysis of expression of MCMs in patients reported in 
panel a. For each MCM subunit, patients with amplification events were annotated. Then the expression of all MCM subunits 
was compared in those patients versus the rest of the cohort. Statistical significance was calculated using a two-tailed Wilcoxon 





4.3.4 Experimental validation of the commonly altered helpers E2F1 
and MCM7 
 
To experimentally validate the predictions of sysSVM and investigate their 
role in the tumorigenesis of OAC, I collaborated with Dr. Lorena Benedetti and 
Dr. Elizabeth Foxall, who assessed the consequences of silencing and 
overexpression of representative helpers in cancer cell lines in vitro. As 
representative, we selected helpers that met all the following criteria: 
1. They were frequently altered helpers in specific OAC clusters or 
rare helpers that contributed to perturbations of enriched pathways, 
across multiple clusters of OACs (as those described in figure 4.2A) 
2. They were expressed in the oesophageal cancer cell lines that 
would be used in the experiments 
3. They were not amplified in the oesophageal cancer cell lines that 
would be used in the experiments (optimisation of CRISPR design) 
The selection of rare, as well as frequent helpers, was performed in order to 
confirm our working hypothesis that tumorigenic pathways aberrations can be 
the result of alterations of multiple genes, regardless of their frequency.  
We used two experimental approaches. In the first one, we assessed the 
consequences of altering representative helpers in FLO-1 cells. This is an OAC 
diploid cell line with no mutations or copy number alterations in any of the 
helpers selected for validation. Therefore, it enabled a direct evaluation of the 
effect of the introduced gene alterations without interference from already 
acquired alterations in the same gene. We measured cell proliferation as a main 
hallmark of cancer and also performed gene-specific assays. In the second 




perturbation of helpers. In this case, we used OAC cell lines with alterations 
similar to those observed in patients (see Methods). 
We started by modifying the most commonly altered helpers in clusters 2H 
and 4H, namely E2F1 (23 out of 24 samples in cluster 2H; Table 4.1) and 
MCM7 (18 out of 37 samples in cluster 4H; Table 4.1). As mentioned in the 
previous paragraph, both E2F1 and MCM7 were amplified in OACs and their 
amplification led to significant overexpression, when compared to copy number 
neutral state (median two-fold increase, p = 6x10-3 and p=8x10-3, respectively 
Wilcoxon rank-sum test; Figure 4.9A). We therefore stably overexpressed E2F1 
and MCM7 in FLO-1 cells to levels comparable to those observed in patients 
(Figure 4.9B). In both cases we observed significantly increased proliferation of 
overexpressing cells as compared to control cells (p=2x10-4 and p=9x10-4, 
respectively, two-tailed t-test; Figure 4.9C), validating the functional impact of 
the overexpression of these helpers to cell proliferation. Since E2F1 promotes 
cell cycle progression, we also assessed DNA replication rate by measuring 
EdU (5-ethynyl-2’-deoxyuridine) incorporation to newly synthesized DNA during 
the cell cycle. We observed increased EdU intensity throughout S phase in 
E2F1 overexpressing cells as compared to control cells (p<10-4, Mann Whiney 
U test; Figure 4.10A). This suggests that E2F1 may help cancer growth by 
promoting S phase entry. Similar to E2F1, to assess the functional 
consequence of MCM7 overexpression, we measured the loading of the MCM 
complex onto chromatin. As described in the previous paragraph, MCM 
complex (MCM2-7) is loaded onto chromatin to promote DNA unwinding and 
formation of the DNA replication fork. We observed that MCM7 overexpressing 
cells displayed a lower MCM fluorescence intensity overall as compared to 




MCM3 (p<10-4, Mann-Whitney U test; Figure 4.10B, 4.10C). This suggested 
that less MCM complex was loaded onto chromatin by the start of S phase. 
Therefore, MCM7 overexpression leads to both increased proliferation and 
perturbation of MCM complex activity. These two findings seem to be conflicting 
as one would expect higher amount of MCM complex being loaded onto the 
chromatin when increased proliferation is observed. More experiments are 
needed to dissect the mechanism behind this observation. However, one 
possible explanation could be that there is a delay between the overexpression 
of one member of MCMs and the physiological adjustment of a cell to produce 
higher amount of the other MCM members and eventually assemble higher 
amounts of the MCM complex as a whole as expected by the stoichiometry 
balance that was observed in figure 4.8B.  
Finally, we utilised a patient-derived cell line, MFD-1 (Garcia et al., 2016), 
in which MCM7 was overexpressed (four-fold higher expression) when 
compared to FLO-1 (Figure 4.11A), to assess the dependency of cancer cells to 
MCM7 perturbation. To reduce the expression of MCM7 in MFD-1 cells to levels 
comparable to the expression of FLO-1 cells, we used doxycycline-inducible 
shRNA lentiviral vector (Table 4.2; Figure 4.11B). This led to a significant 
decrease in cell proliferation (p = 2x10-5, two-tailed t-test; Figure 4.11C), 
indicating that the proliferation rate of MFD-1 cells is dependent of the MCM7 









Figure 4.9. Cancer helper role of E2F1 and MCM7.  (a) E2F1 and MCM7 
expression in OACs where they are amplified (11 samples each) as compared 
to OACs where they are copy number neutral (81 samples each). Significance 
was assessed using the Wilcoxon rank-sum test. (b) E2F1 and MCM7 mRNA 
expression in FLO-1 cells assessed by qRT-PCR. Expression was relativised to 
β-2-microglobulin and normalised to control cells. (c) Proliferation curve of FLO-
1 cells overexpressing E2F1 or MCM7 as compared to the corresponding 
control cells. Two biological replicates were performed, with reactions 
performed in triplicate in all qRT-PCR experiments. In proliferation assays, at 
least two biological replicates were performed, each with four technical 
replicates. Proliferation was assessed every 24 hours and each time point was 








Figure 4.10. Estimation of MCM loading onto the genome during cell cycle. (a) 
Assessment of EdU (5-ethynyl-2'-deoxyuridine) incorporation by flow cytometry 
in E2F1 overexpressing cells as compared to control cells. Cells were 
separated into G1, S and G2 phases, and S phase cells were subdivided into 4 
gates from early to late S phase (S1-S4). The geometric mean fluorescence 
intensity of EdU was measured for the cells in each gate and differences 
between EdU intensity were assessed using the Mann-Whitney U test. Three 
biological replicates were performed, and a representative experiment is shown. 
Quantification of MCM complex loading onto chromatin in MCM7 
overexpressing or control cells via staining of MCM7 (e) or MCM3 (f). Cells 
were pulsed with EdU, and chromatin fractionation was performed before 
staining for MCM7 or MCM3 to detect the MCM complex bound to chromatin. 
Cells were separated into cell cycle phases using EdU and DAPI intensity (see 
Methods). MCM7 or MCM3 fluorescence intensity during S phase illustrates the 
unloading of the MCM complex from chromatin. The geometric mean 
fluorescence intensity of MCM staining was measured for the cells in each cell 
cycle gate and differences in MCM intensity were assessed using Mann-








Figure 4.11. Assessment of dependency of oesophageal cancer cell lines on 
MCM7. (a) MCM7 mRNA expression levels in MFD-1 and FLO-1 cells. 
Expression was relativized to β-2-microglobulin and normalised to FLO-1 cells. 
(b) MCM7 expression levels in MFD-1 cells after transduction with a lentiviral 
vector carrying an inducible shRNA against MCM7. Expression was assessed 
in the absence of doxycycline and after 96 hours of doxycycline treatment, 
relativised to β-2-microglobulin and normalised to FLO-1 cells. (c) Proliferation 
curve of MFD-1 cells with or without doxycycline-induced MCM7 knockdown. 
Two biological replicates were performed, with reactions performed in triplicate 
in all qRT-PCR experiments. In proliferation assays, at least two biological 
replicates were performed, each with four technical replicates. Proliferation was 
assessed every 24 hours and each time point was normalised to time zero. 








Table 4.2. List of oligos used in the study. Reported are the DNA and RNA sequences of the oligos used in this study. * = selected for 
knockdown experiment. NA = not applicable. 









ABI2_crRNA1 GGCAACACTTGCTAAGGAT S57-A62 
ABI2_crRNA2 GCCTATCTGATAAACACCT A62-T67 




NCOR2_crRNA1 TCGCTGCGGGCGGCCGACA L361-H370 





NTC_crRNA1 GATACGTCGGTACCGGACCG NA 
NTC_crRNA2 GTAACGCGAACTACGCGGGT NA 
NTC_crRNA3 GTCGACGTTATTGCCGGTCG NA 
NTC_crRNA4 GGAAACCTACGTCGACGAAT NA 
NTC_crRNA5 GCTCTCGTACGGCGCGTATC NA 
MiSeq 
NCOR2 
NCOR2_forward1 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCCTCGACGTAAACCACCC NA 
NCOR2_reverse1 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCACACTTCTCCTCTGGGG NA 
NCOR2_forward2 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAGTAGGTAGCGCTGGGATT NA 
NCOR2_reverse2 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAGACAGACGACACCTCAGG NA 
NCOR2_forward3 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGGGGTTATAAGATGGGCTGG NA 
NCOR2_reverse3 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTCCCTCTGCGTTGAAAC NA 
ABI2 
ABI2_forward TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGACTCAGCAGAATCGTTG NA 
ABI2_reverse GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGCCAGCATTACAGATAGCCT NA 







RT-PCR MCM7_reverse CTTTTCGTAGAAATCCTCCTC NA 
E2F1 
E2F1_forward CTGATGAATATCTGTACTACGC NA 
E2F1_reverse CTTTGATCACCATAACCATCTG NA 
PAK1 
PAK1_forward AGCTAACTGACTTTGGATTC NA 
PAK1_reverse GGGTTTTCATTGAGGTATGG NA 
PSMD3 
PSMD3_forward CCTATTTCCTTCTGACTCAAG NA 
PSMD3_reverse CCGGATAATTAGGGTGTAGG NA 
Cas9 
Cas9_forward GGGGGACAGTCTTCACGAGC NA 
































4.3.5 Experimental validation of rare helpers  
Next, we experimentally evaluated the role of rare helpers in 
tumorigenesis. To this aim, we selected NCOR2 that was altered in eight OACs 
across five of the six clusters (Appendix Table 7.2). In contrast to E2F1 and 
MCM7, which were informative for patient stratification, NCOR2 was predicted 
by sysSVM but, nevertheless, patients with NCOR2 alterations were distributed 
across different patient clusters. NCOR2 is part of the nuclear receptor 
corepressor complex that favours global chromatin deacetylation and 
transcriptional repression (Figure 4.12A). In accordance to previous reports that 
suggested a tumour suppressor role of NCOR2 in lymphoma and prostate 
cancer, the most frequent NCOR2 alterations in OAC led to loss of function. 
Therefore, we edited NCOR2 in FLO-1 cells using a vector-free CRISPR 
system that was previously developed in our lab. Briefly, three pooled crRNAs 
were co-transfected with Cas9 and the tracrRNA (Methods, Table 4.2) and the 
editing was confirmed and quantified using Miseq (Methods, Figure 4.12B). 
Editing of NCOR2 via CRISPR led to a 1.3-fold increase in proliferation rate in 
the edited cells compared to the control cells (p = 3x10-3, two-tailed t-test test; 
Figure 4.12C), suggesting that loss-of-function perturbation of this gene confers 
a proliferative advantage to cancer cells. 
Next, we focused on members of the Rho GTPase effector pathway, 
which were pervasively perturbed in all six clusters, often through patient-
specific alterations (Figure 4.13A). Aberrant Rho signalling has been long linked 
to oncogenesis (Porter, Papaioannou, and Malliri 2016) and the perturbation of 
optimal signalling levels has been attributed to a wide range of mechanisms. 
Evidence suggests that GTPase signalling can be disrupted both directly, by 




2012), and indirectly via overexpression of guanine exchange factors (GEFs) 
(Cook, Rossman, and Der 2014) or loss of negative regulators (Wolf et al. 
2003). Most of the helpers predicted by sysSVM are located downstream of 
Rho GTPase signalling pathway, which is supportive of their helper role. As 
representative genes of the Rho GTPase effectors, we modified ABI2 and 
PAK1, which underwent damaging alterations and amplification in one and nine 
OACs, respectively (Appendix Table 7.2). We therefore edited ABI2 and 
overexpressed PAK1 as described above and confirmed the editing efficacy 
and overexpression (Figure 4.13B). The proliferation rate of cells harbouring 
editing of ABI2 or overexpression of PAK1 was assessed as before. In both 
cases we observed significantly increased proliferation as compared to control 
cells (ABI2:  p = 4x10-4, PAK1: p = 1x10-3 two-tailed t-test; Figure 4.13C). 
Finally, we focussed on PSMD3 that encodes a subunit of the regulatory 
19S proteasome complex. PSMD3 is amplified and overexpressed in three 
OACs of cluster 1H, which overall contains 14 samples with alterations in six 
proteasome subunits (Figure 4.14A). We identified three OAC cell lines (MFD-1, 
OE19 and OE33) showing higher basal expression of PSMD3 compared to 
FLO-1 (2-, 3- and 4-fold increase respectively, Figure 4.14B). Using a 
doxycycline-inducible lentiviral shRNA vector (Table 4.2), we reduced PSMD3 
expression in MFD-1, OE19 and OE33 cells to levels equivalent to those of 
FLO-1 (Figure 4.14C). In all three cell lines we observed a significant reduction 
in cell proliferation following the reduction of PSMD3 expression (MFD-1: p = 
4x10-8; OE19: p = 2x10-8; OE33: p = 6x10-3, two-tailed t-test; Figure 4.14D). The 
effect was particularly strong in OE19, where the reduction of PSMD3 
expression to diploid levels arrested cell growth completely. In MFD-1 and 




suggests that the extent of OAC reliance upon helper alterations is at least 
partially context dependent. 
Taken together, our experimental data indicated that, independently of the 
alteration frequency, the modification of helpers positively affected OAC cell 
growth. Moreover, we provided evidence that OAC cells became addicted to 
helper alterations, suggesting that targeting helpers, or the pathways in which 








Figure 4.12. Cancer helper role of NCOR2. (a) Function of NCOR2 as part of 
the nuclear receptor co-repressor complex, whose activity results in chromatin 
deacetylation and transcriptional repression. (b) Editing of the NCOR2 gene 
using three pooled crRNAs where cells are transiently co-transfected with Cas9 
protein, crRNAs and tracrRNA (Benedetti et al. 2017). The editing efficiency 
was measured using Miseq and the range of edited alleles and cells was 
derived considering the two opposite scenarios where all three crRNAs edit the 
same alleles/cells or different alleles/cells, respectively. (c) Proliferation curve of 
NCOR2 or NTC edited FLO-1 cells. Proliferation was assessed every 24 hours 
and each time point was normalized to time zero. Mean values at 72 hours were 
compared by two-tailed Student’s t-test. Three biological replicates were 








Figure 4.13. Cancer helper role of ABI2, and PAK1. (a) Manual curation of the 
helpers contributing to the Rho-GTPase effectors pathway. Heatmap indicates 
the number of samples with alterations in each gene. ABI2 (blue) and PAK1 
(red) were selected for experimental validation. (b) Editing of the ABI2 gene (left 
panel) using three pooled crRNAs where cells are transiently co-transfected 
with Cas9 protein, crRNAs and tracrRNA (Benedetti et al. 2017). The editing 
efficiency was measured using Miseq and the range of edited alleles and cells 
was derived considering the two opposite scenarios where all three crRNAs edit 
the same alleles/cells or different alleles/cells, respectively. PAK1 mRNA 




to β-2-microglobulin and normalised to control cells. Experiments were done in 
triplicate in two biological replicates. (c) Proliferation curves of FLO-1 cells after 
ABI2 editing (left panel) or PAK1 overexpression (right panel). Three biological 
replicates were performed, each with four technical replicates. Proliferation was 
assessed every 24 hours and each time point was normalised to time zero. 








Figure 4.14. OAC cell dependence on PSMD3 alteration. (a) Heatmap of 
proteasome subunits predicted as helpers in 261 OACs. (b) PSMD3 basal 
mRNA expression levels in FLO-1, MFD-1, OE19 and OE33 cells. Expression 
was relativized to β-2-microglobulin and normalised to FLO-1 cells. (c) PSMD3 
expression levels in MFD-1, OE19 and OE33 after transduction with a lentiviral 
vector carrying an inducible shRNA against PSMD3. Expression was assessed 
in absence of doxycycline and after 96 hours of doxycycline treatment, 
relativized to β-2-microglobulin and normalised to FLO-1 cells. (d) Proliferation 
curves of MFD-1, OE19 and OE33 cells with or without doxycycline treatment to 
reduce PSMD3 expression to levels comparable to those of FLO-1 cells. For all 
proliferation assays, at least two biological replicates were performed, each with 
four technical replicates. Proliferation was assessed every 24 hours and each 
time point was normalised to time zero. Mean values at 96 hours were 









In this part of my thesis, I utilised cancer helpers that were identified by 
sysSVM to stratify OACs and describe recurrently perturbed biological 
processes with tumorigenic potential. Instead of working at a gene level, 
pathway-level analysis substantially reduces the heterogeneity of the molecular 
landscape in OAC and allows the refinement of subgroups of patients with 
distinct molecular and clinical characteristics. I showed that when only known 
cancer genes were considered, patient groups were dictated by the mutational 
status of TP53 and a few other known driver genes (Figure 4.2A and 4.2B). This 
is possibly a by-product of many years of research on these genes, which led to 
their representation in a high number of biological pathways. Instead, when 
cancer helpers were considered, the mutational status of TP53 was irrelevant to 
the clustering of OACs. This observation suggests that the two clustering 
approaches capture different types of molecular characteristics. Closer 
examination of helper-derived OAC clustering revealed novel dysregulated 
pathways that, upon experimental validation, proved to play a role in 
tumorigenesis. Apart from novel pathways, helpers contributed to several well-
known tumorigenic pathway, including intracellular signalling, cell cycle control 
checkpoints and DNA repair. Interestingly, while known driver genes tend to 
encode upstream players in these pathways, helpers were found to encode 
downstream effectors. For example, we found several Rho GTPase effectors 
(Figure 4.13A) and genes downstream of previously reported OAC drivers in the 
TLR cascades (Appendix Table 7.2). 
Analysis of pathways disrupted by helpers in each OAC group (Figure 
4.2A), revealed many functionally related processes. For example, clusters 1H 




shared perturbations in pathways involved in cell cycle regulation, namely S-
phase entry and DNA replication. This suggests that tumorigenic processes can 
be somatically perturbed by more than one mechanism. Consistent with the 
perturbation of cell cycle regulation, clusters 2H and 4H brought together the 
most genomically unstable tumours. Moreover, several clusters showed 
enrichment in specific known driver alterations.  
To establish the tumorigenic role of helpers in OAC, I collaborated with 
two other members of the Ciccarelli lab to experimentally validate 
representative helpers. By experimentally mimicking the amplification of E2F1 
(representative of cluster 2H) and MCM7 (representative of cluster 4H), we 
showed increased proliferation in OAC cells when these genes were 
overexpressed (Figure 4.9C). We also provided evidence that E2F1 increased 
proliferation by promoting S phase entry (Figure 4.10A), while overexpression of 
MCM7 resulted in a reduction of MCM complex loading onto chromatin (Figure 
4.10B and 4.10C), maybe due to a stoichiometric imbalance of complex 
subunits. This may indicate that MCM7 promotes cell growth through a separate 
mechanism besides its function in the MCM complex. For example, MCM7 
interacts with the tumour suppressor protein Rb, a well-characterised inhibitor of 
E2F1 (Sterner et al. 1998). It is therefore possible that MCM7 overexpression 
may sequester Rb away from E2F1, thereby promoting E2F1-mediated cell 
cycle progression. Alternatively, it is also possible that stoichiometric balance of 
MCM complex was not reached in our experiments due to the duration of the 
experiment. Of note, preliminary evidence from the pan-cancer analysis 
suggests that stoichiometric balance of the MCM complex is reached in cancer 
cells upon overexpression of one member of the complex (Figure 4.8B). Finally, 




levels decreased cell proliferation, suggesting not only a tumorigenic role of 
MCM7 in OAC, but also a dependence of cancer cells on its high expression. 
Apart from E2F1 and MCM7, we also confirmed the cancer promoting role 
of very rare helpers, such as ABI2, NCOR2 and PAK1 that were altered 
between 1% and 4% of OACs. Therefore, irrespective of the frequency, helpers 
have a substantial impact on the progression of the cancer where their 
alteration occurs. This may indicate new, patient-specific gene dependencies 
and suggest possible stratifications that could inform the selection of targeted 
treatments. For example, 14 samples of cluster 1H have alterations of several 
proteasome subunits. Experimentally reverting the expression of the 
proteasome subunit PSMD3 to diploid levels resulted in reduced cell growth in 
three different OAC cell lines (Figure 4.14D). This indicates that OACs depend 
on helper alterations and are vulnerable to their inhibitions. Interestingly, 
proteasome inhibition has been shown to have a synergic effect in combination 
with ERBB2 inhibitors (Issaenko et al. 2012). Since ERBB2 is also significantly 
altered in cluster 1H (Figure 4.2B), a combined therapy may be beneficial to 
patients in this cluster. 
In summary, we provide one of the first attempts to extend the discovery of 
acquired perturbations contributing to cancer beyond those of recurrent drivers. 
Additional efforts are required to fully exploit the potential of these approaches 
to offer a more comprehensive view of the molecular mechanisms behind 








Chapter 5. Discussion and Future Directions 
5.1 Introduction 
This thesis describes the development of the sysSVM algorithm for the 
identification of patient-specific cancer drivers. sysSVM combines supervised 
machine learning and systems biology in order to prioritise genes with 
tumorigenic potential amongst all genes with putative damaging alterations 
within a tumour. This is of particular interest for precision medicine approaches 
whose scope is to tailor therapeutic interventions to the mutational landscape of 
each tumour (Mathur and Sutton 2017; Jiang and Wang 2010; Xue and Wilcox 
2016). In fact, curative treatments in several types of cancer have been 
hindered by widespread inter-tumour heterogeneity (Vogelstein et al. 2013), 
which makes targeted therapies challenging as few recurrent alterations are 
shared across samples. One such cancer type is OAC, in which very few 
alterations exceed 10% of recurrence across patients (Secrier et al. 2016). 
Throughout this thesis, I argued that the reason why very few cancer driver 
genes have been described in OAC, is because current methods, albeit 
statistically complex, use recurrence as a direct or indirect measure to assess 
significance and positive selection (Lawrence et al. 2013; Dees et al. 2012). 
SysSVM is instead focused on the identification of cancer drivers in the 
individual patients by investigating their systems-level and molecular properties. 
The application of sysSVM to OAC provided insights into the rare and 
patient-specific drivers operating in this cancer type and the processes that they 
perturb. It also allowed the identification of sub-groups of patients with 
molecular alterations in shared pathways and processes. In this chapter, I 
summarise the main features of sysSVM, highlighting its limitations and 




5.2 SysSVM features are derived from systems-level and molecular 
properties of known cancer driver genes 
SysSVM builds on previous attempts to define properties of cancer driver 
genes (D’Antonio and Ciccarelli 2013; An et al. 2016; Rambaldi et al. 2008; 
D’Antonio and Ciccarelli 2011) and subsequently uses these features to identify 
drivers in individual tumours (D’Antonio and Ciccarelli 2013). Initial studies, 
aiming to characterise driver genes, primarily concentrated on the human 
protein-protein interaction network and highlighted that proteins encoded by 
cancer genes are highly connected and central (Rambaldi et al. 2008; Jonsson 
and Bates 2006). This has been interpreted as a sign of fragility of cancer 
genes, as damaging alterations in these genes are likely to affect multiple 
biological processes within a cell (Ciccarelli 2010).  
In addition to network-related properties, cancer genes share other 
systems-level properties, as well, that were included in the development of 
sysSVM and are summarised in Table 3.2. For example, cancer genes are 
expressed in a higher number of tissues than the rest of human genes and their 
function is regulated by a high number of miRNAs, indicating a tight control of 
their expression (An et al. 2016). Cancer genes have emerged in two rounds 
during evolution: tumour suppressors are mostly ancient genes with an origin in 
prokaryotes, while oncogenes were mostly acquired in metazoans (Domazet-
Lošo and Tautz 2010). This denotes that damaging alterations in tumour 
suppressors impair mostly basic cell functions, while those in oncogenes affect 
mostly regulatory functions. Moreover, based on data presented in chapter 1, I 
found that cancer genes tend to be located in open-chromatin regions of human 
genome (Figure 2.3). In addition to systems-level properties, several features of 




restrict predictions to genes with putative damaging alterations. These features 
included damaging point mutations, indels, copy number alterations and 
structural variants. 
Despite the wealth of information that the above-mentioned features 
provide sysSVM with, there are some limitations. The positive pairwise 
correlation that was observed between features, such as the number of exonic 
mutations and the number of damaging mutations (Figure 3.5A), denotes a 
level of redundancy that needs to be further investigated. Although a 
“ratiometric” version of these features has been used before to identify driver 
genes (Tokheim et al. 2016), their contribution to the predictive models of 
sysSVM needs to be explored in multiple cancer types. In addition, features 
derived from the protein-protein interaction network, such as degree and 
betweenness, were also correlated. However, this is a known/established 
correlation, as several hubs of the protein-protein interaction network are also 
central proteins. The fact that not all central proteins are hubs justified the 
usage of both these features in sysSVM. 
During the development of sysSVM, I attempted to incorporate as many 
features as possible. Therefore, I performed an empirical selection of features 
exhibiting statistical significance between known cancer genes and the rest of 
human genes. However, there are other methods for feature selection and 
assessment (Anthony and Ruther 2007), whose application was not 
investigated. For instance, dimensionality reduction could be utilised before 
training to identify features enriched in outliers in the training set (Mwangi, Tian, 
and Soares 2014) and subsequently exclude them. 
Moreover, the molecular properties used in this work were limited by the 




post-translational modification and miRNA regulation data could be utilised by 
sysSVM. With the growing availability of additional molecular data, a desirable 
future direction of sysSVM will be to examine whether additional molecular 
properties can reveal novel cancer drivers. For instance, additional data might 
include tumour-specific transcriptional regulation via epigenomic mechanisms 
(Villanueva et al. 2015; Chatterjee, Rodger, and Eccles 2018) or post-
transcriptional modifications (Jewer, Findlay, and Postovit 2012). The former 
has been observed in the case of the proto-oncogene KIT, a type III receptor 
tyrosine kinase, which has been found overexpressed without gene 
amplification or mutation in paediatric renal tumours (Jones et al. 2007). Post-
transcriptional modifications might involve alternative splicing to modulate 
protein structure through inclusion or skipping of exon(s). This has been 
previously reported for CCN proteins, whose alternatively spliced transcripts 
have been identified in multiple malignancies (Jewer, Findlay, and Postovit 
2012). In addition, incorporation of expression data could facilitate modelling of 
complex scenarios contributing to tumorigenesis, such as tumour-specific RNA 
editing (Peng et al. 2018). To this end, direct variant calling from RNA-
sequencing data and subsequent comparison with exome variants and normal 
tissue could be implemented to identify variants present only in the 
transcriptome of the tumour. RNA editing has been considered an overlooked 
source of cancer mutations and it has been shown to generate coding 
mutations and neoantigens in multiple cancer types (Nishikura 2016; Peng et al. 
2018; Ben-Aroya and Levanon 2018; Roth et al. 2018). Although currently there 
are no known drivers with RNA editing mutations, recent studies suggest that 
RNA editing mutations can be driver mutations (Han et al. 2015), and therefore 




5.3 SysSVM is based on one-class support vector machines and 
predicts patient-specific cancer drivers 
In several areas of biology, massive labelled data cannot be easily 
collected and, therefore, binary learning (i.e machine learning with both positive 
and negative observations) is challenging, as there are no negative 
observations that sufficiently represent the “negative” feature space. Although it 
is possible to use unlabelled observations as an opposing class to the positive 
set (Mordelet and Vert 2010; Xiaoli Li and Liu 2003; Chawla and Karakoulas 
2005), this might lead to unbalanced training sets. This problem is even more 
prominent in the case of predicting cancer genes, as cancer drivers can be 
context dependent, and the same gene may or may not be a driver depending 
on the tissue (Schneider et al. 2017).  
Because no available true negative set could be used for training, sysSVM 
employed a one-class support vector machine framework (Scholkopf et al. 
2001), in which the density of known cancer genes in the feature space is 
modelled. Despite the robust theoretical background of one-class support 
vector machines, several other algorithms, such as isolation forest (Liu, Ting, 
and Zhou 2008) and local outlier factor (Breunig et al. 2000), have been 
developed for one-class classification. Such algorithms are directed towards 
outlier detection in an effort to define the high-density regions of the feature 
space. This is particularly relevant to one-class classification, as the absence of 
true negatives might lead to a wide decision boundary that is prone to false 
positives. Isolation forests operate on a fundamentally different approach than 
the one of one-class support vector machines. Rather than modelling positive 
observations, isolation forests model anomalies in the training data based on 




feature values that deviate significantly from the positive observations (Liu, 
Ting, and Zhou 2008). Using a similar approach, in isolation forests local outlier 
factor algorithm uses density-based clustering to indicate which training 
observations have high degree of outlier-ness (Breunig et al. 2000). Although 
one-class support vector machines is the most robust and widely used 
algorithm, the implementation of isolation forests or local outlier factor for the 
identification of patient-specific cancer drivers merits further investigation. 
Future development of sysSVM could be directed towards the combination of 
alternative algorithms to assess whether it would potentially lead to a more 
robust decision boundary around the high-density regions of the feature space 
than each algorithm on its own. 
Another limitation of sysSVM is that it does not explicitly model cancer 
genes as tumour suppressors or oncogenes, but it only does it in an indirect 
way. Since several systems-level properties exhibit differences between tumour 
suppressors and oncogenes, this information is already embedded in the data 
used in sysSVM. But future implementations of the algorithm could leverage on 
this distinction more explicitly and utilise a pre-defined feature weighting vector 
(Zhang et al. 2009) of systems-level properties. First, the tumour suppressor-
specific features, such as ancient evolutionary origin or the absence of 
duplicated copies in the human genome (Repana et al. 2018), could be 
assigned with a higher weight during training, than the rest of the features. This 
would force sysSVM to assign higher score to genes that resemble tumour 
suppressors. Repeating the same process for the oncogene-specific features 
would result in two scoring systems, whose top-scoring genes would 
correspond to predicted tumour suppressors and oncogenes. In addition to 




before or after prediction, could also be implemented to ensure that oncogene 




5.4 Patient-specific cancer drivers reveal widespread perturbation of 
biological processes in OAC 
In chapter 3, I applied sysSVM to a cohort of 261 OACs to identify rare 
and patient-specific cancer drivers. OAC was considered a very good test case 
for the application of sysSVM, as the high inter-patient heterogeneity in this 
cancer type suggests that rare drivers might be involved in tumour 
development. In particular, I hypothesised that alongside the critical role of 
recurrent and well-known drivers, complementary alterations of several other 
genes might contribute to cancer development. These cancer “helper” genes 
were identified using sysSVM and their relevance to OAC was examined using 
pathway analysis and experimental validation. However, as mentioned 
previously, sysSVM is not designed to identify only cancer helpers, but to 
predict cancer drivers in general. In the cohort of 261 OACs, known cancer 
genes were used for training of sysSVM and, therefore, they were not part of 
the prediction set. For this reason, the new predictions did not contain any 
known drivers. Nonetheless, several of the predicted helpers may have a driver 
role in cancer cells that is as strong as the one of the known drivers. The 
potential of sysSVM to identify known drivers, as well as helpers, was 
demonstrated when it was applied to two validation cohorts (Figure 3.10), 




SysSVM highlighted 952 top-scoring genes as helpers in OAC (Appendix 
Table 7.2). The majority of these genes (~ 80%) were implicated in amplification 
events that led to overexpression (Figure 3.11B), suggesting that their 
amplification has a possible functional role in OAC. The number of predicted 
helpers is significantly higher than that of other methods even in pan-cancer 
cohorts (Bailey et al. 2018; Lawrence et al. 2013). This is due to the fact that 
approximately 60% of these genes were rare or patient-specific, with only few 
genes being altered in more than 5% of OACs. However, the recurrence of 
helpers might increase if more than ten high-scoring genes will be considered. 
Intersection of helpers with two lists of false positive cancer drivers (including 
more than 500 genes) confirmed the low false positive rate of sysSVM, as only 
44 helpers (4.6% of the total) were previously identified as possible false 
positives. 
Helpers predicted in multiple OACs did not always harbour the same type 
of alteration. This adds to the growing body of evidence suggesting that 
different alterations in drivers might not have the same impact (Pardo and 
Godzik 2015). One of the most well-known examples is that of the two most 
common mutations in PIK3CA, E545K and H1047L, which contribute to 
tumorigenesis through different mechanisms (Hao et al. 2013). Similar 
observations have been reported for KRAS (Garassino et al. 2011), EGFR 
(Porta-Pardo et al. 2015) and TP53 (Porta-Pardo et al. 2015). These 
observations indicate that sysSVM could be implemented using only systems-
level properties as predictive features and utilise the molecular properties (i.e. 
damaging alterations) only after prediction to refine the predicted drivers. Such 




extension of sysSVM to additional cancer types to assess its feasibility and 
potential biases. 
One line of investigation that has not yet been explored is the relationship 
between the molecular landscape and the ranking of helpers in individual 
OACs. For example, I observed that several genes that harboured damaging 
alterations in multiple OACs were amongst the top-scoring predictions in only a 
fraction of them. This is due to the fact other high-scoring helpers are present in 
these samples. Although by design sysSVM score incorporates information on 
the number of altered genes within each sample (see equation 2.10), the 
extension of sysSVM to additional cancer types will enable further investigation 
of these genes. One possibility will be to explore whether genes with specific 
sysSVM features that have low weight in all kernels tend to be implicated in 
these discrepancies more frequently than others. The investigation of these 
discrepancies is also relevant to the application of sysSVM in new cohorts with 
already-trained models. The analysis that was presented in chapter 4 to assess 
whether sysSVM successfully recognises known cancer drivers may provide 
insights on the aetiology of ranking discrepancies, as not all known cancer 
drivers were amongst the top-scoring genes. 
To examine the mechanisms through which helpers might contribute to 
tumorigenesis, I performed a gene set enrichment analysis using almost 2,000 
pathways. This revealed that several helpers converged towards the 
perturbation of well-known tumorigenic pathways to which known driver genes 
also contribute. These pathways were related to intracellular signalling, cell 
cycle control, apoptosis and DNA repair, and were associated with the most 
recurrently altered known drivers (TP53, CDKN2A, MYC, ERBB2, SMAD4, 




close interactors of known drivers might be true positive predictions of cancer 
drivers in OAC. However, the uncertainty of this observation needs further 
investigation. This might represent an important refinement of my findings, as it 
would provide a better indication of the non-random membership of helpers to 
these pathways and exclude possible false positive findings. Such an extension 
could be implemented via multiple randomisation steps through which random 
sets of helpers would be analysed progressively for their membership to these 
pathways.  
Apart from the known tumorigenic pathways, in chapter 4 I showed that 
helpers perturb several pathways, whose contribution to OAC is not fully 
understood. For example, perturbations in the TLR signalling cascades were 
found dysregulated in more than 10% of OACs. Shortly after our observation, 
an independent study that used a pathway-oriented algorithm to find 
significantly altered biological processes in OAC confirmed these findings (Fels 
Elliott et al. 2017). TLRs are pattern recognition receptors, which are involved in 
innate immune system and in the interaction of cells with microbiota (Akira and 
Takeda 2004). Initial findings reported somatic mutations in TLR4 gene in 
multiple solid tumours, including OAC (Hold et al. 2007; Kurt et al. 2016; Fels 
Elliott et al. 2017; Dulak et al. 2013). My results suggest a wider perturbation of 
TLR signalling cascades in OAC, which might lead to a broader dysregulation of 
inflammatory signalling. Future research will further elucidate the mechanisms 
via which tumour cells utilise TLRs to promote their survival and evade anti-
tumour immune responses in OAC. Furthermore, it is worth noting that the 
specific genes that were predicted by sysSVM, were not identified by alternative 




This finding highlights that sysSVM complements current state-of-the-art 
methods for cancer driver discovery. 
In addition to the TLR cascades, sysSVM predicted Rho GTPase activity 
as another major contributor to OAC pathogenesis in approximately 20% of 
tumours. Recurrent mutations in members of the RAC1 GTPase pathway, such 
as ELMO1 and DOCK2, were previously identified in OAC, but they were found 
related to increased invasive capacity, rather than cell proliferation (Dulak et al. 
2013; Weaver, Ross-Innes, and Fitzgerald 2014). Our results suggest that 
alterations in members of Rho GTPase activity and, in particular, of Rho 
GTPase effector pathways in OAC affect cell proliferation (Figure 4.13). This 
indicates that the implementation of methods oriented towards patient-specific 
detection of cancer drivers can indeed reveal novel perturbations in the level of 
processes that are not detectable when individual recurrently altered driver 
genes are examined. 
 
 
5.5 Cancer helpers highlight six OAC patient sub-groups with 
putative therapeutic implications 
Targeted therapies in OAC lag behind those in other cancer types and 
even recent clinical trials reported disappointing or inconclusive results (Kopp 
and Hofheinz 2016; Woo, Cohen, and Grim 2015; Young and Chau 2016). This 
is at least partially due to the incomplete description of the driver alterations in 
OAC that leads to an inaccurate molecular stratification of patients (Weaver, 
Ross-Innes, and Fitzgerald 2014). The comprehensive characterisation of 
helpers using sysSVM allows a fine-mapping of drivers in each OAC and 




landscape. In chapter 4, I described six OAC clusters based on helpers and 
confirmed that patient stratification using only known drivers is confounded by 
the mutational status of TP53 and a few other known drivers (Figure 4.2). 
Conversely, patient stratification using helpers highlighted sub-groups of OACs 
that were brought together by damaging alterations of different helpers in the 
same pathways. Interestingly, several of these clusters were associated with 
specific background alterations of major drivers such as RECQL4, RARA, MYC, 
SMARCE1 and ERBB2 in cluster 1H, GNAS, SS18L1, and FHIT in cluster 2H 
and TRAPP and CDK6 in cluster 4H.  
Further experimental validation and analysis is needed to confirm the 
clinical relevance of these patient clusters. The findings in this thesis provide 
several lines of evidence to guide future studies, as several associations with 
potential clinical relevance were described in each cluster. For example, a 
profile of increased genomic instability was observed in patients of clusters 2H 
and 4H (Figure 4.5). Given the connection of genomic instability, neoantigen 
generation and tumour infiltration from immune cells (Yaghmour et al. 2016; 
Chan et al. 2018), this analysis could highlight a sub-group of OACs that might 
benefit from immunotherapy. As more expression data become available for this 
cohort, tumour infiltrates and PD1/PD-L1 expression could be quantified and 
linked back to the molecular stratification using helpers. Moreover, clusters 1H 
and 4H exhibited high exposure to BRCA1 and BRCA2-related mutational 
signatures, which may render them sensitive to PARP inhibitors, which have 
shown promising results (Lord and Ashworth 2017). 
The high number of helpers predicted using sysSVM made the 
experimental validation of all of them unfeasible. However, we selected 




defining patient clusters or their rarity. Validation of rare helpers was an 
important step of this project as our hypothesis was that rarely altered genes 
contribute to recurrent perturbations of biological processes. A further validation 
of helpers could be performed on cancer cells with matched background 
alteration of known drivers (e.g. MYC or ERBB2 for helpers in cluster 1H) to 
confirm their helper role in a specific molecular background, such as that 
described in figure 4.2.  
One main question that arises is how sysSVM could be implemented in 
clinical practice. Apart from the refinement of patient sub-groups that may 
provide insights into therapy, practical application of sysSVM for classification of 
individual patients and prediction of drivers and helpers could utilise the already 
trained models that were presented in this thesis. Although the number of OACs 
used in this work is about a third of those that have been sequenced so far by 
multiple studies, further analysis is needed to define the appropriate size of the 
training set in a clinical setting and quantify the contribution of new training 
observations. In addition to that, the training set of sysSVM could be subject to 
regular updates of its training set as new patients come into clinic. To this end 
alternative algorithms to the one used here (i.e. grid search) could be used to 
efficiently optimise the parameters of each kernel (Manurung, Mawengkang, 
and Zamzami 2017; Tsuruoka, Tsujii, and Ananiadou 2009). A paradigm of a 
rolling update of the training set might lead to better description of parts of the 
feature space that are not well represented in the current implementation. As a 
result, sysSVM will be able to analyse the molecular landscape of patients with 
non-recurrent or not previously seen drivers or helpers. Once trained, sysSVM 
models can be applied to individual patients even using personal computers in 





The work presented in this thesis provides new insights to the field of 
cancer driver discovery. The development and application of sysSVM confirmed 
the ability of one-class support vector machines and systems-level properties to 
predict cancer drivers. Our findings provided new insights to the understanding 
of OAC biology, as previously-unknown genes contributing to OAC 
development were revealed by applying sysSVM. Several of these genes, such 
as E2F1 and MCM7, were experimentally validated in OAC cell lines and were 
found to significantly increase the proliferation rate of cancer cells. Another 
important finding is that sysSVM top-scoring predictions converged towards the 
perturbation of the same biological processes, which were further divided into 
well-known and novel tumorigenic processes. Participation of helpers in well-
known tumorigenic pathways denotes that they are true positive predictions as 
they are primary interactors of known cancer drivers. A further important finding 
has been the identification of novel and putative targetable processes operating 
in OAC, such as TLR signalling cascades and proteasome activity. This finding 
may also inform patient stratification, as targeted therapies are in their infancy in 
OAC and initial results have been disappointing. Patient clustering using 
helpers revealed six patient sub-groups with distinctive molecular profiles and 
potential implications for clinical practice. Finally, sysSVM exemplifies cancer 
driver discovery without the use of recurrence of gene alterations. Such 
methods are of interest especially in cancer types with widespread inter-patient 
heterogeneity, such as OAC. The application of sysSVM in other cancer types 
could be used to guide testable hypothesis regarding the activity of cancer 





Chapter 6. Materials and Methods 
6.1 Cohort description 
Samples included in this study provided by the Oesophageal Cancer 
Clinical And Molecular Stratification (OCCAMS) consortium, which was 
incorporated into the International Cancer Genome Consortium (ICGC). All 
patients gave individual informed consent. OAC samples were obtained during 
surgical resection or by biopsy at endoscopic ultrasound, as previously reported 
(Secrier et al. 2016). Briefly, normal squamous oesophageal samples, resected 
at least 5 cm away from the tumour region, or blood were used as germline 
reference. All tissue samples were snap-frozen after collection. Prior to DNA 
extraction, the cellularity of hematoxylin-and-eosin-stained sections of the 
samples were assessed by two expert pathologists. Cancer samples with 
cellularity ≥ 70% were submitted for whole genome sequencing (WGS). DNA 
was extracted from frozen oesophageal tissue and from blood samples as 
previously described (Secrier et al. 2016). A total of 261 cases (matched 
tumour–normal) were sequenced and used in this study (Table 3.3). A smaller 
cohort of 18 OACs, which were part of the 261 cases, was used during the 
development phase of sysSVM. 
 
6.2 Annotation of molecular properties 
Data on somatic single nucleotide variations (SNVs), small insertions and 
deletions (indels), copy number variations (CNVs), structural variations (SVs), 
and mutational signatures for 261 OACs were obtained from ICGC and 




were called using Strelka v.1.0.13 (Saunders et al. 2012) and subsequently 
filtered to obtain high quality calls. Filters are summarised in Table 6.1. For 
CNVs, the absolute copy number for each genomic region was obtained from 
ASCAT-NGS v.2.1 (Van Loo et al. 2010) after correction for tumour content, 
using read counts at germline heterozygous positions as derived from GATK 
v.3.2-2 (McKenna et al. 2010). To account for the high number of amplifications 
occurring in OAC, copy number gains were corrected by the ploidy of each 
sample as estimated by ASCAT-NGS. A gene was assigned with the copy 
number of a CNV region if at least 25% of its length was contained in that 
region. SVs (gene translocations, inversions, insertions) were identified from 
discordant read pairs using Manta (Chen et al. 2016) after excluding SVs that 
were also present in more than two normal samples of a panel of 15 
oesophagus and 50 blood samples. For the validation cohort from TCGA, 
SNVs, indels, and CNVs were derived from level 3 TCGA annotation data of 86 
OACs (https://portal.gdc.cancer.gov/projects/TCGA-ESCA). In the case of 21 
OACs from a previous study (Nones et al. 2014), SNVs, indels, and CNVs were 
called as described for the ICGC samples. The distribution of variant allele 
frequency of SNVs and indels across all samples was used to remove outliers 
likely indicating sequencing or calling artefacts. Variants with <10% frequency 
and indels longer than five base pairs were also removed. For CNVs, genomic 
regions were considered as amplified or deleted if their segment mean was 
higher than 0.3 or lower than -0.3, respectively. A gene was considered as 
amplified or deleted if at least 25% of its length was contained in a CNV region 
and the resulting copy number (CN) was estimated as: 
 





No SV data were available for the validation cohorts.  
Since only genes with predicted damaging alterations were used as input 
for sysSVM, further annotation for the variant damaging effect was performed. 
stopgain, stoploss, frameshift, nonframeshift, nonsynonymous, and splicing 
SNVs and indels were annotated using ANNOVAR (December 2015) (Wang, Li, 
and Hakonarson 2010). All truncating alterations (stopgain, stoploss, and 
frameshift mutations) were considered as damaging. Nonframeshift and 
nonsynonymous mutations were considered as non-truncating damaging 
alterations, if predicted by: 
i) at least five of seven function-based methods: (SIFT (Kumar, Henikoff, 
and Ng 2009), PolyPhen-2 HDIV (Adzhubei et al. 2010), PolyPhen-2 
HVAR (Adzhubei et al. 2010), MutationTaster (Schwarz et al. 2010), 
MutationAssessor (Reva, Antipin, and Sander 2011), LRT (Chun and Fay 
2009) and FATHMM (Shihab et al. 2013)), or 
ii) two out of three conservation-based methods (PhyloP (Pollard et al. 
2010), GERP++ RS (Davydov et al. 2010), SiPhy (Garber et al. 2009)),  
using the scores from dbNSFP v.3.0 (Liu et al. 2016).  
Splicing modifications were considered as damaging if predicted by at 
least one of the two ensemble algorithms implemented in dbNSFP v3.0. 
Putative gain of function alterations were predicted using OncodriveClust 
(Tamborero, Gonzalez-Perez, and Lopez-Bigas 2013) with default parameters 
and a false discovery rate of 10%. The transcript lengths to estimate mutation 
clustering were derived from the refGene table of UCSC Table Browser 
(https://genome.ucsc.edu/cgi-bin/hgTables). Gene gains, homozygous losses, 





Table 6.1. Summary of filters applied to SNV calls from Strelka. Analysis 
pipeline was applied as previously reported (Secrier et al. 2016). 
Filter Description 
DistanceToAlignmentEndMedian The median shortest distance of the 
variant position within the read to either 
aligned end is less than 10 
 
 
DistanceToAlignmentEndMAD The median absolute deviation of the 
shortest distance of the variant position 
within the read to either aligned end is 
less than 3 
 
 
LowMapQual The proportion of reads at the variant 
position with low mapping quality (less 
than 1) is greater than 10% 
 
 
MapQualDiffMedian The difference in the median mapping 
quality of variant reads (in the tumour) 
and reference reads (in the normal) is 
greater than 5 
 
 
VariantMapQualMedian The median mapping quality of variant 
reads is less than 40 
 
 
VariantBaseQualMedian The median base quality at the variant 
position of variant reads is less than 30 
 
 
VariantAlleleCount The number of variant-supporting reads in 
the tumour is less than 4 
 
 
VariantAlleleCountControl The number of variant-supporting reads in 
the normal is greater than 1 
StrandBias The strand bias for variant reads covering 
the variant position, i.e. the fraction of 
reads in either direction, is less than 0.02, 
unless the strand bias for all reads is also 





Repeat The length of repetitive sequence 
adjacent to the variant position, where 




SNVCluster50 The largest number of variant positions 
within any 50 base pair window 
surrounding, but excluding, the variant 
position is greater than 2; variant positions 
are those in which the number of alternate 
allele is supported by at least 2 reads and 
at least 5% of all reads covering that 
position 
 
SNVCluster100 The largest number of variant positions 
within any 100 base pair window 
surrounding, but excluding, the variant 
position is greater than 4; variant positions 
are those in which the number of alternate 
allele is supported by at least 2 reads and 





6.3 Annotation of systems-level properties 
Protein sequences from RefSeq v.63 (Pruitt et al. 2014) were aligned to 
the human reference genome assembly GRCh37 to define unique gene loci, as 
previously described (An et al. 2016). The length of the longest coding 
sequence was taken as the gene length. Genes aligning to more than one gene 
locus for at least 60% of the protein length were considered as duplicated 
genes (Rambaldi et al. 2008). Data on human ohnologs (gene duplicates 
retained after whole genome duplications) were collected from Makino et al., 
2013 (Makino, McLysaght, and Kawata 2013). The number of protein domains 




(a measure of the degree to which the DNA is densely packed) based on Hi-C 
experiments (Lieberman-Aiden et al. 2009) was retrieved from the covariate 
matrix of MutSigCV v1.2.01 (Lawrence et al. 2013). Chromatin state of each 
gene (measured in K562 cells) was ranging approximately from -50 (very 
closed) to +50 (very open). Data on protein-protein and miRNA-gene 
interactions, gene evolutionary origin and gene expression were retrieved as 
described in An et al., 2016 (An et al. 2016). Briefly, human protein-protein 
interaction network was rebuilt from the integration of BioGRID v.3.4.125 
(Chatr-aryamontri et al. 2017); MIntAct v.190 (Orchard et al. 2014); DIP (April 
2015) (Salwinski et al. 2004); HPRD v.9 (Keshava Prasad et al. 2009); the 
miRNA-gene interactions were derived from miRTarBase v.4.5 (Hsu et al. 2014) 
and miRecords (April 2013) (Xiao et al. 2009); gene evolutionary origin was 
assessed as described in D’Antonio et al., 2011 (D’Antonio and Ciccarelli 2011) 
using gene orthology from EggNOG v.4 (Powell et al. 2014); and gene 
expression in 30 normal tissues was retrieved from GTEx v.1.1.8 (Mele et al. 
2015). Except gene length, duplication and ohnologs, all other systems-level 
properties had missing information for several human genes (Table 3.2). To 
account for this, median imputation for continuous properties and mode 
imputation for categorical properties were implemented. Specifically, for each 
property median or mode values were calculated for known cancer genes and 
the rest of mutated genes. All missing values were replaced by their 
corresponding median or mode values. 
 
 
6.4 Application of sysSVM to 261 OACs 
The three steps of sysSVM were applied to 261 OACs (Figure 3.3A). In 




(Table 3.2) were mapped to the 17,078 altered genes in the cohort. Each 
feature was scaled to zero mean and unit variance to correct for the different 
numerical ranges across them. In step 2, 476 known cancer genes with 
damaging alterations (Appendix Table 7.1) were used as a set of true positives 
for model selection. To optimise the parameters of the four kernels (linear, 
radial, sigmoid and polynomial) a grid search using 10,000 iterations of a three-
fold cross validation was performed. At each iteration, the 476 known cancer 
genes were randomly split into 2/3 (approximately 317 genes) that were used 
as a training set and 1/3 (approximately 159 genes) that was used as the test 
set. At each increment of 100 cross validation iterations, the four best models 
(one per kernel) were chosen based on the median and variance of the 
sensitivity distribution across all previous iterations of cross-validation. The 
selection of the 100 sets of best models from all 10,000 cross-validation 
iterations was repeated 5 times, where all iterations were randomly re-ordered. 
In step 3, the resulting 500 best models were trained with the whole training set 
and used to rank the remaining 16,602 unique genes in each patient. A score 
was calculated to combine the predictions form the four kernels and the genes 
that were not expressed in normal oesophagus, according to GTEx annotation, 
were excluded. These produced 500 lists of top 10 genes. Out of 500 best 
models, 38 had a unique set of parameters resulting in 24 unique lists of top 10 
genes (Table 3.4). These 25 lists ranged between 898 and 952 genes, with a 
core set of 598 genes shared across all of them. The most frequent top 10 list 
occurred 207 times (952_A, 41.4%, Table 3.4). It was followed by 952_B 
(32.2%, 161 times) and 951_A (8.6%, 43 times). These three lists accounted for 
82.2% of the 500 sets of top 10 genes, they shared 950 genes and were 




kernel, Table 3.4). Furthermore, the most frequent list was always predicted by 
the same set of best models. Therefore, 952_A represented a robust set of 




6.5 Identification of perturbed processes and patient clustering 
To identify the perturbed biological processes in OAC, both predicted 
cancer helper genes and known cancer driver genes were used. A manual 
revision of 476 known cancer genes that were altered in the ICGC cohort was 
performed and genes were considered as known drivers if: 
i) their somatic alteration had been previously associated with OAC,  
ii) they had a loss-of-function alteration and their tumour suppressor role 
had been reported in other cancer types (Vogelstein et al. 2013), or 
iii) they had a gain-of-function alteration and their oncogenic role had been 
reported in other cancer types (Vogelstein et al. 2013).  
The resulting 202 known cancer drivers and 952 cancer helpers were 
used for the gene set enrichment analysis using as reference Reactome v.58 
(Fabregat et al. 2016), which is composed of 1,877 pathways and 10,131 
genes. After excluding pathways in levels 1 and 2 of Reactome hierarchy and 
those with less than 10 or more than 500 genes, 1,155 pathways were retained. 
These contained 9,061 genes, including 155 known drivers and 648 helpers. 
Gene set enrichment was assessed using a one-sided hypergeometric test and 
the resulting P values were corrected for multiple testing using the Benjamini & 
Hochberg method (Appendix Tables 7.3 and 7.4). Enriched pathways within the 
sets of known drivers or helpers were subsequently used to cluster samples, 




samples. The Jaccard index (A) was calculated by deriving the proportion of 
shared perturbed processes between all possible sample pairs as: 
 
 𝐴𝑖𝑗 = |𝑃𝑖 ∩ 𝑃𝑗| ∕ |𝑃𝑖 ∪ 𝑃𝑗|   
 
where Pi and Pj are the perturbed processes in samples i and j, respectively.  
Complete linkage hierarchical clustering using Euclidean distance 
between each row was performed on the resulting matrix. Clusters were 
visualised using ComplexHeatmap R package (Gu, Eils, and Schlesner 2016). 
To identify the optimal number of clusters, the median silhouette value of the 
samples between 3 and 20 clusters was measured as a measure of clustering 
robustness (Rousseeuw 1987). 
 
 
6.6 Analysis of expression data 
Purified total RNA was extracted from 92 out of the 261 OACs in the ICGC 
cohort and sequenced as described previously (Secrier et al. 2016). RNA 
sequencing reads were then aligned to human reference genome hg19 and 
expression values were calculated using Gencode v19. The 
summariseOverlaps function in the R GenomicAlignments package was used to 
count any fragments overlapping with exons (parameters mode=Union, 
singleEnd, invertStrand and inter.feature were set according to the library 
protocol, fragments=TRUE, ignore.strand=FALSE). Gene length was calculated 
as the number of base pairs in the exons after concatenating the exons per 
gene in non-overlapping regions. FPKM (Fragments Per Kilobase Million) were 





𝐹𝑃𝐾𝑀 =  
𝑔𝑒𝑛𝑒 𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡
(𝑙𝑖𝑏𝑟𝑎𝑟𝑦 𝑠𝑖𝑧𝑒/1000000) × (𝑔𝑒𝑛𝑒 𝑙𝑒𝑛𝑔𝑡ℎ/1000)
 
Pan-cancer expression data for KAT2A, KAT2B and E2F1 were 






6.7 Experimental validation 
6.7.1 Materials 
 
Antibodies and dyes 
 
 
 The dye Alexa Fluor™ 488 NHS Ester (Succinimidyl Ester) used in 
barcoding was supplied from Thermo Fisher 
 The full list of antibodies is provided below 
 
 Table 6.2. List of antibodies used in this study. 
 
Cell lines 
Table 6.3. List of cell lines used in this study. 













Alexa Fluor 555 
polyclonal donkey ThermoFisher 
Scientific 
Anti-rabbit  





Cell line Origin Source 
FLO-1 Human oesophageal 
adenocarcinoma  
European Collection of 





Media and solutions 
Table 6.4. List of media and solutions used in this study. 
Product Supplier 
Dulbecco’s Modified Eagle’s Medium (DMEM) Sigma-Aldrich 
Dulbecco's phosphate buffered saline (DPBS) Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Fetal bovine serum (FBS) Biosera 
Geneticin (G-418) solution 
Sigma-Aldrich 
Glutamine Solution 200 mM Sigma-Aldrich 
HEPES buffer solution 1M Sigma-Aldrich 
Penicillin/Streptomycin solution     






HEK293T Human embryonic 
kidney 
Francis Crick Institute Cell 
Services 
MFD1 Human oesophageal 
adenocarcinoma  
OCCAMS consortium 
OE19 Human oesophageal 
adenocarcinoma 
Francis Crick Institute Cell 
Services 
OE33 Human oesophageal 
adenocarcinoma 
European Collection of 




Kits and reagents 
Table 6.5. List of kits and reagents used in this study. 
Product Supplier 
Blasticidin Sigma-Aldrich 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Brilliant III Ultra-Fast SYBR Green QRT-PCR Master 
Mix 
Agilent Technologies 
CellTiter 96 Non-Radioactive Cell Proliferation Assay Promega 
CellTiter-Glo Luminescent Cell Viability Assay Promega 
Click-iT™ Plus EdU Alexa Fluor™ 647 Flow 
Cytometry Assay Kit 
Invitrogen 
cOmpleteTM EDTA-free protease inhibitor cocktail 
tablets 
Roche 
DAPI  Invitrogen 
Doxycycline Sigma-Aldrich 
EdU Invitrogen 
GeneArt Platinum Cas9 nuclease Life Technologies 
GeneElute mammalian total RNA miniprep kit Sigma-Aldrich 
Hexadimethrine bromide Sigma-Aldrich 
Lipofectamine CRISPR max Life Technologies 




Q5 Hot Start High-Fidelity 2X Master Mix 








Trypan Blue solution (0.4%) 
Sigma-Aldrich 
  
Solutions prepared in-house 
1. 1% BSA/PBS.  
Was prepared by dissolving 1g of BSA in 100 mL of PBS 
2. Cytoskeleton buffer (CSK), provided by the Crick Lab stocks 
 10mM HEPES-KOH pH7.9 
 100mM NaCl 
 3mM MgCL2 
 1mM EGTA (Ethylene glycol tetraacetic acid) 
 300mM sucrose 
 1% BSA 
 0.2 Triton-X 100 
 1mM DTT 
 cOmplete EDTA-free protease inhibitor cocktail tablets, Roche 
 
Vectors 
Table 6.6. List of vectors used in this study. 
 
  
Vector name Insert Selectable marker Supplier 
pCMVHA E2F1 E2F1 neomycin Addgene  
pLX_TRC317 MCM7 puromycin Sigma-Aldrich 
pcDNA3.1+/C-(K)-
DYK 
PAK1 neomycin Genscript 
EZ-Tet-pLKO-
Puro 














All validation experiments were performed by Dr. Lorena Benedetti and Dr. 
Elizabeth Foxhall.  
  
Cell culture 
Overexpression and editing experiments were carried out using the FLO-1 
oesophageal adenocarcinoma cell line. Gene knockdown experiments were 
performed on OE19, OE33 and MFD1 cells. FLO-1 cells were grown at 37°C 
and 5% CO2 in DMEM supplemented with 2mM Glutamine, 10% FBS, 100 
I.U./mL penicillin and 100 μg/mL streptomycin. OE19 and OE33 cells were 
grown in RPMI supplemented with 2mM Glutamine, 10% FBS, 100 I.U./mL 
penicillin and 100 μg/mL streptomycin. MFD1 cells were grown in DMEM 
supplemented with 2mM Glutamine, 10% FBS, 100 I.U./mL penicillin and 100 
μg/mL streptomycin. All cells were maintained at 37°C and five per cent CO2, 
validated by short tandem repeat analysis and routinely checked for 
mycoplasma contamination. For all experiments, cells were harvested in log 
phase growth using Trypsin-EDTA 1x solution, washed and resuspended in 
culture medium. To determine cell numbers and viability, cell suspension was 
mixed with known volume of 0.4% Trypan blue solution and then cells were 
counted using a haemocytometer.  
 
Gene overexpression 
The vectors pCMVHA E2F1 (Lukas et al. 1996), pLX_TRC317 and 
pcDNA3.1+/C-(K)-DYK were used to induce E2F1, MCM7, and PAK1 
overexpression, respectively (Table 6.6). Cells were transfected according to 




G481/Geneticin (E2F1, PAK1) or Puromycin (MCM7). Empty vectors 
pcDNA3.1+/C-(K)-DYK and EZ-Tet-pLKO-Puro, carrying Neomycin or 
Puromycin resistance, respectively, were used as controls (Table 6.6).  
RNA was isolated from transfected cells using GeneElute mammalian total 
RNA miniprep kit, as per manufacturer’s instructions, and was used to assess 
gene overexpression via quantitative RT-PCR. Briefly, qRT-PCR was performed 
in a 20 ul reaction using predesigned SYBR green primers (Table 4.2 Primers, 
Sigma Aldrich) and Brilliant III Ultra-Fast SYBR Green QRT-PCR Master Mix 
(Agilent Technologies) for detection (10ul of 2× SYBR Green QPCR master 
mix, 0.8μl of primers and 7.2ul of dH20). Primers were diluted 1:10 from a 
100uM stock. qRT-PCR was performed on the viiA7 Real-Time PCR System 
(Applied Biosystems) and settings were fixed: Hold Stage (95oC, 2 minutes), 
PCR cycles (40 in total) of Melt (95oC, 5 seconds), Anneal/Extension (63oC, 30 
seconds). 
The average expression level across triplicates (e) was relativized to the 
average expression level of β-2-microglobulin (c): 
 
𝑟 = 𝑒 − 𝑐 
where r is the relative gene expression. The fold change (fc) between the 
relative gene expression after overexpression and the relative gene expression 
in the control condition (rc) was calculated as: 
𝑓𝑐 =  2( 𝑟𝑐− 𝑟𝐾𝐷) 








To induce gene knock-out (KO), the vector-free CRISPR-mediated editing 
approach was used (Lorena Benedetti et al. 2017). Initially, cells were 
transduced with lentiviral vector (Table 6.6) containing Cas9sp and blasticidin 
resistance marker. After 10 days of treatment with blasticidin (25 ug/ml), 
resistant cells were selected and Cas9sp expression was verified via PCR using 
specific primers (Table 4.2).  
Consequently, Cas9sp-expressing cells were co-transfected using 
lipofectamine CRISPR max with a 69-mer tracrRNA, GeneArt Platinum Cas9 
nuclease and three gene-specific crRNAs (Table 4.2). To avoid off-target 
editing, all crRNAs used were verified to map only the gene of interest with a 
perfect match and additional hits in the genome with at least three mismatches. 
Control cells were transfected with the same protocol but using three non-
targeting control (NTC; Table 4.2) crRNAs.  
Gene editing was confirmed with Illumina Miseq sequencing. Genomic 
DNA from edited cells was extracted and regions surrounding the targeted sites 
were amplified with primers containing Illumina adapters (Table 4.2) using Q5 
Hot Start High-Fidelity 2X Master Mix in a 25ul reaction [120ng of DNA 
(DNA+H2O=10ul, 2X Q5 MM=12.5ul, 1.25 ul of each primer)]. DNA barcodes 
were added with a PCR reaction before pooling the samples for sequencing on 
Illumina MiSeq with the 250 base-pair paired-end protocol. Sequencing reads 
were merged into single reads and aligned to the human reference genome 
hg19 using BBMerge and BBMap functions of BBTools (Joint Genome 
Institute), obtaining an average of 78,864 aligned reads per experiment. SNVs 
and small indels in the regions corresponding to each crRNA were called using 








Inducible gene knockdown was carried out using lentiviral pTRIPZ-
TurboRFP (MCM7) or pSMART-TurboGFP (PSMD3) shRNA vectors 
(Dharmacon). For each gene, three shRNA vectors were tested (Table 4.2). 
Virus was produced by co-transfecting HEK293T cells with pTRIPZ or pSMART 
constructs alongside psPAX2 and pMD2.G vectors (Addgene) using Fugene 
HD (Promega). Viral supernatant was collected at 24 and 48 hours and used for 
two rounds of infection of OE19, OE33 or MFD1 cells, using 8μg/ml 
hexadimethrine bromide. Infected cells were selected after 48 hours with 2μg/ml 
puromycin for 7 days. To induce shRNA expression, cells were treated with 
1μg/ml doxycycline for 16 hours. Gene expression with or without doxycycline 
was assessed by qRT-PCR using predesigned SYBR green primers (Sigma-
Aldrich; Table 4.2). Cells with the highest level of knockdown were then sorted 
by FACS to isolate medium expressing cells (the middle 30% of cells based on 
TurboRFP or TurboGFP fluorescence). Gene expression after sorting was 
measured by qRT-PCR 24 hours post-induction with 0-1μg/ml doxycycline, to 
determine the concentration of doxycycline required to reduce expression to 
levels equivalent to FLO-1 cells. The determined concentrations of doxycycline 
used for proliferation assays were 0.05μg/ml for OE19 PSMD3 shRNA3, 
0.25μg/ml for OE33 PSMD3 shRNA3, 0.25μg/ml for MFD1 PSMD3 shRNA3, 







Cell proliferation was assessed using either the CellTiter 96 Non-
Radioactive Cell Proliferation Assay or the CellTiter-Glo Luminescent Cell 
Viability Assay, according to manufacturer’s instructions. Proliferation was 
assessed every 24 hours for three days, starting three hours after seeding the 
cells (time zero) to allow cell adhesion. 
Briefly, 4.5x103 cells/well were seeded on 96-well flat bottom plates in a 
final volume of 100ul per well. For the CellTiter 96 Non-Radioactive Cell 
Proliferation Assay, 15 ul of the Dye Solution was added into each well and 
cells were incubated at 37°C for two hours. The converted dye was released 
from the cells using 100μl of the Solubilisation Solution/Stop mix and 
absorbance was measured at 570nm after one hour using the Paradigm 
detection platform (Beckman Coulter). For the CellTiter-Glo Luminescent Cell 
Viability Assay, 100ul of the CellTiter-Glo reagent was added into each well and 
luminescence was measured after 30 minutes using the Paradigm detection 
platform (Beckman Coulter). Four replicates per condition were measured at 
each time point and each measure was normalised to the average time zero 
measure for each condition.  
 
Flow cytometry 
EdU incorporation and MCM loading were assessed using a modified 
version of the protocol described previously (Galanos et al. 2016). Briefly, in 
each condition, 3x106 cells were pulsed for 30 minutes with 10µM EdU before 
washing in 1% BSA/PBS. Chromatin fractionation was performed by incubating 
on ice for 10 minutes in CSK buffer. Cells were then fixed in 4% 




BSA/PBS. Cells were permeabilised and barcoded (Krutzik and Nolan 2006) by 
incubating in 70% ethanol containing 0-15µg/ml Alexa Fluor 488 for 15 minutes, 
then washed twice in 1% BSA/PBS. Barcoded cells were subsequently pooled 
before incubating in primary antibody (mouse monoclonal anti-MCM7or rabbit 
polyclonal anti-MCM3) diluted 1:100 in 1% BSA/PBS for 1 hour. After washing 
in 1% BSA/PBS, samples were incubated for 30 minutes in secondary antibody 
(Alexa Fluor 555-conjugated donkey anti-mouse or donkey anti-rabbit) diluted 
1:500 in 1% BSA/PBS, then washed again in 1% BSA/PBS. EdU labelling with 
Alexa Fluor 647 azide was performed using Click-iT EdU flow cytometry assay 
kit following the manufacturer’s instructions before washing samples in 1% 
BSA/PBS. Samples were then incubated in 1% BSA/PBS containing RNase 
and 10mg/ml DAPI for 15 minutes before flow cytometry acquisition.  
 
Flow cytometry acquisition and analysis 
A 4-laser BD LSRII Fortessa flow cytometer (Beckton Dickinson, BD) was 
used for all flow cytometry studies. Lasers and filters used include: 407nm laser 
with 450/50 bandpass filter; 488nm laser with 505 longpass and 530/30 
bandpass filters; 561nm laser with 570 longpass and 590/30 bandpass filters; 
640nm laser with 670/14 bandpass filter. All samples were acquired using the 
FACS Diva programme (BD) and analysed using FlowJo software. 
FlowJo 10.3 software (Treestar Inc, Oregon, USA) was used to analyse 
MCM loading onto chromatin and EdU incorporation. Compensation was 
performed manually with single colour controls, using BD FACSDiva software 
(BD Biosciences). Cells were gated to remove debris using FSC-A/SSC-A, then 
gated to isolate singlets using DAPI-H/DAPI-A. The cells were then separated 




separated into cell cycle gates (G1, S1-4, G2) based on EdU-647-A and DAPI-
A, and the geometric mean fluorescence intensity was obtained for each 









Chapter 7. Appendix 
7.1 Known cancer genes with damaging alterations 
List of 476 known cancer genes from the cancer gene census (Forbes et al. 
2017) that acquire potential damaging alterations in 261 OACs. For each gene, 
the number of samples with damaging alterations in the 261 OACs and the 
number of samples in which the gene was considered as a driver is reported. 
This was based on the manual assessment of (a) the literature support for the 
cancer driver role in OAC, (b) the role as a tumour suppressor or oncogene as 
reported in (8) and the type of alterations found in OACs. For the 202 genes 















ABI1 abl-interactor 1 5 0 - 
ABL1 
v-abl Abelson murine 
leukemia viral O homolog 1 4 4 Oncogene 
ABL2 
c-abl O 2, non-receptor 
tyrosine kinase 3 0 - 
ACKR3 
atypical chemokine receptor 
3 1 0 - 
ACSL3 
acyl-CoA synthetase long-
chain family member 3 4 0 - 
ACSL6 
acyl-CoA synthetase long-
chain family member 6 4 0 - 
AFF1 
AF4/FMR2 family, member 
1 6 0 - 
AFF3 
AF4/FMR2 family, member 
3 15 0 - 
AFF4 
AF4/FMR2 family, member 
4 1 0 - 
AKAP9 
A kinase (PRKA) anchor 
protein (yotiao) 9 38 37 Oncogene 
AKT1 
v-akt murine thymoma viral 
O homolog 1 1 1 Oncogene 
AKT2 
v-akt murine thymoma viral 
O homolog 2 12 12 Oncogene 
ALDH2 
aldehyde dehydrogenase 2 
family (mitochondrial) 3 0 - 
ALK 
anaplastic lymphoma kinase 
(Ki-1) 9 0 Oncogene 
AMER1 
APC membrane recruitment 




adenomatous polyposis of 





Rho GTPase activating 





RHO guanine nucleotide 
exchange factor (GEF) 12 
(LARG) 8 0 - 
ARID1A 
AT rich interactive domain 










aryl hydrocarbon receptor 
nuclear translocator 11 0 - 
ASPSCR1 
alveolar soft part sarcoma 
chromosome region, 
candidate 1 1 0 - 










cyclohydrolase 3 0 - 





transporting, alpha 1 





ATPase, Ca++ transporting, 




linked 6 4 
Tumour 
suppressor 




BRCA1 associated protein-1 
(ubiquitin carboxy-terminal 
hydrolase) 3 3 
Tumour 
suppressor 
BCL11A B-cell CLL/lymphoma 11A 11 0 - 
BCL11B 
B-cell CLL/lymphoma 11B  




BCL3 B-cell CLL/lymphoma 3 18 0 - 
BCL6 B-cell CLL/lymphoma 6 5 5 Oncogene 
BCL7A B-cell CLL/lymphoma 7A 4 0 - 
BCL9 B-cell CLL/lymphoma 9 5 0 - 
BCOR BCL6 corepressor 2 2 
Tumour 
suppressor 
BCR breakpoint cluster region 4 4 Oncogene 
BIRC3 
baculoviral IAP repeat-




BLM Bloom Syndrome 11 0 - 
BMPR1A 
bone morphogenetic protein 
receptor, type IA 5 0 - 
BRAF 
v-raf murine sarcoma viral O 
homolog B1 8 8 Oncogene 
BRCA1 
familial breast/ovarian 





cancer gene 2 23 0 
Tumour 
suppressor 
BRD3 bromodomain containing 3 5 4 Oncogene 
BRD4 bromodomain containing 4 6 0 - 
BRIP1 
BRCA1 interacting protein 
C-terminal helicase 1 6 0 
Tumour 
suppressor 






BUB1 budding uninhibited 
by benzimidazoles 1 
homolog beta (yeast) 1 0 - 
C15orf65 
chromosome 15 open 




dependent, L type, alpha 1D 
subunit 6 5 Oncogene 
CALR calreticulin 3 1 Oncogene 
CAMTA1 
calmodulin binding 





nucleotidase 1 3 0 - 
CARD11 
caspase recruitment domain 
family, member 11 6 5 Oncogene 
CARS cysteinyl-tRNA synthetase 2 0 - 
CASC5 
cancer susceptibility 
candidate 5 1 0 - 
CASP8 
caspase 8, apoptosis-related 




core-binding factor, runt 
domain, alpha subunit 2; 
translocated to, 3 (MTG-16) 4 0 - 
CBFB 
core-binding factor, beta 






















containing 6 2 0 - 
CCNB1IP
1 
cyclin B1 interacting protein 
1, E3 ubiquitin protein ligase 6 0 - 
CCND1 cyclin D1 34 34 Oncogene 
CCND2 cyclin D2 7 6 Oncogene 
CCND3 cyclin D3 25 25 Oncogene 
CCNE1 cyclin E1 31 31 Oncogene 
CD274 CD274 molecule 3 0 - 
CD74 
CD74 molecule, major 
histocompatibility complex, 








beta 3 2 Oncogene 




cadherin 1, type 1, E-
cadherin (epithelial) 







cadherin 11, type 2, OB-
cadherin (osteoblast) 12 0 - 
CDK12 cyclin-dependent kinase 12 42 5 
Tumour 
suppressor 
CDK4 cyclin-dependent kinase 4 2 2 Oncogene 
CDK6 cyclin-dependent kinase 6 40 40 Oncogene 
CDKN2A 
cyclin-dependent kinase 
inhibitor 2A (p16(INK4a)) 





inhibitor 2C (p18, inhibits 




caudal type homeo box 
transcription factor 2 13 0 - 
CEBPA 
CCAAT/enhancer binding 





helix domain containing 7 5 0 - 
CHEK2 
CHK2 checkpoint homolog 





domain 2 1 0 - 
CHN1 - 5 0 - 




class II, major 
histocompatibility complex, 





polyadenylation factor I 
subunit 1 1 0 - 
CLTC 
clathrin, heavy polypeptide 
(Hc) 8 0 - 
CLTCL1 
clathrin, heavy polypeptide-
like 1 4 0 - 
CNBP 
CCHC-type zinc finger, 
nucleic acid binding protein 1 0 - 
CNOT3 
CCR4-NOT transcription 
complex subunit 3 11 1 
Tumour 
suppressor 
CNTRL centriolin 6 0 - 
COL1A1 collagen, type I, alpha 1 7 0 - 
COX6C 
cytochrome c oxidase 
subunit VIc 14 0 - 
CREB1 
cAMP responsive element 
binding protein 1 1 0 - 
CREB3L1 
cAMP responsive element 
binding protein 3-like 1 9 0 - 
CREB3L2 
cAMP responsive element 
binding protein 3-like 2 1 0 - 
CREBBP 
CREB binding protein 




cytokine receptor-like factor 
2 23 0 Oncogene 
CRTC1 
CREB regulated 
transcription coactivator 1 4 4 Oncogene 
CRTC3 
CREB regulated 
transcription coactivator 3 9 0 - 
CSF3R 
colony stimulating factor 3 






protein), beta 1 7 7 Oncogene 
CYLD 
familial cylindromatosis 










binding protein 2 9 0 - 
DDIT3 
DNA-damage-inducible 
transcript 3 3 0 - 
DDX10 
DEAD (Asp-Glu-Ala-Asp) 





box polypeptide 5 2 0 - 
DDX6 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 6 6 0 - 
DEK DEK O (DNA binding) 6 0 - 
DICER1 dicer 1, ribonuclease type III 6 5 
Tumour 
suppressor 









DUX4L1 double homeobox 4 like 1 1 0 - 
EBF1 early B-cell factor 1 9 9 Oncogene 
ECT2L 
epithelial cell transforming 




epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) O 
homolog, avian) 34 30 Oncogene 
EIF4A2 
eukaryotic translation 
initiation factor 4A, isoform 
2 6 0 - 
ELK4 
ELK4, ETS-domain protein 
(SRF accessory protein 1) 3 0 - 
ELL 
ELL gene (11-19 lysine-rich 
leukemia gene) 4 0 - 
ELN elastin 12 12 Oncogene 
EML4 
echinoderm microtubule 
associated protein like 4 4 0 - 
EP300 
300 kd E1A-Binding protein 




epidermal growth factor 
receptor pathway substrate 
15 (AF1p) 3 0 - 
ERBB2 
v-erb-b2 erythroblastic 
leukemia viral O homolog 2, 
neuro/glioblastoma derived 




member 1 12 0 - 
ERCC2 
excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 2 (xeroderma 
pigmentosum D) 12 1 
Tumour 
suppressor 




complementing rodent repair 
deficiency, complementation 
group 3 (xeroderma 




complementing rodent repair 
deficiency, complementation 
group 4 4 0 - 
ERCC5 
excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 5 (xeroderma 
pigmentosum, 
complementation group G 
(Cockayne syndrome)) 6 0 - 
ERG 
v-ets erythroblastosis virus 
E26 O like (avian) 3 2 Oncogene 
ETV1 ets variant gene 1 9 0 - 
ETV4 
ets variant gene 4 (E1A 
enhancer binding protein, 
E1AF) 10 0 - 
ETV5 ets variant gene 5 6 0 - 
ETV6 ets variant gene 6 (TEL O) 12 12 Oncogene 
EWSR1 
Ewing sarcoma breakpoint 
region 1 (EWS) 1 0 - 
EXT1 
multiple exostoses type 1 
gene 26 0 - 
EXT2 
multiple exostoses type 2 
gene 6 1 
Tumour 
suppressor 
EZH2 enhancer of zeste homolog 2 6 5 Oncogene 
EZR ezrin 1 0 - 
FAM46C 
family with sequence 










complementation group C 3 0 - 
FANCD2 
Fanconi anemia, 
complementation group D2 7 0 - 
FANCE 
Fanconi anemia, 
complementation group E 2 0 - 
FANCF 
Fanconi anemia, 
complementation group F 2 0 - 
FANCG 
Fanconi anemia, 
complementation group G 12 0 - 
FAS 
Fas cell surface death 
receptor 4 3 
Tumour 
suppressor 




F-box and WD-40 domain 
protein 7 (archipelago 




Fc fragment of IgG, low 
affinity IIb, receptor for 
(CD32) 5 0 - 
FCRL4 Fc receptor-like 4 2 0 - 
FEV 
FEV protein - 





fibroblast growth factor 
receptor 1 12 12 Oncogene 
FGFR1OP FGFR1 O partner (FOP) 2 0 - 
FGFR2 
fibroblast growth factor 
receptor 2 11 8 Oncogene 
FGFR3 
fibroblast growth factor 
receptor 3 4 3 Oncogene 
FH fumarate hydratase 5 1 
Tumour 
suppressor 
FHIT fragile histidine triad gene 77 77 - 
FIP1L1 FIP1 like 1 (S. cerevisiae) 9 0 - 
FLCN folliculin 4 0 - 
FLI1 
Friend leukemia virus 
integration 1 7 0 - 
FLT3 fms-related tyrosine kinase 3 12 11 Oncogene 
FNBP1 
formin binding protein 1 
(FBP17) 4 0 - 
FOXA1 forkhead box A1 4 0 Oncogene 
FOXL2 forkhead box L2 2 0 Oncogene 




FOXO4 forkhead box O4 1 0 - 
FOXP1 forkhead box P1 9 0 - 
FSTL3 
follistatin-like 3 (secreted 
glycoprotein) 3 0 - 
FUBP1 
far upstream element 




fusion, derived from t(12;16) 
malignant liposarcoma 7 0 - 
GAS7 growth arrest-specific 7 5 0 - 
GATA2 GATA binding protein 2 1 1 Oncogene 





synthetase 3 0 - 
GNA11 
guanine nucleotide binding 
protein (G protein), alpha 11 
(Gq class) 2 0 Oncogene 
GNAQ 
guanine nucleotide binding 
protein (G protein), q 
polypeptide 1 0 Oncogene 
GNAS 
guanine nucleotide binding 
protein (G protein), alpha 
stimulating activity 
polypeptide 1 33 30 Oncogene 
GOLGA5 
golgi autoantigen, golgin 
subfamily a, 5  (PTC5) 2 0 - 
GOPC 
golgi associated PDZ and 
coiled-coil motif containing 5 5 Oncogene 
GPC3 glypican 3 4 0 - 
GPHN gephyrin (GPH) 8 0 - 








like domain member 1 
HEY1 
hairy/enhancer-of-split 
related with YRPW motif 1 10 0 - 
HIP1 
huntingtin interacting 
protein 1 13 0 - 
HIST1H3
B histone cluster 1, H3b 7 0 Oncogene 
HIST1H4I histone 1, H4i (H4FM) 8 0 - 
HLF hepatic leukemia factor 5 0 - 
HMGA1 
high mobility group AT-
hook 1 4 0 - 
HMGA2 
high mobility group AT-
hook 2 (HMGIC) 11 0 - 






ribonucleoprotein A2/B1 5 5 Oncogene 
HOOK3 hook homolog 3 13 0 - 
HOXA11 homeo box A11 7 0 - 
HOXA13 homeo box A13 6 0 - 
HOXA9 homeo box A9 6 0 - 
HOXC11 homeo box C11 2 0 - 
HOXC13 homeo box C13 1 0 - 
HOXD11 homeo box D11 1 0 - 
HOXD13 homeo box D13 2 0 - 
HRAS 
v-Ha-ras Harvey rat sarcoma 
viral O homolog 6 6 Oncogene 
HSP90AA
1 
heat shock protein 90kDa 
alpha (cytosolic), class A 
member 1 7 0 - 
HSP90AB
1 
heat shock protein 90kDa 
alpha (cytosolic), class B 
member 1 16 0 - 
IDH1 
isocitrate dehydrogenase 1 
(NADP+), soluble 2 2 Oncogene 
IDH2 
isocitrate dehydrogenase 2 
(NADP+), mitochondrial 7 7 Oncogene 
IKZF1 
IKAROS family zinc finger 
1 12 4 
Tumour 
suppressor 
IL2 interleukin 2 1 0 - 
IL21R interleukin 21 receptor 10 0 - 
IL6ST 
interleukin 6 signal 
transducer (gp130, 
oncostatin M receptor) 3 0 - 
IL7R interleukin 7 receptor 15 12 Oncogene 




ITK IL2-inducible T-cell kinase 3 2 Oncogene 
JAK1 Janus kinase 1 6 5 Oncogene 
JAK2 Janus kinase 2 2 1 Oncogene 
JAK3 Janus kinase 3 3 3 Oncogene 
JAZF1 
juxtaposed with another zinc 






6A 13 12 Oncogene 
KAT6B 
K(lysine) acetyltransferase 




subfamily J; member 5 5 4 Oncogene 
KDM5A 
lysine (K)-specific 
demethylase 5A, JARID1A 11 0 - 
KDM5C 
lysine (K)-specific 





demethylase 6A, UTX 9 4 
Tumour 
suppressor 
KIAA1549 KIAA1549 6 0 - 
KIF5B kinesin family member 5B 8 0 - 
KIT 
v-kit Hardy-Zuckerman 4 
feline sarcoma viral O 
homolog 3 3 Oncogene 
KLF4 Kruppel-like factor 4 2 2 Oncogene 
KLF6 Kruppel-like factor 6 6 1 
Tumour 
suppressor 
KLK2 kallikrein-related peptidase 2 5 0 - 
KMT2A 
lysine (K)-specific 
methyltransferase 2A 12 11 Oncogene 
KMT2C 
lysine (K)-specific 









v-Ki-ras2 Kirsten rat 
sarcoma 2 viral O homolog 39 39 Oncogene 
KTN1 kinectin 1 (kinesin receptor) 5 0 - 
LASP1 LIM and SH3 protein 1 15 14 - 
LCK 
lymphocyte-specific protein 
tyrosine kinase 6 0 - 
LCP1 
lymphocyte cytosolic protein 
1 (L-plastin) 19 0 - 
LHFP 
lipoma HMGIC fusion 
partner 20 15 - 
LIFR 
leukemia inhibitory factor 
receptor 19 0 - 
LMO2 
LIM domain only 2 
(rhombotin-like 1) (RBTN2) 3 0 - 
LPP 
LIM domain containing 
preferred translocation 
partner in lipoma 10 0 - 
LRIG3 
leucine-rich repeats and 
immunoglobulin-like 
domains 3 6 0 - 
LYL1 
lymphoblastic leukemia 
derived sequence 1 1 0 - 
MAF 
v-maf musculoaponeurotic 
fibrosarcoma O homolog 1 0 - 
MAFB 
v-maf musculoaponeurotic 
fibrosarcoma O homolog B 
(avian) 30 0 - 
MAML2 
mastermind-like 2 
(Drosophila) 11 11 Oncogene 
MAP2K1 
mitogen-activated protein 






kinase kinase 4 8 7 
Tumour 
suppressor 




Mdm2 p53 binding protein 
homolog 16 16 Oncogene 
MDM4 
Mdm4 p53 binding protein 
homolog 4 3 Oncogene 
MECOM 
MDS1 and EVI1 complex 
locus 21 21 Oncogene 
MED12 
mediator complex subunit 
12 3 3 Oncogene 
MEN1 
multiple endocrine neoplasia 




met proto-O (hepatocyte 
growth factor receptor) 13 12 Oncogene 
MITF 
microphthalmia-associated 
transcription factor 4 2 Oncogene 
MKL1 
megakaryoblastic leukemia 
(translocation) 1 8 0 - 
MLF1 myeloid leukemia factor 1 2 0 - 





lineage leukemia (trithorax 
homolog, Drosophila); 
translocated to, 1 (ENL) 1 0 - 
MLLT10 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila); 
translocated to, 10 (AF10) 7 0 - 
MLLT11 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila); 
translocated to, 11 11 0 - 
MLLT3 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila); 
translocated to, 3 (AF9) 10 3 Oncogene 
MLLT4 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila); 
translocated to, 4 (AF6) 8 0 - 
MLLT6 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila); 
translocated to, 6 (AF17) 13 13 - 
MN1 
meningioma (disrupted in 
balanced translocation) 1 3 0 - 
MNX1 
motor neuron and pancreas 
homeobox 1 3 0 - 
MPL 
myeloproliferative 
leukaemia virus O, 
thrombopoietin receptor 5 0 Oncogene 




musashi homolog 2 
(Drosophila) 10 0 - 
MSN moesin 5 0 - 




MUC1 mucin 1, transmembrane 13 0 - 
MUTYH mutY homolog (E. coli) 2 0 - 
MYB 
v-myb myeloblastosis viral 
O homolog 8 8 Oncogene 
MYC 
v-myc myelocytomatosis 
viral O homolog (avian) 55 55 Oncogene 
MYCL 
v-myc avian 
myelocytomatosis viral O 
lung carcinoma derived 
homolog 7 7 Oncogene 
MYCN 
v-myc myelocytomatosis 
viral related O, 
neuroblastoma derived 
(avian) 1 1 Oncogene 
MYD88 
myeloid differentiation 
primary response gene (88) 1 1 Oncogene 
MYH11 
myosin, heavy polypeptide 
11, smooth muscle 10 0 - 
MYH9 
myosin, heavy polypeptide 
9, non-muscle 7 0 - 
NACA 
nascent-polypeptide-
associated complex alpha 
polypeptide 2 0 - 
NBN nibrin 15 0 - 
NCOA1 
nuclear receptor coactivator 
1 6 0 - 
NCOA2 
nuclear receptor coactivator 
2 (TIF2) 9 0 - 
NDRG1 
N-myc downstream 
regulated 1 23 0 - 
NF1 
neurofibromatosis type 1 




neurofibromatosis type 2 





derived 2)-like 2 (NRF2) 4 1 Oncogene 
NFIB nuclear factor I/B 7 0 - 
NFKB2 
nuclear factor of kappa light 
polypeptide gene enhancer 
in B-cells 2 (p49/p100) 1 0 - 
NIN 
ninein (GSK3B interacting 
protein) 9 0 - 
NKX2-1 NK2 homeobox 1 5 0 Oncogene 
NONO 
non-POU domain 
containing, octamer-binding 1 0 - 
NOTCH1 
Notch homolog 1, 
translocation-associated 
(Drosophila) (TAN1) 18 10 
Tumour 
suppressor 










nuclear receptor subfamily 
4, group A, member 3 
(NOR1) 2 0 - 
NRAS 
neuroblastoma RAS viral (v-
ras) O homolog 5 3 Oncogene 
NSD1 
nuclear receptor binding 




NT5C2 5'-nucleotidase, cytosolic II 3 2 Oncogene 
NTRK1 
neurotrophic tyrosine kinase, 
receptor, type 1 7 7 Oncogene 
NTRK3 
neurotrophic tyrosine kinase, 
receptor, type 3 11 10 Oncogene 
NUMA1 
nuclear mitotic apparatus 
protein 1 18 0 - 
NUP214 nucleoporin 214kDa (CAN) 5 0 - 
NUP98 nucleoporin 98kDa 5 0 - 
NUTM1 
NUT midline carcinoma, 
family member 1 2 0 - 
NUTM2A NUT family member 2A 1 0 - 
NUTM2B NUT family member 2B 7 0 - 
OLIG2 
oligodendrocyte lineage 
transcription factor 2 
(BHLHB1) 4 0 - 
P2RY8 
purinergic receptor P2Y, G-




acetylhydrolase, isoform Ib, 
beta subunit 30kDa 5 0 - 
PALB2 
partner and localizer of 
BRCA2 5 1 
Tumour 
suppressor 
PATZ1 - 1 0 - 
PAX3 paired box gene 3 1 0 - 
PAX5 
paired box gene 5 (B-cell 
lineage specific activator 
protein) 12 0 
Tumour 
suppressor 
PAX7 paired box gene 7 3 0 - 
PAX8 paired box gene 8 3 0 - 





transcription factor 1 8 0 - 
PCM1 
pericentriolar material 1  
(PTC4) 4 0 - 
PCSK7 
proprotein convertase 
subtilisin/kexin type 7 5 0 - 
PDCD1LG
2 
programmed cell death 1 




(myomegalin) 5 0 - 
PDGFB 
platelet-derived growth 
factor beta polypeptide 
(simian sarcoma viral (v-sis) 
O homolog) 2 0 - 
PDGFRA 
platelet-derived growth 
factor, alpha-receptor 6 6 Oncogene 
PDGFRB 
platelet-derived growth 
factor receptor, beta 
polypeptide 4 4 Oncogene 
PER1 
period homolog 1 
(Drosophila) 2 0 - 
PHF6 PHD finger protein 6 2 2 
Tumour 
suppressor 








clathrin assembly protein 
(CALM) 11 11 Oncogene 
PIK3CA 
phosphoinositide-3-kinase, 
catalytic, alpha polypeptide 23 23 Oncogene 
PIK3R1 
phosphoinositide-3-kinase, 
regulatory subunit 1 (alpha) 4 4 
Tumour 
suppressor 
PIM1 pim-1 O 8 8 Oncogene 
PLAG1 
pleiomorphic adenoma gene 
1 5 0 - 
PML promyelocytic leukemia 1 0 - 
PMS1 
PMS1 postmeiotic 
segregation increased 1 (S. 





segregation increased 2 (S. 
cerevisiae) 6 0 - 
POT1 protection of telomeres 1 1 0 Oncogene 
POU2AF1 
POU domain, class 2, 
associating factor 1 (OBF1) 1 0 - 
POU5F1 
POU domain, class 5, 
transcription factor 1 18 0 - 
PPARG 
peroxisome proliferative 
activated receptor, gamma 2 0 - 
PPP2R1A 
protein phosphatase 2, 
regulatory subunit A, alpha 7 7 Oncogene 
PRCC 
papillary renal cell 
carcinoma (translocation-
associated) 7 0 - 
PRDM1 
PR domain containing 1, 
with ZNF domain 1 0 
Tumour 
suppressor 
PRDM16 PR domain containing 16 9 0 - 
PRF1 
perforin 1 (pore forming 




dependent, regulatory, type 
I, alpha (tissue specific 




PRRX1 paired related homeobox 1 6 0 - 
PSIP1 
PC4 and SFRS1 interacting 
protein 1 (LEDGF) 3 0 - 
PTCH1 
Homolog of Drosophila 




phosphatase and tensin 






type 11 2 2 Oncogene 
PTPRC 
protein tyrosine 
phosphatase, receptor type, 




rabaptin, RAB GTPase 
binding effector protein 1 7 0 - 
RAC1 
ras-related C3 botulinum 
toxin substrate 1 (rho family, 
small GTP binding protein 
Rac1) 4 2 Oncogene 






RAD51B RAD51 paralog B 14 0 - 
RAF1 
v-raf-1 murine leukemia 
viral O homolog 1 2 1 Oncogene 
RALGDS 
ral guanine nucleotide 
dissociation stimulator 4 0 - 




dissociation stimulator 1 3 0 - 
RARA retinoic acid receptor, alpha 35 28 - 




RNA binding motif protein 
15 1 0 - 
RECQL4 RecQ protein-like 4 19 19 - 
REL 
v-rel reticuloendotheliosis 
viral O homolog (avian) 2 1 Oncogene 
RET ret proto-O 8 8 Oncogene 
RHOH 
ras homolog family member 
H 1 0 - 
RMI2 
RecQ mediated genome 
instability 2 6 0 - 
RNF213 ring finger protein 213 5 0 - 




v-ros UR2 sarcoma virus O 
homolog 1 (avian) 7 0 Oncogene 
RPL10 ribosomal protein L10 1 1 Oncogene 
RPL22 
ribosomal protein L22 
(EAP) 4 4 Oncogene 
RPN1 ribophorin I 2 0 - 
RUNX1 
runt-related transcription 





factor 1; translocated to, 1 
(cyclin D-related) 18 18 Oncogene 
SBDS 
Shwachman-Bodian-
Diamond syndrome protein 12 10 - 
SDC4 syndecan 4 35 0 - 
SDHAF2 
succinate dehydrogenase 
complex assembly factor 2 1 0 - 
SDHB 
succinate dehydrogenase 
complex, subunit B, iron 
sulfur (Ip) 2 0 - 
SDHC 
succinate dehydrogenase 
complex, subunit C, integral 
membrane protein, 15kDa 6 0 - 
SDHD 
succinate dehydrogenase 
complex, subunit D, integral 
membrane protein 1 0 - 
SEPT5 septin 5 2 0 - 
SEPT6 septin 6 1 0 - 
SEPT9 septin 9 7 6 Oncogene 
SET SET translocation 3 0 - 
SETBP1 SET binding protein 1 15 12 Oncogene 







splicing factor 3b, subunit 1, 





binding protein associated) 2 2 Oncogene 




SH3-domain GRB2-like 1 
(EEN) 3 0 - 
SLC45A3 
solute carrier family 45, 
member 3 4 0 - 





SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 





SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 





SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily e, member 1 27 23 - 
SMO 
smoothened homolog 
(Drosophila) 3 2 Oncogene 
SNX29 - 15 0 - 
SOCS1 
suppressor of cytokine 




SRY (sex determining 
region Y)-box 2 8 7 Oncogene 
SPECC1 
sperm antigen with calponin 
homology and coiled-coil 
domains 1 11 11 Oncogene 
SRGAP3 
SLIT-ROBO Rho GTPase 
activating protein 3 12 0 - 
SRSF2 
serine/arginine-rich splicing 
factor 2 3 0 Oncogene 
SRSF3 
serine/arginine-rich splicing 




18 11 8 - 
SS18L1 
synovial sarcoma 
translocation gene on 
chromosome 18-like 1 30 29 - 
STAT3 
signal transducer and 
activator of transcription 3 
(acute-phase response 
factor) 9 8 Oncogene 
STAT5B 
signal transducer and 
activator of transcription 5B 8 8 Oncogene 
STIL 
SCL/TAL1 interrupting 
locus 2 0 - 
STK11 
serine/threonine kinase 11 




suppressor of fused homolog 
(Drosophila) 3 0 
Tumour 
suppressor 






TAF15 RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
68kDa 3 1 - 
TAL1 
T-cell acute lymphocytic 
leukemia 1 (SCL) 1 0 - 
TBL1XR1 
transducin (beta)-like 1 X-





factor A (SII), 1 5 0 - 
TCF12 
transcription factor 12 
(HTF4, helix-loop-helix 
transcription factors 4) 5 4 Oncogene 
TCF3 
transcription factor 3 (E2A 
immunoglobulin enhancer 
binding factors E12/E47) 4 0 - 
TCF7L2 transcription factor 7-like 2 3 3 Oncogene 
TERT 
telomerase reverse 
transcriptase 17 0 Oncogene 
TET1 
tet methylcytosine 




TET2 tet O family member 2 4 3 
Tumour 
suppressor 
TFEB transcription factor EB 25 0 - 
TFG TRK-fused gene 1 0 - 
TFPT 
TCF3 (E2A) fusion partner 
(in childhood leukaemia) 9 0 - 
TFRC 
transferrin receptor (p90, 
CD71) 5 0 - 
THRAP3 
thyroid hormone receptor 
associated protein 3 
(TRAP150) 9 0 - 
TMPRSS2 
transmembrane protease, 
serine 2 7 4 Oncogene 
TNFAIP3 
tumor necrosis factor, alpha-





tumor necrosis factor 
receptor superfamily, 
member 14 (herpesvirus 





tumor necrosis factor 
receptor superfamily, 
member 17 8 0 - 
TOP1 topoisomerase (DNA) I 33 0 - 
TP53 tumor protein p53 201 197 
Tumour 
suppressor 
TPM3 tropomyosin 3 11 0 - 
TPM4 tropomyosin 4 7 0 - 
TPR translocated promoter region 6 0 - 
TRAF7 
tumour necrosis factor 
receptor-associated factor 7 3 0 
Tumour 
suppressor 
TRIM24 tripartite motif containing 24 3 0 - 
TRIM27 tripartite motif-containing 27 6 0 - 
TRIM33 
tripartite motif-containing 33 





thyroid hormone receptor 
interactor 11 4 0 - 
TRRAP 
transformation/transcription 
domain-associated protein 39 36 Oncogene 
TSC1 tuberous sclerosis 1 gene 3 1 
Tumour 
suppressor 




thyroid stimulating hormone 
receptor 3 0 Oncogene 
TTL tubulin tyrosine ligase 4 0 - 
U2AF1 
U2 small nuclear RNA 
auxiliary factor 1 2 2 Oncogene 
UBR5 
ubiquitin protein ligase E3 




ubiquitin specific peptidase 
6 (Tre-2 O) 2 0 - 
VHL 
von Hippel-Lindau 




vesicle transport through 
interaction with t-SNAREs 
homolog 1A 2 0 - 
WHSC1 
Wolf-Hirschhorn syndrome 
candidate 1(MMSET) 4 4 Oncogene 
WHSC1L1 
Wolf-Hirschhorn syndrome 
candidate 1-like 1 (NSD3) 15 0 - 
WIF1 WNT inhibitory factor 1 10 0 - 
WRN 
Werner syndrome 
(RECQL2) 4 0 - 




WW domain containing 
transcription regulator 1 2 0 - 
XPA 
xeroderma pigmentosum, 
complementation group A 1 0 - 
XPC 
xeroderma pigmentosum, 
complementation group C 4 0 - 
XPO1 
exportin 1 (CRM1 homolog, 





protein, epsilon polypeptide 
(14-3-3 epsilon) 9 0 - 
ZBTB16 
zinc finger and BTB domain 
containing 16 4 4 Oncogene 




ZNF331 zinc finger protein 331 11 0 - 
ZNF384 
zinc finger protein 384 
(CIZ/NMP4) 9 0 - 
ZNF521 zinc finger protein 521 36 35 Oncogene 
ZRSR2 
zinc finger (CCCH type), 
RNA-binding motif and 








7.2 Cancer helper genes in 261 OACs 
List of 952 cancer helper genes in the 261 OACs. For each gene reported are 







ATP-binding cassette, sub-family A (ABC1), 
member 1 6 2.3 
ABCC1 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 1 10 3.8 
ABI2 abl-interactor 2 2 0.8 
ABLIM1 actin binding LIM protein 1 1 0.4 
ABLIM3 actin binding LIM protein family, member 3 1 0.4 
ABR active BCR-related 4 1.5 
ACACA acetyl-CoA carboxylase alpha 7 2.7 
ACLY ATP citrate lyase 5 1.9 
ACTB actin, beta 2 0.8 
ACTG1 actin, gamma 1 2 0.8 
ACTN4 actinin, alpha 4 14 5.4 
ACVR1 activin A receptor, type I 1 0.4 
ACVR2B activin A receptor, type IIB 1 0.4 
ADAM15 ADAM metallopeptidase domain 15 1 0.4 
ADAM22 ADAM metallopeptidase domain 22 2 0.8 
ADAM9 ADAM metallopeptidase domain 9 4 1.5 
ADARB1 adenosine deaminase, RNA-specific, B1 1 0.4 
ADD2 adducin 2 (beta) 1 0.4 
ADRM1 adhesion regulating molecule 1 4 1.5 
AGO1 argonaute RISC catalytic component 1 3 1.1 
AGO2 argonaute RISC catalytic component 2 16 6.1 
AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 1 0.4 
AGTR1 angiotensin II receptor, type 1 1 0.4 
AHSA1 
AHA1, activator of heat shock 90kDa protein 
ATPase homolog 1 (yeast) 1 0.4 
AIP aryl hydrocarbon receptor interacting protein 4 1.5 
AJUBA ajuba LIM protein 2 0.8 
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 1 0.4 
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 2 0.8 
ALDOA aldolase A, fructose-bisphosphate 1 0.4 
AMPH amphiphysin 2 0.8 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 2 0.8 
ANKRD17 ankyrin repeat domain 17 1 0.4 
ANKRD28 ankyrin repeat domain 28 1 0.4 




ANKRD52 ankyrin repeat domain 52 1 0.4 
ANO6 anoctamin 6 1 0.4 
ANP32E 
acidic (leucine-rich) nuclear phosphoprotein 32 
family, member E 1 0.4 
ANXA1 annexin A1 1 0.4 
ANXA11 annexin A11 7 2.7 
AP1B1 adaptor-related protein complex 1, beta 1 subunit 1 0.4 
AP2B1 adaptor-related protein complex 2, beta 1 subunit 1 0.4 
APLP2 amyloid beta (A4) precursor-like protein 2 3 1.1 
APP amyloid beta (A4) precursor protein 4 1.5 
AQP1 aquaporin 1 (Colton blood group) 2 0.8 
ARCN1 archain 1 1 0.4 
ARG1 arginase 1 1 0.4 
ARHGAP1 Rho GTPase activating protein 1 6 2.3 
ARHGAP12 Rho GTPase activating protein 12 1 0.4 
ARHGAP17 Rho GTPase activating protein 17 4 1.5 
ARHGAP29 Rho GTPase activating protein 29 1 0.4 
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 1 0.4 
ARHGEF10 
Rho guanine nucleotide exchange factor (GEF) 
10 1 0.4 
ARHGEF11 
Rho guanine nucleotide exchange factor (GEF) 
11 1 0.4 
ARHGEF2 
Rho/Rac guanine nucleotide exchange factor 
(GEF) 2 9 3.4 
ARID3A AT rich interactive domain 3A (BRIGHT-like) 3 1.1 
ARID4B AT rich interactive domain 4B (RBP1-like) 3 1.1 
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2 1 0.4 
ARPC2 
actin related protein 2/3 complex, subunit 2, 
34kDa 1 0.4 
ASAP1 
ArfGAP with SH3 domain, ankyrin repeat and 
PH domain 1 20 7.7 
ASH1L 
ash1 (absent, small, or homeotic)-like 
(Drosophila) 1 0.4 
ATAD2 ATPase family, AAA domain containing 2 2 0.8 
ATF3 activating transcription factor 3 1 0.4 
ATF6 activating transcription factor 6 1 0.4 
ATN1 atrophin 1 4 1.5 
ATP10A ATPase, class V, type 10A 1 0.4 
ATP13A3 ATPase type 13A3 1 0.4 
ATP2A2 
ATPase, Ca++ transporting, cardiac muscle, 
slow twitch 2 2 0.8 
ATP6V0A1 
ATPase, H+ transporting, lysosomal V0 subunit 
a1 1 0.4 
ATP6V1B2 
ATPase, H+ transporting, lysosomal 56/58kDa, 
V1 subunit B2 1 0.4 
ATP6V1C1 
ATPase, H+ transporting, lysosomal 42kDa, V1 
subunit C1 5 1.9 
ATP7A ATPase, Cu++ transporting, alpha polypeptide 2 0.8 





ATPase, aminophospholipid transporter, class I, 
type 8B, member 2 4 1.5 
ATXN7 ataxin 7 2 0.8 
AXIN2 axin 2 1 0.4 
AXL AXL receptor tyrosine kinase 8 3.1 
B4GALT1 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 3 1.1 
B4GALT3 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 3 1 0.4 
B4GALT5 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 5 1 0.4 
BACE1 beta-site APP-cleaving enzyme 1 3 1.1 
BACH1 
BTB and CNC homology 1, basic leucine zipper 
transcription factor 1 1 0.4 
BAG6 BCL2-associated athanogene 6 24 9.2 
BAZ1B bromodomain adjacent to zinc finger domain, 1B 5 1.9 
BCAT1 
branched chain amino-acid transaminase 1, 
cytosolic 6 2.3 
BDNF brain-derived neurotrophic factor 1 0.4 
BIRC2 baculoviral IAP repeat containing 2 1 0.4 
BNIP3L 
BCL2/adenovirus E1B 19kDa interacting protein 
3-like 2 0.8 
BPTF bromodomain PHD finger transcription factor 3 1.1 
BRD2 bromodomain containing 2 1 0.4 
BRPF1 bromodomain and PHD finger containing, 1 1 0.4 
BTG2 BTG family, member 2 2 0.8 
BTG3 BTG family, member 3 2 0.8 
BZW2 basic leucine zipper and W2 domains 2 1 0.4 
C3orf62 chromosome 3 open reading frame 62 1 0.4 
CA13 carbonic anhydrase XIII 4 1.5 
CAB39L calcium binding protein 39-like 1 0.4 
CABLES1 Cdk5 and Abl enzyme substrate 1 11 4.2 
CACNA1C 
calcium channel, voltage-dependent, L type, 
alpha 1C subunit 1 0.4 
CALM2 calmodulin 2 (phosphorylase kinase, delta) 2 0.8 
CALU calumenin 4 1.5 
CAMK1D calcium/calmodulin-dependent protein kinase ID 1 0.4 
CAPN1 calpain 1, (mu/I) large subunit 1 0.4 
CAPN15 calpain 15 1 0.4 
CAPN2 calpain 2, (m/II) large subunit 1 0.4 
CAPNS1 calpain, small subunit 1 6 2.3 
CAPRIN1 cell cycle associated protein 1 1 0.4 
CARD6 caspase recruitment domain family, member 6 1 0.4 
CARHSP1 calcium regulated heat stable protein 1, 24kDa 2 0.8 
CASP9 caspase 9, apoptosis-related cysteine peptidase 1 0.4 
CAT catalase 1 0.4 
CBFA2T2 
core-binding factor, runt domain, alpha subunit 




CBS cystathionine-beta-synthase 1 0.4 
CCAR2 cell cycle and apoptosis regulator 2 2 0.8 
CCNA1 cyclin A1 1 0.4 
CCNA2 cyclin A2 1 0.4 
CCNE2 cyclin E2 1 0.4 
CCNG2 cyclin G2 1 0.4 
CCNL1 cyclin L1 1 0.4 
CCNY cyclin Y 2 0.8 
CCT3 chaperonin containing TCP1, subunit 3 (gamma) 1 0.4 
CD151 CD151 molecule (Raph blood group) 1 0.4 
CD2AP CD2-associated protein 9 3.4 
CD36 CD36 molecule (thrombospondin receptor) 2 0.8 
CD44 CD44 molecule (Indian blood group) 2 0.8 
CDC20 cell division cycle 20 1 0.4 
CDC25A cell division cycle 25A 1 0.4 
CDC25B cell division cycle 25B 7 2.7 
CDC42 cell division cycle 42 1 0.4 
CDC6 cell division cycle 6 4 1.5 
CDCA7L cell division cycle associated 7-like 3 1.1 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 3 1.1 
CDK14 cyclin-dependent kinase 14 7 2.7 
CDK18 cyclin-dependent kinase 18 3 1.1 
CDK19 cyclin-dependent kinase 19 2 0.8 
CDK3 cyclin-dependent kinase 3 1 0.4 
CDK5R1 
cyclin-dependent kinase 5, regulatory subunit 1 
(p35) 1 0.4 
CDKN1A 
cyclin-dependent kinase inhibitor 1A (p21, 
Cip1) 4 1.5 
CDKN2B 
cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) 4 1.5 
CDKN2D 
cyclin-dependent kinase inhibitor 2D (p19, 
inhibits CDK4) 1 0.4 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 3 1.1 
CELF2 CUGBP, Elav-like family member 2 1 0.4 
CERS2 ceramide synthase 2 12 4.6 
CHAMP1 
chromosome alignment maintaining 
phosphoprotein 1 1 0.4 
CHD4 chromodomain helicase DNA binding protein 4 2 0.8 
CHD7 chromodomain helicase DNA binding protein 7 3 1.1 
CHD8 chromodomain helicase DNA binding protein 8 2 0.8 
CHRAC1 chromatin accessibility complex 1 1 0.4 
CKAP5 cytoskeleton associated protein 5 3 1.1 
CLIC1 chloride intracellular channel 1 3 1.1 
CLIP1 CAP-GLY domain containing linker protein 1 1 0.4 
CLK1 CDC-like kinase 1 1 0.4 




progressive with mental retardation) 
CNN3 calponin 3, acidic 1 0.4 
CNOT1 CCR4-NOT transcription complex, subunit 1 5 1.9 
CNOT7 CCR4-NOT transcription complex, subunit 7 1 0.4 
CNTNAP2 contactin associated protein-like 2 1 0.4 
COCH cochlin 1 0.4 
COL4A1 collagen, type IV, alpha 1 8 3.1 
COL4A2 collagen, type IV, alpha 2 8 3.1 
COL4A5 collagen, type IV, alpha 5 1 0.4 
COPA coatomer protein complex, subunit alpha 3 1.1 
COPB1 coatomer protein complex, subunit beta 1 1 0.4 
COPS3 COP9 signalosome subunit 3 1 0.4 
CORO1A coronin, actin binding protein, 1A 2 0.8 
CORO1B coronin, actin binding protein, 1B 1 0.4 
CORO1C coronin, actin binding protein, 1C 1 0.4 
CPSF6 
cleavage and polyadenylation specific factor 6, 
68kDa 2 0.8 
CPT1A carnitine palmitoyltransferase 1A (liver) 8 3.1 
CREM cAMP responsive element modulator 1 0.4 
CRIP2 cysteine-rich protein 2 1 0.4 
CRKL 
v-crk avian sarcoma virus CT10 oncogene 
homolog-like 3 1.1 
CRTAP cartilage associated protein 1 0.4 
CRY2 cryptochrome circadian clock 2 1 0.4 
CSDE1 cold shock domain containing E1, RNA-binding 3 1.1 
CTCF CCCTC-binding factor (zinc finger protein) 1 0.4 
CTNND1 catenin (cadherin-associated protein), delta 1 2 0.8 
CTPS1 CTP synthase 1 3 1.1 
CTSB cathepsin B 2 0.8 
CTSD cathepsin D 1 0.4 
CUL3 cullin 3 1 0.4 
CUX1 cut-like homeobox 1 9 3.4 
CYP2E1 
cytochrome P450, family 2, subfamily E, 
polypeptide 1 1 0.4 
DAAM1 
dishevelled associated activator of 
morphogenesis 1 1 0.4 
DCAF7 DDB1 and CUL4 associated factor 7 3 1.1 
DCLRE1B DNA cross-link repair 1B 1 0.4 
DDHD2 DDHD domain containing 2 4 1.5 
DDR1 discoidin domain receptor tyrosine kinase 1 1 0.4 
DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17 2 0.8 
DDX3Y 
DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-
linked 1 0.4 
DEGS1 delta(4)-desaturase, sphingolipid 1 1 0.4 
DENND4B DENN/MADD domain containing 4B 1 0.4 




DHX29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 1 0.4 
DIP2A 
DIP2 disco-interacting protein 2 homolog A 
(Drosophila) 2 0.8 
DLC1 DLC1 Rho GTPase activating protein 24 9.2 
DLG2 discs, large homolog 2 (Drosophila) 5 1.9 
DMWD dystrophia myotonica, WD repeat containing 2 0.8 
DMXL2 Dmx-like 2 1 0.4 
DNAJB5 DnaJ (Hsp40) homolog, subfamily B, member 5 10 3.8 
DNAJC5 DnaJ (Hsp40) homolog, subfamily C, member 5 4 1.5 
DNMBP dynamin binding protein 1 0.4 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 4 1.5 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 25 9.6 
DOCK4 dedicator of cytokinesis 4 1 0.4 
DOCK5 dedicator of cytokinesis 5 2 0.8 
DOCK8 dedicator of cytokinesis 8 2 0.8 
DOPEY1 dopey family member 1 1 0.4 
DPY19L4 dpy-19-like 4 (C. elegans) 1 0.4 
DPYSL2 dihydropyrimidinase-like 2 2 0.8 
DSP desmoplakin 1 0.4 
DST dystonin 2 0.8 
DSTN destrin (actin depolymerizing factor) 1 0.4 
DTNB dystrobrevin, beta 1 0.4 
DTX2 deltex 2, E3 ubiquitin ligase 1 0.4 
DVL1 dishevelled segment polarity protein 1 1 0.4 
DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 1 0.4 
DYRK1A 
dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1A 1 0.4 
DYRK1B 
dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1B 12 4.6 
DYRK2 
dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 2 9 3.4 
DYSF dysferlin 2 0.8 
E2F1 E2F transcription factor 1 29 11.1 
E2F2 E2F transcription factor 2 1 0.4 
E2F3 E2F transcription factor 3 1 0.4 
E2F4 E2F transcription factor 4, p107/p130-binding 1 0.4 
E2F5 E2F transcription factor 5, p130-binding 2 0.8 
E2F6 E2F transcription factor 6 1 0.4 
EAF1 ELL associated factor 1 1 0.4 
ECT2 epithelial cell transforming 2 2 0.8 
EDF1 endothelial differentiation-related factor 1 1 0.4 
EDNRA endothelin receptor type A 1 0.4 
EEA1 early endosome antigen 1 1 0.4 
EFEMP2 
EGF containing fibulin-like extracellular matrix 
protein 2 2 0.8 




EFHD2 EF-hand domain family, member D2 1 0.4 
EFNB2 ephrin-B2 2 0.8 
EGLN3 egl-9 family hypoxia-inducible factor 3 5 1.9 
EGR1 early growth response 1 1 0.4 
EHMT1 
euchromatic histone-lysine N-methyltransferase 
1 1 0.4 
EHMT2 
euchromatic histone-lysine N-methyltransferase 
2 11 4.2 
EIF3C 
eukaryotic translation initiation factor 3, subunit 
C 1 0.4 
EIF4A1 eukaryotic translation initiation factor 4A1 2 0.8 
EIF4E eukaryotic translation initiation factor 4E 1 0.4 
EIF4EBP1 
eukaryotic translation initiation factor 4E 
binding protein 1 3 1.1 
EIF4G1 
eukaryotic translation initiation factor 4 gamma, 
1 4 1.5 
EIF4G2 
eukaryotic translation initiation factor 4 gamma, 
2 1 0.4 
EIF4G3 
eukaryotic translation initiation factor 4 gamma, 
3 2 0.8 
ELAVL1 ELAV like RNA binding protein 1 1 0.4 
ELOVL1 ELOVL fatty acid elongase 1 1 0.4 
ELOVL5 ELOVL fatty acid elongase 5 2 0.8 
ENAH enabled homolog (Drosophila) 3 1.1 
ENPP4 
ectonucleotide 
pyrophosphatase/phosphodiesterase 4 (putative) 2 0.8 
EPB41 erythrocyte membrane protein band 4.1 2 0.8 
EPB41L2 erythrocyte membrane protein band 4.1-like 2 1 0.4 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 1 0.4 
EPC1 enhancer of polycomb homolog 1 (Drosophila) 2 0.8 
EPHA2 EPH receptor A2 2 0.8 
EPHA4 EPH receptor A4 4 1.5 
EPHB1 EPH receptor B1 1 0.4 
EPHB2 EPH receptor B2 3 1.1 
EPHB6 EPH receptor B6 1 0.4 
ERBB2IP erbb2 interacting protein 2 0.8 
ERLIN1 ER lipid raft associated 1 1 0.4 
ERLIN2 ER lipid raft associated 2 6 2.3 
ERO1L ERO1-like (S. cerevisiae) 3 1.1 
ESYT1 extended synaptotagmin-like protein 1 5 1.9 
ETS1 
v-ets avian erythroblastosis virus E26 oncogene 
homolog 1 4 1.5 
ETS2 
v-ets avian erythroblastosis virus E26 oncogene 
homolog 2 1 0.4 
EXOC7 exocyst complex component 7 1 0.4 
EXOSC8 exosome component 8 1 0.4 
EZH1 
enhancer of zeste 1 polycomb repressive 
complex 2 subunit 1 0.4 




FAM126B family with sequence similarity 126, member B 2 0.8 
FAM208B family with sequence similarity 208, member B 1 0.4 
FAM49B family with sequence similarity 49, member B 5 1.9 
FAM57A family with sequence similarity 57, member A 2 0.8 
FANCI Fanconi anemia, complementation group I 1 0.4 
FAR1 fatty acyl CoA reductase 1 1 0.4 
FASN fatty acid synthase 1 0.4 
FBXO28 F-box protein 28 1 0.4 
FCHSD2 FCH and double SH3 domains 2 4 1.5 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 3 1.1 
FER fer (fps/fes related) tyrosine kinase 1 0.4 
FES FES proto-oncogene, tyrosine kinase 1 0.4 
FGF2 fibroblast growth factor 2 (basic) 1 0.4 
FHL3 four and a half LIM domains 3 1 0.4 
FKBP10 FK506 binding protein 10, 65 kDa 3 1.1 
FKBP4 FK506 binding protein 4, 59kDa 4 1.5 
FKBP5 FK506 binding protein 5 1 0.4 
FLNA filamin A, alpha 3 1.1 
FLNB filamin B, beta 3 1.1 
FLT1 fms-related tyrosine kinase 1 8 3.1 
FMNL1 formin-like 1 2 0.8 
FNDC3B fibronectin type III domain containing 3B 5 1.9 
FOS 
FBJ murine osteosarcoma viral oncogene 
homolog 1 0.4 
FOXP2 forkhead box P2 1 0.4 
FRS2 fibroblast growth factor receptor substrate 2 1 0.4 
FTH1 ferritin, heavy polypeptide 1 1 0.4 
FUBP3 far upstream element (FUSE) binding protein 3 1 0.4 
FURIN furin (paired basic amino acid cleaving enzyme) 1 0.4 
FXR2 
fragile X mental retardation, autosomal homolog 
2 1 0.4 
FZD1 frizzled class receptor 1 1 0.4 
G3BP2 
GTPase activating protein (SH3 domain) 
binding protein 2 5 1.9 
GAB1 GRB2-associated binding protein 1 1 0.4 
GAB2 GRB2-associated binding protein 2 1 0.4 
GABRA5 
gamma-aminobutyric acid (GABA) A receptor, 
alpha 5 1 0.4 
GABRB3 
gamma-aminobutyric acid (GABA) A receptor, 
beta 3 1 0.4 
GALNT2 polypeptide N-acetylgalactosaminyltransferase 2 1 0.4 
GANAB glucosidase, alpha; neutral AB 4 1.5 
GATA6 GATA binding protein 6 9 3.4 
GATAD2B GATA zinc finger domain containing 2B 4 1.5 
GBAS glioblastoma amplified sequence 4 1.5 




1-like 1 (yeast) 
GDAP1 
ganglioside induced differentiation associated 
protein 1 1 0.4 
GDI2 GDP dissociation inhibitor 2 2 0.8 
GEM 
GTP binding protein overexpressed in skeletal 
muscle 5 1.9 
GEMIN5 gem (nuclear organelle) associated protein 5 1 0.4 
GFOD1 
glucose-fructose oxidoreductase domain 
containing 1 2 0.8 
GGA3 
golgi-associated, gamma adaptin ear containing, 
ARF binding protein 3 6 2.3 
GIGYF1 GRB10 interacting GYF protein 1 8 3.1 
GIGYF2 GRB10 interacting GYF protein 2 1 0.4 
GLI1 GLI family zinc finger 1 2 0.8 
GLI2 GLI family zinc finger 2 1 0.4 
GLI3 GLI family zinc finger 3 5 1.9 
GNA12 
guanine nucleotide binding protein (G protein) 
alpha 12 5 1.9 
GNA13 
guanine nucleotide binding protein (G protein), 
alpha 13 2 0.8 
GNAI2 
guanine nucleotide binding protein (G protein), 
alpha inhibiting activity polypeptide 2 1 0.4 
GNB1 
guanine nucleotide binding protein (G protein), 
beta polypeptide 1 2 0.8 
GNB2 
guanine nucleotide binding protein (G protein), 
beta polypeptide 2 1 0.4 
GNS glucosamine (N-acetyl)-6-sulfatase 6 2.3 
GOLT1B golgi transport 1B 1 0.4 
GPATCH8 G patch domain containing 8 1 0.4 
GPM6B glycoprotein M6B 1 0.4 
GRB10 growth factor receptor-bound protein 10 1 0.4 
GRB2 growth factor receptor-bound protein 2 3 1.1 
GRIA1 glutamate receptor, ionotropic, AMPA 1 1 0.4 
GRINA 
glutamate receptor, ionotropic, N-methyl D-
aspartate-associated protein 1 (glutamate 
binding) 5 1.9 
GRSF1 G-rich RNA sequence binding factor 1 2 0.8 
GSN gelsolin 1 0.4 
H2AFY H2A histone family, member Y 1 0.4 
HCFC1 host cell factor C1 2 0.8 
HCK HCK proto-oncogene, Src family tyrosine kinase 3 1.1 
HDAC7 histone deacetylase 7 1 0.4 
HDLBP high density lipoprotein binding protein 2 0.8 
HEATR2 HEAT repeat containing 2 5 1.9 
HES1 hes family bHLH transcription factor 1 3 1.1 
HEXA hexosaminidase A (alpha polypeptide) 1 0.4 
HGF 
hepatocyte growth factor (hepapoietin A; scatter 
factor) 5 1.9 
HIP1R huntingtin interacting protein 1 related 1 0.4 




HIPK2 homeodomain interacting protein kinase 2 6 2.3 
HIPK3 homeodomain interacting protein kinase 3 5 1.9 
HIST2H2AC histone cluster 2, H2ac 1 0.4 
HIST2H2BE histone cluster 2, H2be 1 0.4 
HIVEP1 
human immunodeficiency virus type I enhancer 
binding protein 1 5 1.9 
HMGB1 high mobility group box 1 5 1.9 
HMOX1 heme oxygenase (decycling) 1 1 0.4 
HNRNPDL heterogeneous nuclear ribonucleoprotein D-like 1 0.4 
HNRNPF heterogeneous nuclear ribonucleoprotein F 1 0.4 
HNRNPL heterogeneous nuclear ribonucleoprotein L 3 1.1 
HNRNPM heterogeneous nuclear ribonucleoprotein M 2 0.8 
HNRNPUL1 
heterogeneous nuclear ribonucleoprotein U-like 
1 10 3.8 
HSPA4 heat shock 70kDa protein 4 1 0.4 
HSPH1 heat shock 105kDa/110kDa protein 1 14 5.4 
HUS1 HUS1 checkpoint homolog (S. pombe) 1 0.4 
IARS isoleucyl-tRNA synthetase 2 0.8 
ICK intestinal cell (MAK-like) kinase 2 0.8 
ID3 
inhibitor of DNA binding 3, dominant negative 
helix-loop-helix protein 1 0.4 
IGF1R insulin-like growth factor 1 receptor 4 1.5 
IGFBP3 insulin-like growth factor binding protein 3 3 1.1 
IGFBP4 insulin-like growth factor binding protein 4 1 0.4 
IKBKAP 
inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase complex-associated 
protein 1 0.4 
IKBKB 
inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta 4 1.5 
IKZF3 IKAROS family zinc finger 3 (Aiolos) 2 0.8 
IL1RAP interleukin 1 receptor accessory protein 1 0.4 
IMPDH2 
IMP (inosine 5-monophosphate) dehydrogenase 
2 1 0.4 
ING1 inhibitor of growth family, member 1 2 0.8 
INPP5D inositol polyphosphate-5-phosphatase, 145kDa 1 0.4 
INPPL1 inositol polyphosphate phosphatase-like 1 3 1.1 
IPO5 importin 5 1 0.4 
IQGAP1 IQ motif containing GTPase activating protein 1 1 0.4 
IRAK1 interleukin-1 receptor-associated kinase 1 5 1.9 
IRAK2 interleukin-1 receptor-associated kinase 2 1 0.4 
IRAK3 interleukin-1 receptor-associated kinase 3 1 0.4 
IRF2BP2 interferon regulatory factor 2 binding protein 2 1 0.4 
IRF7 interferon regulatory factor 7 1 0.4 
IRS2 insulin receptor substrate 2 5 1.9 
ITGA2 
integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor) 2 0.8 
ITGA3 
integrin, alpha 3 (antigen CD49C, alpha 3 





integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 4 1.5 
ITGA6 integrin, alpha 6 3 1.1 
ITGAV integrin, alpha V 2 0.8 
ITGB1 
integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 5 1.9 
ITM2B integral membrane protein 2B 1 0.4 
ITPR1 inositol 1,4,5-trisphosphate receptor, type 1 4 1.5 
ITPR3 inositol 1,4,5-trisphosphate receptor, type 3 1 0.4 
JAG1 jagged 1 1 0.4 
JUNB jun B proto-oncogene 1 0.4 
JUP junction plakoglobin 14 5.4 
KANK2 KN motif and ankyrin repeat domains 2 2 0.8 
KANSL1 KAT8 regulatory NSL complex subunit 1 2 0.8 
KAT2A K(lysine) acetyltransferase 2A 4 1.5 
KAT2B K(lysine) acetyltransferase 2B 3 1.1 
KAT7 K(lysine) acetyltransferase 7 1 0.4 
KATNAL1 katanin p60 subunit A-like 1 4 1.5 
KCTD12 
potassium channel tetramerization domain 
containing 12 1 0.4 
KCTD2 
potassium channel tetramerization domain 
containing 2 1 0.4 
KCTD20 
potassium channel tetramerization domain 
containing 20 1 0.4 
KCTD5 
potassium channel tetramerization domain 
containing 5 1 0.4 
KCTD6 
potassium channel tetramerization domain 
containing 6 1 0.4 
KDM2A lysine (K)-specific demethylase 2A 1 0.4 
KDM3B lysine (K)-specific demethylase 3B 1 0.4 
KDM4A lysine (K)-specific demethylase 4A 2 0.8 
KDM5B lysine (K)-specific demethylase 5B 2 0.8 
KDM5D lysine (K)-specific demethylase 5D 1 0.4 
KHDRBS1 
KH domain containing, RNA binding, signal 
transduction associated 1 1 0.4 
KIAA0100 KIAA0100 2 0.8 
KIF1A kinesin family member 1A 1 0.4 
KIF1B kinesin family member 1B 2 0.8 
KIF1C kinesin family member 1C 1 0.4 
KIF2C kinesin family member 2C 2 0.8 
KIF3B kinesin family member 3B 4 1.5 
KLC1 kinesin light chain 1 1 0.4 
KLC4 kinesin light chain 4 4 1.5 
KLHL42 kelch-like family member 42 3 1.1 
KPNA2 
karyopherin alpha 2 (RAG cohort 1, importin 
alpha 1) 3 1.1 




KYNU kynureninase 1 0.4 
LAMC1 laminin, gamma 1 (formerly LAMB2) 1 0.4 
LARP1 La ribonucleoprotein domain family, member 1 2 0.8 
LARS leucyl-tRNA synthetase 1 0.4 
LATS2 large tumor suppressor kinase 2 4 1.5 
LBR lamin B receptor 2 0.8 
LDHB lactate dehydrogenase B 2 0.8 
LEPRE1 
leucine proline-enriched proteoglycan (leprecan) 
1 1 0.4 
LEPREL2 leprecan-like 2 1 0.4 
LEPROTL1 leptin receptor overlapping transcript-like 1 1 0.4 
LGALS3 lectin, galactoside-binding, soluble, 3 1 0.4 
LGALS3BP 
lectin, galactoside-binding, soluble, 3 binding 
protein 1 0.4 
LGR4 
leucine-rich repeat containing G protein-coupled 
receptor 4 1 0.4 
LIMCH1 LIM and calponin homology domains 1 1 0.4 
LIMK1 LIM domain kinase 1 6 2.3 
LIN7C lin-7 homolog C (C. elegans) 1 0.4 
LMAN1 lectin, mannose-binding, 1 2 0.8 
LMCD1 LIM and cysteine-rich domains 1 1 0.4 
LMNB1 lamin B1 2 0.8 
LONRF1 
LON peptidase N-terminal domain and ring 
finger 1 18 6.9 
LPCAT1 lysophosphatidylcholine acyltransferase 1 4 1.5 
LRIG1 
leucine-rich repeats and immunoglobulin-like 
domains 1 1 0.4 
LRRC8A 
leucine rich repeat containing 8 family, member 
A 2 0.8 
LUC7L3 LUC7-like 3 (S. cerevisiae) 1 0.4 
MACF1 microtubule-actin crosslinking factor 1 1 0.4 
MAGI1 
membrane associated guanylate kinase, WW and 
PDZ domain containing 1 1 0.4 
MAP1B microtubule-associated protein 1B 5 1.9 
MAP2 microtubule-associated protein 2 1 0.4 
MAP3K10 
mitogen-activated protein kinase kinase kinase 
10 7 2.7 
MAP3K11 
mitogen-activated protein kinase kinase kinase 
11 2 0.8 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 1 0.4 
MAPK1 mitogen-activated protein kinase 1 1 0.4 
MAPK13 mitogen-activated protein kinase 13 1 0.4 
MAPKAPK2 
mitogen-activated protein kinase-activated 
protein kinase 2 3 1.1 
MAPRE1 
microtubule-associated protein, RP/EB family, 
member 1 1 0.4 
MAPRE2 
microtubule-associated protein, RP/EB family, 
member 2 2 0.8 
MARK4 MAP/microtubule affinity-regulating kinase 4 1 0.4 




MCL1 myeloid cell leukemia 1 1 0.4 
MCM2 
minichromosome maintenance complex 
component 2 1 0.4 
MCM3 
minichromosome maintenance complex 
component 3 5 1.9 
MCM7 
minichromosome maintenance complex 
component 7 28 10.7 
MCU mitochondrial calcium uniporter 1 0.4 
MECP2 methyl CpG binding protein 2 1 0.4 
MED1 mediator complex subunit 1 2 0.8 
MED13 mediator complex subunit 13 6 2.3 
MED24 mediator complex subunit 24 11 4.2 
MEF2A myocyte enhancer factor 2A 1 0.4 
MEF2C myocyte enhancer factor 2C 5 1.9 
MEF2D myocyte enhancer factor 2D 7 2.7 
MFHAS1 
malignant fibrous histiocytoma amplified 
sequence 1 2 0.8 
MGRN1 
mahogunin ring finger 1, E3 ubiquitin protein 
ligase 2 0.8 
MIB1 mindbomb E3 ubiquitin protein ligase 1 1 0.4 
MID1 midline 1 1 0.4 
MMP14 matrix metallopeptidase 14 (membrane-inserted) 1 0.4 
MMP2 
matrix metallopeptidase 2 (gelatinase A, 72kDa 
gelatinase, 72kDa type IV collagenase) 1 0.4 
MMP9 
matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 11 4.2 
MPDZ multiple PDZ domain protein 1 0.4 
MPP3 
membrane protein, palmitoylated 3 (MAGUK 
p55 subfamily member 3) 4 1.5 
MPP6 
membrane protein, palmitoylated 6 (MAGUK 
p55 subfamily member 6) 1 0.4 
MTA2 metastasis associated 1 family, member 2 1 0.4 
MTMR12 myotubularin related protein 12 5 1.9 
MTMR3 myotubularin related protein 3 2 0.8 
MTMR4 myotubularin related protein 4 1 0.4 
MTMR9 myotubularin related protein 9 3 1.1 
MTOR 
mechanistic target of rapamycin 
(serine/threonine kinase) 1 0.4 
MTUS1 microtubule associated tumor suppressor 1 2 0.8 
MYH10 myosin, heavy chain 10, non-muscle 2 0.8 
MYO10 myosin X 1 0.4 
MYO1B myosin IB 1 0.4 
MYO1C myosin IC 2 0.8 
MYO1D myosin ID 4 1.5 
MYO5A myosin VA (heavy chain 12, myoxin) 3 1.1 
MYO6 myosin VI 1 0.4 
MYO9A myosin IXA 1 0.4 
NAA15 
N(alpha)-acetyltransferase 15, NatA auxiliary 




NABP2 nucleic acid binding protein 2 2 0.8 
NARF nuclear prelamin A recognition factor 1 0.4 
NBEA neurobeachin 17 6.5 
NCBP2 nuclear cap binding protein subunit 2, 20kDa 1 0.4 
NCEH1 neutral cholesterol ester hydrolase 1 3 1.1 
NCKAP1 NCK-associated protein 1 1 0.4 
NCOA3 nuclear receptor coactivator 3 32 12.3 
NCOA5 nuclear receptor coactivator 5 1 0.4 
NCOR1 nuclear receptor corepressor 1 1 0.4 
NCOR2 nuclear receptor corepressor 2 8 3.1 
NDE1 nudE neurodevelopment protein 1 7 2.7 
NDEL1 nudE neurodevelopment protein 1-like 1 3 1.1 
NEDD4L 
neural precursor cell expressed, developmentally 
down-regulated 4-like, E3 ubiquitin protein 
ligase 2 0.8 
NEDD9 
neural precursor cell expressed, developmentally 
down-regulated 9 1 0.4 
NEK6 NIMA-related kinase 6 1 0.4 
NEK9 NIMA-related kinase 9 1 0.4 
NELFCD negative elongation factor complex member C/D 1 0.4 
NET1 neuroepithelial cell transforming 1 1 0.4 
NFATC2 
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2 9 3.4 
NFIA nuclear factor I/A 1 0.4 
NFKB1 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 2 0.8 
NFKBIZ 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 1 0.4 
NHLRC3 NHL repeat containing 3 1 0.4 
NID1 nidogen 1 1 0.4 
NKIRAS2 NFKB inhibitor interacting Ras-like 2 1 0.4 
NKRF NFKB repressing factor 1 0.4 
NLGN4Y neuroligin 4, Y-linked 1 0.4 
NLK nemo-like kinase 2 0.8 
NMT1 N-myristoyltransferase 1 5 1.9 
NOD1 
nucleotide-binding oligomerization domain 
containing 1 1 0.4 
NOS3 nitric oxide synthase 3 (endothelial cell) 1 0.4 
NPAS2 neuronal PAS domain protein 2 1 0.4 
NPC1 Niemann-Pick disease, type C1 1 0.4 
NR1H3 
nuclear receptor subfamily 1, group H, member 
3 3 1.1 
NR2C2 
nuclear receptor subfamily 2, group C, member 
2 2 0.8 
NR2F6 nuclear receptor subfamily 2, group F, member 6 1 0.4 
NR3C1 
nuclear receptor subfamily 3, group C, member 
1 (glucocorticoid receptor) 1 0.4 
NR3C2 
nuclear receptor subfamily 3, group C, member 





nuclear receptor subfamily 4, group A, member 
2 3 1.1 
NRP1 neuropilin 1 5 1.9 
NRXN3 neurexin 3 1 0.4 
NSUN2 
NOP2/Sun RNA methyltransferase family, 
member 2 2 0.8 
NUFIP2 
nuclear fragile X mental retardation protein 
interacting protein 2 7 2.7 
NUP153 nucleoporin 153kDa 2 0.8 
NUP205 nucleoporin 205kDa 1 0.4 
OPTN optineurin 1 0.4 
OSBPL10 oxysterol binding protein-like 10 1 0.4 
OSBPL1A oxysterol binding protein-like 1A 1 0.4 
OSBPL8 oxysterol binding protein-like 8 2 0.8 
OTUD4 OTU deubiquitinase 4 2 0.8 
OXCT1 3-oxoacid CoA transferase 1 3 1.1 
PABPC1 poly(A) binding protein, cytoplasmic 1 1 0.4 
PACSIN3 
protein kinase C and casein kinase substrate in 
neurons 3 1 0.4 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 10 3.8 
PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 15 5.7 
PAPD7 PAP associated domain containing 7 6 2.3 
PARD6B par-6 family cell polarity regulator beta 2 0.8 
PBX2 pre-B-cell leukemia homeobox 2 2 0.8 
PCBP1 poly(rC) binding protein 1 1 0.4 
PCBP2 poly(rC) binding protein 2 1 0.4 
PCDH18 protocadherin 18 1 0.4 
PCGF2 polycomb group ring finger 2 3 1.1 
PCGF3 polycomb group ring finger 3 3 1.1 
PCLO piccolo presynaptic cytomatrix protein 1 0.4 
PDE4D phosphodiesterase 4D, cAMP-specific 5 1.9 
PDHX pyruvate dehydrogenase complex, component X 1 0.4 
PDLIM7 PDZ and LIM domain 7 (enigma) 1 0.4 
PDS5A 
PDS5, regulator of cohesion maintenance, 
homolog A (S. cerevisiae) 2 0.8 
PDS5B 
PDS5, regulator of cohesion maintenance, 
homolog B (S. cerevisiae) 1 0.4 
PEX11B peroxisomal biogenesis factor 11 beta 2 0.8 
PFAS phosphoribosylformylglycinamidine synthase 1 0.4 
PFDN2 prefoldin subunit 2 1 0.4 
PFKM phosphofructokinase, muscle 1 0.4 
PFKP phosphofructokinase, platelet 7 2.7 
PGRMC1 progesterone receptor membrane component 1 1 0.4 
PHC2 polyhomeotic homolog 2 (Drosophila) 1 0.4 
PHF1 PHD finger protein 1 2 0.8 




PHKG2 phosphorylase kinase, gamma 2 (testis) 2 0.8 
PHTF1 putative homeodomain transcription factor 1 1 0.4 
PIAS3 protein inhibitor of activated STAT, 3 1 0.4 
PIGS 
phosphatidylinositol glycan anchor biosynthesis, 
class S 2 0.8 
PIP5K1A 
phosphatidylinositol-4-phosphate 5-kinase, type 
I, alpha 1 0.4 
PITPNA phosphatidylinositol transfer protein, alpha 2 0.8 
PKD2 
polycystic kidney disease 2 (autosomal 
dominant) 1 0.4 
PKN3 protein kinase N3 1 0.4 
PKP4 plakophilin 4 1 0.4 
PLAT plasminogen activator, tissue 4 1.5 
PLAU plasminogen activator, urokinase 1 0.4 
PLD3 phospholipase D family, member 3 1 0.4 
PLEKHA5 
pleckstrin homology domain containing, family 
A member 5 1 0.4 
PLEKHF2 
pleckstrin homology domain containing, family 
F (with FYVE domain) member 2 1 0.4 
PLEKHG2 
pleckstrin homology domain containing, family 
G (with RhoGef domain) member 2 3 1.1 
PLOD1 
procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 1 1 0.4 
PLOD2 
procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2 3 1.1 
PLOD3 
procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 3 18 6.9 
PLS1 plastin 1 1 0.4 
PNN pinin, desmosome associated protein 3 1.1 
PNPLA7 patatin-like phospholipase domain containing 7 1 0.4 
POGK pogo transposable element with KRAB domain 1 0.4 
POGZ pogo transposable element with ZNF domain 11 4.2 
POLR2A 
polymerase (RNA) II (DNA directed) 
polypeptide A, 220kDa 1 0.4 
POLR2L 
polymerase (RNA) II (DNA directed) 
polypeptide L, 7.6kDa 1 0.4 
POU2F1 POU class 2 homeobox 1 1 0.4 
PPARA peroxisome proliferator-activated receptor alpha 2 0.8 
PPARD peroxisome proliferator-activated receptor delta 2 0.8 
PPFIA1 
protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein 
(liprin), alpha 1 1 0.4 
PPFIBP1 
PTPRF interacting protein, binding protein 1 
(liprin beta 1) 1 0.4 
PPIA peptidylprolyl isomerase A (cyclophilin A) 2 0.8 
PPIB peptidylprolyl isomerase B (cyclophilin B) 1 0.4 
PPIF peptidylprolyl isomerase F 1 0.4 
PPL periplakin 1 0.4 
PPP1R12A protein phosphatase 1, regulatory subunit 12A 3 1.1 
PPP1R12C protein phosphatase 1, regulatory subunit 12C 1 0.4 





PPP6R1 protein phosphatase 6, regulatory subunit 1 2 0.8 
PPP6R3 protein phosphatase 6, regulatory subunit 3 12 4.6 
PRKAA1 
protein kinase, AMP-activated, alpha 1 catalytic 
subunit 3 1.1 
PRKCI protein kinase C, iota 1 0.4 
PRKD3 protein kinase D3 1 0.4 
PRKG1 protein kinase, cGMP-dependent, type I 1 0.4 
PRPF8 pre-mRNA processing factor 8 3 1.1 
PRRC2A proline-rich coiled-coil 2A 19 7.3 
PRRC2B proline-rich coiled-coil 2B 1 0.4 
PRUNE2 prune homolog 2 (Drosophila) 1 0.4 
PSD3 pleckstrin and Sec7 domain containing 3 1 0.4 
PSMB5 
proteasome (prosome, macropain) subunit, beta 
type, 5 4 1.5 
PSMD11 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 11 3 1.1 
PSMD13 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 13 1 0.4 
PSMD3 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 3 3 1.1 
PSMD6 
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 6 2 0.8 
PSME3 
proteasome (prosome, macropain) activator 
subunit 3 (PA28 gamma; Ki) 1 0.4 
PSPC1 paraspeckle component 1 1 0.4 
PSTPIP1 
proline-serine-threonine phosphatase interacting 
protein 1 1 0.4 
PTBP1 polypyrimidine tract binding protein 1 2 0.8 
PTBP3 polypyrimidine tract binding protein 3 1 0.4 
PTGS2 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 1 0.4 
PTK2 protein tyrosine kinase 2 14 5.4 
PTK2B protein tyrosine kinase 2 beta 1 0.4 
PTP4A3 
protein tyrosine phosphatase type IVA, member 
3 1 0.4 
PTPN1 
protein tyrosine phosphatase, non-receptor type 
1 18 6.9 
PTPN12 
protein tyrosine phosphatase, non-receptor type 
12 9 3.4 
PTPN3 
protein tyrosine phosphatase, non-receptor type 
3 1 0.4 
PTPRD protein tyrosine phosphatase, receptor type, D 1 0.4 
PTPRF protein tyrosine phosphatase, receptor type, F 1 0.4 
PTPRJ protein tyrosine phosphatase, receptor type, J 6 2.3 
PUM1 pumilio RNA-binding family member 1 3 1.1 
QKI QKI, KH domain containing, RNA binding 1 0.4 
QRICH2 glutamine rich 2 1 0.4 
QSOX2 quiescin Q6 sulfhydryl oxidase 2 1 0.4 




RAB34 RAB34, member RAS oncogene family 4 1.5 
RABGAP1 RAB GTPase activating protein 1 1 0.4 
RABGAP1L RAB GTPase activating protein 1-like 1 0.4 
RABL6 RAB, member RAS oncogene family-like 6 1 0.4 
RAD23B RAD23 homolog B (S. cerevisiae) 1 0.4 
RAD9A RAD9 homolog A (S. pombe) 2 0.8 
RAE1 ribonucleic acid export 1 1 0.4 
RAI14 retinoic acid induced 14 2 0.8 
RALY RALY heterogeneous nuclear ribonucleoprotein 3 1.1 
RANBP10 RAN binding protein 10 1 0.4 
RANBP9 RAN binding protein 9 1 0.4 
RAP1B RAP1B, member of RAS oncogene family 1 0.4 
RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 1 0.4 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 1 0.4 
RARS arginyl-tRNA synthetase 2 0.8 
RASAL2 RAS protein activator like 2 1 0.4 
RASSF8 
Ras association (RalGDS/AF-6) domain family 
(N-terminal) member 8 1 0.4 
RBBP8 retinoblastoma binding protein 8 4 1.5 
RBL1 retinoblastoma-like 1 11 4.2 
RBL2 retinoblastoma-like 2 2 0.8 
RBM10 RNA binding motif protein 10 1 0.4 
RBM12B RNA binding motif protein 12B 3 1.1 
RBM5 RNA binding motif protein 5 1 0.4 
RBM6 RNA binding motif protein 6 1 0.4 
RBM8A RNA binding motif protein 8A 1 0.4 
RELA 
v-rel avian reticuloendotheliosis viral oncogene 
homolog A 1 0.4 
RELB 
v-rel avian reticuloendotheliosis viral oncogene 
homolog B 2 0.8 
REPS1 RALBP1 associated Eps domain containing 1 7 2.7 
RERE arginine-glutamic acid dipeptide (RE) repeats 2 0.8 
RFC3 replication factor C (activator 1) 3, 38kDa 1 0.4 
RFFL 
ring finger and FYVE-like domain containing 
E3 ubiquitin protein ligase 1 0.4 
RGS19 regulator of G-protein signaling 19 3 1.1 
RHOT1 ras homolog family member T1 2 0.8 
RICTOR 
RPTOR independent companion of MTOR, 
complex 2 1 0.4 
RIMS1 regulating synaptic membrane exocytosis 1 1 0.4 
RIMS2 regulating synaptic membrane exocytosis 2 1 0.4 
RIN3 Ras and Rab interactor 3 1 0.4 
RIPK2 receptor-interacting serine-threonine kinase 2 1 0.4 
RIPK3 receptor-interacting serine-threonine kinase 3 1 0.4 
RLF rearranged L-myc fusion 2 0.8 




RNF114 ring finger protein 114 1 0.4 
RNF149 ring finger protein 149 1 0.4 
RNF167 ring finger protein 167 1 0.4 
RNF40 
ring finger protein 40, E3 ubiquitin protein 
ligase 4 1.5 
RNF5 ring finger protein 5, E3 ubiquitin protein ligase 1 0.4 
RNH1 ribonuclease/angiogenin inhibitor 1 1 0.4 
ROCK1 
Rho-associated, coiled-coil containing protein 
kinase 1 15 5.7 
RPIA ribose 5-phosphate isomerase A 1 0.4 
RPL23 ribosomal protein L23 1 0.4 
RPL28 ribosomal protein L28 1 0.4 
RPRD1A 
regulation of nuclear pre-mRNA domain 
containing 1A 2 0.8 
RPRD1B 
regulation of nuclear pre-mRNA domain 
containing 1B 5 1.9 
RPS2 ribosomal protein S2 1 0.4 
RPS24 ribosomal protein S24 2 0.8 
RPS27 ribosomal protein S27 2 0.8 
RPS6KA5 
ribosomal protein S6 kinase, 90kDa, polypeptide 
5 1 0.4 
RRBP1 ribosome binding protein 1 1 0.4 
RTN4 reticulon 4 2 0.8 
RUNDC3B RUN domain containing 3B 1 0.4 
RUNX2 runt-related transcription factor 2 7 2.7 
RXRB retinoid X receptor, beta 10 3.8 
SCAMP1 secretory carrier membrane protein 1 1 0.4 
SCARB1 scavenger receptor class B, member 1 2 0.8 
SCD stearoyl-CoA desaturase (delta-9-desaturase) 1 0.4 
SCRIB scribbled planar cell polarity protein 19 7.3 
SCRN1 secernin 1 1 0.4 
SEC23A Sec23 homolog A (S. cerevisiae) 1 0.4 
SEC23IP SEC23 interacting protein 1 0.4 
SEC24B SEC24 family member B 1 0.4 
SEC24C SEC24 family member C 4 1.5 
SEC31A SEC31 homolog A (S. cerevisiae) 1 0.4 
SENP1 SUMO1/sentrin specific peptidase 1 4 1.5 
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 2 0.8 
SENP3 SUMO1/sentrin/SMT3 specific peptidase 3 2 0.8 
SEPT2 septin 2 1 0.4 
SERINC5 serine incorporator 5 1 0.4 
SERPINE1 
serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 
1 4 1.5 
SETD5 SET domain containing 5 4 1.5 
SETD7 
SET domain containing (lysine 




SF3A1 splicing factor 3a, subunit 1, 120kDa 1 0.4 
SF3B2 splicing factor 3b, subunit 2, 145kDa 1 0.4 
SF3B3 splicing factor 3b, subunit 3, 130kDa 1 0.4 
SFXN1 sideroflexin 1 1 0.4 
SGK1 serum/glucocorticoid regulated kinase 1 1 0.4 
SH2D4A SH2 domain containing 4A 1 0.4 
SH3D19 SH3 domain containing 19 1 0.4 
SH3PXD2A SH3 and PX domains 2A 1 0.4 
SIK2 salt-inducible kinase 2 1 0.4 
SIPA1L3 signal-induced proliferation-associated 1 like 3 1 0.4 
SIRT1 sirtuin 1 1 0.4 
SKI SKI proto-oncogene 3 1.1 
SLC13A3 
solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 3 2 0.8 
SLC16A1 
solute carrier family 16 (monocarboxylate 
transporter), member 1 1 0.4 
SLC19A2 
solute carrier family 19 (thiamine transporter), 
member 2 1 0.4 
SLC25A13 
solute carrier family 25 (aspartate/glutamate 
carrier), member 13 10 3.8 
SLC25A40 solute carrier family 25, member 40 4 1.5 
SLC25A6 
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 6 1 0.4 
SLC2A4 
solute carrier family 2 (facilitated glucose 
transporter), member 4 3 1.1 
SLC39A1 
solute carrier family 39 (zinc transporter), 
member 1 7 2.7 
SLC39A10 
solute carrier family 39 (zinc transporter), 
member 10 3 1.1 
SLC39A14 
solute carrier family 39 (zinc transporter), 
member 14 1 0.4 
SLC39A8 
solute carrier family 39 (zinc transporter), 
member 8 1 0.4 
SLC46A3 solute carrier family 46, member 3 3 1.1 
SLC7A1 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 7 2.7 
SLC7A2 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 2 1 0.4 
SLC9A3R1 
solute carrier family 9, subfamily A (NHE3, 
cation proton antiporter 3), member 3 regulator 1 1 0.4 
SLC9A6 
solute carrier family 9, subfamily A (NHE6, 
cation proton antiporter 6), member 6 2 0.8 
SMARCA2 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 2 2 0.8 
SMARCC2 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 2 5 1.9 
SMC1A structural maintenance of chromosomes 1A 1 0.4 
SMCHD1 
structural maintenance of chromosomes flexible 
hinge domain containing 1 2 0.8 
SMG1 
SMG1 phosphatidylinositol 3-kinase-related 
kinase 1 0.4 




SMYD2 SET and MYND domain containing 2 1 0.4 
SMYD3 SET and MYND domain containing 3 2 0.8 
SNAP25 synaptosomal-associated protein, 25kDa 1 0.4 
SNAP29 synaptosomal-associated protein, 29kDa 1 0.4 
SNRPA small nuclear ribonucleoprotein polypeptide A 1 0.4 
SNX1 sorting nexin 1 1 0.4 
SORBS3 sorbin and SH3 domain containing 3 1 0.4 
SOS2 son of sevenless homolog 2 (Drosophila) 1 0.4 
SOX5 SRY (sex determining region Y)-box 5 14 5.4 
SP1 Sp1 transcription factor 1 0.4 
SP4 Sp4 transcription factor 1 0.4 
SPAG9 sperm associated antigen 9 5 1.9 
SPEN spen family transcriptional repressor 1 0.4 
SPNS1 spinster homolog 1 (Drosophila) 1 0.4 
SPRY1 
sprouty homolog 1, antagonist of FGF signaling 
(Drosophila) 1 0.4 
SPTBN1 spectrin, beta, non-erythrocytic 1 7 2.7 
SRCAP Snf2-related CREBBP activator protein 1 0.4 
SRF 
serum response factor (c-fos serum response 
element-binding transcription factor) 5 1.9 
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 2 0.8 
SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 2 0.8 
SRI sorcin 8 3.1 
SRSF1 serine/arginine-rich splicing factor 1 1 0.4 
SRSF4 serine/arginine-rich splicing factor 4 1 0.4 
SSRP1 structure specific recognition protein 1 1 0.4 
STAG1 stromal antigen 1 1 0.4 
STAM 
signal transducing adaptor molecule (SH3 
domain and ITAM motif) 1 2 0.8 
STAMBPL1 STAM binding protein-like 1 1 0.4 
STAT1 
signal transducer and activator of transcription 1, 
91kDa 1 0.4 
STK24 serine/threonine kinase 24 1 0.4 
STK3 serine/threonine kinase 3 14 5.4 
STK35 serine/threonine kinase 35 1 0.4 
STK4 serine/threonine kinase 4 10 3.8 
STOM stomatin 1 0.4 
STRN striatin, calmodulin binding protein 3 1.1 
STX1A syntaxin 1A (brain) 6 2.3 
STX7 syntaxin 7 1 0.4 
STXBP1 syntaxin binding protein 1 4 1.5 
STXBP3 syntaxin binding protein 3 1 0.4 
SUPT5H suppressor of Ty 5 homolog (S. cerevisiae) 1 0.4 
SYNE1 spectrin repeat containing, nuclear envelope 1 1 0.4 




SYPL1 synaptophysin-like 1 1 0.4 
TADA2A transcriptional adaptor 2A 1 0.4 
TAF4 
TAF4 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 135kDa 1 0.4 
TARS threonyl-tRNA synthetase 3 1.1 
TAX1BP1 
Tax1 (human T-cell leukemia virus type I) 
binding protein 1 1 0.4 
TBC1D22B TBC1 domain family, member 22B 2 0.8 
TBC1D4 TBC1 domain family, member 4 5 1.9 
TBC1D9 
TBC1 domain family, member 9 (with GRAM 
domain) 1 0.4 
TCEA2 transcription elongation factor A (SII), 2 4 1.5 
TEK TEK tyrosine kinase, endothelial 1 0.4 
TES testis derived transcript (3 LIM domains) 7 2.7 
TESK1 testis-specific kinase 1 3 1.1 
TGFB1I1 
transforming growth factor beta 1 induced 
transcript 1 1 0.4 
TGFBR2 
transforming growth factor, beta receptor II 
(70/80kDa) 1 0.4 
TGM2 transglutaminase 2 2 0.8 
THAP1 
THAP domain containing, apoptosis associated 
protein 1 1 0.4 
THBS1 thrombospondin 1 3 1.1 
THOP1 thimet oligopeptidase 1 3 1.1 
THRA thyroid hormone receptor, alpha 20 7.7 
TIAM1 T-cell lymphoma invasion and metastasis 1 6 2.3 
TIMM50 
translocase of inner mitochondrial membrane 50 
homolog (S. cerevisiae) 2 0.8 
TJP2 tight junction protein 2 1 0.4 
TLE4 transducin-like enhancer of split 3 2 0.8 
TLE4 transducin-like enhancer of split 4 1 0.4 
TLN1 talin 1 3 1.1 
TLR2 toll-like receptor 2 1 0.4 
TLR4 toll-like receptor 4 5 1.9 
TMEM14A transmembrane protein 14A 2 0.8 
TMEM170B transmembrane protein 170B 1 0.4 
TMEM2 transmembrane protein 2 1 0.4 
TMEM30A transmembrane protein 30A 2 0.8 
TMEM63B transmembrane protein 63B 1 0.4 
TMEM87A transmembrane protein 87A 1 0.4 
TNFAIP1 
tumor necrosis factor, alpha-induced protein 1 
(endothelial) 9 3.4 
TNKS 
tankyrase, TRF1-interacting ankyrin-related 
ADP-ribose polymerase 3 1.1 
TNPO1 transportin 1 1 0.4 
TNRC6B trinucleotide repeat containing 6B 3 1.1 
TNS3 tensin 3 1 0.4 




TOB2 transducer of ERBB2, 2 1 0.4 
TOM1 target of myb1 (chicken) 1 0.4 
TOMM34 translocase of outer mitochondrial membrane 34 33 12.6 
TPD52 tumor protein D52 1 0.4 
TPD52L2 tumor protein D52-like 2 1 0.4 
TRA2B transformer 2 beta homolog (Drosophila) 4 1.5 
TRAF2 TNF receptor-associated factor 2 1 0.4 
TRAF4 TNF receptor-associated factor 4 1 0.4 
TRAP1 TNF receptor-associated protein 1 1 0.4 
TRAPPC3 trafficking protein particle complex 3 2 0.8 
TRERF1 transcriptional regulating factor 1 1 0.4 
TRIB1 tribbles pseudokinase 1 4 1.5 
TRIB3 tribbles pseudokinase 3 6 2.3 
TRIM2 tripartite motif containing 2 3 1.1 
TRIM21 tripartite motif containing 21 1 0.4 
TRIM28 tripartite motif containing 28 10 3.8 
TRIM37 tripartite motif containing 37 1 0.4 
TRIM39 tripartite motif containing 39 5 1.9 
TRIM69 tripartite motif containing 69 1 0.4 
TRIP12 thyroid hormone receptor interactor 12 3 1.1 
TRIP6 thyroid hormone receptor interactor 6 4 1.5 
TRMT2A 
tRNA methyltransferase 2 homolog A (S. 
cerevisiae) 1 0.4 
TSC22D4 TSC22 domain family, member 4 2 0.8 
TTC37 tetratricopeptide repeat domain 37 1 0.4 
TUBA1C tubulin, alpha 1c 1 0.4 
TUBB tubulin, beta class I 6 2.3 
TUBB4B tubulin, beta 4B class IVb 3 1.1 
TULP3 tubby like protein 3 1 0.4 
TXLNA taxilin alpha 4 1.5 
TXNIP thioredoxin interacting protein 2 0.8 
TYMS thymidylate synthetase 3 1.1 
U2AF2 U2 small nuclear RNA auxiliary factor 2 1 0.4 
UBAP2 ubiquitin associated protein 2 1 0.4 
UBAP2L ubiquitin associated protein 2-like 5 1.9 
UBASH3B 
ubiquitin associated and SH3 domain containing 
B 1 0.4 
UBE2R2 ubiquitin-conjugating enzyme E2R 2 3 1.1 
UBR1 
ubiquitin protein ligase E3 component n-
recognin 1 2 0.8 
UCHL3 
ubiquitin carboxyl-terminal esterase L3 
(ubiquitin thiolesterase) 4 1.5 
UFM1 ubiquitin-fold modifier 1 1 0.4 
UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 1 0.4 




UNC119 unc-119 homolog (C. elegans) 2 0.8 
UNC93B1 unc-93 homolog B1 (C. elegans) 5 1.9 
USF1 upstream transcription factor 1 1 0.4 
USF2 upstream transcription factor 2, c-fos interacting 4 1.5 
USP10 ubiquitin specific peptidase 10 1 0.4 
USP15 ubiquitin specific peptidase 15 1 0.4 
USP2 ubiquitin specific peptidase 2 2 0.8 
USP21 ubiquitin specific peptidase 21 6 2.3 
USP22 ubiquitin specific peptidase 22 2 0.8 
USP25 ubiquitin specific peptidase 25 6 2.3 
USP28 ubiquitin specific peptidase 28 1 0.4 
USP31 ubiquitin specific peptidase 31 5 1.9 
USP36 ubiquitin specific peptidase 36 3 1.1 
USP45 ubiquitin specific peptidase 45 1 0.4 
USP49 ubiquitin specific peptidase 49 1 0.4 
USP5 ubiquitin specific peptidase 5 (isopeptidase T) 7 2.7 
USP7 
ubiquitin specific peptidase 7 (herpes virus-
associated) 1 0.4 
USP9Y ubiquitin specific peptidase 9, Y-linked 1 0.4 
UTP20 
UTP20, small subunit (SSU) processome 
component, homolog (yeast) 1 0.4 
UTRN utrophin 2 0.8 
UTY 
ubiquitously transcribed tetratricopeptide repeat 
containing, Y-linked 1 0.4 
VAC14 Vac14 homolog (S. cerevisiae) 1 0.4 
VAMP3 vesicle-associated membrane protein 3 2 0.8 
VAPB 
VAMP (vesicle-associated membrane protein)-
associated protein B and C 26 10 
VARS valyl-tRNA synthetase 3 1.1 
VASP vasodilator-stimulated phosphoprotein 4 1.5 
VAV2 vav 2 guanine nucleotide exchange factor 1 0.4 
VCP valosin containing protein 1 0.4 
VDAC2 voltage-dependent anion channel 2 2 0.8 
VDAC3 voltage-dependent anion channel 3 1 0.4 
VEGFA vascular endothelial growth factor A 23 8.8 
VIM vimentin 2 0.8 
VPS13C 
vacuolar protein sorting 13 homolog C (S. 
cerevisiae) 3 1.1 
VPS37B 
vacuolar protein sorting 37 homolog B (S. 
cerevisiae) 2 0.8 
WBP2 WW domain binding protein 2 1 0.4 
WDR17 WD repeat domain 17 1 0.4 
WDR62 WD repeat domain 62 6 2.3 
WDR78 WD repeat domain 78 1 0.4 
WEE1 WEE1 G2 checkpoint kinase 2 0.8 
WIPF2 
WAS/WASL interacting protein family, member 




WNK1 WNK lysine deficient protein kinase 1 1 0.4 
XPO7 exportin 7 2 0.8 
XYLT2 xylosyltransferase II 2 0.8 
YES1 
YES proto-oncogene 1, Src family tyrosine 
kinase 3 1.1 
YY1 YY1 transcription factor 1 0.4 
ZBED1 zinc finger, BED-type containing 1 2 0.8 
ZBTB17 zinc finger and BTB domain containing 17 1 0.4 
ZBTB18 zinc finger and BTB domain containing 18 1 0.4 
ZBTB34 zinc finger and BTB domain containing 34 1 0.4 
ZBTB7B zinc finger and BTB domain containing 7B 6 2.3 
ZBTB9 zinc finger and BTB domain containing 9 3 1.1 
ZC3H12C zinc finger CCCH-type containing 12C 2 0.8 
ZDHHC7 zinc finger, DHHC-type containing 7 1 0.4 
ZEB2 zinc finger E-box binding homeobox 2 1 0.4 
ZFR zinc finger RNA binding protein 1 0.4 
ZFY zinc finger protein, Y-linked 1 0.4 
ZFYVE9 zinc finger, FYVE domain containing 9 1 0.4 
ZMIZ1 zinc finger, MIZ-type containing 1 1 0.4 
ZNF16 zinc finger protein 16 3 1.1 
ZNF250 zinc finger protein 250 1 0.4 
ZNF274 zinc finger protein 274 1 0.4 
ZNF408 zinc finger protein 408 1 0.4 
ZNF687 zinc finger protein 687 1 0.4 






7.3 Gene set enrichment analysis of OAC drivers 
Shown are the 212 pathways enriched in drivers (FDR <0.01). For each 
pathway, the number of genes and samples, the p-value of one-tailed 
hypergeometric test and the False Discovey Rate (FDR) using the Benjamini 
and Hochberg method are reported. Pathway size refers to the total number of 
genes in the pathway. Universal pathways are those with at least one perturbed 











348 Y 35 240 3.72E-24 4.27E-21 
NGF signalling via 
TRKA from the 
plasma membrane 
382 Y 36 240 7.39E-24 4.27E-21 
DAP12 signaling 351 Y 34 240 6.07E-23 1.75E-20 
Fc epsilon receptor 
(FCERI) signaling 
405 Y 36 241 5.49E-23 1.75E-20 
DAP12 interactions 366 Y 34 240 2.37E-22 5.47E-20 
Signaling by the B 
Cell Receptor (BCR) 
242 Y 29 240 2.87E-22 5.52E-20 
IGF1R signaling 
cascade 
292 Y 30 183 4.72E-21 5.09E-19 
Insulin receptor 
signalling cascade 
291 Y 30 183 4.28E-21 5.09E-19 
IRS-mediated 
signalling 
288 Y 30 183 3.16E-21 5.09E-19 
IRS-related events 
triggered by IGF1R 
292 Y 30 183 4.72E-21 5.09E-19 
Signaling by 
Interleukins 
402 Y 34 194 4.85E-21 5.09E-19 
Downstream 
signaling events of B 
Cell Receptor (BCR) 
198 Y 25 239 7.10E-20 6.84E-18 
PI3K/AKT activation 130 Y 21 237 3.97E-19 3.53E-17 
Interleukin-3, 5 and 
GM-CSF signaling 
265 Y 27 182 6.25E-19 5.15E-17 
PI3K events in 
ERBB4 signaling 
127 Y 20 236 4.84E-18 3.73E-16 
GAB1 signalosome 130 Y 20 236 7.81E-18 5.64E-16 
VEGFA-VEGFR2 
Pathway 
324 Y 28 187 1.08E-17 7.32E-16 
Interleukin-2 
signaling 
256 Y 25 180 3.74E-17 2.40E-15 
PI3K/AKT Signaling 
in Cancer 
90 Y 17 147 6.71E-17 4.08E-15 
RET signaling 264 Y 25 180 7.80E-17 4.51E-15 
Interleukin receptor 
SHC signaling 
249 Y 24 180 2.24E-16 1.23E-14 
ARMS-mediated 
activation 
243 Y 23 175 1.46E-15 7.33E-14 
Signalling to p38 via 
RIT and RIN 
243 Y 23 175 1.46E-15 7.33E-14 
Frs2-mediated 
activation 
244 Y 23 175 1.60E-15 7.69E-14 









170 Y 20 236 1.69E-15 7.76E-14 
Prolonged ERK 
activation events 
246 Y 23 175 1.91E-15 8.17E-14 
Signalling to RAS 250 Y 23 175 2.71E-15 1.12E-13 
Negative regulation 
of the PI3K/AKT 
network 
94 Y 16 135 3.21E-15 1.28E-13 
Signalling to ERKs 257 Y 23 175 4.95E-15 1.90E-13 
FCERI mediated 
MAPK activation 
296 Y 24 175 1.12E-14 3.59E-13 
GRB2 events in 
EGFR signaling 
239 Y 22 172 1.12E-14 3.59E-13 
RAF/MAP kinase 
cascade 
239 Y 22 172 1.12E-14 3.59E-13 
SHC1 events in 
EGFR signaling 
239 Y 22 172 1.12E-14 3.59E-13 
SHC1 events in 
ERBB4 signaling 
239 Y 22 172 1.12E-14 3.59E-13 
SOS-mediated 
signalling 
239 Y 22 172 1.12E-14 3.59E-13 
NCAM signaling for 
neurite out-growth 
270 Y 23 173 1.44E-14 4.49E-13 
VEGFR2 mediated 
cell proliferation 
252 Y 22 172 3.35E-14 1.02E-12 
PI5P, PP2A and 
IER3 Regulate 
PI3K/AKT Signaling 
87 N 14 126 4.06E-13 1.20E-11 
TCF dependent 
signaling in response 
to WNT 
202 Y 19 143 5.35E-13 1.55E-11 
Transcriptional 
Regulation by TP53 
366 Y 24 238 1.16E-12 3.27E-11 
Signaling by FGFR 
in disease 
63 N 12 92 2.47E-12 6.80E-11 
Constitutive 
Signaling by 
Aberrant PI3K in 
Cancer 
65 N 12 123 3.66E-12 9.84E-11 
Signaling by FGFR1 
in disease 
38 N 10 84 5.35E-12 1.40E-10 
Signaling by FGFR3 40 N 10 79 9.41E-12 2.42E-10 




60 N 11 112 3.22E-11 8.09E-10 
Gastrin-CREB 
signalling pathway 
via PKC and MAPK 




15 N 7 92 8.24E-11 1.90E-09 
Regulation of TP53 
Degradation 
35 Y 9 226 8.02E-11 1.90E-09 
Signaling by 
EGFRvIII in Cancer 
15 N 7 92 8.24E-11 1.90E-09 






Signaling by FGFR1 50 N 10 85 1.04E-10 2.35E-09 
RAF activation 25 N 8 58 1.31E-10 2.85E-09 
Cyclin D associated 
events in G1 
38 Y 9 140 1.80E-10 3.78E-09 
G1 Phase 38 Y 9 140 1.80E-10 3.78E-09 
Signaling by FGFR3 
fusions in cancer 
10 N 6 65 2.71E-10 5.58E-09 
Signaling by FGFR4 41 N 9 76 3.77E-10 7.63E-09 









19 N 7 92 6.23E-10 1.18E-08 
Signaling by EGFR 
in Cancer 
19 N 7 92 6.23E-10 1.18E-08 
Signaling by Ligand-
Responsive EGFR 
Variants in Cancer 
19 N 7 92 6.23E-10 1.18E-08 
PI3K Cascade 79 N 11 61 7.13E-10 1.33E-08 
PKMTs methylate 
histone lysines 
47 N 9 66 1.39E-09 2.50E-08 
RMTs methylate 
histone arginines 
47 N 9 105 1.39E-09 2.50E-08 
Mitotic G1-G1/S 
phases 
141 Y 13 177 3.58E-09 6.37E-08 
GPVI-mediated 
activation cascade 
54 N 9 45 5.07E-09 8.88E-08 
Oxidative Stress 
Induced Senescence 
95 Y 11 228 5.31E-09 9.15E-08 
Downstream 
signaling of activated 
FGFR3 
25 N 7 66 5.63E-09 9.56E-08 
Signaling by FGFR2 75 N 10 80 6.67E-09 1.12E-07 
Interleukin-7 
signaling 




18 N 6 45 2.23E-08 3.57E-07 
Tie2 Signaling 18 N 6 63 2.23E-08 3.57E-07 
Downstream 
signaling of activated 
FGFR2 
30 N 7 68 2.28E-08 3.60E-07 
Downstream 
signaling of activated 
FGFR1 
31 N 7 72 2.92E-08 4.49E-07 
FGFR1 mutant 
receptor activation 
31 N 7 53 2.92E-08 4.49E-07 
Regulation of TP53 
Activity through 
Methylation 
19 Y 6 214 3.23E-08 4.90E-07 
Signaling by RAS 
mutants 
48 N 8 55 3.70E-08 5.55E-07 






11 N 5 25 5.65E-08 8.16E-07 
Signaling by FGFR4 
in disease 
11 N 5 62 5.65E-08 8.16E-07 
Oncogene Induced 
Senescence 
34 Y 7 226 5.81E-08 8.28E-07 
CD209 (DC-SIGN) 
signaling 
21 N 6 56 6.34E-08 8.93E-07 
Oncogenic MAPK 
signaling 
72 N 9 89 6.89E-08 9.58E-07 
Transcriptional 
regulation by the AP-
2 (TFAP2) family of 
transcription factors 
35 N 7 119 7.19E-08 9.89E-07 
Signaling by FGFR3 
in disease 
22 N 6 65 8.64E-08 1.16E-06 
Signaling by FGFR3 
point mutants in 
cancer 
22 N 6 65 8.64E-08 1.16E-06 
Paradoxical 
activation of RAF 
signaling by kinase 
inactive BRAF 





38 N 7 52 1.31E-07 1.72E-06 
Regulation of TP53 
Activity 
159 Y 12 229 1.36E-07 1.76E-06 
Negative regulation 
of MAPK pathway 
40 N 7 58 1.91E-07 2.45E-06 
Signaling by BRAF 
and RAF fusions 
59 N 8 86 1.97E-07 2.50E-06 
Downstream 
signaling of activated 
FGFR4 
27 N 6 63 3.28E-07 4.12E-06 
GRB2 events in 
ERBB2 signaling 
16 N 5 115 5.11E-07 6.35E-06 
Activation of anterior 

















51 N 7 44 1.07E-06 1.28E-05 
Signaling by high-
kinase activity BRAF 
mutants 
34 N 6 52 1.40E-06 1.63E-05 
Signaling by WNT in 
cancer 
34 N 6 46 1.40E-06 1.63E-05 
FRS-mediated 
FGFR3 signaling 
20 N 5 50 1.75E-06 2.03E-05 
Constitutive 
Signaling by 










57 N 7 82 2.32E-06 2.55E-05 
Signaling by 
NOTCH1 HD+PEST 
Domain Mutants in 
Cancer 
57 N 7 82 2.32E-06 2.55E-05 
Signaling by 
NOTCH1 in Cancer 
57 N 7 82 2.32E-06 2.55E-05 
Signaling by 
NOTCH1 PEST 
Domain Mutants in 
Cancer 
57 N 7 82 2.32E-06 2.55E-05 
MAPK3 (ERK1) 
activation 
10 N 4 9 2.47E-06 2.69E-05 
MAP2K and MAPK 
activation 
38 N 6 52 2.78E-06 3.00E-05 
SHC1 events in 
ERBB2 signaling 
22 N 5 115 2.93E-06 3.13E-05 
FRS-mediated 
FGFR1 signaling 
23 N 5 58 3.71E-06 3.93E-05 
MET activates RAS 
signaling 
11 N 4 58 3.85E-06 4.01E-05 
RHO GTPases 
activate IQGAPs 




41 Y 6 213 4.40E-06 4.54E-05 
Constitutive 
Signaling by AKT1 
E17K in Cancer 
25 N 5 50 5.76E-06 5.83E-05 
FRS-mediated 
FGFR2 signaling 
25 N 5 54 5.76E-06 5.83E-05 
Signaling by FGFR2 
in disease 
43 N 6 67 5.86E-06 5.89E-05 
PTK6 Regulates 
RHO GTPases, RAS 
GTPase and MAP 
kinases 
26 N 5 51 7.06E-06 6.97E-05 
SHC-mediated 
cascade:FGFR2 
26 N 5 54 7.06E-06 6.97E-05 
AKT phosphorylates 
targets in the cytosol 
13 N 4 29 8.20E-06 8.03E-05 
Interleukin-6 family 
signaling 
27 N 5 25 8.60E-06 8.34E-05 
Cyclin E associated 
events during G1/S 
transition 
71 N 7 110 1.03E-05 9.91E-05 
Signaling by 
NOTCH1 




of FGFR3 signaling 





205 Y 11 225 1.26E-05 
0.000118
6 
Costimulation by the 
CD28 family 













mutants of CTNNB1 
are not targeted to the 
proteasome by the 
destruction complex 
15 N 4 34 1.54E-05 
0.000135
771 
Regulation of TP53 
Activity through 
Acetylation 
30 Y 5 203 1.48E-05 
0.000135
771 
S33 mutants of beta-
catenin aren't 
phosphorylated 
15 N 4 34 1.54E-05 
0.000135
771 
S37 mutants of beta-
catenin aren't 
phosphorylated 
15 N 4 34 1.54E-05 
0.000135
771 
S45 mutants of beta-
catenin aren't 
phosphorylated 
15 N 4 34 1.54E-05 
0.000135
771 
T41 mutants of beta-
catenin aren't 
phosphorylated 
15 N 4 34 1.54E-05 
0.000135
771 
PI3K events in 
ERBB2 signaling 
16 N 4 96 2.04E-05 
0.000176
825 
Spry regulation of 
FGF signaling 
16 N 4 26 2.04E-05 
0.000176
825 




of FGFR1 signaling 















of FGFR2 signaling 






















repair and signaling 
proteins at DNA 
double strand breaks 
59 Y 6 205 3.76E-05 
0.000306
168 
G1/S Transition 118 N 8 111 3.81E-05 
0.000307
416 
DNA Double Strand 
Break Response 
60 Y 6 205 4.15E-05 
0.000332
52 
Toll Like Receptor 4 
(TLR4) Cascade 
124 N 8 28 5.43E-05 
0.000432
191 




















64 Y 6 221 5.99E-05 
0.000464
611 















21 N 4 44 6.42E-05 
0.000484
848 
G1/S DNA Damage 
Checkpoints 




















97 N 7 27 7.88E-05 
0.000569
13 
Toll Like Receptor 3 
(TLR3) Cascade 

























Transcription of Cell 
Death Genes 




Transcription of Cell 
Cycle Genes 







through the activation 
of Ras 












Antigen activates B 
Cell Receptor (BCR) 
leading to generation 
of second messengers 













mediated induction of 
IFN-alpha/beta 
pathways 

































growth factors and 
their receptors 










Disassembly of the 
destruction complex 
and recruitment of 
AXIN to the 
membrane 














of FGFR4 signaling 





NICD traffics to 
nucleus 



































































Regulation of IFNG 
signaling 








































Regulation of TP53 
Activity through 























Post NMDA receptor 
activation events 












Regulation of TNFR1 
signaling 






necroptotic cell death 







DNA Repair Genes 






of cellular proteins 
















TriC/CCT with target 
proteins during 
biosynthesis 






signaling by CBL 













associated events at S 
phase entry 





Intrinsic Pathway for 
Apoptosis 














Genes Involved in 
Cytochrome C 
Release 





Regulation of gene 
expression in beta 
cells 







additional cell cycle 
genes whose exact 
role in the p53 
pathway remain 
uncertain 


















7.4 Gene set enrichment analysis of OAC helpers 
Shown are the 189 pathways enriched in drivers (FDR <0.01; 76 also enriched 
in drivers). For each pathway, the number of genes and samples, the p-value of 
one-tailed hypergeometric test and the False Discovey Rate (FDR) using the 
Benjamini and Hochberg method are reported. Pathway size refers to the total 
number of genes in the pathway. Universal pathways are those with at least 













348 Y 38 84 5.57E-06 
0.0001463
38 
NGF signalling via 
TRKA from the 
plasma membrane 
382 Y 43 93 6.06E-07 2.41E-05 
DAP12 signaling 351 Y 37 83 1.63E-05 
0.0003307
33 
Fc epsilon receptor 
(FCERI) signaling 
405 Y 44 103 1.19E-06 3.92E-05 
DAP12 interactions 366 Y 37 83 4.06E-05 
0.0006427
26 
Signaling by the B 
Cell Receptor (BCR) 



















triggered by IGF1R 





402 Y 43 87 2.36E-06 7.56E-05 
Downstream 
signaling events of B 
Cell Receptor (BCR) 
198 Y 26 68 6.70E-06 
0.0001612
52 





Interleukin-3, 5 and 
GM-CSF signaling 
265 Y 30 66 2.67E-05 
0.0004886
87 
PI3K events in 
ERBB4 signaling 












324 Y 44 128 1.69E-09 4.89E-07 
Interleukin-2 
signaling 
256 Y 28 63 8.97E-05 
0.0012186
76 



















Signalling to p38 via 
RIT and RIN 






































GRB2 events in 
EGFR signaling 












SHC1 events in 
EGFR signaling 





SHC1 events in 
ERBB4 signaling 












NCAM signaling for 
neurite out-growth 











Regulation by TP53 
366 Y 47 127 3.01E-09 6.94E-07 
Signaling by FGFR 
in disease 
63 N 12 26 5.81E-05 
0.0008602
86 
Signaling by FGFR1 
in disease 
38 N 9 24 8.34E-05 
0.0011463
84 
Regulation of TP53 
Degradation 





Regulation of TP53 
Expression and 
Degradation 





Cyclin D associated 
events in G1 
38 Y 10 50 1.24E-05 
0.0002600
54 
G1 Phase 38 Y 10 50 1.24E-05 
0.0002600
54 







141 Y 27 102 1.55E-09 4.89E-07 
Oxidative Stress 
Induced Senescence 

























Deubiquitination 280 Y 44 78 1.38E-11 1.59E-08 
Oncogene Induced 
Senescence 
34 Y 11 49 4.63E-07 1.98E-05 
Regulation of TP53 
Activity 
159 Y 26 60 9.23E-08 4.84E-06 
MET activates RAS 
signaling 





Cyclin E associated 
events during G1/S 
transition 









NOTCH1 923 79 
Ub-specific 
processing proteases 
205 Y 32 60 9.99E-09 1.26E-06 













G1/S Transition 118 N 18 88 2.29E-05 
0.0004334
37 
Toll Like Receptor 4 
(TLR4) Cascade 
124 N 23 45 4.67E-08 3.23E-06 
C-type lectin 
receptors (CLRs) 























21 N 7 25 4.83E-05 
0.0007248
38 
G1/S DNA Damage 
Checkpoints 







97 N 20 41 5.59E-08 3.23E-06 
Toll Like Receptor 3 
(TLR3) Cascade 




97 N 20 41 5.59E-08 3.23E-06 
TP53 Regulates 
Transcription of Cell 
Cycle Genes 
48 Y 12 52 3.03E-06 8.14E-05 
VEGFR2 mediated 
vascular permeability 














151 N 26 53 3.13E-08 2.41E-06 
NOD1/2 Signaling 
Pathway 





Regulation of TP53 
Activity through 
Phosphorylation 







257 N 37 93 6.89E-09 1.16E-06 
Apoptotic cleavage 
of cellular proteins 




associated events at S 
phase entry 
70 N 13 31 3.81E-05 
0.0006205
48 






domain, leucine rich 
repeat containing 
receptor (NLR) 







Apoptotic execution  
phase 
52 N 11 45 4.27E-05 
0.0006665
46 
S Phase 128 N 22 69 3.66E-07 1.69E-05 
MAPK6/MAPK4 
signaling 
























MET activates RAP1 
and RAC1 









72 N 16 35 4.03E-07 1.79E-05 
TP53 Regulates 
Transcription of 
Genes Involved in 
G1 Cell Cycle Arrest 














44 N 12 39 1.10E-06 3.75E-05 
MyD88 cascade 
initiated on plasma 
membrane 
83 N 16 35 3.01E-06 8.14E-05 
Toll Like Receptor 
10 (TLR10) Cascade 
83 N 16 35 3.01E-06 8.14E-05 
Toll Like Receptor 5 
(TLR5) Cascade 
83 N 16 35 3.01E-06 8.14E-05 
TRAF6 mediated 
induction of NFkB 
and MAP kinases 
upon TLR7/8 or 9 
activation 
83 N 16 35 3.01E-06 8.14E-05 
MyD88 dependent 
cascade initiated on 
endosome 
85 N 17 35 8.66E-07 3.17E-05 
Toll Like Receptor 
7/8 (TLR7/8) 
Cascade 
85 N 17 35 8.66E-07 3.17E-05 
Toll Like Receptor 9 
(TLR9) Cascade 
89 N 18 36 3.48E-07 1.67E-05 
MyD88:Mal cascade 
initiated on plasma 
membrane 
93 N 20 43 2.64E-08 2.18E-06 
Toll Like Receptor 2 
(TLR2) Cascade 
93 N 20 43 2.64E-08 2.18E-06 
Toll Like Receptor 
TLR1:TLR2 Cascade 
93 N 20 43 2.64E-08 2.18E-06 
Toll Like Receptor 
TLR6:TLR2 Cascade 
93 N 20 43 2.64E-08 2.18E-06 
Negative regulation 
of MET activity 
















activation in TLR 
cascade 











































MET promotes cell 
motility 
29 N 11 37 7.05E-08 3.88E-06 












125 N 21 61 9.91E-07 3.47E-05 
Signaling by Robo 
receptor 






regulation of rRNA 
expression 





Regulation of insulin 
secretion 






Activate WASPs and 
WAVEs 
36 N 10 28 7.29E-06 
0.0001719
5 
G alpha (12/13) 
signalling events 





42 N 14 62 8.04E-09 1.16E-06 
Activation of gene 
expression by 
SREBF (SREBP) 










Resolution of Sister 
Chromatid Cohesion 









































activate type I IFN 
and inflammatory 
cytokines production 










p75NTR signals via 
NF-kB 
16 N 6 13 8.05E-05 
0.0011340
03 












MET activates PTK2 
signaling 













activation via ZBP1 




























G0 and Early G1 25 N 11 47 1.09E-08 1.26E-06 
Diseases associated 
with the TLR 
signaling cascade 








activation of IKKs 
complex 
26 N 9 23 2.75E-06 8.14E-05 
ZBP1(DAI) mediated 
induction of type I 
IFNs 



















Separation of Sister 
Chromatids 






95 N 22 98 1.22E-09 4.89E-07 
p75 NTR receptor-
mediated signalling 
96 N 19 36 2.37E-07 1.19E-05 







mediated by MAP 
kinases 








Major Pathway 87 























100 N 16 51 3.53E-05 
0.0005916
94 






repulsion of cells 
48 N 12 34 3.03E-06 8.14E-05 
Nuclear Receptor 
transcription pathway 




death through JNK 





Orc1 removal from 
chromatin 
71 N 13 53 4.46E-05 
0.0006775
47 
Switching of origins 
to a post-replicative 
state 
71 N 13 53 4.46E-05 
0.0006775
47 
Removal of licensing 
factors from origins 












mediates p38 MAPK 
activation 





Activation of ATR in 
response to 
replication stress 













Assembly of the pre-
replicative complex 




with the ORC:origin 
complex 





Cell death signalling 
via NRAGE, NRIF 
and NADE 





COPII (Coat Protein 
2) Mediated Vesicle 
Transport 






causes cystic fibrosis 











22 N 8 23 6.54E-06 
0.0001612
52 






















growth cone collapse 





ER to Golgi 
Anterograde 
Transport 

















MHC class II antigen 
presentation 
















Regulation of DNA 
replication 
76 N 16 84 8.78E-07 3.17E-05 
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The identification of somatic alterations with a cancer promoting role is 
challenging in highly unstable and heterogeneous cancers, such as esophageal 
adenocarcinoma (EAC). Here we used a machine learning approach to identify 
cancer genes in individual patients considering all types of damaging alterations 
simultaneously (mutations, copy number alterations and structural 
rearrangements). Analysing 261 EACs from the OCCAMS Consortium, we 
discovered a large number of novel cancer genes that, together with well-known 
drivers, help promote cancer. Validation using 107 additional EACs confirmed 
the robustness of the approach. Unlike known drivers whose alterations recur 
across patients, the large majority of the newly discovered cancer genes are 
rare or patient-specific. Despite this, they converge towards perturbing similar 
biological processes, including cell cycle progression, proteasome activity, 
intracellular signalling, Toll-like receptor cascade and DNA replication. 
Recurrence of process perturbation, rather than individual genes, divides EACs 
into six clusters that differ in their molecular features and suggest patient 
stratifications for targeted treatments. Experimental validation of selected genes 
by mimicking the same alterations found in patients leads to cancer-related 
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Synchronous colorectal cancers (syCRCs) are physically separated tumours 
that develop simultaneously. To understand how the genetic and environmental 
background influences the development of multiple tumours, here we conduct a 
comparative analysis of 20 syCRCs from 10 patients. We show that syCRCs 
have independent genetic origins, acquire dissimilar somatic alterations, and 
have different clone composition. This inter- and intratumour heterogeneity must 
be considered in the selection of therapy and in the monitoring of resistance. 
SyCRC patients show a higher occurrence of inherited damaging mutations in 
immune-related genes compared to patients with solitary colorectal cancer and 
to healthy individuals from the 1,000 Genomes Project. Moreover, they have a 
different composition of immune cell populations in tumour and normal mucosa, 
and transcriptional differences in immune-related biological processes. This 
suggests an environmental field effect that promotes multiple tumours likely in 
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Cereda, M., Mourikis, T. P. and Ciccarelli, F. D. (2016) Genetic Redundancy, 
Functional Compensation, and Cancer Vulnerability, Trends in Cancer, pp. 





Cancer genomes acquire somatic alterations that largely differ between and 
within cancer types. Several of these alterations inactivate genes that are 
normally functional with no deleterious consequences on cancer cells due to 
genetic redundancy. Here we discuss how this leads to cancer synthetic 
dependencies that can be exploited in therapy. 
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The Network of Cancer Genes (NCG, http://ncg.kcl.ac.uk/) is a manually 
curated repository of cancer genes derived from the scientific literature. Due to 
the increasing amount of cancer genomic data, we have introduced a more 
robust procedure to extract cancer genes from published cancer mutational 
screenings and two curators independently reviewed each publication. NCG 
release 5.0 (August 2015) collects 1571 cancer genes from 175 published 
studies that describe 188 mutational screenings of 13 315 cancer samples from 
49 cancer types and 24 primary sites. In addition to collecting cancer genes, 
NCG also provides information on the experimental validation that supports the 
role of these genes in cancer and annotates their properties (duplicability, 
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